<SEC-DOCUMENT>0001140361-25-046135.txt : 20251219
<SEC-HEADER>0001140361-25-046135.hdr.sgml : 20251219
<ACCEPTANCE-DATETIME>20251219092626
ACCESSION NUMBER:		0001140361-25-046135
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20251219
DATE AS OF CHANGE:		20251219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		251585527

	BUSINESS ADDRESS:	
		STREET 1:		47 HULFISH STREET
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08542
		BUSINESS PHONE:		(609) 662-2000

	MAIL ADDRESS:	
		STREET 1:		47 HULFISH STREET
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08542

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ef20061157_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="display: none;" id="DSPFiXBRLHidden">false12-31000117887900011788792025-12-192025-12-19</div>
    <div style="line-height: initial;">
      <div style="text-align: right;">
        <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
        <div>
          <div>
            <div style="text-align: center; font-weight: bold; font-size: 14pt;">UNITED STATES</div>
          </div>
          <div style="text-align: center; font-weight: bold; font-size: 14pt;">SECURITIES AND EXCHANGE COMMISSION</div>
          <div style="text-align: center; font-weight: bold; font-size: 12pt;">WASHINGTON, D.C. 20549</div>
          <div><font style="font-size: 12pt;"> </font> <br>
          </div>
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;">
          <div style="text-align: center; font-weight: bold; font-size: 18pt;">FORM 8-K</div>
          <div>
            <div>&#160; </div>
            <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"></div>
          <div style="text-align: center; font-weight: bold;">CURRENT REPORT</div>
          <div style="text-align: center; font-weight: bold;">Pursuant to Section 13 or 15(d)</div>
          <div style="text-align: center; font-weight: bold;">of The Securities Exchange Act of 1934</div>
          <div>&#160;</div>
          <div style="text-align: center; font-weight: bold;">Date of Report (Date of earliest event reported): December 19, 2025</div>
          <div>
            <div>&#160; </div>
            <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"></div>
          <div style="text-align: center; font-weight: bold; font-size: 24pt;">AMICUS THERAPEUTICS, INC.<br>
          </div>
          <div style="text-align: center; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>
          <div>
            <div>&#160; </div>
            <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"></div>
          <div> <br>
          </div>
          <table cellspacing="0" cellpadding="0" border="0" id="z11ca217d93634b76b30d122dd674b18f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">

              <tr>
                <td style="width: 33%; vertical-align: top;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Delaware<br>
                  </div>
                </td>
                <td style="width: 34%; vertical-align: top;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">001-33497<br>
                  </div>
                </td>
                <td style="width: 33%; vertical-align: top;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">71-0869350<br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 33%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(State of incorporation)</div>
                </td>
                <td style="width: 34%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Commission File No.)</div>
                </td>
                <td style="width: 33%; vertical-align: top;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(IRS Employer Identification No.)</div>
                </td>
              </tr>

          </table>
          <div style="text-align: center;"><font style="font-weight: bold; color: #000000;"> <br>
            </font></div>
          <div style="text-align: center; font-weight: bold;">
            <table cellspacing="0" cellpadding="0" border="0" id="z1228c27335a84a608bd5ac6108ecd91a" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%; border-spacing: 0;">

                <tr>
                  <td style="width: 49%;">
                    <div style="text-align: center;"><font style="font-weight: bold; color: rgb(0, 0, 0);">47 Hulfish Street, Princeton, New Jersey</font></div>
                  </td>
                  <td colspan="1" style="width: 2%; text-align: center;">&#160;</td>
                  <td style="width: 49%;">
                    <div style="text-align: center;"><font style="font-weight: bold; color: rgb(0, 0, 0);">08542<br>
                      </font></div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 49%; font-weight: bold; text-align: center;">(Address of principal executive offices and zip code)</td>
                  <td colspan="1" style="width: 2%; font-weight: bold; text-align: center;">&#160;</td>
                  <td style="width: 49%; font-weight: bold; text-align: center;">(Zip Code)</td>
                </tr>

            </table>
            <div><br>
            </div>
          </div>
          <div style="text-align: center; font-weight: bold;">Registrant&#8217;s telephone number, including area code: (609) 662-2000</div>
          <div>&#160;</div>
          <div style="text-align: center; font-weight: bold;">Not Applicable</div>
          <div style="text-align: center; font-weight: bold;">(Former name or former address, if changed since last report.)</div>
          <div>&#160;</div>
          <div>
            <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"> </div>
          <div style="text-align: left;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</div>
          <div>&#160;</div>
          <div>
            <table cellspacing="0" cellpadding="0" id="z49300658b7e94a47bcb41a8b3ec51e77" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">

                <tr>
                  <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9744;<br>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="color: #000000;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
                  </td>
                </tr>

            </table>
            <div style="font-size: 8pt;">&#160;</div>
            <div>
              <table cellspacing="0" cellpadding="0" id="zf09950c97b754603a7e5e7482d4872e8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">

                  <tr style="vertical-align: top;">
                    <td style="text-align: right; vertical-align: top; width: 18pt;">
                      <div style="text-align: left;"><font style="color: #000000;">&#9746;<br>
                        </font></div>
                    </td>
                    <td style="text-align: left; vertical-align: top; width: auto;">
                      <div><font style="color: #000000;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="font-size: 8pt;">&#160;</div>
            <div>
              <table cellspacing="0" cellpadding="0" id="z615a3b619d7e49ac8b6b4e279650c564" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">

                  <tr style="vertical-align: top;">
                    <td style="text-align: right; vertical-align: top; width: 18pt;">
                      <div style="text-align: left;"><font style="color: #000000;">&#9744;<br>
                        </font></div>
                    </td>
                    <td style="text-align: left; vertical-align: top; width: auto;">
                      <div><font style="color: #000000;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="font-size: 8pt;">&#160;</div>
            <div>
              <table cellspacing="0" cellpadding="0" id="zf9847a01b91e44c6808840356838584b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">

                  <tr style="vertical-align: top;">
                    <td style="text-align: right; vertical-align: top; width: 18pt;">
                      <div style="text-align: left;"><font style="color: #000000;">&#9744;<br>
                        </font></div>
                    </td>
                    <td style="text-align: left; vertical-align: top; width: auto;">
                      <div><font style="color: #000000;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
          <div> <br>
          </div>
          <div style="text-align: left;">Securities registered pursuant to Section 12(b) of the Act:</div>
          <div>&#160;</div>
          <table cellspacing="0" cellpadding="0" border="0" id="zd948e6e3b13f47ffafd71ccd97f4e8ad" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">

              <tr>
                <td style="width: 59.12%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Title of Each Class</div>
                </td>
                <td style="width: 0.88%; vertical-align: bottom;">
                  <div style="color: rgb(0, 0, 0);">&#160;</div>
                </td>
                <td style="width: 9.85%; vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Trading</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Symbol</div>
                </td>
                <td style="width: 0.88%; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0);">&#160;</div>
                </td>
                <td style="width: 29.27%; vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Name of Each Exchange</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">on Which Registered</div>
                </td>
              </tr>
              <tr>
                <td style="width: 59.12%; vertical-align: top;">
                  <div style="text-align: center; color: rgb(0, 0, 0);">Common Stock, par value $0.01 per share<br>
                  </div>
                </td>
                <td style="width: 0.88%; vertical-align: bottom;">
                  <div style="color: rgb(0, 0, 0);">&#160;</div>
                </td>
                <td style="width: 9.85%; vertical-align: top;">
                  <div style="text-align: center; color: rgb(0, 0, 0);">FOLD<br>
                  </div>
                </td>
                <td style="width: 0.88%; vertical-align: bottom;">
                  <div style="color: rgb(0, 0, 0);">&#160;</div>
                </td>
                <td style="width: 29.27%; vertical-align: top;">
                  <div style="text-align: center; color: rgb(0, 0, 0);">NASDAQ<br>
                  </div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <div style="text-align: left;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
            (&#167;240.12b-2 of this chapter).</div>
          <div>&#160;</div>
          <div style="text-align: left;">Emerging growth company&#8194;&#9744;</div>
          <div>&#160;</div>
          <div style="text-align: left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
            Section 13(a) of the Exchange Act.&#8194;&#9744;</div>
          <div><br>
          </div>
          <div>
            <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z9aac30337e904ed1aa440c02975eb56c" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">

              <tr>
                <td style="width: 72.35pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">Item&#8201;1.01</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="color: #000000; font-weight: bold;">Entry into a Material Definitive Agreement.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <div style="font-weight: bold; text-align: left;">Agreement and Plan of Merger</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">On December 19, 2025, Amicus Therapeutics, Inc. (the &#8220;<font style="text-decoration: underline;">Company</font>&#8221; or &#8220;<font style="text-decoration: underline;">Amicus</font>&#8221;) entered into an
            Agreement and Plan of Merger (the &#8220;<font style="text-decoration: underline;">Merger Agreement</font>&#8221;) with BioMarin Pharmaceutical Inc., a Delaware corporation (&#8220;<font style="text-decoration: underline;">Parent</font>&#8221;), and Lynx Merger Sub 1,
            Inc., a Delaware corporation and wholly owned subsidiary of Parent (&#8220;<font style="text-decoration: underline;">Merger Sub</font>&#8221;), providing for the merger of Merger Sub with and into the Company (the &#8220;<font style="text-decoration: underline;">Merger</font>&#8221;),


            with the Company surviving the Merger as a wholly owned subsidiary of Parent. Capitalized terms used herein and not otherwise defined herein have the meanings set forth in the Merger Agreement.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">At the effective time of the Merger (the &#8220;<font style="text-decoration: underline;">Effective Time</font>&#8221;), each share of Company Common Stock, par value $0.01 per share (the &#8220;<font style="text-decoration: underline;">Shares</font>&#8221;), issued and outstanding immediately prior to the Effective Time (other than Excluded Shares and Dissenting Shares) will be cancelled and converted into the right to receive $14.50 per Share
            in cash, without interest thereon (the &#8220;<font style="text-decoration: underline;">Merger Consideration</font>&#8221;) and subject to any applicable withholdings of Taxes.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">At the Effective Time, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is less than the Merger Consideration
            (each, an &#8220;<font style="text-decoration: underline;">In the Money Option</font>&#8221;), will be cancelled and converted into the right to receive a cash payment equal to (a)&#160;the excess of (i)&#160;the Merger Consideration over (ii)&#160;the exercise price
            payable per share under such In the Money Option, multiplied by (b)&#160;the total number of shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). In addition, at the Effective Time, each
            Company Option other than an In the Money Option that is then outstanding and unexercised, whether or not vested, will be cancelled with no consideration payable in respect thereof. At the Effective Time, each then outstanding Company RSU will
            be cancelled and the holder thereof will be entitled to receive a cash payment equal to (x)&#160;the Merger Consideration multiplied by (y)&#160;the number of shares subject to such Company RSU. At the Effective Time, each then outstanding Company PSU
            will be cancelled and converted into a cash-based award, which will entitle the holder thereof to receive a cash payment equal to the product of (A) the number of shares subject to such Company PSU immediately prior to the Effective Time at
            specified levels of performance, without any pro-ration, as of immediately prior to the Effective Time <font style="font-style: italic;">multiplied by</font> (B) an amount equal to the Merger Consideration.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">Consummation of the Merger is subject to customary closing conditions, including the absence of certain legal restraints preventing or otherwise making illegal the consummation of the Merger,
            the absence of any Material Adverse Effect having occurred since the signing of the Merger Agreement that is continuing, the expiration or termination of any waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
            amended (the &#8220;<font style="text-decoration: underline;">HSR Act</font>&#8221;), applicable to the Merger, the obtainment of any clearance or affirmative approval applicable to the Merger under the antitrust and foreign direct investment laws of other
            Specified Antitrust Authorities, and the adoption of the Merger Agreement by holders of Company Common Stock representing at least a majority of the outstanding Company&#8217;s Common Stock.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">The parties expect the Merger and the other transactions contemplated by the Merger Agreement to close in the second quarter of the calendar year 2026. The Merger Agreement provides that as
            promptly as reasonably practicable (and in any event within 20 Business Days) after the date of the Merger Agreement, the Company will prepare and file a preliminary proxy statement in anticipation of the Company&#8217;s meeting of its stockholders
            for the purpose of voting upon the adoption of the Merger Agreement.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">The Company and Parent have each made customary representations and warranties in the Merger Agreement and has agreed to customary covenants regarding the operation of the business of the
            Company and its Subsidiaries between the Agreement Date and the earlier of the Effective Time and the valid termination of the Merger Agreement (the &#8220;<font style="text-decoration: underline;">Interim Period</font>&#8221;). The Company is also subject
            to customary restrictions on its ability to solicit alternative acquisition proposals from third parties and to provide non-public information to, and participate in discussions and engage in negotiations with, third parties regarding
            alternative acquisition proposals, with customary exceptions to allow the Board of Directors to exercise its fiduciary duties during the Interim Period. These exceptions include that, subject to the terms and conditions of the Merger Agreement,
            if the Company receives an acquisition proposal that did not result from the Company&#8217;s (or its Representatives&#8217;) breach of its no-shop covenants, and following such receipt, the Board of Directors determines in good faith, after consultation
            with its outside legal counsel and financial advisors, that such acquisition proposal is or could lead to a Superior Offer and the failure to terminate the Merger Agreement and change its recommendation of the Merger to the Company&#8217;s
            stockholders would be inconsistent with the Board of Directors&#8217; fiduciary duties under applicable law, then prior to the Cut-Off Time the Company is permitted to terminate the Merger Agreement and the Board of Directors is permitted to change
            its recommendation of the Merger to the Company&#8217;s stockholders (subject to certain customary match rights in favor of Parent).</div>
          <div>&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-indent: 24.5pt; text-align: left;">The Merger Agreement contains certain termination rights for&#160;the Company and Parent. Subject to the terms and conditions of the Merger Agreement, the Merger Agreement may be terminated under
            certain circumstances, including (i) by mutual written consent of Parent and the Company, (ii) by either the Company or Parent, if the Merger is not consummated by midnight Eastern Time, on June 19, 2026, which period will be extended for two
            automatic three-month periods if at the end of the prior period, all conditions to closing of the Merger other than conditions relating to the HSR Act or other applicable antitrust and foreign direct investment laws have been obtained or waived
            as of such date (such date, as extended, the &#8220;<font style="text-decoration: underline;">End Date</font>&#8221;), (iii) by either the Company or Parent if a&#160;Specified Governmental Body of competent jurisdiction issues any order, directive, judgment,
            decree or ruling, or takes any other action permanently restraining, enjoining or otherwise prohibiting the consummation of the Merger, and such order becomes final and non-appealable, (iv) by Parent (A) due to certain breaches by the Company
            of its representations, warranties and covenants contained in the Merger Agreement, subject to certain cure rights, or (B) at any time before the Cut-Off Time, if (1) the Board of Directors fails to include the Company Board Recommendation in
            the Merger Proxy Statement when filed with the SEC or mailed, or effects a Company Adverse Recommendation Change, (2) in the case of an acquisition proposal structured as a tender offer or exchange offer&#160;the Board of Directors (I) states that
            the Board of Directors recommends such tender or exchange offer or expresses no opinion or is unable to take a position (other than a &#8220;stop, look and listen&#8221; communication pursuant to Rule 14d-9(f) promulgated under the Exchange Act) with
            respect to such tender or exchange offer, or (II) fails to recommend rejection of such tender offer or exchange offer or fails to reaffirm the Company Board Recommendation within 10 Business Days after the commencement of such tender offer or
            exchange offer, (3) after any public announcement of an acquisition proposal (other than a tender offer or exchange offer), the Board of Directors fails to publicly affirm the Company Board Recommendation within three Business Days after a
            written request by Parent to do so, or (4) the Board of Directors fails to publicly reaffirm the Company Board Recommendation within three Business Days after Parent so requests in writing, and (v) by the Company (A) due to certain breaches by
            Parent of its representations, warranties and covenants contained in the Merger Agreement, subject to certain cure rights or (B) in order to substantially concurrently with such termination enter into a binding written definitive acquisition
            agreement providing for the consummation of the Superior Offer approved by the Board of Directors.</div>
          <div>&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">Upon termination of the Merger Agreement, under specified circumstances, the Company will be required to pay Parent a termination fee of $175,000,000. Such circumstances include where the Merger
            Agreement is terminated (i) in connection with the Company accepting a Superior Offer approved by the Board of Directors and entering into a binding written definitive acquisition agreement for the consummation of a transaction which the Board
            of Directors determines constitutes a Superior Offer, (ii) due to the Board of Directors&#8217; change or withdrawal of, or failure to reaffirm as required by the Merger Agreement, its recommendation of the Merger to the Company&#8217;s stockholders, or
            (iii) because the Board of Directors or the Company breach their non-solicit obligations under the Merger Agreement in any material respect. The termination fee will also be payable if the Merger Agreement is terminated (i) (a) by Parent or the
            Company because the Merger is not consummated before the End Date (but in the case of a termination by the Company, only if Parent would not be prohibited from terminating the Merger Agreement on this basis because its material breach had
            proximately caused or resulted in the Merger not being consummated by the End Date), (b) by Parent or the Company due to failure to obtain the requisite Company stockholder vote to adopt the Merger Agreement, or (c) by Parent because the
            Company breaches its representations, warranties or covenants in a manner that would cause the related closing conditions to not be met (provided that neither Parent nor Merger Sub is then in breach of its representations, warranties or
            covenants in a manner that would cause the related closing conditions to not be met), and (ii) in the case of each of such events and prior to any such termination, a proposal to acquire at least 50%&#160; of the Company&#8217;s stock or assets is
            communicated to the Board of Directors or publicly disclosed and has not been withdrawn, and (iii) the Company enters into an agreement for, or consummates, a transaction involving an acquisition of at least 50% of the Company&#8217;s stock or assets
            within 12 months of such termination.</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-indent: 24.5pt; text-align: left;">The Merger Agreement and the above description of the Merger Agreement have been included to provide investors with information regarding the terms of the Merger Agreement. It is not intended to
            provide any other factual information about the Company, Parent or their respective subsidiaries, affiliates or businesses. The representations, warranties and covenants contained in the Merger Agreement were made only for the purposes of that
            agreement and as of specific dates, were solely for the benefit of the parties to the Merger Agreement and may be subject to limitations agreed upon by the parties in connection with negotiating the terms of the Merger Agreement. In addition,
            such representations, warranties and covenants have been included in the Merger Agreement for the purpose of allocating risk between the contracting parties rather than establishing matters as fact. In addition, the representations, warranties
            and covenants have been qualified by (a) matters specifically disclosed in certain of the Company&#8217;s filings with the United States Securities and Exchange Commission (&#8220;<font style="text-decoration: underline;">SEC</font>&#8221;), (b) confidential
            disclosures made to Parent and Merger Sub in the disclosure letter delivered in connection with the Merger Agreement and (c) materiality qualifications contained in the Merger Agreement, which may differ from what may be viewed as material by
            investors. Accordingly, the Merger Agreement is included with this filing only to provide investors with information regarding the terms of the Merger Agreement, and not to provide investors with any other factual information regarding the
            Company, Parent or their respective businesses.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="font-weight: bold; text-align: left;">Additional Information</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of
            the Merger Agreement, a copy of which is attached hereto as Exhibit 2.1 and is incorporated by reference herein.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company, Parent or
            any of their subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected
            in the Company&#8217;s public disclosures. The Merger Agreement should not be read alone, but should instead be read in conjunction with the other information regarding the Company that is or will be contained in, or incorporated by reference into,
            the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents that the Company files with the SEC.</div>
          <div style="text-align: left;">&#160;</div>
          <div>
            <table cellspacing="0" cellpadding="0" id="zf54a39c1d2a547beb1fb5b450d5936e5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">

                <tr style="vertical-align: top;">
                  <td style="text-align: right; vertical-align: top; width: 72.35pt;">
                    <div style="text-align: left;"><font style="font-weight: bold;">Item 5.03</font></div>
                  </td>
                  <td style="text-align: left; vertical-align: top; width: auto;">
                    <div><font style="font-weight: bold;">Amendments to Articles of Incorporation or Bylaws.</font></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">On December 19, 2025, the Board approved and adopted an amendment (the &#8220;<font style="text-decoration: underline;">Forum Selection Amendment</font>&#8221;) to the Company&#8217;s existing By-laws that amends
            Article VI to include a new Section 6.5.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">The Forum Selection Amendment is filed as Exhibit 3.1 hereto and incorporated by reference herein.</div>
          <div style="text-indent: 24.5pt;"> <br>
          </div>
          <div>
            <table cellspacing="0" cellpadding="0" id="ze689490f11d6473483128dc516a52815" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">

                <tr>
                  <td style="width: 72.35pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">Item&#8201;7.01</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="color: #000000; font-weight: bold;">Regulation FD.</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">On December 19, 2025, the Company and Parent issued a joint press release announcing the execution of the Merger Agreement. A copy of the joint press release is attached as Exhibit 99.1 hereto
            and is incorporated herein by reference.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">On December 19, 2025, the Company distributed an email to its employees regarding the proposed transaction. A copy of the email is attached as Exhibit 99.2 hereto and is incorporated herein by
            reference.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">On December 19, 2025, the Company posted a message on LinkedIn regarding the proposed transaction. A copy of the posted message is attached as Exhibit 99.3 hereto and is incorporated herein by
            reference.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">On December 19, 2025, the Company distributed an email to its employees regarding BioMarin&#8217;s CEO Alexander Hardy&#8217;s attendance at a town hall meeting with Amicus employees and distributed Mr.
            Hardy&#8217;s letter addressed to Amicus employees. A copy of the email is attached as Exhibit 99.4 hereto and is incorporated herein by reference.</div>
          <div style="text-align: left;">&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-indent: 24.5pt; text-align: left;">On December 19, 2025, the Company distributed a FAQ document to its employees regarding the proposed transaction. A copy of such document is attached as Exhibit 99.5 hereto and is incorporated
            herein by reference.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">On December 19, 2025, the Company distributed a letter to certain of its stakeholders, including vendors, suppliers, policymakers, clinical trial partners, patients and advocate groups,
            regarding the proposed transaction. A form of this letter is attached as Exhibit 99.6 hereto and is incorporated herein by reference.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">On December 19, 2025, the Company distributed a fact sheet to certain of its investors and analysts regarding the proposed transaction. A copy of this fact sheet is attached as Exhibit 99.7
            hereto and is incorporated herein by reference.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">On December 19, 2025, the Company distributed an email to certain of its investors and analysts regarding the proposed transaction. A form of this email is attached as Exhibit 99.8 hereto and is
            incorporated herein by reference.</div>
          <div><br>
          </div>
          <div style="text-indent: 24.5pt; text-align: left;">The information contained in Exhibits 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7 and 99.8 is being furnished, not filed, pursuant to this Item 7.01. Accordingly, such information will not be
            incorporated by reference into any filing filed by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (the &#8220;<font style="text-decoration: underline;">Exchange Act</font>&#8221;), unless
            specifically identified therein as being incorporated by reference therein. The furnishing of the information in this Current Report on Form&#160;8-K (this &#8220;<font style="text-decoration: underline;">Current Report</font>&#8221;)&#160;with respect to Exhibits
            99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7 and 99.8 is not intended to, and does not, constitute a determination or admission by the Company that such information is material or complete, or that investors should consider this information before
            making an investment decision with respect to any security of the Company.</div>
          <div>
            <div style="text-align: left;">&#160; </div>
            <table cellspacing="0" cellpadding="0" id="zb7583243b2cc49cfbaea177d93da1dd6" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">

                <tr>
                  <td style="width: 72.35pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">Item&#8201;9.01.</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="color: #000000; font-weight: bold;">Financial Statements and Exhibits.</div>
                  </td>
                </tr>

            </table>
          </div>
          <div>
            <div>&#160; </div>
            <table cellspacing="0" cellpadding="0" id="zb9800917b8e94ed3a4b85874cee7ab5c" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">

                <tr>
                  <td style="width: 72pt; vertical-align: top; color: rgb(0, 0, 0);">(d)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="color: #000000;">Exhibits.</div>
                  </td>
                </tr>

            </table>
          </div>
          <div>&#160;</div>
          <table cellspacing="0" cellpadding="0" border="0" id="zcc853f97fbe14dc7afca1e4594523d6d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">

              <tr>
                <td style="vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Exhibit<br>
                    No.</div>
                </td>
                <td style="width: 93.59%; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: middle;">&#160;</td>
                <td style="width: 1%; vertical-align: middle;" colspan="1">&#160;</td>
                <td style="width: 93.59%; vertical-align: middle;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: right; color: rgb(0, 0, 0);"><a href="#Exhibit2.1">2.1</a></div>
                </td>
                <td style="width: 1%; vertical-align: top; white-space: nowrap;" colspan="1">&#160;</td>
                <td style="width: 93.59%; vertical-align: top;">
                  <div><font style="color: #000000;">Agreement and Plan of Merger, dated as of </font><font style="color: rgb(0, 0, 0);">December </font>19<font style="color: rgb(0, 0, 0);">, 2025, by and among Amicus Therapeutics, Inc., BioMarin
                      Pharmaceutical Inc., and Lynx Merger Sub 1, Inc.*</font></div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: right; color: rgb(0, 0, 0);"><a href="#Exhibit3.1">3.1</a></div>
                </td>
                <td style="width: 1%; vertical-align: top; white-space: nowrap;" colspan="1">&#160;</td>
                <td style="width: 93.59%; vertical-align: top;">
                  <div>Amendment to Amicus Therapeutics, Inc.&#8217;s Second Amended and Restated By-laws, dated December 19, 2025.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: right; color: rgb(0, 0, 0);"><a href="#Exhibit99.1">99.1</a></div>
                </td>
                <td style="width: 1%; vertical-align: top; white-space: nowrap;" colspan="1">&#160;</td>
                <td style="width: 93.59%; vertical-align: top;">
                  <div>Joint Press Release issued by Amicus Therapeutics, Inc. and BioMarin Pharmaceutical Inc. on December 19, 2025.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: right; color: rgb(0, 0, 0);"><a href="#Exhibit99.2">99.2</a></div>
                </td>
                <td style="width: 1%; vertical-align: top; white-space: nowrap;" colspan="1">&#160;</td>
                <td style="width: 93.59%; vertical-align: top;">
                  <div>Employee email dated December 19, 2025.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: right; color: rgb(0, 0, 0);"><a href="#Exhibit99.3">99.3</a></div>
                </td>
                <td style="width: 1%; vertical-align: top; white-space: nowrap;" colspan="1">&#160;</td>
                <td style="width: 93.59%; vertical-align: top;">
                  <div>LinkedIn post dated December 19, 2025.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: right; color: rgb(0, 0, 0);"><a href="#Exhibit99.4">99.4</a></div>
                </td>
                <td style="width: 1%; vertical-align: top; white-space: nowrap;" colspan="1">&#160;</td>
                <td style="width: 93.59%; vertical-align: top;">
                  <div>BioMarin CEO email dated December 19, 2025.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: right; color: rgb(0, 0, 0);"><a href="#Exhibit99.5">99.5</a></div>
                </td>
                <td style="width: 1%; vertical-align: top; white-space: nowrap;" colspan="1">&#160;</td>
                <td style="width: 93.59%; vertical-align: top;">
                  <div>Employee FAQ dated December 19, 2025.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: right; color: rgb(0, 0, 0);"><a href="#Exhibit99.6">99.6</a></div>
                </td>
                <td style="width: 1%; vertical-align: top; white-space: nowrap;" colspan="1">&#160;</td>
                <td style="width: 93.59%; vertical-align: top;">
                  <div>
                    <div>Form of stakeholder letter, first sent December 19, 2025.</div>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: right; color: rgb(0, 0, 0);"><a href="#Exhibit99.7">99.7</a></div>
                </td>
                <td style="width: 1%; vertical-align: top; white-space: nowrap;" colspan="1">&#160;</td>
                <td style="width: 93.59%; vertical-align: top;">
                  <div>Investor Fact Sheet dated December 19, 2025.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: right; color: rgb(0, 0, 0);"><a href="#Exhibit99.8">99.8</a></div>
                </td>
                <td style="width: 1%; vertical-align: top; white-space: nowrap;" colspan="1">&#160;</td>
                <td style="width: 93.59%; vertical-align: top;">
                  <div>
                    <div>Form of email to certain investors and analysts, first sent December 19, 2025.</div>
                  </div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <div>
            <table cellspacing="0" cellpadding="0" id="zd21236b6080e4e478f2ea6ceccab0f51" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">

                <tr>
                  <td style="width: 9pt; vertical-align: top; color: rgb(0, 0, 0);">*</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="color: #000000;">Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the
                      SEC; provided, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedules so furnished.</div>
                  </td>
                </tr>

            </table>
          </div>
          <div> <br>
          </div>
          <div style="text-align: center;">*&#8195;*&#8195;*</div>
          <div style="text-align: center;"> <br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="font-weight: bold; text-align: left;"><font style="text-decoration: underline;">Important Information and Where to Find It</font></div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 36pt; text-align: left;">In connection with the<font style="color: rgb(0, 0, 0);"> proposed acquisition of Amicus by Parent (the &#8220;<font style="text-decoration: underline;">Transaction</font>&#8221;)</font>, Amicus intends to
            file with the SEC a proxy statement (the &#8220;<font style="text-decoration: underline;">Proxy Statement</font>&#8221;), the definitive version of which will be sent or provided to Amicus stockholders. Amicus may also file other documents with the SEC
            regarding the proposed transaction. This document is not a substitute for the Proxy Statement or any other document which Amicus may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT
            DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND
            RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy Statement (when it is available) and other documents that are filed or will be filed with the SEC by Amicus through the website maintained by the SEC at
            www.sec.gov, Amicus&#8217;s website at https://ir.amicusrx.com/financial-information/sec-filings or by contacting the Amicus investor relations department at the following:</div>
          <div><br>
          </div>
          <div style="text-align: left;">Andrew Faughnan</div>
          <div style="text-align: left;">(609) 662-3809</div>
          <div style="text-align: left;"><font style="text-decoration: underline;">afaughnan@amicusrx.com</font></div>
          <div><br>
          </div>
          <div style="font-weight: bold; text-align: left;"><font style="text-decoration: underline;">No Offer or Solicitation</font></div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 36pt; text-align: left;">This Current Report is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to
            purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance
            or transfer of securities in any jurisdiction in contravention of applicable law.</div>
          <div style="text-align: left;">&#160;</div>
          <div style="font-weight: bold; text-align: left;"><font style="text-decoration: underline;">Participants in the Solicitation</font></div>
          <div style="text-align: left;">&#160;</div>
          <div style="text-indent: 36pt; text-align: left;">Amicus and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Amicus&#8217;s
            directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in (i) Amicus&#8217; Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the
            SEC on <font style="text-decoration: underline;">February 19, 2025</font>, including the sections therein entitled &#8220;Directors, Executive Officers, and Corporate Governance,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Security Ownership of Certain
            Beneficial Owners and Management and Related Stockholder Matters&#8221;, and (ii) Amicus&#8217;s proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on <font style="text-decoration: underline;">April 24, 2025</font>,
            including the sections therein entitled &#8220;Proposal 1 &#8211; Election of Class Directors,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Compensation and Equity Tables,&#8221; and &#8220;Share Ownership of Certain Beneficial Owners and Management,&#8221; and (iii) other
            documents subsequently filed with the SEC from time to time, including the Proxy Statement to be filed by Amicus in connection with the proposed transaction and the special meeting of stockholders of Amicus. To the extent holdings of Amicus&#8217;
            securities by its directors or executive officers have changed since the amounts set forth in the filings described in the foregoing, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or
            Statements of Beneficial Ownership on Form 4 filed with the SEC. Amicus stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the
            proposed transaction, including the interests of Amicus directors and executive officers in the transaction, which may be different than those of Amicus stockholders generally, by reading the Proxy Statement and any other relevant documents
            that are filed or will be filed with the SEC relating to the transaction. These documents (when available) may be obtained free of charge from the website maintained by the SEC at <font style="text-decoration: underline;">www.sec.gov</font>
            and Amicus&#8217;s website at https://ir.amicusrx.com/financial-information/sec-filings.</div>
          <div>&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="font-weight: bold; text-align: left;"><font style="text-decoration: underline;">Forward Looking Statements</font></div>
          <div><br>
          </div>
          <div style="text-align: left;"><font style="color: rgb(0, 0, 0);">This Current Report contains certain&#160;&#8220;forward-looking statements&#8221; intended to qualify for the &#8220;safe harbor&#8221; from liability established by the Private Securities Litigation Reform
              Act of 1995, as amended, including, but not limited to, statements about the anticipated timing of closing of the Transaction</font> in the second quarter of the calendar year 2026; and the timing of the filing of the proxy statement for the
            Amicus&#8217; special stockholder meeting in connection with the Transaction<font style="color: rgb(0, 0, 0);">. Forward-looking statements include any statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221;, &#8220;goal,&#8221;
              &#8220;may&#8221;, &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions. Forward-looking statements are subject to certain risks, uncertainties, or other factors that
              are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results
              to differ from expectations contemplated by forward-looking statements include, among other things: </font>consummating the Transaction and financing in the anticipated timeframe, if at all<font style="color: rgb(0, 0, 0);">; the occurrence
              of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; uncertainties as to the ability to obtain shareholder approval; the possibility that competing </font>acquisition proposals<font style="color: rgb(0, 0, 0);"> will be made; the possibility that various closing conditions for the Transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the
              consummation of the Transaction </font>(or only grant approval subject to adverse conditions or limitations)<font style="color: rgb(0, 0, 0);">; the effects of the Transaction on relationships with employees, customers, suppliers, other
              business partners or governmental entities</font>, including the risk that the Transaction adversely affects employee retention<font style="color: rgb(0, 0, 0);">; the difficulty of predicting the timing or outcome of regulatory approvals or
              actions; the impact of competitive products and pricing; the risk that Parent may not realize the potential benefits of the Transaction, </font>including the possibility that the expected benefits from the proposed Transaction will not be
            realized or will not be realized within the expected time period and that Parent and Amicus will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected<font style="color: rgb(0, 0, 0);">; the risks related to disruption of management&#8217;s time from ongoing business operations as a result of the Transaction;</font> risks that the Transaction disrupts current plans and operations;<font style="color: rgb(0, 0, 0);">&#160;</font>obtaining

            and maintaining adequate coverage and reimbursement for Amicus&#8217; products;<font style="color: rgb(0, 0, 0);">&#160;</font>changes in Amicus&#8217; business during the period between announcement and closing of the Transaction; any legal proceedings and/or
            regulatory actions that may be instituted related to the Transaction; <font style="color: rgb(0, 0, 0);">other business effects, including the effects of industry, economic or political conditions outside of the companies&#8217; control; costs and
              expenses related to the Transaction; actual or contingent liabilities; </font>the effects of the Transaction (or the announcement thereof) on Amicus&#8217; and Parent&#8217;s stock price and/or operating results; <font style="color: rgb(0, 0, 0);">and
              the other risks and uncertainties discussed in Amicus&#8217;s periodic reports filed with the SEC, including Amicus&#8217; quarterly reports on Form 10-Q and annual reports on Form 10-K. </font>These risks, as well as other risks associated with the
            Transaction, are more fully discussed in the Proxy Statement to be filed with the SEC in connection with the Transaction. The list of factors presented in the foregoing is not complete and<font style="color: rgb(0, 0, 0);"> you should not place
              undue reliance on these statements. Actual results could differ materially from those anticipated in these forward-looking statements. All forward-looking statements are based on information currently available to Amicus and Parent, and,
              except as required by applicable law, Amicus and Parent disclaim any obligation to update the information contained in this Current Report as new information becomes available.</font>&#160;<font style="color: rgb(0, 0, 0);">All forward-looking
              statements in this Current Report or made in connection therewith in writing or orally are qualified in their entirety by this cautionary statement.</font></div>
          <div><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
          <div>&#160;</div>
          <div style="text-indent: 24.5pt; text-align: left;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>
          <div>&#160;</div>
          <div style="text-align: left;">Date: December 19, 2025</div>
          <div>&#160;</div>
          <table cellspacing="0" cellpadding="0" border="0" id="z8fe7dc9e8a17425daadda15039f6d92f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">

              <tr>
                <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
                <td colspan="2" rowspan="1" style="width: 5%; vertical-align: middle;">
                  <div style="color: rgb(0, 0, 0); font-weight: bold;">Amicus Therapeutics, Inc.</div>
                </td>
              </tr>
              <tr>
                <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
                <td style="width: 5%; vertical-align: middle;">&#160;</td>
                <td style="width: 45%; vertical-align: middle;">&#160;</td>
              </tr>
              <tr>
                <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0);">By:</div>
                </td>
                <td style="width: 45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div>
                    <div style="color: rgb(0, 0, 0);">/s/ Ellen S. Rosenberg</div>
                  </div>
                </td>
              </tr>
              <tr>
                <td colspan="1" style="width: 50%; vertical-align: bottom;">&#160;</td>
                <td style="width: 5%; vertical-align: bottom;">&#160;</td>
                <td style="width: 45%; vertical-align: bottom;">
                  <div style="color: rgb(0, 0, 0);">Ellen S. Rosenberg</div>
                </td>
              </tr>
              <tr>
                <td colspan="1" style="width: 50%; vertical-align: bottom;">&#160;</td>
                <td style="width: 5%; vertical-align: bottom;">&#160;</td>
                <td style="width: 45%; vertical-align: bottom;">
                  <div style="color: rgb(0, 0, 0);">Chief Legal Officer and Corporate Secretary</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <a name="Exhibit2.1"><!--Anchor--></a><font style="font-weight: bold;">Exhibit 2.1</font><br>
      </div>
    </div>
  </div>
  <div>
    <div>
      <div style="text-align: right;">
        <div style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Execution Version</div>
        <div>&#160;</div>
        <font style="font-weight: bold;"> </font></div>
      <u> </u>&#160; </div>
    <div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">AGREEMENT AND PLAN OF MERGER</div>
      <div>&#160;</div>
      <div style="text-align: center;">among:</div>
      <div>&#160;</div>
      <div style="text-align: center;">Amicus Therapeutics, Inc.,</div>
      <div>&#160;</div>
      <div style="text-align: center;">a Delaware corporation;</div>
      <div>&#160;</div>
      <div style="text-align: center;">BioMarin Pharmaceutical Inc.,</div>
      <div>&#160;</div>
      <div style="text-align: center;">a Delaware corporation;</div>
      <div>&#160;</div>
      <div style="text-align: center;">Lynx Merger Sub 1, Inc.,</div>
      <div>&#160;</div>
      <div style="text-align: center;">a Delaware corporation,</div>
      <div>&#160;</div>
      <div style="text-align: center;">Dated as of December 19, 2025</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%LCR%1%-%-%-->
      <div>
        <div style="text-align: center; margin-right: 5.75pt; margin-left: 5.75pt; font-weight: bold;">TABLE OF CONTENTS</div>
        <div><br>
        </div>
        <div style="text-align: right; margin-right: 5.75pt; margin-left: 5.75pt; font-weight: bold;">Page</div>
        <div>&#160;</div>
      </div>
      <div style="text-align: center;">SECTION 1</div>
      <div style="text-align: center;"><br>
        MERGER TRANSACTION</div>
      <div style="text-align: center;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zbed618cc4037498cb550e411c316af78">

          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>1.1</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Merger of Merger Sub into the Company</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">2</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>1.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Effect of the Merger</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">2</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>1.3</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Closing; Effective Time.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">2</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>1.4</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Certificate of Incorporation and Bylaws; Directors and Officers.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">2</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>1.5</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Conversion of Shares.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">3</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>1.6</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Surrender of Certificates; Stock Transfer Books.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">4</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>1.7</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Dissenters&#8217; Rights</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">7</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>1.8</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Treatment of Company Equity Awards.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">7</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>1.9</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Further Action</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">8</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: center;">SECTION 2</div>
      <div style="text-align: center;"><br>
        REPRESENTATIONS AND WARRANTIES OF THE COMPANY</div>
      <div style="text-align: center;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z2f5446b2aa5b4fe4bbe28b15b3099cec">

          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>2.1</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Due Organization; Subsidiaries, Etc.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">9</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>2.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Certificate of Incorporation and Bylaws</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">10</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>2.3</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Capitalization, Etc.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">10</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>2.4</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>SEC Filings; Financial Statements.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">12</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>2.5</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Absence of Changes; No Material Adverse Effect</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">14</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>2.6</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Title to Assets</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">14</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>2.7</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Real Property.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">15</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>2.8</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Intellectual Property.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">15</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>2.9</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Contracts.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">18</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>2.10</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Liabilities</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>2.11</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Compliance with Legal Requirements.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>2.12</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Regulatory Matters.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">23</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>2.13</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Governmental Authorizations.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">25</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>2.14</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Tax Matters.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">26</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>2.15</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Employee Matters.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">30</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>2.16</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Benefit Plans.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">33</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>2.17</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Environmental Matters.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">36</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>2.18</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Insurance</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">37</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>2.19</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Legal Proceedings; Orders.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">37</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>2.20</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Authority; Binding Nature of Agreement</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">38</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>2.21</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Takeover Laws</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">38</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>2.22</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Non-Contravention; Consents.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">38</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>2.23</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Opinion of Financial Advisors</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">39</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>2.24</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Brokers and Other Advisors</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">39</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>2.25</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Acknowledgment by Company</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">39</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-i-</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <div style="text-align: center; margin-right: 5.75pt; margin-left: 5.75pt; font-weight: bold;">TABLE OF CONTENTS</div>
        <div style="text-align: center; margin-right: 5.75pt; margin-left: 5.75pt;">(continued)</div>
        <div style="text-align: right; margin-right: 5.75pt; margin-left: 5.75pt; font-weight: bold;">Page</div>
        <div style="text-align: right; margin-right: 5.75pt; margin-left: 5.75pt; font-weight: bold;"> <br>
        </div>
      </div>
      <div style="text-align: center;">SECTION 3</div>
      <div style="text-align: center;"><br>
        REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</div>
      <div style="text-align: center;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z924428b478f8410391c03e6da6a40918">

          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>3.1</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Due Organization</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">40</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>3.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Merger Sub</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">40</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>3.3</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Authority; Binding Nature of Agreement</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">40</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>3.4</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Non-Contravention; Consents.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">41</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>3.5</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Disclosure</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">41</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>3.6</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Absence of Litigation</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">42</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>3.7</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Funds.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">42</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>3.8</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Ownership of Shares</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">42</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>3.9</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Acknowledgement by Parent and Merger Sub.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">43</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>3.10</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Brokers and Other Advisors</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">44</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: center;">SECTION 4</div>
      <div style="text-align: center;"><br>
        CERTAIN COVENANTS OF THE COMPANY</div>
      <div style="text-align: center;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z496646939b194f6cb64e72fbe8edb085">

          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>4.1</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Access and Investigation; Notice of Certain Events.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">44</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>4.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Operation of the Acquired Companies&#8217; Business</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">46</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>4.3</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>No Solicitation.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">51</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>4.4</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Preparation of Proxy Statement; Stockholder Meeting.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">54</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: center;">SECTION 5</div>
      <div style="text-align: center;"><br>
        ADDITIONAL COVENANTS OF THE PARTIES</div>
      <div style="text-align: center;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z08de88efa28746ff9d59c69ec07426ba">

          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>5.1</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Company Board Recommendation.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">56</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>5.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Filings, Consents and Approvals.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">58</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>5.3</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Employee Benefits.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">61</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>5.4</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Indemnification of Officers and Directors.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">63</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>5.5</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Stockholder Litigation</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">64</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>5.6</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Additional Agreements</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">65</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>5.7</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Disclosure</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">65</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>5.8</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Takeover Laws</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">65</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>5.9</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Section 16 Matters</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">66</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>5.10</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Senior Secured Term Loan Agreement</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">66</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>5.11</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Financing.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">67</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>5.12</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Parent Financing.</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">70</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>5.13</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Stock Exchange Delisting; Deregistration</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">72</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>5.14</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>FIRPTA Certificate</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">72</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-ii-</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center;">
        <div style="margin-right: 5.75pt; margin-left: 5.75pt; font-weight: bold;">TABLE OF CONTENTS</div>
        <div style="margin-right: 5.75pt; margin-left: 5.75pt;">(continued)</div>
        <div style="text-align: right; margin-right: 5.75pt; margin-left: 5.75pt; font-weight: bold;">Page</div>
        <div style="text-align: right; margin-right: 5.75pt; margin-left: 5.75pt; font-weight: bold;">&#160;</div>
      </div>
      <div style="text-align: center;">SECTION 6</div>
      <div style="text-align: center;"><br>
        CONDITIONS PRECEDENT TO THE MERGER</div>
      <div style="text-align: center;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze0a464aa16b641ec817cc62e399dd159">

          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>6.1</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Conditions to Each Party&#8217;s Obligation to Effect the Merger</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">72</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>6.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Conditions to Obligations of Parent and Merger Sub to Effect the Merger</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">73</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>6.3</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Conditions to Obligations of the Company to Effect the Merger</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">74</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: center;">SECTION 7</div>
      <div style="text-align: center;"><br>
        TERMINATION</div>
      <div style="text-align: center;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0f700cd6f2e440a5a8f856911bb10c2a">

          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>7.1</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Termination</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">75</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>7.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Effect of Termination</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">77</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>7.3</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Expenses; Termination Fees.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">77</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: center;">SECTION 8</div>
      <div style="text-align: center;"><br>
        MISCELLANEOUS PROVISIONS</div>
      <div style="text-align: center;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z017fe18e120945e9b49a775301ee48a9">

          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>8.1</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Amendment</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">79</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>8.2</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Waiver</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">80</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>8.3</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>No Survival of Representations and Warranties</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">80</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>8.4</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Entire Agreement; Counterparts</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">80</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>8.5</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Applicable Legal Requirements; Jurisdiction; Specific Performance; Remedies.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">81</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>8.6</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Assignability</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">83</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>8.7</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>No Third Party Beneficiaries</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">83</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>8.8</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Notices</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">84</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>8.9</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Severability</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">84</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>8.10</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Obligation of Parent</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">85</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>8.11</div>
            </td>
            <td style="width: 89%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Construction.</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">86</div>
            </td>
          </tr>
          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div>8.12</div>
            </td>
            <td style="width: 89%; vertical-align: top;">
              <div>Liability of the Financing Sources</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">87</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><u>Exhibits</u></div>
      <div>&#160;</div>
      <div>Exhibit A&#160;&#160;&#160;&#160;&#160;&#160; Certain Definitions</div>
      <div>&#160;</div>
      <div><u>Annexes</u></div>
      <div>&#160;</div>
      <div>Annex I&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form of Certificate of Incorporation of the Surviving Corporation</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-iii-</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">AGREEMENT AND PLAN OF MERGER</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">THIS AGREEMENT AND PLAN OF MERGER</font><font style="font-size: 10pt;"> (&#8220;<u>Agreement</u>&#8221;) is made and entered into as of December 19, 2025 (the &#8220;<u>Agreement












            Date</u>&#8221;), by and among (i) BioMarin Pharmaceutical Inc., a Delaware corporation (&#8220;<u>Parent</u>&#8221;), (ii) Lynx Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (&#8220;<u>Merger Sub</u>&#8221;), and (iii) Amicus
          Therapeutics, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;).&#160; Certain capitalized terms used in this Agreement are defined in <u>Exhibit&#160;A</u>.</font></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">INTRODUCTION</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">A.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Parent desires to acquire the Company through the merger of Merger Sub with and into the Company (the &#8220;<u>Merger</u>&#8221;), with the Company continuing as the surviving
        corporation in the Merger (the &#8220;<u>Surviving Corporation</u>&#8221;), on the terms and subject to the conditions set forth in this Agreement, whereby (i)&#160;each issued and outstanding share of Company Common Stock (collectively, the &#8220;<u>Shares</u>&#8221;) as of
        the Effective Time (other than Excluded Shares and Dissenting Shares) shall be cancelled and converted into the right to receive $14.50 per Share, in cash, without interest (the &#8220;<u>Merger Consideration</u>&#8221;) and subject to any applicable
        withholding of Taxes, and (ii)&#160;the Company shall become a wholly owned Subsidiary of Parent as a result of the Merger.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">B.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The board of directors of the Company (the &#8220;<u>Board of Directors</u>&#8221;) has unanimously (i)&#160;determined that this Agreement and the Transactions, including the Merger,
        are advisable and fair to, and in the best interest of, the Company and its stockholders, (ii) declared it advisable to enter into this Agreement, (iii) approved the execution, delivery and performance by the Company of this Agreement and the
        consummation of the Transactions, including the Merger, (iv) resolved that the Merger shall be governed by Section 251(c) of the DGCL, upon the terms and subject to the conditions set forth in this Agreement, and (v) resolved to recommend that the
        stockholders of the Company adopt this Agreement at any meeting of the Company&#8217;s stockholders held for such purpose and any adjournment or postponement thereof (the preceding <u>clauses </u><u>(i)</u>, <u>(ii)</u> and <u>(v)</u> collectively,
        the &#8220;<u>Company Board Recommendation</u>&#8221;), in each case, on the terms and subject to the conditions of this Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">C.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The board of directors of each of Parent and Merger Sub have approved this Agreement and declared it advisable for Parent and Merger Sub, respectively, to enter into
        this Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">AGREEMENT</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">The Parties, intending to be legally bound, agree as follows:</div>
      <div>&#160;
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <!--PROfilePageNumberReset%Num%2%%%--></div>
      <div style="text-align: center; font-weight: bold;">SECTION 1<br>
        <br>
        <u>MERGER TRANSACTION</u></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">1.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Merger of Merger Sub into the Company</font>.&#160; Upon the terms and subject to the conditions set forth in this Agreement and in
        accordance with Section 251(c) of the DGCL, at the Effective Time, the Company and Parent shall consummate the Merger, whereby Merger Sub shall be merged with and into the Company, the separate existence of Merger Sub shall cease, and the Company
        will continue as the Surviving Corporation.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">1.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Effect of the Merger</font>.&#160; The Merger shall have the effects set forth in this Agreement and in the applicable provisions of the
        DGCL.&#160; Without limiting the generality of the foregoing, at the Effective Time, all of the property, rights, privileges, immunities, powers and franchises of the Company and Merger Sub shall vest in the Surviving Corporation, and all of the debts,
        liabilities and duties of the Company and Merger Sub shall become the debts, liabilities and duties of the Surviving Corporation.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">1.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Closing; Effective Time</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unless this Agreement shall have been terminated pursuant to <u>Section </u><u>7</u>, and unless otherwise mutually agreed in writing among the Company, Parent and Merger Sub, the consummation of the
        Merger (the &#8220;<u>Closing</u>&#8221;) shall take place by means of a virtual closing via the electronic exchange of documents and signatures by the Parties as soon as practicable (and in no event later than three Business Days) following the satisfaction
        or, to the extent permitted by applicable Legal Requirements, waiver (by the Party or Parties entitled to the benefits thereof) of the last of the conditions set forth in <u>Section </u><u>6</u> (other than conditions that by their nature are to
        be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted by applicable Legal Requirements, waiver of such conditions at the Closing); <font style="font-style: italic;">provided</font> that if the Parties mutually
        agree in writing upon another date, the Closing shall take place on such date.&#160; The date on which the Closing occurs is referred to in this Agreement as the &#8220;<u>Closing Date</u>&#8221;.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the provisions of this Agreement, as soon as practicable on the Closing Date, the Company and Merger Sub shall file or cause to be filed a certificate of merger with the Secretary of State of
        the State of Delaware with respect to the Merger, in such form reasonably agreed upon between the Parties and as required by, and executed and acknowledged in accordance with, the relevant provisions of the DGCL, and the Parties shall take all such
        further actions as may be required by applicable Legal Requirements to make the Merger effective.&#160; The Merger shall become effective upon the date and time of the filing of that certificate of merger with the Secretary of State of the State of
        Delaware or such later date and time as is agreed upon in writing by the Parties and specified in the certificate of merger (such date and time the Merger is effective, the &#8220;<u>Effective Time</u>&#8221;).</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">1.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Certificate of Incorporation and Bylaws; Directors and Officers</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As of the Effective Time, the certificate of incorporation of the Company shall by virtue of the Merger and without any further action, be amended and restated to read in its entirety as set forth on <u>Annex













          I</u> and, as so amended and restated, shall be the certificate of incorporation of the Surviving Corporation until thereafter changed or amended as provided therein or by applicable Legal Requirements, subject to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.4(a)</u></font>.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As of the Effective Time, the bylaws of the Surviving Corporation shall be amended and restated to conform to the bylaws of Merger Sub as in effect immediately prior to the Effective Time, until thereafter
        changed or amended as provided therein or by applicable Legal Requirements, subject to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.4(a)</u></font>, except that references to the name of Merger Sub shall be replaced by references to the
        name of the Surviving Corporation.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As of the Effective Time, the directors and officers of the Surviving Corporation shall be the respective individuals who served as the directors and officers of Merger Sub as of immediately prior to the
        Effective Time, until their respective successors are duly elected and qualified, or their earlier death, resignation or removal.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">1.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Conversion of Shares</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At the Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Sub, the Company or any stockholder of the Company:</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; any Shares held immediately prior to the Effective Time by the Company (or held in the Company&#8217;s treasury) shall automatically be cancelled and retired and shall cease to exist, and no consideration
        shall be delivered in exchange therefor;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any Shares held immediately prior to the Effective Time by Parent, Merger Sub or any other direct or indirect wholly owned Subsidiary of Parent or Merger Sub shall automatically be cancelled and retired
        and shall cease to exist, and no consideration shall be delivered in exchange therefor;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; any Shares held immediately prior to the Effective Time by any direct or indirect wholly owned Subsidiary of the Company shall be converted into such number of shares of stock of the Surviving
        Corporation such that each such Subsidiary shall own the same percentage of the outstanding capital stock of the Surviving Corporation immediately following the Effective Time as such Subsidiary owned in the Company immediately prior to the
        Effective Time and no other consideration shall be delivered in exchange therefor (such Shares together with the Shares described in the preceding <u>clauses </u><u>(i)</u> and <u>(ii)</u>, the &#8220;<u>Excluded Shares</u>&#8221;);</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; except as provided in <u>clauses </u><u>(i)</u>, <u>(ii)</u> and <u>(iii)</u> above and subject to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.5(b)</u></font>, each Share outstanding
        immediately prior to the Effective Time (other than any Dissenting Shares, which shall have only those rights set forth in <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.7</u></font>) shall be converted into the right to receive Merger
        Consideration, in each case without any interest thereon and subject to any applicable withholding of Taxes in accordance with <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.6(e)</u></font>; and</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;each share of the common stock, $0.001 par value per share, of Merger Sub then outstanding shall be converted into one share of common stock of the Surviving Corporation.</div>
      <div>&#160;</div>
      <div>From and after the Effective Time, subject to this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.5(a)</u></font>, all Shares shall no longer be outstanding and shall automatically be cancelled and shall cease to exist, and each
        applicable holder of such Shares (other than Dissenting Shares) shall cease to have any rights with respect thereto, except the right to receive the Merger Consideration therefor upon the surrender of such Shares in accordance with <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.6</u></font>, or, in the case of Dissenting Shares, the rights set forth in <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.7</u></font>.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">3</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If, between the Agreement Date and the Effective Time, the outstanding Shares are changed into a different number or class of shares by reason of any stock split, division or subdivision of shares, stock
        dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction, then the Merger Consideration shall be appropriately adjusted; <font style="font-style: italic;">provided</font> that nothing
        in this <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>1.5(b)</u></font><u>&#160;</u>shall be construed to permit the Company to take any action that is prohibited by <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>4.2</u></font> or the
        other terms of this Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">1.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Surrender of Certificates; Stock Transfer Books</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior to the Closing Date, Parent shall designate a bank or trust company reasonably acceptable to the Company to act as agent (the &#8220;<u>Paying Agent</u>&#8221;) for the holders of Shares to receive the aggregate
        Merger Consideration to which holders of such Shares shall become entitled pursuant to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.5</u></font>.&#160; On or prior to the Closing Date, Parent shall deposit, or shall cause to be deposited,
        with the Paying Agent cash sufficient to pay the aggregate Merger Consideration payable pursuant to <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>1.5</u></font> and <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>1.8</u></font> (the &#8220;<u>Payment












          Fund</u>&#8221;).&#160; The Payment Fund shall not be used for any purpose other than to pay the aggregate Merger Consideration in the Merger; <font style="font-style: italic;">provided</font> that any interest or other income earned on investment of the
        Payment Fund shall be promptly returned to Parent and treated as earned by Parent for all U.S. federal (and applicable state or local) income tax purposes.&#160; The Payment Fund shall be invested by the Paying Agent as directed by Parent;<font style="font-style: italic;"> provided</font> that such investments shall be (w) in obligations of or guaranteed by the United States of America, (x) in commercial paper obligations rated A-1 or P-1 or better by Moody&#8217;s Investors Service, Inc. or
        Standard &amp; Poor&#8217;s Corporation, respectively, (y) in certificates of deposit, bank repurchase agreements or banker&#8217;s acceptances of commercial banks with capital exceeding $1 billion, or (z) in money market funds having a rating in the highest
        investment category granted by a recognized credit rating agency at the time of acquisition or a combination of the foregoing and, in any such case, no such instrument shall have a maturity exceeding three months.&#160; To the extent Parent becomes
        aware that (i) there are any losses with respect to any such investments, or (ii) the Payment Fund has diminished for any reason below the level required for the Paying Agent to make prompt cash payment pursuant to <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>1.5</u></font>, Parent or the Surviving Corporation shall promptly replace or restore the cash in the Payment Fund so as to ensure that the Payment Fund is, at all times during the duration of the Payment Fund,
        maintained at a level sufficient for the Paying Agent to promptly make such payments pursuant to <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>1.5</u></font>.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">4</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Promptly after the Effective Time (but in no event later than three Business Days thereafter), the Surviving Corporation shall cause to be delivered to each Person who was, at the Effective Time, a holder
        of record of (i) Shares represented by a certificate evidencing such Shares (&#8220;<u>Certificated Shares</u>&#8221;), or (ii) Book-Entry Shares, who, in each case of <u>clauses </u><u>(i)</u> and <u>(ii)</u> was entitled to receive the Merger
        Consideration pursuant to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.5</u></font>, (A)&#160;a form of letter of transmittal, which shall be in reasonable and customary form and shall specify that delivery shall be effected, and risk of
        loss and title to the Certificated Shares shall pass, only upon proper delivery of the stock certificates evidencing such Certificated Shares (the &#8220;<u>Certificates</u>&#8221;) (or affidavits of loss in lieu thereof in accordance with <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.6(f)</u></font>, if applicable) to the Paying Agent, or a customary agent&#8217;s message with respect to Book-Entry Shares, and (B) instructions (including the requirement for each holder of Shares to provide IRS Form
        W-9 or applicable series of IRS Form W-8) for use in effecting the surrender of the Certificates or Book-Entry Shares in exchange for the Merger Consideration payable in respect of such Shares pursuant to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.5</u></font>.&#160; Upon surrender to the Paying Agent of Certificates (or affidavits of loss in lieu thereof in accordance with <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.6(f)</u></font>, if applicable) or Book-Entry
        Shares, together with such letter of transmittal in the case of Certificates, duly completed and validly executed in accordance with the instructions thereto, and such other documents as may be required pursuant to the instructions, the holder of
        such Certificated Shares or Book-Entry Shares shall be entitled to receive in exchange therefor the Merger Consideration for each Certificated Share or Book-Entry Share, and such Certificates and Book-Entry Shares shall then be cancelled.&#160; No
        interest shall accrue or be paid on the Merger Consideration payable upon the surrender of any Certificates or Book-Entry Shares for the benefit of the holder thereof.&#160; If the payment of any Merger Consideration is to be made to a Person other than
        the Person in whose name the surrendered Certificates formerly evidencing the Certificated Shares is registered on the stock transfer books of the Company, it shall be a condition of payment that the Certificate so surrendered shall be endorsed
        properly or otherwise be in proper form for transfer and that the Person requesting such payment shall have paid all Transfer Taxes required by reason of the payment of the Merger Consideration to a Person other than the registered holder of the
        Certificate surrendered, or shall have established to the reasonable satisfaction of Parent that such Transfer Taxes either have been paid or are not applicable.&#160; None of Parent, Merger Sub or the Surviving Corporation shall have any liability for
        the Transfer Taxes described in the immediately preceding sentence.&#160; Payment of the applicable Merger Consideration with respect to Book-Entry Shares shall only be made to the Person in whose name such Book-Entry Shares are registered.&#160; Until
        surrendered as contemplated by this <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>1.6</u></font>, each Certificated Share and Book-Entry Share (in each case, other than Dissenting Shares) shall be deemed at any time after the Effective Time
        to represent only the right to receive the Merger Consideration as contemplated by <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>1.5</u></font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At any time following 12 months after the Effective Time, Parent shall be entitled to require the Paying Agent to deliver to it any funds (with respect to the aggregate Merger Consideration to which
        holders of Shares shall become entitled pursuant to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.5</u></font>) which had been made available to the Paying Agent and not disbursed to holders of Certificated Shares or Book-Entry Shares in
        accordance with this <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>1.6</u></font> (including all interest and other income received by the Paying Agent in respect of all funds made available to it), and, thereafter, such holders shall be
        entitled to look to the Surviving Corporation (subject to abandoned property, escheat and other similar Legal Requirements) only as general creditors thereof with respect to the Merger Consideration that may be payable upon due surrender of the
        Certificates or Book-Entry Shares held by them, without any interest thereon.&#160; Notwithstanding the foregoing, neither the Surviving Corporation nor the Paying Agent shall be liable to any holder of Certificated Shares or Book-Entry Shares for the
        Merger Consideration delivered in respect of such Share to a public official pursuant to any abandoned property, escheat or other similar Legal Requirements.&#160; Any amounts remaining unclaimed by such holders at such time at which such amounts would
        otherwise escheat to or become property of any Governmental Body shall become, to the extent permitted by applicable Legal Requirements, the property of the Surviving Corporation or its designee, free and clear of all claims or interest of any
        Person previously entitled thereto.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">5</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At the close of business on the day of the Effective Time, the stock transfer books of the Company with respect to the Shares shall be closed and thereafter there shall be no further registration of
        transfers of Shares on the records of the Company.&#160; From and after the Effective Time, the holders of the Shares outstanding immediately prior to the Effective Time shall cease to have any rights with respect to such Shares except as otherwise
        provided herein or by applicable Legal Requirements.&#160; If, after the Effective Time, Certificates or Book-Entry Shares are presented to the Surviving Corporation for any reason, they shall be cancelled and exchanged as provided in this Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each of the Company, the Surviving Corporation, Parent, Merger Sub, the Paying Agent and their Affiliates, shall be entitled to deduct and withhold (or cause the Paying Agent to deduct and withhold) from
        the Merger Consideration payable to any holder of the Shares or any holder of Company Options, Company PSUs, Company RSUs or any other consideration otherwise payable pursuant to this Agreement such amounts as it is required by any Legal
        Requirement to deduct and withhold with respect to Taxes.&#160; Each such withholding agent shall use commercially reasonable efforts to reduce or eliminate any such withholding and shall request any necessary Tax forms, including IRS Form W-9 or the
        appropriate series of IRS Form W-8, as applicable, or any similar information.&#160; Each such withholding agent shall use reasonable best efforts to take all action that may be necessary to ensure that any such amounts so withheld are properly remitted
        to the appropriate Governmental Body in accordance with applicable Tax Legal Requirements.&#160; To the extent that amounts are so withheld and properly remitted to the appropriate Governmental Body in accordance with applicable Tax Legal Requirements,
        such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the holder of the Shares, holder of Company Options, Company PSUs, Company RSUs or other recipient of consideration hereunder in respect of which such
        deduction and withholding was made.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the holder of the Certificated Shares formerly represented by that Certificate, or by a
        representative of that holder, claiming that Certificate to be lost, stolen or destroyed and, if required by the Surviving Corporation, the posting by that holder of a bond, in such reasonable amount as Parent may direct, as indemnity against any
        claim that may be made against it with respect to such Certificate (which amount shall not exceed the Merger Consideration payable with respect to such Certificated Shares), the Paying Agent will pay (less any amounts entitled to be deducted or
        withheld pursuant to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.6(e)</u></font>), in exchange for such lost, stolen or destroyed Certificate, the applicable Merger Consideration to be paid in respect of the Certificated Shares
        formerly represented by such Certificate, as contemplated by this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.6</u></font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as otherwise provided in <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.6(b)</u></font>, Transfer Taxes and fees imposed with respect to the transactions contemplated by this Agreement
        shall be borne by the Company or Parent and expressly shall not be a liability of holders of Shares or any holder of Company Options or Company RSUs.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">6</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">1.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Dissenters&#8217; Rights</font>.&#160; Notwithstanding anything to the contrary in this Agreement, any Shares outstanding immediately prior to
        the Effective Time which are held by holders who are entitled to appraisal rights under Section 262 of the DGCL and have properly exercised and perfected their respective demands for appraisal of such Shares in the time and manner provided in
        Section 262 of the DGCL and, as of the Effective Time, have neither effectively withdrawn nor lost their rights to such appraisal and payment under the DGCL (the &#8220;<u>Dissenting Shares</u>&#8221;), shall not be converted into the right to receive the
        Merger Consideration, but shall, by virtue of the Merger, be automatically cancelled and no longer outstanding, shall cease to exist and shall be entitled to only such consideration as shall be determined pursuant to Section 262 of the DGCL; <font style="font-style: italic;">provided </font>that if any such holder shall have failed to perfect or shall have effectively withdrawn or lost such holder&#8217;s right to appraisal and payment under the DGCL, such holder&#8217;s Shares shall be deemed to
        have been converted as of the Effective Time into the right to receive the Merger Consideration (less any amounts entitled to be deducted or withheld pursuant to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.6(e)</u></font>), and such
        Shares shall no longer be deemed to be Dissenting Shares.&#160; The Company shall give prompt notice to Parent and Merger Sub of any demands received by the Company for appraisal of any Dissenting Shares, withdrawals of such demands and any other
        instruments served pursuant to Section 262 of the DGCL, in each case prior to the Effective Time.&#160; Parent and Merger Sub shall have the right to direct and participate in all negotiations and proceedings with respect to such demands, and the
        Company shall not, without the prior written consent of Parent and Merger Sub, settle or offer to settle, or make any payment with respect to, any such demands, approve any withdrawal of any such demands, waive any failure of any holder of such
        Shares to timely deliver a written demand for appraisal or agree or commit to do any of the foregoing.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">1.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Treatment of Company Equity Awards</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At the Effective Time, (i) each Company Option that is then outstanding and unexercised, whether or not vested, and which has a per share exercise price that is less than the Merger Consideration (each, an
        &#8220;<u>In the Money Option</u>&#8221;) shall be cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess of (x) the Merger Consideration over (y) the exercise price payable per Share under such In the Money
        Option, <font style="font-style: italic;">multiplied by</font> (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting), and (ii) each Company Option other than an In
        the Money Option that is then outstanding and unexercised, whether or not vested, shall be cancelled with no consideration payable in respect thereof.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At the Effective Time, each then outstanding Company RSU shall, automatically and without any required action on the part of the Company, Parent or holder thereof, be canceled and the holder thereof shall
        be entitled to receive a cash payment equal to the product of (i) the Merger Consideration <font style="font-style: italic;">multiplied by</font> (ii) the number of Shares subject to such Company RSU.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">7</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At the Effective Time, each Company PSU, whether vested or unvested, that is outstanding as of immediately prior to the Effective Time shall, automatically and without any required action on the part of
        the Company, Parent or holder thereof, be cancelled and the holder thereof shall be entitled to receive a cash payment equal to the product of (rounded down to the nearest whole number) (i) the number of Shares subject to such Company PSU
        immediately prior to the Effective Time (determined at the level of performance set forth in Section 1.8(c) of the Company Disclosure Schedule), without any pro-ration, as of immediately prior to the Effective Time multiplied by (ii) an amount
        equal to the Merger Consideration.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As soon as reasonably practicable after the Effective Time (but no later than the second payroll date after the Effective Time), the Surviving Corporation or its Affiliate, as applicable, shall pay the
        aggregate consideration payable pursuant to <u>Section </u><u>1.8</u> to holders of Company RSUs, Company PSUs and Company Options that were not granted in connection with the optionholder&#8217;s service as a non-employee member of the Board of
        Directors net of any applicable withholding Taxes, as applicable.&#160; As soon as reasonably practicable after the Effective Time (but no later than the second payroll date after the Effective Time), the Surviving Corporation or its Affiliate, as
        applicable, shall pay the aggregate consideration payable to holders of Company Options and Company RSUs that were granted in connection with the holder&#8217;s service as a non-employee member of the Board of Directors pursuant to <u>Section </u><u>1.8(b)</u>
        via the Surviving Corporation&#8217;s or its Affiliate&#8217;s accounts payable net of any applicable withholding Taxes, as applicable.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior to the Effective Time, the Company shall take all actions necessary (under the Company Equity Plans and award agreements pursuant to which Company Options, Company RSUs and Company PSUs are
        outstanding or otherwise) to effect the transactions described in this <u>Section&#160;</u><u>1.8</u>, including in order to comply with the provisions of the Company Equity Plans, such that immediately following the Effective Time there are no
        obligations of the Acquired Companies, Parent, Merger Sub or their Affiliates in respect of Company Options, Company RSUs and Company PSUs, except as set forth in this <u>Section&#160;</u><u>1.8</u>. All Company Options, Company RSUs and Company PSUs
        shall terminate as of the Effective Time, and following the Effective Time, no holder of any Company Options, Company RSUs and Company PSUs will have any right to acquire any equity securities of the Company or the Surviving Corporation as a result
        of such holder&#8217;s Company Options, Company RSUs and Company PSUs.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the extent any payment made pursuant to this <u>Section&#160;</u><u>1.8</u> would trigger a Tax or penalty under Section 409A of the Code, such payment shall be made on the earliest date after the Effective
        Time that payment would not trigger such Tax or penalty or be structured in such a way as to comply with Section 409A of the Code.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">1.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Further Action</font>.&#160; The Parties agree to take all necessary action to cause the Merger to become effective in accordance with
        Section 251(c) of the DGCL and this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.9</u></font> as soon as practicable following the satisfaction or, to the extent permitted by applicable Legal Requirements, waiver of the last of the
        conditions set forth in <u>Section </u><u>6</u> (other than conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted by applicable Legal Requirements, waiver of such
        conditions).&#160; If, at any time after the Effective Time, any further action is reasonably determined by Parent to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation with full right, title and
        possession of and to all rights and property of Merger Sub and the Company, the officers and directors of the Surviving Corporation and Parent shall be fully authorized (in the name of Merger Sub, in the name of the Company and otherwise) to take
        such action.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">8</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SECTION 2<br>
        <br>
        <u>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</u></div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">The Company hereby represents and warrants to Parent and Merger Sub as follows, it being understood that each representation and warranty contained in this <u>Section </u><u>2</u> is subject to (a)&#160;exceptions and
        disclosures set forth in the section or subsection of <u>Section </u><u>2</u> of the Company Disclosure Schedule corresponding to the particular section or subsection in this <u>Section </u><u>2</u>, (b)&#160;any exception or disclosure set forth in
        any other section or subsection of <u>Section </u><u>2</u> of the Company Disclosure Schedule to the extent it is reasonably apparent on the face of such exception or disclosure that such exception or disclosure is applicable to qualify such
        section or subsection, and (c) disclosure in the Company SEC Documents filed on or after February 19, 2025 and publicly available prior to the close of business on the second Business Day preceding the Agreement Date (other than any information in
        the &#8220;Risk Factors&#8221; or &#8220;Forward-Looking Statements&#8221; sections of such Company SEC Documents or other general cautionary, predictive or forward-looking statements in any other sections of such Company SEC Documents); <font style="font-style: italic;">provided</font>
        that (x)&#160;<u>clauses&#160;(b)</u> and <u>(c)</u> of this paragraph shall not apply to the representation and warranty set forth in <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>2.5(b)</u></font> (No Material Adverse Effect), and (y)&#160;<u>clause&#160;(c)</u>
        of this paragraph shall not apply to any of the representations and warranties set forth in <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>2.1</u></font> (Due Organization; Subsidiaries, Etc.), <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>2.2</u></font> (Certificate of Incorporation and Bylaws), <u>Section&#160;</u><font style="color: rgb(0, 0, 0);">2.3</font> (Capitalization, Etc.), <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>2.20</u></font> (Authority; Binding
        Nature of Agreement), <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>2.21</u></font> (Takeover Laws), <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>2.22</u></font> (Non-Contravention; Consents), <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>2.23</u></font> (Opinion of Financial Advisors) or <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>2.24</u></font> (Brokers and Other Advisors):</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Due Organization; Subsidiaries, Etc</font>.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, and the Company&#8217;s only Subsidiaries are set forth on <u>Section












        </u><font style="color: rgb(0, 0, 0);"><u>2.1</u></font> of the Company Disclosure Schedule (the Company and each such Subsidiary, an &#8220;<u>Acquired Company</u>&#8221; and collectively, the &#8220;<u>Acquired Companies</u>&#8221;).&#160; Each of the Company&#8217;s Subsidiaries
        is duly organized and validly existing under the Legal Requirements of the jurisdiction of its organization.&#160; Each Acquired Company has all necessary power and authority (i)&#160;to conduct its business in the manner in which its business is currently
        being conducted, and (ii)&#160;to own and use its assets in the manner in which its assets are currently owned and used.&#160; Each Acquired Company is qualified or licensed to do business as a foreign corporation, and is in good standing, in each
        jurisdiction where the nature of its business requires such qualification or licensing, except where such failure does not have, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.&#160; Each of the
        Company&#8217;s Subsidiaries is in good standing (where such concept is recognized under applicable Legal Requirements) under the Legal Requirements of the jurisdiction of its organization.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">9</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company owns beneficially and of record all of the outstanding shares of capital stock or ordinary shares of the other Acquired Companies, free and clear of all Encumbrances and transfer restrictions,
        except for Encumbrances or transfer restrictions of general applicability as may be provided under the Securities Act or applicable securities laws.&#160; Except for the shares of capital stock or ordinary shares of the other Acquired Companies held by
        the Company, no Acquired Company owns, directly or indirectly, any capital stock or equity interests of any nature in, or subscriptions, options, calls, warrants or rights (whether or not currently exercisable) to acquire, or other securities
        convertible into or exchangeable or exercisable for, any capital stock or equity interests of, any Entity.&#160; None of the Acquired Companies has agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make,
        any future investment in or capital contribution to any other Entity (other than another directly or indirectly wholly owned Acquired Company).</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Certificate of Incorporation and Bylaws</font>.&#160; The Company has delivered or made available to Parent accurate and complete copies
        of the certificate of incorporation, bylaws and other charter and organizational documents of each Acquired Company, including all amendments thereto, as in effect on the Agreement Date.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Capitalization, Etc</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The authorized capital stock of the Company consists of (i)&#160;500,000,000 Shares, of which 309,309,349 Shares had been issued and were outstanding and 7,390 Shares were held in the Company&#8217;s treasury, in
        each case, as of the close of business on December 17, 2025 (the &#8220;<u>Capitalization Date</u>&#8221;), and (ii)&#160;10,000,000 shares of Company Preferred Stock, of which no shares are outstanding on the Capitalization Date.&#160; All of the outstanding shares of
        the capital stock of the Company have been duly authorized and validly issued, and are fully paid and nonassessable.&#160; In the period between the Capitalization Date and the execution and delivery of this Agreement, the Company has not issued any new
        Shares except pursuant to the exercise of Company Options or the settlement of Company RSUs or Company PSUs in accordance with their terms, in each case outstanding as of the Capitalization Date and, since the Capitalization Date, the Company has
        not issued any Company Options, Company RSUs, Company PSUs or other equity based awards.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All of the outstanding shares of the capital stock or ordinary shares, as applicable, of the Company&#8217;s Subsidiaries have been duly authorized and validly issued, and are fully paid and nonassessable.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;None of the outstanding shares of capital stock of the Acquired Companies are entitled or subject to any preemptive right, right of repurchase or forfeiture, right of participation, right of
        maintenance or any similar right, (ii)&#160;none of the outstanding shares of capital stock of the Acquired Companies are subject to any right of first refusal in favor of any Acquired Company, (iii)&#160;there are no outstanding bonds, debentures, notes or
        other Indebtedness of any Acquired Company having a right to vote on any matters on which the stockholders of the Acquired Companies have a right to vote, and (iv)&#160;there is no Contract relating to the voting or registration of, or restricting any
        Person from purchasing, selling, pledging or otherwise disposing of (or from granting any option or similar right with respect to), any shares of capital stock of the Acquired Companies.&#160; No Acquired Company is under any obligation, or bound by any
        Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of capital stock of the Acquired Companies.&#160; The Shares constitute the only outstanding class of securities of the Company
        registered under the Securities Act.&#160; There are no voting trusts or other Contracts with respect to the voting of any Shares.&#160; All outstanding Shares have been offered and issued in compliance in all material respects with all applicable securities
        Legal Requirements, including the Securities Act and &#8220;blue sky&#8221; Legal Requirements.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">10</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As of the close of business on the Capitalization Date, (i) 27,612,945 Shares were subject to issuance pursuant to Company Options granted and outstanding under the Company Equity Plans, such outstanding
        Company Options having a weighted average exercise price of $11.62 per share as of the Capitalization Date, (ii) 9,512,096 Shares were subject to issuance pursuant to Company RSUs and 5,913,820 Shares were subject to issuance pursuant to Company
        PSUs (determined at the maximum level of performance), in each case, granted and outstanding under the Company Equity Plans, and (iii) 14,958,781 Shares were available for future awards under Company Equity Plans.&#160; Other than as set forth in this <u>Section












        </u><font style="color: rgb(0, 0, 0);"><u>2.3(d)</u></font>, there are no issued, reserved for issuance, outstanding or authorized stock option, stock appreciation, phantom stock, stock unit, restricted stock unit, stock based performance unit,
        profit participation or similar rights or equity-based awards with respect to the Company.&#160; None of the Subsidiaries of the Company holds any equity interest in the Company.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each outstanding Company Option has an exercise price equal to or above the fair market value of a Share as of the date of grant (within the meaning of Section 409A of the Code).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There are no issued, reserved for issuance, outstanding or authorized stock option, stock appreciation, phantom stock, stock unit, profit participation or similar rights or equity-based awards with respect
        to any Subsidiary of the Company.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except (y) as set forth in this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>2.3</u></font>, and (z) for Company Options, Company RSUs and Company PSUs outstanding as of the Agreement Date, there
        are no (i)&#160;outstanding shares of capital stock of or other securities of any Acquired Company, (ii)&#160;outstanding subscriptions, options, calls, equity or equity-based compensation awards, phantom socks, stock appreciations, profit participations or
        other equity or equity based interests, warrants or rights (whether or not currently exercisable) to acquire, or the value of which is measured by reference to, any shares of the capital stock, restricted stock unit, stock-based performance unit or
        any other right that is linked to, or the value of which is in any way based on or derived from the value of any shares of capital stock or other securities of any Acquired Company, in each case other than derivative securities not issued by an
        Acquired Company, (iii)&#160;outstanding securities, instruments, bonds, debentures, notes or obligations that are or may become convertible into or exchangeable for any shares of the capital stock or other securities of any Acquired Company, or
        (iv)&#160;stockholder rights plans (or similar plans commonly referred to as a &#8220;poison pill&#8221;) or Contracts under which any Acquired Company is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">11</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Section&#160;</u><u>2.3(h)</u> of the Company Disclosure Schedule sets forth a listing of all Persons who hold outstanding Company Options, Company RSUs, and Company PSUs as of the Capitalization Date,
        indicating, with respect to each Company Option, Company RSU, and Company PSU, the number of Shares subject thereto (including for Company PSUs, the number of Shares subject thereto at the level of actual performance attained as of the
        Capitalization Date at the target level of performance and at the maximum level of performance), the date of grant, the vesting schedule (including whether the terms of such award provide that its vesting will accelerate upon the Merger), the per
        Share exercise price (if applicable), the expiration date and, with respect to Company Options, whether such Company Option is intended to be an incentive stock option (within the meaning of Section 422 of the Code).&#160; All Company Options, Company
        RSUs, and Company PSUs are evidenced by agreements in the forms that have been provided to Parent.&#160; No offering period has commenced with respect to the Company ESPP.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">SEC Filings; Financial Statements</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Since January 1, 2023 (the &#8220;<u>Applicable Date</u>&#8221;), the Company has filed or furnished on a timely basis all reports, schedules, forms, statements and other documents (including exhibits and all other
        information incorporated therein) required to be filed or furnished by the Company with the SEC (as supplemented, modified or amended since the time of filing, the &#8220;<u>Company SEC Documents</u>&#8221;).&#160; As of their respective dates, or, if amended prior
        to the Agreement Date, as of the date of (and giving effect to) the last such amendment (and, in the case of registration statements and proxy statements, on the date of effectiveness and the dates of the relevant meetings, respectively), the
        Company SEC Documents complied in all material respects with the requirements of the Securities Act, the Exchange Act or the Sarbanes-Oxley Act of 2002 (the &#8220;<u>Sarbanes-Oxley Act</u>&#8221;), as the case may be, and the rules and regulations of the SEC
        promulgated thereunder applicable to those Company SEC Documents, and, except to the extent that information contained in such Company SEC Document has been revised, amended, modified or superseded (prior to the Agreement Date) by a later filed
        Company SEC Document, none of the Company SEC Documents when filed or furnished contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
        therein, in light of the circumstances under which they were made, not misleading.&#160; No executive officer of the Company has failed to make the certifications required of him or her under Section 302 or 906 of the Sarbanes-Oxley Act with respect to
        any Company SEC Documents.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The financial statements (including any related notes and schedules) contained or incorporated by reference in the Company SEC Documents (i)&#160;complied as to form in all material respects with the published
        rules and regulations of the SEC applicable thereto, (ii)&#160;were prepared in accordance with United States generally accepted accounting principles (&#8220;<u>GAAP</u>&#8221;) applied on a consistent basis throughout the periods covered (except as may be
        indicated in the notes to such financial statements or, in the case of unaudited interim financial statements, as may be permitted by the SEC on Form 10-Q, Form 8-K or any successor form under the Exchange Act), and (iii)&#160;fairly presented, in all
        material respects, the financial position of the Company as of the respective dates thereof and the results of operations and cash flows of the Company for the periods covered thereby (subject, in the case of the unaudited financial statements, to
        the absence of notes and to normal and recurring year-end adjustments that are not individually or in the aggregate material).</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">12</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company maintains, and at all times since the Applicable Date has maintained, a system of internal control over financial reporting (as defined in Rule 13a-15 under the Exchange Act) which is designed
        to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, and includes those policies and procedures that (i) pertain to the
        maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of
        financial statements in conformity with GAAP and that receipts and expenditures are being made only in accordance with authorizations of management and the Board of Directors, and (iii) provide reasonable assurance regarding prevention or timely
        detection of unauthorized acquisition, use or disposition of the assets of the Company that could have a material effect on the financial statements.&#160; The Company&#8217;s management has completed an assessment of the effectiveness of the Company&#8217;s system
        of internal control over financial reporting in compliance with the requirements of Section 404 of the Sarbanes-Oxley Act for the fiscal year ended December 31, 2024, and, except as set forth in the Company SEC Documents filed prior to the
        Agreement Date, that assessment concluded that those controls were effective.&#160; To the knowledge of the Company, since January 1, 2025, neither the Company nor the Company&#8217;s independent registered accountant has identified or been made aware of (A)
        any significant deficiency or material weakness in the design or operation of the internal control over financial reporting utilized by the Company, (B) any illegal act or fraud, whether or not material, that involves the management or other
        employees of the Company, or (C) any claim or allegation regarding any of the foregoing.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company maintains, and at all times since the Applicable Date has maintained, disclosure controls and procedures as defined in and required by Rule 13a-15 or 15d-15 under the Exchange Act that are
        reasonably designed to ensure that all information required to be disclosed in the Company&#8217;s reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and
        forms of the SEC and that all such information is accumulated and communicated to the Company&#8217;s management as appropriate to allow timely decisions regarding required disclosure and to enable the principal executive officer of the Company and the
        principal financial officer of the Company to make the certifications required under the Exchange Act with respect to such reports.&#160; The Company is, and at all times since the Applicable Date has been, in compliance in all material respects with
        all current listing and corporate governance requirements of Nasdaq and has not received any notice of non-compliance from Nasdaq since the Applicable Date.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Since January 1, 2025, (i) no Acquired Company has received any material written complaint, allegation, assertion or claim regarding the accounting or auditing practices, procedures, methodologies or
        methods of any of the Acquired Companies or their respective internal accounting controls, including any credible complaint, allegation, assertion or claim that any of the Acquired Companies has engaged in questionable accounting or auditing
        practices, and (ii) no attorney representing any of the Acquired Companies (whether or not employed by any Acquired Company) has reported evidence of a material violation of the applicable Legal Requirements, breach of fiduciary duty or similar
        violation by any of the Acquired Companies or their respective officers, directors, employees or agents to the Board of Directors or any committee thereof or to any director or officer of the Acquired Companies pursuant to the rules of the SEC
        adopted under Section 307 of the Sarbanes-Oxley Act.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">13</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of the Acquired Companies is a party to, nor does any Acquired Company have any obligation or other commitment to become a party to, &#8220;off-balance sheet arrangements&#8221; (as defined in Item 303(a) of
        Regulation S-K under the Exchange Act) where the result, purpose or intended effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, such Acquired Company in the Company SEC Documents.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As of the Agreement Date, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to the Company SEC Documents.&#160; None of the Company SEC Documents is the
        subject of ongoing SEC review and there are no inquiries or investigations by the SEC or any internal investigations pending or threatened, in each case regarding any accounting practices of the Company.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each document required to be filed by the Company with the SEC in connection with the Transactions, including a proxy statement in preliminary form related to the Company Stockholder Meeting (together with
        any supplements or amendments thereto, the &#8220;<u>Merger Proxy Statement</u>&#8221;), when filed, distributed or otherwise disseminated to the Company&#8217;s stockholders, as applicable, will comply as to form in all material respects with the applicable
        requirements of the Exchange Act.&#160; The Merger Proxy Statement, at the time of filing of such Merger Proxy Statement or any supplement or amendment thereto with the SEC and at the time such Merger Proxy Statement or any supplements or amendments
        thereto are first distributed or otherwise disseminated to the Company&#8217;s stockholders, will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the
        statements made therein, in light of the circumstances under which they were made, not misleading.&#160; The Company makes no representation with respect to statements made or incorporated by reference therein based on information supplied by or on
        behalf of Parent or Merger Sub for inclusion or incorporation by reference in the Merger Proxy Statement.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Absence of Changes; No Material Adverse Effect</font>.&#160; Except as expressly contemplated by this Agreement, from January 1, 2025
        through the Agreement Date:</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;except for discussions, negotiations and activities related to this Agreement or other potential strategic transactions, the Acquired Companies have operated in all material respects in the ordinary course
        of business;</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;there has not occurred a Material Adverse Effect; and</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;there has not been any action taken by any of the Acquired Companies that, if taken during the Pre-Closing Period without Parent&#8217;s prior written consent, would require Parent&#8217;s consent pursuant to <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>4.2</u></font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Title to Assets</font>.&#160; Each Acquired Company has good and valid title to all assets (excluding Intellectual Property Rights) owned
        or purported to be owned by it as of the Agreement Date and necessary for the conduct of the Acquired Companies&#8217; business, taken as a whole, and such assets are owned by the Acquired Companies free and clear of any Encumbrances (other than
        Permitted Encumbrances).</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">14</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Real Property</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Acquired Companies do not own and have not owned any real property.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 2.7(b) of the Company Disclosure Schedule sets forth a complete and accurate list in all material respects of all real property currently leased, subleased or licensed by or from the Acquired
        Companies or otherwise used or occupied by the Acquired Companies.&#160; The Acquired Companies hold valid and existing leasehold interests in the real property that is leased or subleased by the Acquired Companies from another Person (the &#8220;<u>Leased
          Real Property</u>&#8221;), free and clear of all Encumbrances other than Permitted Encumbrances.&#160; Since the Applicable Date, no Acquired Company has received any notice regarding (i) any material violation or breach or default under any lease related
        to the Leased Real Property that has not since been cured, (ii) pending or threatened condemnation of any portion of the Leased Real Property, or (iii) building, fire or zoning code violations with respect to the Leased Real Property.&#160; None of the
        Leased Real Property is subleased.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Intellectual Property</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 2.8(a) of the Company Disclosure Schedule sets forth an accurate and complete list that identifies the following for each item of material Company IP that is Registered IP as applicable:&#160; (i)&#160;the
        title or mark, (ii) the name of the current owner or co-owners, (iii)&#160;the jurisdiction of application or registration, and (iv)&#160;the application, Patent or registration number.&#160; All such Registered IP is subsisting and, to the knowledge of the
        Company, other than pending applications therefor, valid and enforceable.&#160; Section <font style="color: rgb(0, 0, 0);">2.8(a)</font> of the Company Disclosure Schedule sets forth an accurate and complete list of all Domain Names for which any
        Acquired Company is the registrant or holder.&#160; As of the Agreement Date, no interference, opposition, reissue, reexamination proceeding, cancellation proceeding or other Legal Proceeding (other than routine examination proceedings with respect to
        pending applications) is pending, threatened in writing or, to the knowledge of the Company, otherwise threatened against any Acquired Company, in which the scope, validity, enforceability, priority, inventorship or ownership of any Company IP is
        being contested or challenged.&#160; All application, registration, issuance, renewal and maintenance fees due for such Company IP that is Registered IP having a final due date on or before the Agreement Date have been paid in full and are current.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Acquired Companies are the sole and exclusive owners of all right, title and interest in and to all Company IP owned or purported to be owned by the Acquired Companies, free and clear of all
        Encumbrances, other than Permitted Encumbrances, and have the right, pursuant to valid and enforceable agreements, to use all other material Intellectual Property Rights necessary for, used in or held for use by the Acquired Companies&#8217; business.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">15</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Company Associate owns or has any valid claim, right (whether or not currently exercisable) or interest in or to, and no other third party owns or has an exclusive right in or to, any material Company
        IP owned or purported to be owned by an Acquired Company and each Company Associate or any third party who is or was involved in the invention, creation, authorship or development of any material Intellectual Property Rights for or on behalf of an
        Acquired Company has signed a valid and enforceable written agreement (i) containing a present-tense assignment to an Acquired Company of all such Intellectual Property Rights for all such Persons in the United States, (ii) or containing a valid
        assignment to an Acquired Company of all such Intellectual Property Rights to the extent required under applicable Legal Requirements for all such Persons outside the United States, and (iii) in each case of the foregoing <u>clauses (i)</u> and <u>(ii)</u>,
        including reasonable non-use and non-disclosure obligations with respect to any Company IP, including Trade Secrets, and there is no material breach under any such agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No funding, facilities, Intellectual Property Rights or personnel or other resources of any Governmental Body or any university, college, research institute or other educational institution is being or has
        been used to create, in whole or in part, material Company IP owned or purported to be owned by the Acquired Companies or, to the knowledge of the Company, any other Company IP, except for any such funding or use of facilities or personnel that
        does not result in such Governmental Body or institution obtaining ownership or any other rights, title or interest in or to such Intellectual Property Rights, or the right to receive royalties for the practice of such Intellectual Property Rights
        (whether on a present or contingent basis).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Acquired Companies have taken reasonable steps, including reasonable security measures and other steps, to maintain the confidentiality of and otherwise protect and enforce their rights in all
        information that is a trade secret under applicable Legal Requirements and all other material Trade Secrets held by an Acquired Company in all material respects.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section&#160;2.8(f) of the Company Disclosure Schedule sets forth each license agreement pursuant to which an Acquired Company has obtained a license to, or has been granted a covenant not to sue under,
        immunity from suit with respect to or other equivalent rights to, any Intellectual Property Right (each an &#8220;<u>In-bound License</u>&#8221;) or has granted a license or covenant not to sue, immunity from suit or other equivalent right to any Intellectual
        Property Right owned or purported to be owned by, or licensed to, an Acquired Company (each an &#8220;<u>Out-bound License</u>&#8221;); <font style="font-style: italic;">provided</font> that (i) In-bound Licenses shall not include commercially available
        off-the-shelf software having an annual or one-time fee of less than $200,000, clinical trial agreements that are consistent in all material respects with the form clinical trial agreement used by the Acquired Companies in the United States (the
        form of which has been made available to Parent), or on a jurisdiction-specific form clinical trial agreement for activities outside the United States, non-disclosure agreements that are consistent in all material respects with the form
        non-disclosure agreement used by the Acquired Companies, non-exclusive licenses to an Acquired Company in employee, contractor, or similar agreements, material transfer agreements that are not material, or non-exclusive licenses ancillary to the
        primary purpose of the Contract, in each case, entered into in the ordinary course of business, and (ii) Out-bound Licenses shall not include non-exclusive outbound licenses contained in contractor agreements, vendor or service provider agreements,
        clinical trial agreements, contract manufacturing agreements, contract research organization agreements, non-disclosure agreements or material transfer agreements, in each case, entered into in the ordinary course of business, or non-exclusive
        licenses ancillary to the primary purpose of the Contract, in each case entered into in the ordinary course of business.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">16</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the knowledge of the Company, the operation of the Acquired Companies&#8217; businesses as currently conducted and presently contemplated to be conducted by the Acquired Companies with respect to the
        presently contemplated commercialization of their Products does not infringe, misappropriate or otherwise violate and has not since the Applicable Date, infringed, misappropriated or otherwise violated, any Intellectual Property Rights owned by any
        other Person.&#160; As of the Agreement Date, (i) no Legal Proceeding is pending or, to the knowledge of the Company, is being threatened, including cease and desist letters or offers to take a license, against an Acquired Company relating to any
        actual, alleged or suspected infringement, misappropriation or other violation of any Intellectual Property Rights of another Person, and (ii) since the Applicable Date, no Acquired Company has received any written notice or other written
        communication claiming any actual, alleged or suspected infringement, misappropriation or other violation of any Intellectual Property Right of another Person by an Acquired Company (including invitations to license).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the knowledge of the Company, no Person is infringing, misappropriating or otherwise violating, or has infringed, misappropriated or otherwise violated, any Company IP.&#160; No Legal Proceeding is, or has
        been, pending or threatened in writing since the Applicable Date by an Acquired Company relating to any actual, alleged or suspected infringement, misappropriation or other violation of any Company IP.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; None of the Company IP owned by an Acquired Company, or, to the knowledge of the Company, any other Company IP, is subject to any pending or outstanding injunction, directive, order, judgment, settlement,
        consent ruling or other disposition of dispute that adversely restricts the use, transfer or licensing of any Company IP by an Acquired Company or otherwise adversely affects the validity, scope, use, registrability or enforceability of any Company
        IP.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The consummation of the Transactions will not result in the loss or impairment of, alteration in, forfeiture of, termination of or payment of any additional amounts with respect to any Company IP.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as would not be, or would not reasonably be expected to be, individually or in the aggregate, material to the Acquired Companies taken as a whole, (i) the Company IT Assets operate in accordance
        with their specifications and related documentation and perform in a manner that permits the Acquired Companies to conduct its business as currently conducted, and (ii) the Company has taken commercially reasonable actions, consistent with current
        industry standards, to protect the confidentiality, integrity and security of the Company IT Assets (and all data and other information and transactions stored or contained therein or processed or transmitted thereby) against any unauthorized use,
        access, interruption, modification or corruption, including the implementation of commercially reasonable data backup, incident response and recovery procedures and business continuity procedures.&#160; Since the Applicable Date, there has been no
        material unauthorized or unlawful access to, or interruption, modification, loss, Processing or corruption of any Company IT Assets (or any data or other information stored or contained therein or processed or transmitted thereby), and the Acquired
        Companies have no reason to reasonably suspect that any such breach or incident has occurred.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">17</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; Except as set forth on Section 2.8(l) of the Company Disclosure Schedule, the Acquired Companies are the sole owner of all material data arising from any non-clinical trial and any Clinical Trial, in each
        case performed by or on behalf of an Acquired Company and relating to the Products.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Acquired Companies have established and implemented organizational, physical, administrative and technical measures regarding privacy, cybersecurity and data security that are commercially reasonable
        and compliant in all material respects with all (i)&#160;Data Privacy Laws, (ii) binding industry standards including the Payment Card Industry Data Security Standard (as applicable), (iii) internal and/or publicly available written privacy and security
        policies, commitments and notices of the Company relating to Personal Information, and (iv) applicable portions of Contract obligations of the Acquired Companies relating to the collection, Processing, disclosure and storage of Personal
        Information, and (v) consents and authorizations pursuant to which Personal Information was disclosed to the Acquired Companies (the foregoing <u>clauses&#160;(i)</u> through <u>(iv)</u>, collectively, the &#8220;<u>Privacy and Security Requirements</u>&#8221;).&#160;
        The Acquired Companies are, and since the Applicable Date have been, in all material respects, in compliance with and not in material default under, or in material violation of, any applicable Privacy and Security Requirements.&#160; Except as would not
        be material to the Company, the Acquired Companies have contractually obligated all Persons who Process Personal Information on their behalf to maintain safeguards substantially similar to those implemented by the Acquired Companies and comply with
        Privacy and Security Requirements, as applicable and as required by Data Privacy Laws. Since the Applicable Date, no Acquired Company has been given written notice of, or been charged in writing with, any material violation of any applicable
        Privacy and Security Requirement.&#160; Since the Applicable Date, no Acquired Company has experienced any material security breach or cybersecurity event, including any theft, loss, unlawful or unauthorized Processing of Personal Information or Company
        Data held by or on behalf of an Acquired Company (a &#8220;<u>Security Breach</u>&#8221;) and the Acquired Companies have no reason to reasonably suspect a material Security Breach has occurred.&#160; The Acquired Companies have since the Applicable Date used
        commercially reasonable controls, technologies, processes and practices to prevent, detect, identify and remediate Security Breaches.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Acquired Companies have not included any Trade Secrets or other material confidential and proprietary information in any prompts or inputs into any Generative AI Tool owned or controlled by any other
        Person (unless the Contract relating to such Generative AI Tool includes terms that do not permit the use of any such prompt or input to train or improve the Generative AI Tool), or used any Generative AI Tool in a manner that does not comply in
        all material respects with the applicable license or other Contract terms.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Contracts</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section <font style="color: rgb(0, 0, 0);">2.9(a)</font> of the Company Disclosure Schedule identifies each Contract to which any Acquired Company is a party, or by which it is bound, that constitutes a
        Material Contract as of the Agreement Date and identifies, with respect to each Material Contract, the clause of this <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>2.9(a)</u></font> to which it applies.&#160; For purposes of this Agreement, each
        of the following (excluding any Employee Plan) to which any Acquired Company is a party or by which it is bound as of the Agreement Date constitutes a &#8220;<u>Material Contract</u>&#8221;:</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">18</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; any Contract that is a settlement, conciliation or similar agreement between any Acquired Company and any Governmental Body and pursuant to which an Acquired Company will be required after the Agreement
        Date to pay any monetary obligations in excess of $500,000;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; any Contract between any Acquired Company and any third Person (A)&#160;materially limiting the freedom or right of any Acquired Company to engage in any line of business or to compete with any other Person
        in any location or line of business, (B)&#160;containing any &#8220;most favored nations&#8221; terms and conditions (including with respect to pricing) granted by any Acquired Company, or (C)&#160;containing exclusivity obligations (other than pursuant to exclusivity
        obligations resulting from the scope of the license granted in any Inbound License) or otherwise materially limiting the freedom or right of any Acquired Company (or following the Closing, Parent or any of its Affiliates) to sell, distribute or
        manufacture any products or services or any technology or other assets to or for any other Person;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; any Contract that requires by its terms or is reasonably expected to require the payment or delivery of cash or other consideration (A) to any Acquired Company in an amount having an expected value in
        excess of $1,000,000 in the fiscal year ending December&#160;31, 2025, or (B) by any Acquired Company in an amount having an expected value in excess of $1,000,000 in the fiscal year ending December 31, 2025, and in each case (y) which cannot be
        cancelled by such Acquired Company without penalty or further payment without more than 60 days&#8217; notice, and (z) excluding commercially available off-the-shelf software licenses and Software-as-a-Service offerings, generally available patent
        license agreements, material transfer agreements, clinical trial agreements and non-exclusive outbound license agreements (in each case, entered into in the ordinary course of business);</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any Contract relating to Indebtedness of any Acquired Company in an aggregate principal amount in excess of $250,000 (whether incurred, assumed, guaranteed or secured by any asset);</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(v)&#160;&#160;&#160;&#160;&#160; &#160; &#160; any Contract between an Acquired Company and a third Person (A) for the disposition of any material assets or material portion of the Acquired Companies&#8217; business, or (B) for the acquisition of a material
        portion of the assets or business of any third Person (whether by merger, sale of stock or assets or otherwise), in each case of the foregoing <u>clause </u><u>(A)</u> or <u>(B)</u> that contains continuing indemnities or other material
        obligations or any continuing royalties or other amounts calculated based upon any revenues or income of the Company or any &#8220;earn out&#8221;, &#8220;milestone&#8221; or other contingent payment obligations on the part of an Acquired Company;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any Contract between any Acquired Company and any third Person constituting or relating to the formation, creation, operation, management or control of a joint venture, partnership or similar profit or
        revenue sharing arrangement;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(vii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; any Contract that by its express terms requires an Acquired Company, or any successor to, or acquirer of, an Acquired Company, to make any payment to another Person as a result of a change of control of
        such Acquired Company (a &#8220;<u>Change of Control Payment</u>&#8221;) or gives another Person a right to receive or elect to receive a Change of Control Payment;</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">19</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 108pt;">(viii)&#160;&#160;&#160;&#160;&#160;&#160; any Contract that prohibits the declaration or payment of dividends or distributions in respect of the capital stock of an Acquired Company, the pledging of the capital stock or other equity interests of
        an Acquired Company or the issuance of any guaranty by an Acquired Company;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(ix)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; any (A) In-bound License and (B) Out-bound License;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any Contract that relates to the assignment of any Company IP to an Acquired Company, other than Contracts that assign Intellectual Property Rights from employees, consultants or contractors of an
        Acquired Company that have been entered into between such Acquired Company and such employee, consultant or contractor on the Acquired Company&#8217;s standard form (or form substantially equivalent thereto);</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(xi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; any Government Contract;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(xii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; any Contract that relates to the research, development, distribution, marketing, supply, collaboration, co-promotion or manufacturing of the Products, which if terminated or not renewed, would reasonably
        be expected to have a material and adverse effect on the Products;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(xiii)&#160;&#160;&#160;&#160;&#160;&#160; any Contract for the lease or sublease of any real property;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(xiv)&#160;&#160;&#160;&#160;&#160;&#160; any Contract that relates to any swap, forward, futures or other similar derivative transactions;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(xv)&#160;&#160;&#160;&#160;&#160;&#160;&#160; any Contract with any university or other academic institution, research center, international organization or Governmental Body, other than any In-Bound Licenses, Out-Bound Licenses, sponsored research
        agreements, clinical trial site agreements, material transfer agreements, sponsorship agreements or grant agreements entered into in the ordinary course of business;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(xvi)&#160;&#160;&#160;&#160;&#160;&#160; any Contract for the engagement of any Person as an independent contractor, providing for annual base salary compensation in excess of $50,000, in each case, that cannot be terminated by the Company or any
        Acquired Company without penalty and on no more than 60 days&#8217; notice;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(xvii)&#160;&#160;&#160;&#160;&#160; any Contract that requires any capital commitment or capital expenditure (or series of capital expenditures) by the Company or any Acquired Company after the Agreement Date in an amount in excess of
        $1,000,000 in the aggregate.</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(xviii)&#160;&#160;&#160;&#160; any other Contract that is currently in effect and has been filed (or is required to be filed) by the Company as an exhibit pursuant to Item 601(b)(10) of Regulation S&#8209;K under the Securities Act or that
        would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act; and (xix) any Contract (A) with any Affiliate (other than an Acquired Company), director, executive officer (as such term is defined in the Exchange Act),
        Person holding 5% or more of the Shares, or, to the knowledge of the Company, any Affiliate (other than an Acquired Company) or immediate family member of any of the foregoing, or (B) in which any of the foregoing Persons has a direct or indirect
        material financial interest.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">20</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As of the Agreement Date, the Company has either delivered or made available to Parent an accurate, unredacted and complete copy of each Material Contract or has publicly made available such Material
        Contract in the Electronic Data Gathering, Analysis and Retrieval (EDGAR) database of the SEC.&#160; No Acquired Company nor, to the knowledge of the Company, any other party thereto is in material breach of, or material default under, any Material
        Contract and no Acquired Company, or to the knowledge of the Company, any other party to a Material Contract has taken or failed to take any action that with or without notice, lapse of time or both would constitute a material breach of or material
        default under any Material Contract.&#160; Each Material Contract is, with respect to the Acquired Companies and, to the knowledge of the Company, each other party thereto, a valid and binding agreement in full force and effect, enforceable in
        accordance with its terms, except as such enforcement may be subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar Legal Requirements of general applicability relating to or affecting creditors&#8217;
        rights, and by general equitable principles.&#160; Since the Applicable Date, (i) the Acquired Companies have not received or delivered any written notice regarding any material violation or breach or default under any Material Contract that has not
        since been cured, and (ii) no Acquired Company has waived in writing any material rights under any Material Contract.&#160; As of the Agreement Date, no Acquired Company has received any written notice from any third party to any Material Contract that
        such party intends to terminate, or not renew such Material Contract.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Acquired Companies are, and, since the Applicable Date, have been, in compliance with all Legal Requirements and contractual requirements applicable to each Government Contract, and no performance
        evaluation of any Acquired Company since the Applicable Date with respect to any Government Contract has cited a material default or other material failure to perform thereunder.&#160; With respect to each Government Contract, since the Applicable Date
        there has been no (i) civil fraud, criminal or bribery investigation, inquiry or audit by any Governmental Body against or involving any Acquired Company, (ii) internal investigation conducted by or on behalf of an Acquired Company in connection
        with any alleged fraud, bribery, contractual noncompliance or any other issue in connection with such Government Contract, (iii) suspension or debarment action against any Acquired Company or any manager, director or officer of any Acquired
        Company, (iv) written request by a Governmental Body for a contract price adjustment based on a claimed disallowance by the Defense Contract Audit Agency (or other applicable Governmental Body) or written claim of defective pricing against any
        Acquired Company, or (v) dispute between any Acquired Company and a Governmental Body that has resulted in a government contracting officer&#8217;s final decision against an Acquired Company.&#160; In the past six years, (i) all written representations,
        certifications and disclosures made by the Acquired Companies in connection with each Government Contract were current, accurate and complete when made and such representations and certifications were updated so that they remained current, accurate
        and complete, if updating was required, and (ii) neither any Governmental Body nor any prime contractor, subcontractor or other Person has notified any Acquired Company, that any Acquired Company has, or is alleged to have, breached or violated any
        Legal Requirement, representation, certification, disclosure, clause, provision or requirement pertaining to any Government Contract.&#160; In the past six years, there has been no termination for default, cure notice or show cause notice issued to an
        Acquired Company by any Governmental Body in connection with any Government Contract.&#160; There are no facts or circumstances that would support any material breach or termination for default of any Government Contract, or warrant the institution of
        suspension, debarment or other disqualification proceedings or the finding of non-responsibility or ineligibility on the part of any Acquired Company or any manager, officer, director or employee of any Acquired Company.&#160; There are no outstanding
        claims against the Acquired Companies, either by a Governmental Body or by any prime contractor, arising under any Government Contract.&#160; No Government Contract is or was set aside or reserved based in whole or in part on the Acquired Companies&#8217;
        size status or other set aside or preference category and none of the Acquired Companies have made any representations in connection with any Government Contracts indicating that it would be entitled to any preference based on its size or any other
        preference category.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">21</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 2.9(d) of the Company Disclosure Schedule lists each Encumbrance securing the obligations of the Acquired Companies under the Senior Secured Term Loan Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.10</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Liabilities</font>.&#160; The Acquired Companies do not have any liabilities (whether accrued, absolute, contingent or otherwise), except
        for (a)&#160;liabilities reflected or reserved against in the Company&#8217;s audited consolidated balance sheet (or the notes thereto) included in the Company&#8217;s most recent Annual Report on Form 10-K filed with the SEC prior to the Agreement Date,
        (b)&#160;liabilities or obligations incurred pursuant to the terms of this Agreement, (c)&#160;liabilities for performance of obligations under Contracts binding upon the Acquired Companies (none of which are the result of any breach of Contract, breach of
        warranty, tort, infringement, misappropriation, dilution, violation of any applicable Legal Requirements) delivered or made available to Parent prior to the Agreement Date or entered into thereafter in the ordinary course and not in breach of the
        provisions of <u>Section&#160;</u><font style="color: rgb(0, 0, 0);"><u>4.2</u></font>, (d)&#160;liabilities incurred in the ordinary course of business since the date of the balance sheet referenced in the foregoing <u>clause </u><u>(a)</u>, and
        (e)&#160;liabilities that have not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.11</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Compliance with Legal Requirements</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Acquired Companies are, and since the Applicable Date have been, in compliance with all applicable Legal Requirements, except as would not be, individually or in the aggregate, material to the Acquired
        Companies taken as a whole.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Acquired Company produces, designs, tests, manufactures, fabricates or develops a &#8220;critical technology,&#8221; as that term is defined in 31 C.F.R. Section 800.215.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Since January 1, 2020, (except, in the case of Sanctions Laws, since April 24, 2019), each Acquired Company has been in compliance with all applicable Global Trade Laws.&#160; Since April 24, 2019, no Acquired
        Company nor any Acquired Company&#8217;s Representatives has been (i) a Sanctioned Person or acted on behalf of a Sanctioned Person, (ii) located, organized or resident in a Sanctioned Country, or (iii) engaged in any dealings, directly or indirectly,
        with or involving or for the benefit of a Sanctioned Person or with or involving any Sanctioned Country in violation of Sanctions Laws.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">22</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;"><font style="color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Since January 1, 2020<font style="color: rgb(0, 0, 0);">, no Acquired Company has, in connection with or relating to the business of any Acquired Company, (A)
          received from any Governmental Body or any other Person any written, or, to the knowledge of the Company, oral notice, or (B)&#160;been subject to an actual or threatened investigation, inquiry, enforcement action or audit or made any disclosure to a
          Governmental Body, in either case concerning any actual or potential violations concerning applicable Anti-Corruption or Global Trade Laws; and (ii) no Governmental Body has assessed any fine or penalty against, or issued any warning letter to,
          any Acquired Company with regard to compliance with any Global Trade Laws or Anti-Corruption Laws. There are no written, or to the knowledge of the Company threatened, claims, nor, to the knowledge of the Company, any presently existing facts or
          circumstances that would constitute a reasonable basis for any future claims, with respect to actual or alleged violations of Global Trade Laws or Anti-Corruption Laws by the Acquired Companies.</font></div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of the products or materials (including Products) imported by, for or on behalf of the Acquired Companies, for which final liquidation has not yet occurred is subject to or otherwise covered by an
        antidumping duty order or countervailing duty order that remains in effect or is subject to or otherwise covered by any pending antidumping or countervailing duty investigation by any Governmental Body. The Acquired Companies are not importing and
        have not imported products or materials (including Products) mined, produced or manufactured, wholly or in part, with the use of forced labor or mined, produced or manufactured wholly or in part in the Xinjiang Uyghur Autonomous Region or by an
        Entity on the Uyghur Forced Labor Prevention Act Entity List.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Since January 1, 2020, the Acquired Companies have, in all material respects, implemented and maintained in effect policies, procedures and internal controls designed to ensure continued compliance by the
        Acquired Companies and their respective officers, directors, employees and agents with Global Trade Laws and Anti-Corruption Laws.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.12</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Regulatory Matters</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Acquired Company is, and since the Applicable Date has been, in compliance in all material respects with all Health Care Laws, in each case as applicable to the operation of the Acquired Company&#8217;s
        business.&#160; Since the Applicable Date, no Acquired Company, nor any Affiliate of the Company, or to the knowledge of the Company, any third parties including any CMO, CRO, Clinical Trial site or investigator (each, a &#8220;<u>Collaboration Partner</u>&#8221;),
        that has performed or is performing any Exploitation activities on behalf of an Acquired Company or with respect to any Product (i) has been subject to any enforcement, regulatory or administrative proceedings alleging non-compliance with any
        Health Care Laws, (ii) has received written, or, to the knowledge of the Company, oral, notice threatening any such enforcement, regulatory or administrative proceeding, or (iii) has been issued an FDA Form 483, warning letter, notice of violation
        of Health Care Laws, similar correspondence or other notice from any Governmental Body, except where any such issuance or violation in (i) &#8211; (iii) would not be reasonably expected, individually or in the aggregate, to be material to the Acquired
        Companies taken as a whole.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">23</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Since the Applicable Date, all preclinical and clinical investigations, testing, studies or trials that are required or permitted by applicable Legal Requirements to obtain or maintain or confirm the
        findings of a Governmental Authorization for, or to support the pricing, reimbursement or use of any Product including a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial or Phase IV Clinical Trial (&#8220;<u>Clinical Trials</u>&#8221;)
        sponsored or conducted by or on behalf of the Acquired Companies have been and are being conducted in material compliance with applicable Health Care Laws and Data Privacy Laws.&#160; No Acquired Company, nor any Company Associate or, to the knowledge
        of the Company, any of their Collaboration Partners or other Persons acting on their behalf, has received any written, or, to the knowledge of the Company, oral, notice or other correspondence from the FDA, the EMA or any other Governmental Body
        performing functions similar to those performed by the FDA with respect to any Clinical Trial requiring or recommending a clinical hold, or the termination, suspension or material modification of any such Clinical Trials, and to the knowledge of
        the Acquired Companies, no grounds that could serve as the basis for such hold, termination, suspension or modification by an applicable Governmental Body exist.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Since the Applicable Date, the Acquired Companies have filed with the FDA, the EMA or any other Governmental Body all required material filings, declarations, listings, registrations, reports or
        submissions, including but not limited to adverse event reports, and any required updates, corrections or modifications to each of the foregoing.&#160; All such filings, declarations, listings, registrations, reports or submissions were in material
        compliance with applicable Health Care Laws when filed, and no deficiencies have been asserted in writing, or, to the knowledge of the Company, orally, by any applicable Governmental Body with respect thereto and to the knowledge of the Acquired
        Companies, no deficiencies that could serve as the basis for such an assertion by an applicable Governmental Body exists.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Since the Applicable Date, no Acquired Company, nor any of its directors, officers, or employees, or, to the knowledge of the Company, any Collaboration Partner or other Person acting on its behalf has
        (i)&#160;made an untrue statement of a material fact or fraudulent statement to the FDA, EMA or any Governmental Body, (ii)&#160;failed to disclose a material fact required to be disclosed to the FDA, EMA or any Governmental Body, or (iii)&#160;committed any
        other act, made any statement or failed to make any statement, that (in any such case) could reasonably form a reasonable basis for the FDA, EMA or any Governmental Body to invoke its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal
        Gratuities Final Policy or any similar policies or rules that may be applicable in another jurisdiction to an Acquired Company.&#160; No Acquired Company is the subject of any pending or, to the knowledge of the Company, threatened investigation by the
        FDA pursuant to its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities Final Policy or by any Governmental Body to invoke a similar Legal Requirement.&#160; No Acquired Company, nor any Company Associate or, to the knowledge of
        the Company, any of their Collaboration Partners or other Persons acting on their behalf, has been debarred or disqualified, excluded from participation in federal healthcare programs or convicted of any crime or engaged in any conduct that would
        reasonably be expected to result in (A) debarment under 21 U.S.C. &#167;&#160;335a or any similar Legal Requirement, (B) exclusion under 42 U.S.C. &#167;&#160;1320a-7 or any similar Legal Requirement, (C) disqualification pursuant to 21 CFR Part 312.70 or any similar
        Legal Requirement, or (D) any results similar to <u>clauses </u><u>(A)</u>, <u>(B)</u> or <u>(C)</u> according to any Legal Requirements in any foreign jurisdiction and, to the knowledge of the Acquired Companies, no circumstances exist that
        could result in any of <u>clauses </u><u>(A)</u>, <u>(B)</u>, <u>(C)</u> or <u>(D)</u>.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">24</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Since the Applicable Date, the Acquired Companies have not received any notice from a Governmental Body that any of their Products are misbranded or adulterated, as those terms are used in the FDCA at 21
        U.S.C. &#167;&#167;&#160;352 and 351, respectively, and the rules and regulations promulgated thereunder, or as defined in comparable Legal Requirements in any jurisdiction.&#160; Since the Applicable Date, the manufacture of the Acquired Companies&#8217; Products has been
        conducted in material compliance with applicable Legal Requirements, including GMP, and no such Products have been misbranded or adulterated.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, the Acquired Companies, or its directors, officers employees and, to the
        knowledge of the Company, their Collaboration Partners, or other Persons acting on their behalf have prepared, submitted and implemented timely responses and, as applicable, any corrective action plans required to be prepared and submitted in
        response to all internal or third-party (including by any Governmental Body) audits, inspections, investigations or examinations of the Products or the Acquired Company&#8217;s business.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.13</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Governmental Authorizations</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Since January 1, 2020, the Acquired Companies have held all Governmental Authorizations required for their business as then-conducted, each Governmental Authorization required for their business as
        currently conducted is valid and in full force and effect and, to the knowledge of the Acquired Companies.&#160; The Acquired Companies are, and, since January 1, 2020, have been, in compliance in all material respects with the terms and requirements of
        such Governmental Authorizations.&#160; Since January 1, 2020, (i) no Acquired Company has received any notice from any Governmental Body that (A) alleges any violation or noncompliance (or reflects that an Acquired Company is under investigation or the
        subject of an inquiry or audit by any such Governmental Body for such alleged noncompliance) with any applicable Legal Requirement or Governmental Authorization, or (B) threatens any fine, assessment, enforcement action, or cease and desist order,
        or the suspension, revocation or limitation or restriction of any Governmental Authorization held by an Acquired Company, and (ii) no Acquired Company has entered into any agreement or settlement with any Governmental Body with respect to its
        alleged noncompliance with, or violation of, any applicable Legal Requirement or Governmental Authorization.&#160; None of the Acquired Companies has received written notice that any material Governmental Authorization will not or is likely not to be
        issued.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There is no pending or, to the knowledge of the Company, threatened, termination, expiration, suspension, withdrawal, modification, limitation or revocation of any Governmental Authorization, and no event
        has occurred that would give rise to or serve as a basis for such termination, expiration, suspension, withdrawal, modification, limitation or revocation of any Governmental Authorization.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">25</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.14</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Tax Matters</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;Each of the income (or franchise) and other material Tax Returns required to be filed by or on behalf of an Acquired Company with any Governmental Body have been filed on or before the applicable due
        date (including any applicable and validly obtained extensions of such due date), have been prepared in accordance with all applicable Legal Requirements, and are accurate and complete, in each case in all material respects, and (ii)&#160;all income (or
        franchise) and other material Taxes due and payable by an Acquired Company (whether or not shown on any Tax Returns) have been timely paid, and all material Taxes required to be withheld (including with respect to payment or allocations made to any
        Company Associate, other service provider, creditor, shareholder, customer, vendor or other third party) by any Acquired Company have been withheld and paid, in each case, to the relevant Governmental Body.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There are no pending examinations or audits of any Tax Return in progress involving material Taxes, and no such examinations or audits have been threatened in writing, and (ii) no written claim has been
        received in the six-year period ending on the Agreement Date by any Acquired Company from any Governmental Body in any jurisdiction where such Acquired Company does not file Tax Returns that such Acquired Company is or may be subject to Taxes in
        that jurisdiction for which it does not file Tax Returns.&#160; No Acquired Company is, or has been, subject to Tax in any country other than its country of organization by virtue of having a permanent establishment (as defined by applicable Tax treaty)
        or other place of business or taxable presence in that jurisdiction.&#160; No extension or waiver of the statute of limitation period applicable to any income (or franchise) or other material Tax Returns of any Acquired Company has been granted that
        will remain in effect after Closing, other than automatic extensions or automatic waivers obtained in the ordinary course of business.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Adequate reserves have been established on the Company&#8217;s consolidated financial statements to provide for the payment of any Taxes which are not yet due and payable with respect to any Acquired Company for
        taxable periods or portions thereof ending on or before the date of the most recent financial statements of the Company.&#160; All Taxes of the Acquired Companies incurred through the date of the most recent financial statements of the Company do not
        exceed Taxes accrued on such financial statements, and all Taxes of the Acquired Companies accrued following the end of the most recent period covered by the most recent financial statements of the Company have been accrued in the ordinary course
        of business.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Legal Proceeding involving the IRS or any other Governmental Body is pending, ongoing, or has been threatened in writing against or with respect to any Acquired Company in respect of any income (or
        franchise) or other material Tax, and no deficiency of income (or franchise) or other material Taxes has been asserted in writing as a result of any audit or examination by any Governmental Body that has not been paid, settled or otherwise
        resolved.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Acquired Company (i)&#160;has been a member of an affiliated group (within the meaning of Section 1504(a) of the Code) filing a consolidated federal income Tax Return (other than a group the common parent of
        which is or was the Company or another Acquired Company), or (ii)&#160;has any liability for the Taxes of any other Person (other than another Acquired Company) under Section 1.1502-6 of the Treasury Regulations (or any similar provision of any state,
        local or non-U.S. Legal Requirement), or as a transferee or successor or pursuant to any written Contract (other than pursuant to agreements not primarily related to Taxes).</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">26</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During the two-year period ending on the Agreement Date, none of the Acquired Companies has been either a &#8220;distributing corporation&#8221; or a &#8220;controlled corporation&#8221; in a distribution of stock intended to
        qualify for tax-free treatment under Section&#160;355 of the Code.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Acquired Company has participated in any &#8220;reportable transaction&#8221; within the meaning of Treasury Regulations Section 1.6011-4(b) or any comparable provision of any state, local or non-U.S. Legal
        Requirement (including European Council Directive 2011/16 (&#8220;<u>DAC 6</u>&#8221;) and domestic implementation of DAC 6 and U.K. or foreign tax evasion facilitation offense within the meaning of the Criminal Finance Act 2017 of the United Kingdom).&#160; Each
        Acquired Company has disclosed on its U.S. federal income Tax Returns all positions taken therein that could give rise to a substantial understatement of U.S. federal income Tax within the meaning of Section&#160;6662 of the Code (or any corresponding
        or similar provision of any state, local or non-U.S. Legal Requirement).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Acquired Company will be required to include any material item of income in, or exclude any material item of deduction from, the computation of taxable income for any taxable period (or portion thereof)
        beginning after the Closing Date as a result of any (i)&#160;change in method of accounting made prior to the Closing for a taxable period ending on or prior to the Closing Date as a result of transactions or events occurring, or accounting methods
        employed, prior to the Closing, (ii)&#160;&#8220;closing agreement&#8221; as described in Section 7121 of the Code (or any corresponding or similar provision of any state, local or non-U.S. income Tax Legal Requirement) executed prior to the Closing,
        (iii)&#160;installment sale or open transaction disposition made prior to the Closing, or any &#8220;excess loss account&#8221; within the meaning of the Treasury Regulations under Section 1502 of the Code (or any analogous or similar provision of any state, local
        or non-U.S. Tax Legal Requirement) existing as of immediately prior to the Closing, (iv) prepaid amount or any other income eligible for deferral under the Code or Treasury Regulations promulgated thereunder (including, without limitation, pursuant
        to Sections 451, 455 or 456 of the Code) or under state, local or non-U.S. Tax Legal Requirements received on or prior to the Closing Date, (v) a gain recognition agreement pursuant to Treasury Regulations Section 1.367(a)-8 (or any similar
        provision of any state, local or non-U.S. Tax Legal Requirement) executed prior to the Closing, or (vi) income or gain by reason of Section 367(d) of the Code (or any similar provision of any state, local or non-U.S. Tax Legal Requirement) with
        respect to a transaction entered into prior to the Closing.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of the Acquired Companies has made an election under Section&#160;965(h) of the Code or otherwise has any liability for Taxes pursuant to Section 965 of the Code that has not been fully paid to the
        appropriate Governmental Body.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Acquired Company is party to, bound by or has any obligation under any written Tax allocation or Tax sharing agreement or any written Tax indemnity or other written Tax allocation agreement or
        arrangement with any Person (other than another Acquired Company), other than any agreement not primarily related to Taxes.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">27</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There are no material Encumbrances with respect to Taxes upon any of the assets or properties of any Acquired Company, other than Permitted Encumbrances.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section&#160;2.14(l) of the Company Disclosure Schedule discloses for each Acquired Company (i)&#160;all applied for or received loans or payments under the CARES Act and COVID Relief Programs, (ii)&#160;Tax credits
        claimed under the CARES Act and COVID Relief Programs, and (iii)&#160;any other credits, deferrals or benefits available that any Acquired Company availed itself of under the CARES Act and COVID Relief Programs.&#160; With respect to each benefit under the
        CARES Act and COVID Relief Programs disclosed in Section <font style="color: rgb(0, 0, 0);">2.14(l)</font> of the Company Disclosure Schedule, each Acquired Company satisfied all applicable requirements to qualify for each such benefit and holds
        and retains documentation and information to fully support the accuracy of each claim for each such benefit under the applicable Legal Requirements.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each Acquired Company has timely and accurately filed all required foreign accounts on a Report of Foreign Bank Accounts on FinCEN Form 114.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as otherwise set forth in Section 2.14(n) of the Company Disclosure Schedule, none of the Acquired Companies has been a party to, or the beneficiary of, any Tax exemption, Tax holiday or other Tax
        reduction agreement or arrangement with, or order by, any Governmental Body (collectively, the &#8220;<u>Tax Benefits</u>&#8221;), in each case, other than Tax Benefits generally available under the Code (or any applicable state, local or non-U.S. Legal
        Requirement) without a requirement to enter into any agreement with a Governmental Body that will continue to apply after the Closing Date.&#160; The Acquired Companies are, and have been, in full compliance with any Tax Benefit to which it is a party
        or the beneficiary (whether or not disclosed in Section 2.14(n) of the Company Disclosure Schedule), and no basis exists as of the Closing, and the Transactions do not (and will not) create any basis, for any clawback or disgorgement of such Tax
        Benefit in any taxable period (or portion thereof) ending after the Closing Date.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of the Acquired Companies owns, directly or indirectly, any equity interest in a &#8220;passive foreign investment company&#8221; within the meaning of Section 1297 of the Code (&#8220;<u>PFIC</u>&#8221;) or has ever been
        classified as a PFIC.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All transactions entered into or conducted by any Acquired Company with any Person who is a member of the &#8220;controlled group&#8221; (within the meaning of Treasury Regulations Section 1.482-1 or any similar or
        comparable provision of any state, local or non-U.S. Legal Requirement) of which such Acquired Company is a member have been made on arm&#8217;s length terms and no Governmental Body has imposed any different terms on any such transactions.&#160; None of the
        Acquired Companies is a party to any advance pricing agreement, or any similar Contract, with any Governmental Body.&#160; Contemporaneous transfer pricing documentation, local files, master files, intercompany agreements, benchmarking studies and any
        other record mandated by all applicable Legal Requirements have been timely prepared, are complete and accurate in all material respects, and have been maintained for all relevant periods.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of the Acquired Companies has filed (or has had filed on its behalf) a request for (i) private letter ruling, (ii) administrative relief, (iii) technical advice, or (iv) change of any method of
        accounting, in each case, with any Governmental Body that relates to Taxes or Tax Returns of any of the Acquired Companies.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">28</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt;">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of the Acquired Companies has (i) entered into any settlement or arrangement (including a closing agreement within the meaning of Section 7121 of the Code or a comparable or similar provision of any
        state, local or non-U.S. Legal Requirement) with respect to Taxes with any Governmental Body that would be binding or result in a material Tax liability for any Tax period (or portion thereof) beginning after the Closing Date, or (ii) granted any
        power of attorney with respect to any Taxes that is currently in force and will remain in effect after the Closing.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of the Acquired Companies violated any antiboycott prohibitions, or failed to comply with the reporting requirements, of the Tax Reform Act of 1976 (26 U.S.C. &#167;&#160;999).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 2.14(t) of the Company Disclosure Schedule provides the current entity classification for U.S. federal income tax purposes for each Acquired Company.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of the Acquired Companies is, or has been in the last five years, a United States Real Property Holding Corporation within the meaning of Section 897(c)(2) of the Code and Treasury Regulations issued
        thereunder.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Acquired Company is in possession and control of all records and documentation that is obliged to hold, preserve and retain for the purposes of any Tax under applicable Legal Requirements and of
        sufficient information to enable it to compute correctly its liability for Tax in so far as it relates to any event occurring before the Closing.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(w)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Acquired Company has a current and valid registration for Tax purposes (included for purposes of value added Tax or similar Tax) in each jurisdiction that requires such a registration by such Acquired
        Company, and each such Acquired Company is in compliance with all conditions and requirements with respect to each such registration.&#160; Each Acquired Company has complied with all statutory provisions, rules, regulations, orders and directions
        concerning value added Tax or similar Tax, and related registrations, including timely filing correct and accurate Tax Returns and payments thereof and keeping correct and accurate records and documents related thereto.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Acquired Company directly or indirectly holds real estate within the meaning of the German Real Estate Transfer Tax Act.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">29</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.15</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Employee Matters</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Acquired Company is, nor at any time since the Applicable Date has been, a party to, bound by or negotiated, any collective bargaining agreement or similar Contract with a labor union, labor
        organization, an employee representative, or works council representing any of its employees, and no employees of an Acquired Company are, or have since the Applicable Date been, represented by any labor union or other labor organization, an
        employee representative, or works council with respect to their employment with an Acquired Company.&#160; No Acquired Company has, or at any time since the Applicable Date had, any duty to bargain with any labor union, labor organization, an employee
        representative or works council.&#160; To the knowledge of the Company, since the Applicable Date, there have been no activities or proceedings of any labor union to organize any Company Associate for the purpose of collective bargaining.&#160; No
        application, demand, petition or proceeding is pending for an election of or certification or recognition of a collective bargaining agent representing the employees of an Acquired Company.&#160; No labor dispute, strike, picketing or work stoppage
        against any Acquired Company is now pending, has occurred since the Applicable Date, or, to the knowledge of the Company, is now threatened that would reasonably be expected to interfere with the Acquired Companies&#8217; business.&#160; No Acquired Company
        is, or has since the Applicable Date, engaged in any unfair labor practices.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Acquired Companies are, and at all times since the Applicable Date have been, in compliance in all material respects with all Legal Requirements governing the employment of labor, including Legal
        Requirements relating to employment practices, wages, compensation and benefits, hours, working time arrangements, classification of employees and independent contractors, overtime and overtime payments, working during rest days, social benefits
        contributions, severance pay, affirmative action, collective bargaining, discrimination, equity, harassment, retaliation, civil rights, disability rights or benefits, terms and conditions of employment, immigration, safety and health, hiring,
        promotions, plant closings, termination of service, severance, gratuity, pay transparency and disclosures, pay equity, employee privacy, leaves of absence, paid sick leave, unemployment insurance, child labor, whistleblowing, pension insurance,
        medical insurance, work-related-injury insurance, maternity insurance, the withholding and payment of social security and other Taxes (&#8220;<u>Employment Practices</u>&#8221;), such as the Age Discrimination in Employment Act, Title VII of the Civil Rights
        Act of 1964, the Civil Rights Act of 1991, ERISA, the Fair Labor Standards Act, the Americans with Disabilities Act, the Occupational Safety and Health Act, the Family and Medical Leave Act, the National Labor Relations Act of 1935, any executive
        orders or regulations governing affirmative action, EEO and VETS-100 reporting obligations, and the Immigration and Nationality Act and other similar Legal Requirements of the jurisdictions in which the Acquired Companies are qualified or do
        business.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There are no, nor have there been at any time since the Applicable Date any, material Legal Proceedings pending or, to the knowledge of the Company, threatened in writing or reasonably anticipated
        involving any regulatory organization, any Company Associate or group of Company Associates alleging non-compliance by an Acquired Company with Employment Practices.&#160; No Acquired Company is, nor at any time since the Applicable Date has been, a
        party to a conciliation agreement, consent decree or other agreement with any Governmental Body with respect to Employment Practices pursuant to which such Acquired Company will have material outstanding monetary obligations following the Agreement
        Date. Since the Applicable Date, no Company Associate has filed a formal complaint or claim with an Acquired Company with respect to Employment Practices.&#160; No Company Associate has been involved in an accident in the course of his or her service
        with the Acquired Companies that would have caused other than minor injury, nor has any such Person been exposed to occupational health hazards in the service of the Acquired Companies.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">30</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <!--PROfilePageNumberReset%Num%31%%%-->
        <div>
          <div>
            <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No Acquired Company has at any time since the Applicable Date taken any action that (i) would constitute a &#8220;mass layoff&#8221; or &#8220;plant closing&#8221; within the meaning of the Worker Adjustment and Retraining
              Notification Act of 1988 (29 U.S.C. &#167; 2101) (the &#8220;<u>WARN Act</u>&#8221;) or that triggered notice requirements or liability under any other Legal Requirement that is comparable to the WARN Act without complying in all material respects with the
              WARN Act or such other comparable Legal Requirement, or (ii) resulted in the termination of employment of 50 or more Company Associates or more than 10% of the Company Associates of the Acquired Companies during any 90-day period.&#160; As of the
              Agreement Date, no Acquired Company has any plans to undertake any action that would trigger the WARN Act or other similar notification requirements.&#160; The Acquired Companies are, and have been at all times since the Applicable Date, in
              material compliance with the WARN Act and any applicable state laws or other Legal Requirements regarding redundancies, reductions in force, mass layoffs, and plant closings, including obligations to promptly and correctly furnish all notices
              required to be given thereunder in connection with any redundancy, reduction in force, mass layoff or plant closing to affected employees, representatives, any state dislocated worker unit and local government officials, or any other
              Governmental Body.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the knowledge of the Company, no Company Associate is or has been at any time since the Applicable Date in any material respect in violation of any employment contract, non-disclosure,
              confidentiality agreement, non-competition agreement, non-solicitation agreement, restrictive covenant, consulting agreement, or work rules or other internal employment related rules with an Acquired Company.&#160; To the knowledge of the Company,
              no Company Associate has been at any time since the Applicable Date in any material respect in violation of any employment contract, non-disclosure, confidentiality agreement, non-competition agreement, non-solicitation agreement, restrictive
              covenant, consulting agreement, or work rules or other internal employment related rules with a former employer or service recipient relating to the right of any such Company Associate to be employed by or provide services to the Acquired
              Companies because of the nature of the business conducted or presently proposed to be conducted by it or to the use of Trade Secrets or proprietary information of others.&#160; The Company has made available to Parent copies of form offer letters,
              employment contracts, indemnification agreements, severance agreements, consulting agreements, contracts related to change of control payments with any Company Associates to which the Acquired Company is a party, or by which the Acquired
              Companies are bound, or under which the Acquired Companies have an outstanding material liability or obligation to re-employ or re-instate, and work rules or other internal employment related rules used in each jurisdiction in which Company
              Associates are or were based or located.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Acquired Company has incurred any material liability for breach of employment contracts, consulting contracts or work rules or other internal employment related rules.&#160; No Acquired Company has any
              current material liability for accrued and vested but unpaid severance, pay in lieu of notice, provident fund contributions, gratuity payments or other payment arising from the termination of the service of anyone who was once a Company
              Associate.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company has made available to Parent a correct and complete list of employees of the Acquired Companies setting forth each such individual&#8217;s current (i) title or position, (ii) status as full-time
              or part-time, (iii) if an employee, status as exempt or non-exempt (to the extent applicable under Legal Requirements), (iv) date of commencement of service, (v) primary work location, including country and state, (vi) status of any required
              visa or work permit, (vii) leave of absence status, including whether the individual has given a written request for a leave of absence, (viii) employing entity, and (ix) whether the individual is engaged through a leasing agency or a
              temporary staffing agency.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">31</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (i) All individuals characterized and treated as independent contractors by the Acquired Companies have been correctly classified for the purposes of employment rights and taxes under applicable Legal
              Requirements and the Acquired Companies have applied employment rights and taxes in accordance with the correct classification, and (ii) no tax authority has made enquiries regarding any contractor&#8217;s status and no contractor has objected to
              being treated as a self-employed contractor.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) All employees of the Acquired Companies are employed on an at will basis, except as provided by applicable Legal Requirements outside of the United States, and (ii) no Acquired Company has any
              obligation to provide any particular form or period of notice before terminating the employment of any of their respective employees, except as provided by applicable Legal Requirements outside of the United States.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the knowledge of the Company, there are no, nor have there been since the Applicable Date, any (i)&#160; allegations of sexual harassment or other sexual misconduct or race discrimination or other type
              of unlawful harassment made against any Company Associate with the title of senior vice president (or the equivalent title based on role, responsibility or pay grade) or above through any formal human resources communication channels at the
              Acquired Companies, or (ii) actions or investigations pending related to any allegations of sexual harassment, other sexual misconduct or race discrimination or other type of harassment by any employee of the Acquired Company with the title
              of senior vice president (or the equivalent title based on role, responsibility or pay grade) or above.&#160; Since the Applicable Date, to the knowledge of the Company, no Acquired Company has entered into any settlement agreements related to
              allegations of sexual harassment, other sexual misconduct or race discrimination or other types of unlawful harassment by any employee of an Acquired Company with the title of senior vice president (or the equivalent title based on role,
              responsibility or pay grade) or above.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No visa or work permit held by a Company Associate with respect to his or her service with the Acquired Companies will expire during the 12-month period beginning on the Agreement Date. All current
              Company Associates who work in the United States are, and all individuals who were former Company Associates who worked in the United States whose engagement terminated, voluntarily or involuntarily, within the four years prior to the
              Agreement Date were, legally authorized to work in the United States.&#160; The Acquired Companies have obtained all required material licenses to employ or engage non-resident workers or employees.&#160; The Acquired Companies are and have been in
              compliance in all material respects with both the employment verification provisions (including the paperwork and documentation requirements) and the anti-discrimination provisions of the Immigration Reform and Control Act of 1986 or
              equivalent or similar requirements under Legal Requirements in other jurisdictions for all Company Associates engaged or providing services to an Acquired Company since the Applicable Date.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">32</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All Company Associates have been duly and properly remunerated for all services they performed in the course of their working relationship with the Acquired Companies in compliance with Legal
              Requirements and any employment contracts therewith, and all other material payments due to them have been made and, with respect to any such amounts or rights that have matured in favor of such Company Associates but which are not yet
              payable, funds sufficient to cover such payments have been reserved.&#160; With respect to the remuneration paid to the Company Associates, all contributions have been made relating to compulsory health insurance and social security and to Tax
              withholdings required by Legal Requirements.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160; As of the Agreement Date, there are no performance improvements or disciplinary actions contemplated or pending against any of the Acquired Companies&#8217; Company Associates with a title of senior director
              or higher, nor do the Acquired Companies have an intention as of the Agreement Date to terminate the employment or other relationship of any of their Company Associates.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No current Company Associates are or have been (or have been notified that they may be) found by a Governmental Body to have violated any securities, commodities or unfair trade practices Legal
              Requirement, or identified on any of the following documents: (i) the OFAC list of &#8220;Specially Designated Nationals and Blocked Persons;&#8221; (ii) the Bureau of Industry and Security of the United States Department of Commerce &#8220;Denied Persons
              List,&#8221; &#8220;Entity List&#8221; or &#8220;Unverified List;&#8221; (iii) the Office of Defense Trade Controls of the United States Department of State &#8220;List of Debarred Parties;&#8221; or (iv) the United Nations Security Council Counter-Terrorism Committee &#8220;Consolidated
              List&#8221;.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.16</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Benefit Plans</font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 2.16(a) of the Company Disclosure Schedule sets forth an accurate and complete list of the material Employee Plans and separately denotes each material Employee Plan that constitutes a
              Non-U.S. Plan; <font style="font-style: italic;">provided, however</font>, that the following shall not be individually listed:&#160; (i) individual employment agreements, offer letters or consulting agreements that (A) do not vary from a form of
              employment agreement, offer letter or consulting agreement that has been made available to Parent, (B) do not provide for any retention or transaction bonus payments, and (C) may be terminated at any time without any liability; and (ii) award
              agreements that do not vary from a form of award agreement that has been made available to Parent.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company has made available to Parent with respect to each material Employee Plan accurate and complete copies of (i) all plan documents and all amendments thereto, and in the case of unwritten
              material Employee Plans, written descriptions thereof, (ii) the most recent annual actuarial valuation, if any, and the most recent annual report (Form Series 5500 and all schedules and financial statements attached thereto), (iii) all trust
              agreements, insurance contracts and other documents relating to the funding or payment of benefits under any Employee Plan, (iv) all material correspondence to or from the IRS, the United States Department of Labor or any other Governmental
              Body with respect to an Employee Plan dated within the last six years, (v) all determination letters, rulings, opinion letters, information letters or advisory opinions issued by the IRS or the United States Department of Labor, and (vi) the
              most recent summary plan descriptions and any material modifications thereto.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">33</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Neither the Company nor any ERISA Affiliate currently has, and at no time in the past has had, an obligation to contribute to a &#8220;defined benefit plan&#8221; (as defined in Section 3(35) of ERISA), a pension
              plan subject to the funding standards of Section 302 of ERISA or Section 412 of the Code, a &#8220;multiemployer plan&#8221; (as defined in Section 3(37) of ERISA or Section 414(f) of the Code), a &#8220;multiple employer plan&#8221; (within the meaning of Section
              210(a) of ERISA or Section 413(c) of the Code) or a &#8220;multiple employer welfare arrangement&#8221; (as defined in Section 3(40) of ERISA).&#160; There are no unfunded obligations to make payments to or relating to any Company Associate on early
              retirement or redundancy or other termination of employment under any Employee Plan.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each of the Employee Plans that is intended to be qualified under Section 401(a) of the Code has obtained or is entitled to rely upon a favorable determination letter (or opinion letter, if
              applicable) as to its qualified status under the Code (and each trust created thereunder has been determined by the IRS to be exempt from Tax under the provisions of Section 501(a) of the Code), and there are no existing circumstances or any
              events that have occurred that would reasonably be expected to materially adversely affect the qualified status of any such Employee Plan.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each of the Employee Plans is now and has been maintained, operated and administered in all material respects in compliance with its terms and all applicable Legal Requirements, including but not
              limited to ERISA and the Code.&#160; There have been no prohibited transactions or breaches of any of the duties imposed on &#8220;fiduciaries&#8221; (within the meaning of Section 3(21) of ERISA) by ERISA with respect to any of the Employee Plans that could
              result in any material liability or material excise Tax under ERISA or the Code being imposed on any Acquired Company.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With respect to each group health plan benefiting any current or former employee of any Acquired Company or an ERISA Affiliate that is subject to Section 4980B of the Code, each Acquired Company and
              each ERISA Affiliate has complied in all material respects with the continuation coverage requirements of Section 4980B of the Code and Part 6 of Subtitle B of Title I of ERISA. No Employee Plan provides health, welfare or retirement benefits
              to any individual who is not a current or former employee of an Acquired Company or the dependents or other beneficiaries of any such current or former employee.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; None of the Acquired Companies has agreed or committed to institute any plan, program, arrangement or agreement for the benefit of any Company Associates other than the Employee Plans identified
              pursuant to <u>Section </u><u>2.16(a)</u>, or to make any amendments to any of the Employee Plans.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There is no pending or, to the knowledge of the Company, threatened claim (other than routine claims for benefits in the ordinary course of business) or Legal Proceeding with respect to any Employee
              Plan nor, to the knowledge of the Company, is there any basis for one.&#160; No Employee Plan is under audit or, to the Company&#8217;s knowledge, the subject of an investigation by the IRS, the U.S. Department of Labor, the Pension Benefit Guaranty
              Corporation, the SEC or any other Governmental Body, nor is any such audit or investigation pending or, to the knowledge of the Company, threatened.&#160; The Company is not and could not reasonably be expected to be subject to either a material
              liability pursuant to Section 502 of ERISA or a material Tax imposed pursuant to Section 4975 or 4976 of the Code.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">34</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Employee Plan and any other payment or arrangement for which any Acquired Company has liability that is subject to Section 409A of the Code is, in all material respects, in documentary and
              operational compliance with Section 409A of the Code.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All (i) insurance premiums required to be paid with respect to, (ii) benefits, expenses and other amounts due and payable under, and (iii) contributions, transfers or payments required to be made to,
              any Employee Plan on or prior to the Closing Date will have been paid, made or accrued on or prior to the Closing Date in all material respects.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except to the extent required under Section 601 et seq. of ERISA or 4980B of the Code (or any other similar state or local Legal Requirement), no Acquired Company nor any Employee Plan has any present
              or future obligation to provide post-employment death, medical or welfare benefits to or make any payment to, or with respect to, any present or former employee, officer, director or service provider of the Acquired Companies pursuant to any
              retiree medical benefit plan or similar plan.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as provided in <u>Section </u><u>1.8</u>, neither the execution or delivery of this Agreement nor the consummation of the Transactions would reasonably be expected to, either alone or in
              conjunction with any other event (whether contingent or otherwise) (i) constitute a stated triggering event under any Employee Plan that will result in any payment (whether of severance pay or otherwise) becoming due to any Company Associate
              who is a natural Person (or dependents of such Persons) of any Acquired Company, (ii) accelerate the time of payment or vesting or increase the amount of compensation due to any Company Associate who is a natural Person (or dependents of such
              Persons) of any Acquired Company, or (iii) result in any forgiveness of Indebtedness with respect to any Company Associate who is a natural Person (or dependents of such Persons) of any Acquired Company, (iv) trigger any funding obligation
              under any Employee Plan or (v) impose any restrictions or limitations on the rights of any Acquired Company to administer, amend or terminate any Employee Plan other than as imposed by any Legal Requirement.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160; No amount, economic benefit or other entitlement that could be received (whether in cash or property or the vesting of property) as a result of any of the Transactions (alone or in combination with any
              other event) by any &#8220;disqualified individual&#8221; (as such term is defined in Treasury Regulation Section 1.280G-1) with respect to the Company or any of its Affiliates under any employment, severance or termination agreement, other compensation
              arrangement or Employee Plan in effect as of the Closing Date would be characterized as an &#8220;excess parachute payment&#8221; (as such term is defined in Section 280G(b)(1) of the Code).</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No Employee Plan provides for the gross-up, reimbursement or obligation to make whole for the payment of Taxes under Section 4999 or 409A of the Code.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">35</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each Non-U.S. Plan complies with all applicable Legal Requirements (including applicable Legal Requirements regarding the form, funding and operation of the Non-U.S. Plan) in all material respects.&#160;
              The financial statements accurately reflect the Non-U.S. Plan liabilities and accruals for contributions required to be paid to the Non-U.S. Plans in all material respects, in accordance with applicable generally accepted accounting
              principles consistently applied.&#160; All contributions required to have been made to all Non-U.S. Plans on or prior to the Closing Date will have been made on or prior to the Closing Date in all material respects.&#160; There are no Legal Proceedings
              pending or, to the knowledge of the Company, threatened with respect to the Non-U.S. Plans (other than routine claims for benefits).&#160; There have not occurred, nor are there continuing, any transactions or breaches of fiduciary duty under
              applicable Legal Requirements with respect to any Non-U.S. Plan which would reasonably be likely to have a material and adverse effect on (i) any Non-U.S. Plan, or (ii) the condition of the Company, any of its Subsidiaries or any ERISA
              Affiliate.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; With respect to any insurance policy providing funding for benefits under any Employee Plan, there is no liability of any Acquired Company in the nature of a retroactive rate adjustment, loss sharing
              arrangement or other actual or contingent liability, nor would there be any such liability if such insurance policy was terminated on the Closing Date.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.17</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Environmental Matters</font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Acquired Companies are and since the Applicable Date have been in compliance, in all material respects, with all applicable Environmental Laws, which compliance includes obtaining, maintaining or
              complying with all Governmental Authorizations required under Environmental Laws for the operation of the Acquired Companies&#8217; business.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; As of the Agreement Date, there is no Legal Proceeding relating to or arising under any Environmental Law that is pending or, to the knowledge of the Company, threatened against any Acquired Company
              or in respect of any Leased Real Property, except as would not be, individually or in the aggregate, material to the Acquired Companies taken as a whole.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Since the Applicable Date through the Agreement Date, no Acquired Company has received any written notice, report or other information of or entered into any legally binding agreement, order,
              settlement, judgment, injunction or decree involving uncompleted, outstanding or unresolved material violations, liabilities or requirements on the part of any Acquired Company relating to or arising under Environmental Laws.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To the knowledge of the Company (i) no Person has been exposed to any Hazardous Material at a property or facility of an Acquired Company at levels in excess of applicable permissible exposure levels,
              and (ii) there are and since the Applicable Date have been no Hazardous Materials present or Releases on, at, under or from any property or facility, including the Leased Real Property, in a manner and concentration that would reasonably be
              expected to result in any material claim against or material liability of an Acquired Company under any Environmental Law.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No Acquired Company has assumed, undertaken, or otherwise become subject to any material liability of another Person relating to Environmental Laws.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">36</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.18</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Insurance</font>.&#160; The Company has delivered or made available to Parent accurate and complete copies of all material insurance
              policies and all self-insurance programs and arrangements (other than in connection with any Employee Plan) relating to the business, assets and operations of the Acquired Companies.&#160; The Acquired Companies maintain insurance coverage in such
              amounts and covering such risks as are in accordance, in all material respects, with normal industry practice for companies of similar size and stage of development.&#160; All such insurance policies are in full force and effect, no notice of
              termination, cancellation, non-renewal or material modification has been received (other than a notice in connection with ordinary renewals), all premiums due and payable thereon have been paid in accordance with the terms of such policies
              and there is no existing material default or event which, with the giving of notice or lapse of time or both, would constitute a material default, by any insured thereunder.&#160; As of the Agreement Date, there is no claim pending under any of
              the Company&#8217;s insurance policies as to which coverage has been questioned, denied or disputed by the underwriters of such policies, except as would not be, or would not, individually or in the aggregate, reasonably be expected to be, material
              to the Acquired Companies taken as a whole.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.19</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Legal Proceedings; Orders</font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There are no Legal Proceedings pending and served (or, to the knowledge of the Company, pending and not served or threatened in writing) against any Acquired Company or, to the knowledge of the
              Company, against any present or former officer, director or employee of an Acquired Company in such individual&#8217;s capacity as such, except as, individually or taken together (i) would not be, or would not reasonably be expected to be, material
              to the Acquired Companies taken as a whole, and (ii) would not reasonably be expected to prevent, materially delay or materially impair the ability of the Company to perform its obligations under this Agreement or to consummate the
              Transactions in a timely manner.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There is no material order, writ, injunction, award or judgment to which an Acquired Company is subject.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the knowledge of the Company, no investigation, audit or review by any Governmental Body with respect to an Acquired Company is pending or is threatened in writing.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">37</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.20</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Authority; Binding Nature of Agreement</font>.&#160; The Company has the corporate power and authority to execute and deliver, and
              to perform its obligations under, this Agreement and to consummate the Transactions, including the Merger, subject to the adoption of this Agreement by holders of at least a majority of the outstanding shares of Company Common Stock entitled
              to vote thereon (the &#8220;<u>Company Stockholder Approval</u>&#8221;), The Company has taken all corporate action necessary, and no other corporate actions or proceedings on the part of the Company or vote of the Company&#8217;s stockholders is necessary to
              authorize the consummation of the Transactions, other than the Company Stockholder Approval.&#160; The Board of Directors has unanimously (a) determined that this Agreement and the Transactions, including the Merger, are advisable and fair to, and
              in the best interest of, the Company and its stockholders, (b) declared it advisable to enter into this Agreement, (c) approved the execution, delivery and performance by the Company of this Agreement and the consummation of the Transactions,
              including the Merger, (d) resolved that the Merger shall be governed by Section 251(c) of the DGCL, in each case, upon the terms and subject to the conditions set forth in this Agreement, and (e) resolved to recommend that the stockholders of
              the Company adopt this Agreement at any meeting of the Company&#8217;s stockholders held for such purpose and any adjournment or postponement thereof, in each case, on the terms and subject to the conditions of this Agreement.&#160; As of the Agreement
              Date, the resolutions in the foregoing sentence have not been subsequently withdrawn or modified in a manner adverse to Parent.&#160; This Agreement has been duly executed and delivered by the Company, and assuming due authorization, execution and
              delivery by Parent and Merger Sub, this Agreement constitutes the legal, valid and binding obligation of the Company and is enforceable against the Company in accordance with its terms, except as such enforcement may be subject to bankruptcy,
              insolvency, fraudulent transfer, reorganization, moratorium and other similar Legal Requirements of general applicability relating to or affecting creditors&#8217; rights, and by general equitable principles.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.21</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Takeover Laws</font>.&#160; Assuming the accuracy of the representations and warranties of Parent and Merger Sub set forth in <u>Section













              </u><font style="color: rgb(0, 0, 0);"><u>3.8</u></font>, the Board of Directors has taken and will take all actions so that the restrictions applicable to business combinations contained in Section 203 of the DGCL and any other Takeover Law
              are, and will be inapplicable to the execution, delivery and performance of this Agreement to the consummation of the Merger and the other Transactions.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.22</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Non-Contravention; Consents</font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Assuming compliance with the applicable provisions of the DGCL, the HSR Act, any applicable filing, notification or approval in any foreign jurisdiction required by Antitrust Laws (if any), and the
              rules and regulations of the SEC and Nasdaq, the execution and delivery of this Agreement by the Company and the consummation of the Transactions will not (i) cause a violation of any of the provisions of the certificate of incorporation or
              bylaws (or other organizational documents) of any Acquired Company, (ii) cause a violation by any Acquired Company of any Legal Requirement or order applicable to an Acquired Company, or to which an Acquired Company is subject, (iii) require
              any consent or notice under, conflict with, result in breach of, or constitute a default under (or an event that with notice or lapse of time or both would become a default), or give rise to any right of purchase, termination, amendment,
              cancellation, acceleration or other adverse change of any right or obligation or the loss of any benefit to which an Acquired Company is entitled under any provision of any Contract, or (iv) result in an Encumbrance (other than a Permitted
              Encumbrance) on any of the property or assets of any Acquired Company; except, in the case of the foregoing <u>clauses </u><u>(iii)</u> and <u>(iv)</u>, as would not reasonably be expected to have, individually or in the aggregate, a
              Material Adverse Effect.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">38</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except for the filing of the certificate of merger with the Secretary of State of the State of Delaware pursuant to the DGCL or as may be required by the Exchange Act (including the filing with the
              SEC of the Merger Proxy Statement and such reports under the Exchange Act as may be required in connection with this Agreement and the Transactions), the DGCL, the HSR Act and any applicable filing, notification or approval in any foreign
              jurisdiction required by Antitrust Laws and the applicable rules and regulations of the SEC and any national securities exchange, the Acquired Companies are not required to give notice to, make any filing with, or obtain any Consent from, any
              Governmental Body at any time prior to the Closing in connection with the execution and delivery of this Agreement by the Company, or the consummation by the Company of the Merger or the other Transactions, except those that the failure to
              make or obtain would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.23</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Opinion of Financial Advisors</font>.&#160; The Board of Directors has, as of the Agreement Date, received (a) the oral opinion, to
              be subsequently confirmed by delivery of its written opinion, of Centerview Partners LLC, financial advisor to the Company, to the effect that, as of the date of such opinion, and based on and subject to the matters set forth therein,
              including the various assumptions made, procedures followed, matters considered and qualifications and limitations set forth in such opinion, the Merger Consideration to be paid to the holders of Shares (other than Excluded Shares, Dissenting
              Shares or any Shares held by any Affiliate of the Company or Parent) in the Merger pursuant to this Agreement is fair, from a financial point of view, to such holders and (b) the oral opinion, to be subsequently confirmed by delivery of its
              written opinion, of Goldman Sachs &amp; Co. LLC, financial advisor to the Company, to the effect that, as of the date of such opinion, and based on and subject to the matters set forth therein, including the various assumptions made,
              procedures followed, matters considered and qualifications and limitations set forth in such opinion, the Merger Consideration to be paid to the holders of Shares (other Parent and its Affiliates) in the Merger pursuant to this Agreement is
              fair, from a financial point of view, to such holders.&#160; The Company will make available to Parent solely for informational purposes and on a non-reliance basis, a signed copy of each such opinion as soon as possible following the Agreement
              Date.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.24</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Brokers and Other Advisors</font>.&#160; Except for Centerview Partners LLC and Goldman Sachs &amp; Co. LLC, no broker, finder,
              investment banker, financial advisor or other Person is entitled to any brokerage, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission, or the reimbursement of expenses in connection therewith, in connection with the Transactions
              based upon arrangements made by or on behalf of the Company.&#160; The Company has made available to Parent accurate copies of all agreements under which any such fee, commission or expense reimbursement is payable and all indemnification and
              other agreements related to the engagement of the Persons to whom any such fee is payable.&#160; Section 2.24 of the Company Disclosure Schedule sets forth a good faith estimate as of the Agreement Date of all fees and expenses of any brokerage,
              finder, financial advisor, investment banker, legal counsel, accountant or other advisor or consultant payable by any Acquired Company in connection with this Agreement or the Transactions.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">39</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.25</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Acknowledgment by Company</font>.&#160; The Company is not relying and has not relied on any representations or warranties
              whatsoever regarding the Transactions or the subject matter of this Agreement, express or implied, except for the representations and warranties of Parent and Merger Sub set forth in <u>Section </u><u>3</u>.&#160; Such representations and
              warranties by Parent and Merger Sub constitute the sole and exclusive representations and warranties of Parent and Merger Sub in connection with the Transactions and the Company understands, acknowledges and agrees that all other
              representations and warranties of any kind or nature whether express, implied or statutory are specifically disclaimed by Parent and Merger Sub.</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">SECTION 3</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;"><u>REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</u></div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;">Parent and Merger Sub represent and warrant to the Company as follows:</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">3.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Due Organization</font>.&#160; Each of Parent and Merger Sub is a corporation or other Entity duly organized, validly existing and
              in good standing under the laws of its jurisdiction of organization and has all necessary power and authority (a) to conduct its business in the manner in which its business is currently being conducted, and (b) to own and use its assets in
              the manner in which its assets are currently owned and used, except as would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">3.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Merger Sub</font>.&#160; Merger Sub was formed solely for the purpose of engaging in the Transactions and activities incidental
              thereto and has not engaged, and prior to the Effective Time will not engage, in any business activities or conducted any operations other than as contemplated by this Agreement in connection with the Transactions and those incident to Merger
              Sub&#8217;s formation and capitalization.&#160; Either Parent or a wholly owned Subsidiary of Parent owns beneficially and of record all of the outstanding capital stock of Merger Sub, free and clear of all Encumbrances and transfer restrictions, except
              for Encumbrances or transfer restrictions of general applicability as may be provided under the Securities Act or applicable securities laws.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">3.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Authority; Binding Nature of Agreement</font>.&#160; Parent and Merger Sub each have the corporate power and authority to execute
              and deliver and to perform their respective obligations under this Agreement and to consummate the Transactions.&#160; The board of directors of each of Parent and Merger Sub have approved the respective execution, delivery and performance by
              Parent and Merger Sub of this Agreement and the consummation of the Transactions, including the Merger.&#160; This Agreement has been duly executed and delivered by Parent and Merger Sub, and assuming due authorization, execution and delivery by
              the Company, this Agreement constitutes the legal, valid and binding obligation of Parent and Merger Sub and is enforceable against Parent and Merger Sub in accordance with its terms, except as such enforcement may be subject to bankruptcy,
              insolvency, fraudulent transfer, reorganization, moratorium and other similar Legal Requirement of general applicability relating to or affecting creditors&#8217; rights, and by general equitable principles.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">40</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">3.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Non-Contravention; Consents</font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Assuming compliance with the applicable provisions of the DGCL, the HSR Act and any applicable filing, notification or approval in any foreign jurisdiction required by Antitrust Laws (if any), and the
              rules and regulations of the SEC and Nasdaq, the execution and delivery of this Agreement by Parent and Merger Sub and the consummation of the Transactions, will not (i) cause a violation of any of the provisions of the certificate of
              incorporation or bylaws (or other organizational documents) of Parent or Merger Sub, (ii) cause a violation by Parent or Merger Sub of any Legal Requirement or order applicable to Parent or Merger Sub, or to which Parent or Merger Sub are
              subject, or (iii) require any consent or notice under, conflict with, result in breach of, or constitute a default under (or an event that with notice or lapse of time or both would become a default), or give rise to any right of purchase,
              termination, amendment, cancellation, acceleration or other adverse change of any right or obligation or the loss of any benefit to which Parent or Merger Sub is entitled under any provision of any Contract, except in the case of the
              foregoing <u>clauses </u><u>(ii)</u> and <u>(iii)</u>, as would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except for the filing of the certificate of merger with the Secretary of State of the State of Delaware pursuant to the DGCL or as may be required by the Exchange Act, Takeover Laws, the DGCL, the HSR
              Act and any applicable filing, notification or approval in any foreign jurisdiction required by Antitrust Laws and the applicable rules and regulations of the SEC and any national securities exchange, neither Parent nor Merger Sub, nor any of
              Parent&#8217;s other Affiliates, is required to give notice to, make any filing with or obtain any Consent from, any Governmental Body at any time prior to the Closing in connection with the execution and delivery of this Agreement by Parent or
              Merger Sub, or the consummation by Parent or Merger Sub of the Merger or the other Transactions, except those that the failure to make or obtain would not, individually or in the aggregate, reasonably be expected to have a Parent Material
              Adverse Effect.&#160; No vote of Parent&#8217;s, Merger Sub&#8217;s stockholders is necessary to approve this Agreement or any of the Transactions (except in the case of Merger Sub as has been obtained prior to the execution and delivery of this Agreement).</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">3.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Disclosure</font>.&#160; None of the information with respect to Parent or Merger Sub supplied or to be supplied by or on behalf of
              Parent or Merger Sub or any of their Subsidiaries, specifically for inclusion or incorporation by reference in the Merger Proxy Statement will, (a) at the time such document is filed with the SEC, (b) at any time such document is amended or
              supplemented, or (c) at the time such document is first published, sent or given to the Company&#8217;s stockholders, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in
              order to make the statements therein, in light of the circumstances under which they were made, not misleading.&#160; For clarity, the representations and warranties in this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>3.5</u></font>
              will not apply to statements or omissions included or incorporated by reference in the Merger Proxy Statement based upon information supplied by the Company to Parent or Merger Sub or any of their respective Representatives on behalf of the
              Company specifically for inclusion therein.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">41</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">3.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Absence of Litigation</font>.&#160; As of the Agreement Date, there is no Legal Proceeding pending and served or, to the knowledge
              of Parent, pending and not served, against Parent or Merger Sub, except as would not, and would not reasonably be expected to, individually or in the aggregate, have a Parent Material Adverse Effect.&#160; To the knowledge of Parent or Merger Sub,
              as of the Agreement Date, neither Parent nor Merger Sub is subject to any continuing order of, consent decree, settlement agreement or similar written agreement with, or continuing investigation by, any Governmental Body, or any order, writ,
              judgment, injunction, decree, determination or award of any Governmental Body, except as would not, and would not reasonably be expected to, individually or in the aggregate, have a Parent Material Adverse Effect.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">3.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Funds</font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Prior to the Agreement Date, Parent has delivered to the Company true and correct copies of a fully executed debt commitment letter, dated as of the Agreement Date (including all exhibits, schedules
              annexes and amendments thereto, the &#8220;<u>Debt Commitment Letter</u>&#8221;), and the fee letter (redacted in a customary fashion as to economic terms and other commercially sensitive numbers and provisions specified in any such fee letter (including
              any provisions relating to &#8220;flex&#8221; terms or similar concepts), none of which could adversely affect the availability, conditionality, enforceability or amount (except by reason of any increased fees or original issue discount resulting from
              the &#8220;flex&#8221; terms or similar concepts contained in any such fee letter) of the Financing contemplated thereby) referred to in the Debt Commitment Letter (the &#8220;<u>Debt Financing Fee Letter</u>&#8221;) from the Financing Sources named therein,
              pursuant to which those Financing Sources have committed, subject only to the terms and conditions set forth therein, to provide to the Parent or Merger Sub the amount of debt financing as described therein, the proceeds of which shall be
              used to, among other things, fund the Transactions (the &#8220;<u>Financing</u>&#8221;).</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as expressly set forth in the Debt Commitment Letter, there are no conditions precedent to the obligations of the Financing Sources to fund the full amount contemplated by the Debt Commitment
              Letter as of the Agreement Date and no contingencies that would permit the Financing Sources to reduce the total amount of the Financing from the amount contemplated by the Debt Commitment Letter as of the Agreement Date, including any
              condition or other contingency relating to the amount (except by reason of any increased fees or original issue discount resulting from the &#8220;flex&#8221; terms or similar concepts contained in any such fee letter) or availability of the Financing
              pursuant to any &#8220;flex&#8221; provision.&#160; There are no side letters, understandings or other agreements, Contracts or other arrangements of any kind that could affect the conditions precedent to the availability of the Financing on the Closing Date
              contemplated by the Debt Commitment Letter.&#160; As of the Agreement Date, the Debt Commitment Letter has been duly executed and delivered by, and is a legal, valid and binding obligation of Parent and, to the knowledge of Parent, each other
              party thereto (except as such enforcement may be subject to bankruptcy and other similar Legal Requirements and by general equitable principles).&#160; As of the Agreement Date, the Debt Commitment Letter is in full force and effect against Parent
              and, to the knowledge of Parent, against each other party thereto and, as of the Agreement Date, has not been withdrawn, rescinded, terminated or otherwise amended or modified as of the Agreement Date, and, assuming the satisfaction of the
              conditions set forth in <u>Section </u><u>6</u>, no such withdrawal, rescission, termination, amendment or modification is currently contemplated (except for amendments or modifications contemplated by the Debt Commitment Letter as of the
              Agreement Date to add additional arrangers or bookrunners).&#160; All commitment and other fees required to be paid under the Debt Commitment Letter and Debt Financing Fee Letter on or before the Agreement Date have been fully paid, and Parent and
              Merger Sub will pay in full any amounts due on or before the Closing Date.&#160; The aggregate proceeds of the Financing (including any Alternate Financing), when funded in accordance with, and subject to, the terms and conditions of the Debt
              Commitment Letter, will be sufficient to enable Parent and Merger Sub to pay in cash the aggregate Merger Consideration and amounts set forth in the Payoff Letter payable at and following the Effective Time and the aggregate amounts payable
              to holders of In the Money Director Options and Company RSUs following the Effective Time pursuant to <u>Section </u><u>1.8</u> and the expenses contemplated by <u>Section </u><font style="color: rgb(0, 0, 0);"><u>7.3(a)</u></font>
              (collectively, the &#8220;<u>Required Amount</u>&#8221;).&#160; In no event shall receipt by, or the availability of any funds or financing (including the Financing) to, the Parent, Merger Sub or any of their Affiliates be or be deemed, construed or alleged
              to be a condition precedent to any obligations of Parent and Merger Sub under this Agreement.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">42</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">3.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Ownership of Shares</font>.&#160; Except as contemplated by this Agreement, neither Parent nor any of Parent&#8217;s controlled
              Affiliates, directly or indirectly, owns, and at all times for the past three years, neither Parent nor any of Parent&#8217;s controlled Affiliates has owned, beneficially or otherwise, any Shares or any securities, Contracts or obligations
              convertible into or exercisable or exchangeable for Shares, excluding investments made in the ordinary course of business in connection with retirement plans, 401(k) plans, mutual funds, pension plans or similar arrangements, in each case,
              not specifically targeted to an investment in Shares and not resulting in record or beneficial ownership of any Shares by Parent or any of its controlled Affiliates.&#160; Neither Parent nor Merger Sub is, nor for the past three years has been, an
              &#8220;interested stockholder&#8221; of the Company subject to the restrictions on &#8220;business combinations&#8221; (in each case, as such quote terms are defined under Section 203(c) of the DGCL).</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">3.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Acknowledgement by Parent and Merger Sub</font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither Parent nor Merger Sub is relying and neither Parent nor Merger Sub has relied on any representations or warranties whatsoever regarding the Transactions or the subject matter of this
              Agreement, express or implied, except for the representations and warranties of the Company set forth in <u>Section </u><u>2</u>, including the Company Disclosure Schedule.&#160; Such representations and warranties by the Company constitute the
              sole and exclusive representations and warranties of any of the Acquired Companies in connection with the Transactions and each of Parent and Merger Sub understands, acknowledges and agrees that all other representations and warranties of any
              kind or nature whether express, implied or statutory are specifically disclaimed by the Acquired Companies.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">43</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In connection with the due diligence investigation of the Acquired Companies by Parent and Merger Sub and their respective Affiliates, stockholders or Representatives, Parent and Merger Sub and their
              respective Affiliates, stockholders and Representatives have received and may continue to receive after the Agreement Date from the Company, the other Acquired Companies and their respective Affiliates and Representatives certain estimates,
              projections, forecasts and other forward-looking information, as well as certain business plan information, regarding the Acquired Companies and their business and operations.&#160; Parent and Merger Sub hereby acknowledge that there are
              uncertainties inherent in attempting to make such estimates, projections, forecasts and other forward-looking statements, as well as in such business plans, and agree that, except in the case of fraud, Parent and Merger Sub will have no claim
              against the Acquired Companies, or any of their respective Affiliates, stockholders or Representatives, or any other Person with respect thereto unless any such information is expressly addressed or included in a representation or warranty
              contained in this Agreement.&#160; Accordingly, Parent and Merger Sub hereby acknowledge and agree that neither the Acquired Companies nor any of their respective Affiliates, stockholders or Representatives, nor any other Person, has made or is
              making any express or implied representation or warranty with respect to such estimates, projections, forecasts, forward-looking statements or business plans unless any such information is expressly addressed or included in a representation
              or warranty contained in this Agreement.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">3.10</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Brokers and Other Advisors</font>.&#160; Except for Persons, if any, whose fees and expenses shall be paid by Parent or Merger Sub,
              no broker, finder, investment banker, financial advisor or other Person is entitled to any brokerage, finder&#8217;s, financial advisor&#8217;s or other similar fee or commission, or the reimbursement of expenses in connection therewith, in connection
              with the Transactions based upon arrangements made by or on behalf of Parent, Merger Sub or any of their respective Subsidiaries.</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;">SECTION 4</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;"><u>CERTAIN COVENANTS OF THE COMPANY</u></div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">4.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Access and Investigation; Notice of Certain Events</font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the period from the execution and delivery of this Agreement until the earlier of the Effective Time and the valid termination of this Agreement pursuant to <u>Section </u><u>7</u> (the &#8220;<u>Pre-Closing













                Period</u>&#8221;), upon reasonable advance notice to the Company, the Company shall, and shall cause the other Acquired Companies and the respective Representatives of the Acquired Companies to, (1) provide Parent and Parent&#8217;s Representatives
              with reasonable access during normal business hours of each of the Acquired Companies, respectively, to the Acquired Companies&#8217; Representatives and to their properties and assets, and to all existing books, records, documents and information
              relating to the Acquired Companies, and (2) promptly provide Parent and Parent&#8217;s Representatives with all reasonably requested information regarding the Acquired Companies&#8217; business and such additional financial, operating and other data and
              information regarding the Acquired Companies, in each case, as Parent may reasonably request; <font style="font-style: italic;">provided</font>,<font style="font-style: italic;"> however</font>, that any such access to the Acquired
              Companies&#8217; assets and personnel shall be conducted at Parent&#8217;s expense, at a reasonable time, and (to the extent conducted at an Acquired Company&#8217;s facilities) under the supervision of appropriate personnel of the Acquired Companies and all
              such information shall be requested in such a manner as not to unreasonably interfere with the normal operation of Acquired Companies&#8217; business.&#160; Nothing herein shall require any of the Acquired Companies to disclose any information to Parent
              if such disclosure would, in the Company&#8217;s reasonable determination (after consultation with outside counsel) and after notice to Parent (i) jeopardize any attorney-client or other legal privilege (so long as the Acquired Companies have
              reasonably cooperated with Parent and used their reasonable best efforts to permit such inspection of or to disclose such information on a basis that does not waive such privilege with respect thereto), (ii) contravene any applicable Legal
              Requirement (so long as the Acquired Companies have reasonably cooperated with Parent and used their reasonable best efforts to permit disclosure to the extent permitted by Legal Requirements, <font style="font-style: italic;">e.g.</font>,
              through the use of customary &#8220;clean room&#8221; arrangements pursuant to which certain Representatives of Parent could be provided access to such information), or (iii) contravene any Contract to which an Acquired Company is a party or by which an
              Acquired Company is bound as of the Agreement Date (so long as the Acquired Companies have reasonably cooperated with Parent and used their reasonable best efforts to permit disclosure on a basis that would not contravene such Contract).&#160;
              Notwithstanding the foregoing, nothing in this <u>Section 4.1</u> shall require an Acquired Company to disclose any information to Parent or Parent&#8217;s Representatives to the extent such information relates to the applicable portions of the
              minutes of the meetings of the Board of Directors or any committee thereof (including any presentations or other materials prepared by or for the Board of Directors or such committee thereof) in which the Board of Directors or committee
              thereof discussed (x) the Transactions, or any similar transaction involving an Acquired Company, (y) any Acquisition Proposal, or (z) a Company Adverse Recommendation Change; <font style="font-style: italic;">provided</font> that upon
              Parent&#8217;s request in accordance with this <u>Section 4.1</u>, the Company shall disclose versions of such minutes, presentations or other materials to Parent and its Representatives in which such information is redacted.&#160; With respect to the
              information disclosed pursuant to this <u>Section 4.1</u>, Parent shall comply with, and shall instruct Parent&#8217;s Representatives to comply with, all of its obligations under the Confidential Disclosure Agreement dated October 15, 2025,
              between the Company and Parent, as amended (the &#8220;<u>Confidentiality Agreement</u>&#8221;).</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">44</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to applicable Legal Requirements, during the Pre-Closing Period, each of the Company and Parent shall promptly notify the other in writing of (i) any notice or other communication received by
              such Party from any Governmental Body in connection with this Agreement (except with respect to the matters covered by, and subject to, <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.2</u></font>, which shall be governed by the
              terms thereof or the Transactions, or from any Person alleging that the consent of such Person is or may be required in connection with this Agreement or the Transactions), or (ii) any Legal Proceeding commenced or, to such Party&#8217;s knowledge,
              threatened in writing, against the other Party or any of its Subsidiaries or otherwise relating to, involving or affecting such Party or any of its Subsidiaries, in each case in connection with, arising from or otherwise relating to this
              Agreement or the Transactions.&#160; In furtherance of the foregoing, during the Pre-Closing Period, the Company shall promptly furnish Parent a copy of each report, schedule and other document filed or submitted by it pursuant to the requirements
              of federal or state securities Legal Requirements and a copy of any communication received by the Company from the SEC concerning compliance with securities laws with respect to matters unrelated to the Transactions.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No investigation conducted or notice given pursuant to this <u>Section 4.1</u> shall affect or be deemed to qualify, modify or limit, or cure the breach of, any representation or warranty made by the
              Company in this Agreement</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">45</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">4.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Operation of the Acquired Companies&#8217; Business</font>.&#160; During the Pre-Closing Period, except (a) as expressly required under
              this Agreement or as required by applicable Legal Requirements, (b) with the prior written consent of Parent (which consent shall be in Parent&#8217;s sole discretion, other than with respect to the matters set forth in <u>Sections </u><font style="color: rgb(0, 0, 0);"><u>4.2(b)(vi)</u></font> through <u>(ix)</u>, <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.2(b)(xii)</u></font>, <u>Section 4.2(b)(xiii)</u> and <u>Section 4.2(b)(xv)</u>, for which Parent&#8217;s
              consent shall not be unreasonably withheld, conditioned or delayed), or (c) with respect to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.2(a)</u></font>, as set forth in Section <font style="color: rgb(0, 0, 0);">4.2(a)</font> of
              the Company Disclosure Schedule and with respect to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.2(b)</u></font>, as set forth in Section <font style="color: rgb(0, 0, 0);">4.2(b)</font> of the Company Disclosure Schedule:</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the Company shall, and shall cause each other Acquired Company to conduct its business in the ordinary course in all material respects, and to the extent consistent therewith to use its reasonable
              best efforts to preserve intact its material assets (including technology), properties, Contracts, licenses and business organization, keep available the services of its employees and maintain satisfactory business relationships with
              licensors, licensees, suppliers, lessors, Governmental Bodies and others having material business dealings with the Acquired Companies; and</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the Acquired Companies shall not:</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(A) establish a record date for, declare, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock (including the Shares), (B) enter into any
              Contract with respect to the voting of securities, or (C) repurchase, redeem or otherwise reacquire any of the Shares, or any rights, warrants or options to acquire any of the Shares, other than (1) repurchases of Shares outstanding as of the
              Agreement Date pursuant to the Company&#8217;s right (under written commitments in effect as of the Agreement Date that have been made available to Parent) to purchase Shares held by a Company Associate only upon termination of such Person&#8217;s
              employment or engagement by the Acquired Companies, (2) forfeitures of Company Options, Company RSUs or Company PSUs (or, in each case, Shares issued upon the exercise or settlement thereof) outstanding on the Agreement Date pursuant to the
              terms of any such Company Option, Company RSU or Company PSU (as in effect as of the Agreement Date) between the Company and a Company Associate or member of the Board of Directors in accordance with the terms thereof as in effect on the
              Agreement Date, (3) in connection with withholding to satisfy the exercise price or Tax obligations with respect to Company Options, Company RSUs or Company PSUs pursuant to the terms thereof (as in effect as of the Agreement Date), or (4)
              the declaration and payment of dividends or distributions between the Company and a wholly owned Subsidiary of the Company or between wholly owned Subsidiaries of the Company;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; split, combine, subdivide or reclassify any Shares or other equity interests;</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">46</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; sell, issue, grant, deliver, pledge, transfer, encumber, dispose of, or otherwise divest or authorize the sale, issuance, grant, delivery, pledge, transfer, encumbrance, disposal or divestiture of
              (A) any capital stock, equity interest or other security, including the Shares, (B) any option, call option, warrant, restricted securities or other right to acquire any capital stock, equity interest or other security, or (C) any instrument
              convertible into or exchangeable for any capital stock, equity interest or other security or any &#8220;phantom&#8221; stock, &#8220;phantom&#8221; stock rights, stock appreciation rights or stock-based performance units (except (x) that the Company may issue Shares
              as required to be issued upon the exercise or vesting (as the case may be) of the Company Options, Company RSUs and Company PSUs outstanding as of the Agreement Date and listed in Section <font style="color: rgb(0, 0, 0);">2.3(h)</font> of
              the Company Disclosure Schedule, in each case pursuant to the terms thereof (as in effect as of the Agreement Date), or (y) with respect to the creation of pledges or encumbrances on capital stock of a Subsidiary of the Company (or
              authorizations with respect any of the foregoing) constituting Permitted Encumbrances under <u>clause (f)</u> of the definition thereof that are required by the terms of the Senior Secured Term Loan Agreement in effect on the Agreement Date;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160; except as set forth in <u>Section </u><u>1.8</u>, or as required under any Employee Plan as in effect on the Agreement Date and listed in Section 2.16(a) of the Company Disclosure Schedule, (A)
              establish, adopt, enter into, terminate or amend any Employee Plan (or any plan, program, policy, Contract, arrangement or agreement that would be an Employee Plan if it were in existence on the Agreement Date), (B) amend or waive any of
              their rights under, or accelerate the payment, funding or vesting under, any provision of any of the Employee Plans (or any plan, program, policy, Contract, arrangement or agreement that would be an Employee Plan if it were in existence on
              the Agreement Date), including any Company Options, Company RSUs or Company PSUs, (C) make any contributions or payments to any trust or other funding vehicle with respect to any Employee Plan, (D) change any actuarial or other assumptions
              used to calculate funding obligations with respect to any Employee Plan or change the manner in which contributions to such plans are made or the basis on which such contributions are determined, except as may be required by GAAP, (E) grant,
              provide, promise, amend or increase for any employee or director any compensation, bonuses, severance, retention or other payments or benefits, other than merit or market-based increases of no more than five percent, made in the ordinary
              course of business, to base compensation or wage rate for any employee, <font style="font-style: italic;">provided</font> that the aggregate of such increases shall not be greater than three percent of the total base compensation for the
              employee population as in effect as of November 30, 2025, (F) hire or retain any Company Associate with annual base compensation or an annual base retainer of $200,000 or more or any employee at or above the level of senior director, (G)
              terminate (other than for cause) the employment or services of a Company Associate whose annual base salary or annual base retainer is in excess of $200,000 or an employee who is at or above the level of senior director, (H) forgive any loans
              or other amounts payable to an Acquired Company by any Company Associate, or (I) enter into any Contract that that indemnifies any director or executive officer of the Company or any Acquired Company (other than any indemnification provisions
              set forth in the certificate of incorporation or bylaws or comparable governing documents of the Company or any Acquired Company as of the Agreement Date);</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; amend or permit the adoption of any amendment to its certificate of incorporation or bylaws or other charter or organizational documents;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160; (A) form any Subsidiary, (B) acquire any equity or voting interest (including by merger, consolidation, acquisition of stock or otherwise) in any other Entity (C) acquire material assets or a
              business (or any division thereof) of any other Person (other than any acquisition of supplies, raw materials, inventory or products in the ordinary course of business), or (D) enter into any joint venture, partnership limited liability
              corporation or similar arrangement;</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">47</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 108pt;">(vii)&#160;&#160;&#160;&#160;&#160;&#160; make, commit to make or authorize any capital expenditure (other than capital expenditures that do not exceed $250,000 individually or $500,000 in the aggregate);</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(viii)&#160;&#160;&#160;&#160;&#160; lease, sublease, license, sublicense, pledge, sell or otherwise dispose of, divest or spin-off, abandon, surrender, cancel, waive, relinquish or permit to lapse, covenant not to assert, fail to
              diligently prosecute, enforce or maintain, fail to renew (other than any Patent (1) expiring at the end of its statutory term or (2) abandonment of any application for registration of any Intellectual Property Right in the ordinary course of
              business, and that is not material to the operation of the Acquired Companies&#8217; businesses taken as a whole), transfer or assign, guarantee, exchange or swap, mortgage or subject to any material Encumbrance (other than, in each case, Permitted
              Encumbrances) any material right or other material asset or property (except (A) with respect to Intellectual Property Rights, granting non-exclusive licenses in the ordinary course of business (including entering into clinical trial
              agreements, but solely with respect to Clinical Trials that are ongoing as of the Agreement Date (and have been disclosed to Parent) and material transfer agreements), (B) with respect to tangible assets, pursuant to dispositions of obsolete,
              surplus or worn out assets that are no longer useful in the conduct of the Acquired Companies&#8217; businesses, or (C) transactions between the Company and another wholly owned Subsidiary of the Company or between wholly owned Subsidiaries of the
              Company);</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(ix)&#160;&#160;&#160;&#160;&#160;&#160;&#160; extend any lease with respect to any Leased Real Property or acquire an ownership interest in any real property;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; disclose or otherwise fail to preserve and maintain any material Trade Secrets or disclose or release any other material confidential information relating to any of the Acquired Companies&#8217;
              businesses, including Products, other than pursuant to a binding written confidentiality and non-disclosure agreement entered into in the ordinary course of business, and with respect to any Trade Secrets qualifying as a Trade Secret under
              applicable Legal Requirements, with protections sufficient to protect and maintain such Trade Secret as a Trade Secret under applicable Legal Requirements;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xi)&#160;&#160;&#160;&#160;&#160;&#160;&#160; enter into any new line of business or abandon or discontinue any existing line of business, it being understood that Clinical Trials planned as of the Agreement Date and conducted in the ordinary
              course of business shall not constitute new lines of business;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xii)&#160;&#160;&#160;&#160;&#160;&#160; lend money or make capital contributions or advances to or make investments in, any Person, or incur, assume, guarantee, endorse or otherwise become responsible for (or amend or modify the terms of)
              any Indebtedness (except for (A) advances to directors, employees and consultants for travel and other business related expenses in the ordinary course of business and in compliance with the Company&#8217;s policies related thereto that are in
              effect as of the Agreement Date, (B) advances of expenses as required under the Company&#8217;s certificate of incorporation or bylaws or any indemnification agreement with the Company&#8217;s directors or officers made available to Parent, (C) the
              issuance of surety bonds, letters of credit, bank guarantees or similar instruments entered into for the benefit of Governmental Bodies in connection with the anticipated licensure or distribution of any Product, (D) capital expenditures
              permitted by <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.2(b)(vii)</u></font>, and (E) the issuance of Indebtedness by a wholly owned Subsidiary of the Company to the Company or another wholly owned Subsidiary of the Company);</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">48</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 108pt;">(xiii)&#160;&#160;&#160;&#160;&#160; (A) enter into or terminate, or (B) materially amend, renew, extend, materially modify or waive any material rights or obligations under any Material Contract (or any Contract that if entered into
              prior to the Agreement Date would be a Material Contract), including any letter agreement, schedule, exhibit or similar document ancillary to such Material Contract, except (x) in the case of <u>clause </u><u>(A)</u>, for (i) normal
              expirations of Material Contracts in the ordinary course of business, and (ii) entry into commercial contracts in the ordinary course of business that are not the type of Material Contract contemplated by <u>Section </u><font style="color: rgb(0, 0, 0);"><u>2.9(a)(ii)</u></font>, <u>Section </u><font style="color: rgb(0, 0, 0);"><u>2.9(a)(iii)</u></font>, <u>Section </u><font style="color: rgb(0, 0, 0);"><u>2.9(a)(vii)</u></font>, <u>Section 2.9(a)(viii)</u>, <u>Section
              </u><font style="color: rgb(0, 0, 0);"><u>2.9(a)(xii)</u></font>, <u>Section </u><font style="color: rgb(0, 0, 0);"><u>2.9(a)(xiv)</u></font> or <u>Section 2.9(a)(xvii)</u>, and (y) in the case of <u>clause </u><u>(B)</u>, amendments,
              renewals, extensions, modifications and waivers in the ordinary course of business; <font style="font-style: italic;">provided</font> that any such amendment, renewal, extension, modification or waiver (i) does not materially extend the term
              or duration of such Material Contract, and (ii) would not create or result in new or additional obligations on the part of an Acquired Company of the type contemplated by <u>Section </u><font style="color: rgb(0, 0, 0);"><u>2.9(a)(ii)</u></font>,
              <u>Section </u><font style="color: rgb(0, 0, 0);"><u>2.9(a)(iii)</u></font>, <u>Section </u><font style="color: rgb(0, 0, 0);"><u>2.9(a)(vii)</u></font>, <u>Section 2.9(a)(viii)</u>, <u>Section </u><font style="color: rgb(0, 0, 0);"><u>2.9(a)(xii)</u></font>,
              <u>Section </u><font style="color: rgb(0, 0, 0);"><u>2.9(a)(xiv)</u></font> or <u>Section 2.9(a)(xvii)</u>;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xiv)&#160;&#160;&#160;&#160;&#160; enter into any agreement, arrangement or commitment that purports to bind or restrict Parent or any of its Subsidiaries, other than, following the Effective Time, the Surviving Corporation and its
              Subsidiaries;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xv)&#160;&#160;&#160;&#160;&#160;&#160; (A) make any change to any accounting method or accounting period used for Tax purposes, (B) make (except in the ordinary course of business), rescind or change any material Tax election, (C) file an
              amended income or other material amended Tax Return, (D) enter into a closing agreement with any Governmental Body regarding any material Tax liability or assessment, (E) settle, compromise or consent to any material Tax claim or assessment
              or surrender a right to any income or other material Tax refund, (F) waive or extend the statute of limitations with respect to any income or other material Tax or income or other material Tax Return, other than automatic waivers or automatic
              extensions obtained in the ordinary course of business, (G) request any private letter, technical advice or similar Tax ruling from any Governmental Body with respect to Taxes, (H) enter into any written Tax allocation, indemnity or sharing
              agreement (other than any such agreements not relating primarily to Taxes), or (I) fail to pay any material Taxes when due consistent with past practice, taking into account any automatic extensions obtained in the ordinary course of business
              and growth or changes in the Acquired Companies&#8217; business activities consistent with past practice; provided that, solely for purposes of this <u>Section 4.2(b)(xv)</u>, &#8220;material&#8221; shall mean $250,000 per each action and $750,000 for all
              such actions in the aggregate; and <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">further</font> that the Company shall provide Parent with advance written notice of any proposed closing agreement with
              any Governmental Body regarding Tax liability or assessment, or any proposed settlement, compromise, or consent to any Tax claim or assessment, in each case, that is not considered &#8220;material&#8221; pursuant to this Section 4.2(b)(xv);</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xvi)&#160;&#160;&#160;&#160;&#160; change the Acquired Companies&#8217; financial accounting methods, principles or practices, except as required by changes in GAAP or in Regulation S-X of the Exchange Act, as agreed to by the Company&#8217;s
              independent public accountants;</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">49</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 108pt;">(xvii)&#160;&#160;&#160;&#160; settle, release, waive or compromise any Legal Proceeding or other claim (or threatened Legal Proceeding or other claim) against any Acquired Company, other than with respect to Tax matters (but
              solely to the extent any such Tax matter is addressed in <u>Section </u><u>4.2(b)(xv)</u>) and any settlement, release, waiver or compromise that (A) results solely in monetary obligations involving only the payment of monies by the
              Acquired Companies of not more than $250,000 in the aggregate (excluding monetary obligations that are funded by an indemnity obligation to, or an insurance policy of, any Acquired Companies), (B) does not involve the admission of wrongdoing
              by, does not impose any material restrictions or changes on the business or operations of, and does not involve any injunctive or equitable or other nonmonetary relief (other than immaterial and non-monetary relief incidental thereto)
              against, any Acquired Company, (C) does not provide for the grant to any third party of a license, cross license, covenant not to sue, or other grant of rights to any material Intellectual Property Rights, and (D) provides for a complete
              release of the claims in dispute giving rise to such settlement, release, waiver or compromise; <font style="font-style: italic;">provided</font> that the settlement, release, waiver or compromise of any Legal Proceeding or claim brought by
              the stockholders of the Company against the Company and/or its directors relating to the Transactions or a breach of this Agreement or any other agreements contemplated hereby shall be subject to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>1.7</u></font> or <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.5</u></font>, as applicable;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xviii)&#160;&#160;&#160; commence any material Legal Proceeding against any third Person (other than with respect to Tax matters solely to the extent any such Tax matter is addressed in subject to <u>Section </u><u>4.2(b)(xv)</u>);</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xix)&#160;&#160;&#160;&#160;&#160; affirmatively waive or release any noncompetition, nonsolicitation, noninterference, nondisparagement, nondisclosure or other material restrictive covenant obligation of any Company Associate;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xx)&#160;&#160;&#160;&#160;&#160;&#160; terminate any Clinical Trials in respect of any Product that are ongoing as of the execution and delivery of this Agreement, other than pursuant to the terms thereof and in the ordinary course of
              business, or commence (alone or with any third party) any new preclinical or clinical development, including commencement of a Clinical Trial, in respect of any Product that is not a Product as of the Agreement Date;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xxi)&#160;&#160;&#160;&#160;&#160; (A) create, implement, operate, participate in or offer any patient assistance or patient support program that offers, provides or intends to provide free drug product (including any Product) or any
              cost-sharing assistance, such as co-pay coupons or co-pay cards in relation to a drug product (including any Product), to any patient, including any federal healthcare program beneficiaries (each, a &#8220;<u>Patient Assistance Program</u>&#8221;), or
              (B) offer, make or provide any grants, charitable contributions, donations, sponsorships or similar support (whether in cash or in kind) that relates to or otherwise supports any third-party Patient Assistance Program;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xxii)&#160;&#160;&#160;&#160; fail to maintain in full force and effect the existing insurance policies of the Acquired Companies or to renew or replace such insurance policies with comparable insurance policies;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xxiii)&#160;&#160;&#160; enter into any collective bargaining agreement or similar agreement with any labor organization or employee representative body or recognize or certify any labor union, works council or similar labor
              organization or employee representative body as the bargaining representative for any employees of an Acquired Company;</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">50</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 108pt;">(xxiv)&#160;&#160;&#160; implement any employee layoffs, furloughs, reductions in force, or plant closings that would trigger notice obligations under the WARN Act or similar state or ex-U.S. Legal Requirements;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xxv)&#160;&#160;&#160;&#160; adopt or implement any stockholder rights plan or similar arrangement;</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xxvi)&#160;&#160;&#160; adopt a plan or agreement of complete or partial liquidation or dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of any of the Acquired Companies; or</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(xxvii)&#160;&#160; authorize any of, or agree or commit to take, any of the actions described in the foregoing <u>clauses </u><u>(i)</u> through <u>(xxvi)</u> of this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.2(b)</u></font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;">Notwithstanding the foregoing, nothing contained herein shall give to Parent or Merger Sub, directly or indirectly, rights to control or direct the operations of the Acquired Companies prior to the Effective
              Time.&#160; Prior to the Effective Time, each of Parent and the Company shall exercise, consistent with the terms and conditions hereof, complete control and supervision of its and its, if applicable, Subsidiaries&#8217; respective operations.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">4.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">No Solicitation</font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as expressly permitted by this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3</u></font>, during the Pre-Closing Period the Acquired Companies shall cause their Representatives not
              to, directly or indirectly (i) continue any solicitation, knowing encouragement, discussions or negotiations with any Persons that may be ongoing with respect to an Acquisition Proposal, (ii) (A) solicit, initiate or knowingly facilitate or
              encourage (including by way of furnishing information) any inquiries regarding, or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, an Acquisition Proposal, (B) engage in, continue or otherwise
              participate in any discussions or negotiations regarding, or furnish to any other Person any information in connection with an Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to an Acquisition Proposal,
              or (C) adopt, approve, endorse, recommend, declare advisable or enter into any letter of intent, memorandum of understanding, agreement in principle, term sheet or similar agreement, whether binding or nonbinding, or any Contract (other than
              an Acceptable Confidentiality Agreement permitted to be executed pursuant to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3(b)</u></font>), in each case, with respect to, or that could reasonably be expected to lead to, an
              Acquisition Proposal or that would reasonably be expected to cause the Company to abandon, terminate, delay or fail to consummate, or that would otherwise materially impede, interfere with or be inconsistent with, the Transactions, (iii)
              waive or release any Person from, forebear in the enforcement of or amend any standstill agreement or any standstill provisions of any other Contract, or take any action to exempt any Person (other than Parent, Merger Sub or their Affiliates)
              from the restrictions on &#8220;business combinations&#8221; or any similar provision contained in applicable Takeover Laws or the organizational and other governing documents of an Acquired Company, unless in the case of this <u>clause </u><u>(iii)</u>,
              the Board of Directors determines in good faith, after consultation with the Company&#8217;s outside legal counsel, that the failure to do so would be inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s stockholders
              under applicable Legal Requirements and notifies Parent of any such release, forbearance or amendment within one Business Day thereof, or (iv) resolve or publicly propose to take any of the actions set forth in the foregoing <u>clauses </u><u>(i)</u>
              through <u>(iii)</u> of this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3(a)</u></font>.&#160; As promptly as reasonably practicable (and in any event within one Business Day) following the Agreement Date, the Company shall
              terminate access to any data room or similar facility established by the Company or its Representatives in connection with a potential Acquisition Proposal (including the process that culminated in the execution and delivery of this
              Agreement) and request (unless such a request was previously made by an Acquired Company before the execution and delivery of this Agreement) the prompt return or destruction of all non-public information previously furnished to any Person
              (other than Parent, Merger Sub and their respective Representatives) that has since December 1, 2023 made or indicated an intention to make an Acquisition Proposal or executed a confidentiality agreement in connection with its consideration
              of an Acquisition Proposal (or the process that culminated in the execution and delivery of this Agreement).&#160; The Company shall be fully responsible for any action taken by its or the other Acquired Companies&#8217; Representatives that, had such
              action been taken by the Company, would constitute a breach of this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3</u></font>, and any such action taken by any Representative of an Acquired Company shall constitute a breach of
              this <u>Section </u><u>4.3</u> by the Company.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">51</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding anything in this Agreement to the contrary, if at any time after the execution and delivery of this Agreement and prior to the receipt of the Company Stockholder Approval (the &#8220;<u>Cut-off














                Time</u>&#8221;) any Acquired Company or its Representatives receives a <font style="font-style: italic;">bona fide</font> written Acquisition Proposal from any Person or group of Persons, which Acquisition Proposal was made or renewed after the
              execution and delivery of this Agreement and did not arise out of or result from a breach of this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3</u></font> or of <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.1</u></font>,
              and the Board of Directors determines in good faith, after consultation with the Company&#8217;s financial advisors and outside legal counsel, that (i) such Acquisition Proposal constitutes or would reasonably be expected to lead to a Superior
              Offer, and (ii) the failure to take such action described in <u>clauses </u><u>(x)</u> or <u>(y)</u> of this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3(b)</u></font> would be inconsistent with the fiduciary duties of the
              Board of Directors to the Company&#8217;s stockholders under applicable Legal Requirements, then the Company and its Representatives may, until the Cut-off Time, (x) furnish, pursuant to an Acceptable Confidentiality Agreement, information
              (including non-public information) with respect to the Acquired Companies to the Person or group of Persons who has made such Acquisition Proposal and the Representatives of such Person or group of Persons; <font style="font-style: italic;">provided













              </font>that the Company shall as promptly as practicable (and in any event within 24 hours) provide to Parent any non-public information concerning the Acquired Companies that is provided to any Person to the extent access to such information
              is not then available to Parent and its Representatives, and (y) engage in or otherwise participate in discussions or negotiations with the Person or group of Persons making such Acquisition Proposal and the Representatives of such Person or
              group of Persons.&#160; If the Board of Directors makes any determination described in the foregoing <u>clauses </u><u>(i)</u> and <u>(ii)</u> of this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3(b)</u></font> or initially takes
              any action set forth in the foregoing <u>clauses </u><u>(x)</u> or <u>(y)</u> of this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3(b)</u></font>, the Company shall notify Parent within 24 hours thereof.</div>
            <div>&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">52</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the Pre-Closing Period, the Company shall (i) promptly (and in any event within 24 hours after receipt thereof by an Acquired Company) notify Parent if any request, inquiry, proposal or offer
              with respect to, or that could reasonably be expected to lead to, an Acquisition Proposal is received by any Acquired Company or any Representative thereof and provide to Parent (w) copies of any written request, inquiry, proposal, offer or
              other materials, including proposed agreements (including any proposed term sheet, letter of intent, acquisition agreement, financing commitments or similar agreements with respect thereto) received in connection therewith, (x) a summary of
              any material unwritten terms and conditions thereof, (y) a summary of the nature of any information requested, and (z) the identity of the Person or each member in the group of Persons making such request, inquiry, proposal or offer, (ii)
              keep Parent reasonably informed of any material developments, discussions or negotiations regarding any such request, inquiry, proposal, offer or Acquisition Proposal (including by furnishing copies of any further requests, inquires or
              proposals or amendments thereto) on a prompt basis (and in any event within 24 hours of such material development, discussion or negotiation), and (iii) upon the request of Parent, reasonably inform Parent of the status of such Acquisition
              Proposal.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Nothing in this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3</u></font> or elsewhere in this Agreement shall prohibit the Company from (i) taking and disclosing to the stockholders of
              the Company a position contemplated by Rule 14e-2(a), Rule 14d-9 or Item 1012(a) of Regulation M-A promulgated under the Exchange Act, including any &#8220;stop, look and listen&#8221; communication pursuant to Rule 14d-9(f) promulgated under the
              Exchange Act, or (ii) making any disclosure to the stockholders of the Company that the Board of Directors determines, after consultation with outside counsel, is required by applicable Legal Requirements; <font style="font-style: italic;">provided</font>,
              <font style="font-style: italic;">however</font>, that nothing in this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3(d)</u></font> shall permit the Board of Directors to make a Company Adverse Recommendation Change and, unless
              the Board of Directors has made a Company Adverse Recommendation Change in accordance with the provisions of <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.1(b)</u></font> that remains in effect and has not been withdrawn, such
              disclosure shall state that the Company Board Recommendation continues to be in effect.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">53</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">4.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Preparation of Proxy Statement; Stockholder Meeting</font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall as promptly as reasonably practicable (and in any event within 20 Business Days) after the Agreement Date, prepare and file with the SEC the Merger Proxy Statement.&#160; The Company
              shall give Parent and its Representatives a reasonable opportunity to review and comment on the initial preliminary Merger Proxy Statement and all subsequent forms or versions of or amendments or supplements to the Merger Proxy Statement
              prior to the filing thereof with the SEC or dissemination to the holders of Shares and the Company shall give reasonable and good faith consideration to any timely comments thereon made by Parent or its Representatives.&#160; Parent and Merger Sub
              shall promptly supply to the Company in writing, for inclusion in the Merger Proxy Statement, all information concerning Parent and Merger Sub and their controlled Affiliates required under applicable Legal Requirements to be included in the
              Merger Proxy Statement as is reasonably requested by the Company.&#160; Parent, Merger Sub and the Company shall cooperate in good faith to determine the information regarding each of them that is necessary to include in the Merger Proxy Statement
              in order to satisfy applicable Legal Requirements.&#160; The Company agrees that the Merger Proxy Statement filed by the Company with the SEC shall (x) comply in all material respects with the Exchange Act and other applicable Legal Requirements,
              and (y) not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not
              misleading; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that no covenant is made by the Company with respect to information supplied by or on behalf of Parent or Merger Sub for
              inclusion or incorporation by reference in the Merger Proxy Statement.&#160; Each of Parent, Merger Sub and the Company agrees to respond promptly to any comments of the SEC or its staff and to promptly correct any information provided by it for
              use in the Merger Proxy Statement if and to the extent that such information shall have become false or misleading in any material respect, and the Company further agrees to take all steps necessary to cause the Merger Proxy Statement as so
              corrected to be promptly filed with the SEC and to be disseminated to holders of Shares, in each case as and to the extent required by applicable Legal Requirements.&#160; The Company shall (A) promptly notify Parent of the receipt of, and
              promptly provide Parent copies of, all comments (including oral comments) from, and all correspondence with, the SEC or its staff with respect to the Merger Proxy Statement and shall promptly notify Parent of any request by the SEC or its
              staff for any amendment or supplement thereto or for additional information, (B) provide Parent and its counsel with a reasonable opportunity to review and comment on any proposed correspondence between the Company or any of its
              Representatives, on the one hand, and the SEC or its staff, on the other hand, with respect to the Merger Proxy Statement and shall give reasonable and good faith consideration to any timely comments thereon made by Parent or its
              Representatives, and (C) promptly provide Parent with final copies of any correspondence sent by the Company or any of its Representatives to the SEC or its staff with respect to the Merger Proxy Statement, and of any amendments or
              supplements to the Merger Proxy Statement.&#160; The Merger Proxy Statement shall include the Company Board Recommendation, unless the Board of Directors has made a Company Adverse Recommendation Change in compliance with <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.1</u></font>.&#160; The Merger Proxy Statement shall include (x) the fairness opinion of the Company&#8217;s financial advisors referenced in <u>Section </u><font style="color: rgb(0, 0, 0);"><u>2.23</u></font>, (y)
              the notice of the Company Stockholder Meeting, and (z) the notice and other information required by Section 262(d) of the DGCL.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">54</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall establish a record date for, duly call, convene and hold a meeting of its stockholders for the purpose of voting upon the adoption of this Agreement (together with any adjournments
              or postponements thereof, the &#8220;<u>Company Stockholder Meeting</u>&#8221;) as reasonably promptly as practicable after the SEC Clearance Date (and shall initially schedule the Company Stockholder Meeting to be held within 25 Business Days from the
              date of the mailing of the Merger Proxy Statement, or if the Company&#8217;s nationally recognized proxy solicitor advises the Company that 25 Business Days from the date of the mailing of the Merger Proxy Statement is insufficient time to obtain
              the Company Stockholder Approval, such later date to which Parent consents in writing (such consent not to be unreasonably withheld, conditioned or delayed)), and any adjournments or postponements of such meeting shall require the prior
              written consent of Parent (not to be unreasonably withheld, conditioned or delayed) other than to the extent necessary to allow reasonable additional time for the filing and/or mailing, and review by the Company&#8217;s stockholders prior to the
              date of the Company Stockholder Meeting, of any supplemental or amended disclosure that the Board of Directors determines in good faith (after consultation with outside legal counsel) is required by applicable Legal Requirements or the rules
              and regulations of Nasdaq.&#160; Notwithstanding the foregoing, the Company may, and Parent may require the Company to, adjourn or postpone the Company Stockholder Meeting two times (for a period of not more than 10 Business Days each but not past
              three Business Days prior to the End Date), unless prior to such adjournment or postponement, the Company shall have received an aggregate number of proxies voting for the adoption of this Agreement, which have not been withdrawn, such that
              the condition in <u>Section </u><font style="color: rgb(0, 0, 0);"><u>6.1(a)</u></font> would be satisfied at such meeting if it were to be held without such postponement or adjournment.&#160; In connection with the foregoing, the Company shall
              (i) file the definitive Merger Proxy Statement with the SEC and cause the definitive Merger Proxy Statement to be mailed to the Company&#8217;s stockholders as of the record date established for the Company Stockholder Meeting as reasonably
              promptly as practicable (and in any event within four Business Days) after the date on which the SEC confirms that it has no further comments on the Merger Proxy Statement (the &#8220;<u>SEC Clearance Date</u>&#8221;); <font style="font-style: italic;">provided</font>
              that if the SEC has failed to affirmatively notify the Company within 10 days after the initial filing of the Merger Proxy Statement with the SEC that it intends to review the Merger Proxy Statement, then such 10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> day shall be the &#8220;<u>SEC Clearance Date</u>&#8221;.&#160; Once the Company has established a record date for the Company Stockholder Meeting, the Company shall not change such record date or
              establish a different record date for the Company Stockholder Meeting without the prior written consent of Parent (such consent not to be unreasonably withheld, conditioned or delayed), unless required to do so by applicable Legal
              Requirements.&#160; Unless the Board of Directors shall have made a Company Adverse Recommendation Change in compliance with <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.1</u></font>, the Company shall use reasonable best efforts to
              obtain the Company Stockholder Approval, including to solicit proxies in favor of the adoption of this Agreement.&#160; Unless this Agreement is validly terminated in accordance with <u>Section </u><u>7</u>, the Company shall submit this
              Agreement to its stockholders at the Company Stockholder Meeting even if the Board of Directors shall have made a Company Adverse Recommendation Change or proposed or announced any intention to do so.&#160; The Company shall, upon the reasonable
              request of Parent, advise Parent at least on a daily basis on each of the last seven Business Days prior to the date of the Company Stockholder Meeting as to the aggregate tally of proxies received by the Company with respect to the Company
              Stockholder Approval.&#160; Without the prior written consent of Parent, the adoption of this Agreement and a nonbinding advisory vote on compensation matters shall be the only matters (other than related procedural matters) that the Company shall
              propose to be acted on by the stockholders of the Company at the Company Stockholder Meeting.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">55</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-align: center; font-weight: bold;">SECTION 5</div>
            <div>&#160;</div>
            <div style="text-align: center; font-weight: bold;"><u>ADDITIONAL COVENANTS OF THE PARTIES</u></div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Company Board Recommendation</font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the Pre-Closing Period, subject to the Board of Directors making a Company Adverse Recommendation Change in accordance with the provisions of <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.1(b)</u></font>,
              neither the Board of Directors nor any committee thereof shall (i) (A) withdraw or qualify (or modify in a manner adverse to Parent or Merger Sub), or publicly propose to withdraw or qualify (or modify in a manner adverse to Parent or Merger
              Sub), the Company Board Recommendation, or (B) approve, recommend or declare advisable, or publicly propose to approve, recommend or declare advisable, any Acquisition Proposal (any action described in <u>clause </u><u>(i)</u> of this <u>Section













              </u><font style="color: rgb(0, 0, 0);"><u>5.1(a)</u></font> being referred to as a &#8220;<u>Company Adverse Recommendation Change</u>&#8221;), or (ii) adopt, approve, recommend or declare advisable, or propose to adopt, approve, recommend or declare
              advisable, or allow the Company to execute or enter into any Contract with respect to any Acquisition Proposal, or Contract that would require, or would reasonably be expected to cause, the Company to abandon, terminate, delay or fail to
              consummate, or that would otherwise materially impede, interfere with or be inconsistent with, the Transactions (other than an Acceptable Confidentiality Agreement).</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">56</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding anything to the contrary contained in this Agreement, at any time prior to the Cut-off Time:</div>
            <div>&#160;</div>
            <div style="text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;if, after the Agreement Date, any Acquired Company receives a <font style="font-style: italic;">bona fide</font> written Acquisition Proposal, and such Acquisition Proposal has not been withdrawn,
              and after consultation with the Company&#8217;s financial advisors and outside legal counsel, the Board of Directors shall have determined, in good faith, that such Acquisition Proposal is a Superior Offer, (x) the Board of Directors may make a
              Company Adverse Recommendation Change, or (y) if such Acquisition Proposal did not arise out of or result from a material breach of <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3</u></font> or <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.1(a)</u></font>, the Company may terminate this Agreement pursuant to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>7.1(e)</u></font> to enter into a Specified Agreement with respect to such Superior Offer, but
              in each case under the foregoing <u>clause </u><u>(x)</u> or <u>(y)</u>, only if (A) the Board of Directors determines in good faith, after consultation with the Company&#8217;s financial advisors and outside legal counsel, that the failure to
              do so would be inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s stockholders under applicable Legal Requirements, (B) the Company has given Parent prior written notice of its intention to make a Company
              Adverse Recommendation Change or terminate this Agreement pursuant to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>7.1(e)</u></font> (a &#8220;<u>Determination Notice</u>&#8221;) (which notice shall not constitute a Company Adverse
              Recommendation Change or termination), and, if desired by Parent, during the Negotiation Period, the Company has negotiated in good faith with respect to any revisions to the terms of this Agreement or another proposal, to the extent proposed
              by Parent, so that such Acquisition Proposal would cease to constitute a Superior Offer, and (C)(1) the Company has, prior to the commencement of the Negotiation Period, provided to Parent information required to have been provided pursuant
              to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3(b)</u></font> and <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3(c)</u></font>, (2) the Company has given Parent the full Negotiation Period to propose revisions to the
              terms of this Agreement or make another proposal so that such Acquisition Proposal would cease to constitute a Superior Offer, and (3) after giving effect to the proposals made by Parent during the Negotiation Period, if any, after
              consultation with the Company&#8217;s financial advisors and outside legal counsel, the Board of Directors has determined, in good faith, that such Acquisition Proposal continues to constitute a Superior Offer and that the failure to make the
              Company Adverse Recommendation Change or terminate this Agreement pursuant to <u>Section </u><font style="color: rgb(0, 0, 0);"><u>7.1(e)</u></font> would be inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s
              stockholders under applicable Legal Requirements.&#160; Issuance of any &#8220;stop, look and listen&#8221; communication by or on behalf of the Company pursuant to Rule 14d-9(f) promulgated under the Exchange Act shall not be considered a Company Adverse
              Recommendation Change and shall not require the giving of a Determination Notice or compliance with the procedures set forth in this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.1</u></font> to the extent that any such
              communication expressly reaffirms the Company Board Recommendation.&#160; The provisions of this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.1(b)(i)</u></font> shall also apply to any material amendment (which shall be deemed to
              include any change to the financial terms thereof) to any Acquisition Proposal and shall require a new Determination Notice; and</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">57</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; other than in connection with an Acquisition Proposal, the Board of Directors may make a Company Adverse Recommendation Change in response to an Intervening Event, but only if (A) the Board of
              Directors determines in good faith, after consultation with the Company&#8217;s outside legal counsel, that the failure to do so would be inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s stockholders under
              applicable Legal Requirements, (B) the Company has given Parent a Determination Notice describing in reasonable detail the facts and circumstances resulting in such Intervening Event and that render a Company Adverse Recommendation Change
              necessary and, if desired by Parent, during the Negotiation Period, the Company has negotiated in good faith with respect to any revisions to the terms of this Agreement or another proposal, to the extent proposed by Parent, so that a Company
              Adverse Recommendation Change in response to such Intervening Event would no longer be necessary, and (C)(1) the Company has given Parent the full Negotiation Period to propose revisions to the terms of this Agreement or make another proposal
              so that a Company Adverse Recommendation Change would no longer be necessary, and (2) after giving effect to the proposals made by Parent during the Negotiation Period, if any, after consultation with the Company&#8217;s outside legal counsel, the
              Board of Directors has determined, in good faith, that the failure to make the Company Adverse Recommendation Change would continue to be inconsistent with the fiduciary duties of the Board of Directors to the Company&#8217;s stockholders under
              applicable Legal Requirements as a result of such Intervening Event.&#160; The provisions of this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.1(b)(ii)</u></font> shall also apply to any material change to the facts and circumstances
              relating to such Intervening Event, which shall require a new Determination Notice.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Filings, Consents and Approvals</font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to the terms and conditions of this Agreement, the Parties agree to use (and shall cause their respective Affiliates to use) their reasonable best efforts to take promptly any and all steps
              necessary to avoid or eliminate each and every impediment under Antitrust Laws that may be asserted by any Governmental Body so as to enable the Closing to occur as promptly as practicable, but in no case later than the End Date, including
              providing as promptly as reasonably practicable all information reasonably required by any Governmental Body pursuant to its evaluation of the Transactions under the HSR Act or other applicable Antitrust Laws.&#160; Notwithstanding the foregoing
              and any other provision of this Agreement to the contrary, in no event shall Parent, Merger Sub, the Company or any of their respective Subsidiaries be obligated to defend any lawsuit, injunction, or any proceeding before courts whether
              judicial or administrative, brought by any Governmental Body challenging or seeking to restrain, prohibit or place conditions on the consummation of the Transactions.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to the terms and conditions of this Agreement, (i) each of the Parties shall (and shall cause their respective Affiliates, if applicable, to) promptly, but in no event later than 20 Business
              Days after the Agreement Date, make an appropriate filing of all notification and report forms as required by the HSR Act with respect to the Transactions and (ii) each of the Parties shall (and shall cause their respective Affiliates, if
              applicable, to) as promptly as reasonably practicable make any filing or notification that is required to be made with, or seek any consent, approval, permit or authorization that is required to be obtained from, a Specified Antitrust
              Authority set forth on Section 5.2(b) of the Company Disclosure Schedule (the foregoing <u>clauses </u><u>(i)</u> and <u>(ii)</u> collectively, &#8220;<u>Regulatory Filings</u>&#8221;).</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">58</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Without limiting the generality of anything contained in this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.2</u></font>, during the Pre-Closing Period, each Party shall give the other
              Parties prompt notice of (i) the making or commencement of any request or inquiry, or any investigation, action or Legal Proceeding brought or threatened in writing to be brought by a Governmental Body or brought or threatened in writing to
              be brought by a third party before any Governmental Body, in each case, with respect to the Transactions (other than any request, inquiry, investigation, action or Legal Proceeding brought or threatened in writing to be brought by the holders
              of Shares against the Company and/or its directors relating to the Transactions or a breach of this Agreement or any other agreements contemplated hereby, which are addressed in <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.5</u></font>),













              and (ii) its receipt of any notice or other communication from any third party alleging that the consent of a third party is or may be required in connection with the Transactions (the information described in the foregoing <u>clauses </u><u>(i)</u>
              and <u>(ii)</u>, the &#8220;<u>Identified Communications</u>&#8221;).&#160; Additionally, each Party shall (A) keep the other Parties reasonably informed as to the status of any Regulatory Filings and Identified Communications or response thereto, (B)
              promptly inform the other Parties of, and (wherever practicable) give the other Parties reasonable advance notice of, and the opportunity to participate in, any communication to or from the FTC, DOJ or any other Governmental Body or third
              party in connection with any such Regulatory Filings and Identified Communication, (C) promptly furnish to the other Parties, subject to an appropriate confidentiality agreement, copies of documents provided to or received from any
              Governmental Body in connection with any Regulatory Filings or Identified Communication (other than &#8220;4(c) documents&#8221; as that term is used in the rules and regulations under the HSR Act, that contain valuation information (which can be
              redacted)), (D) to the extent reasonably practicable and subject to an appropriate confidentiality agreement, consult and cooperate with the other Parties and consider in good faith the views of the other Parties in connection with any
              analysis, appearance, presentation, memorandum, brief, argument, opinion or proposal made or submitted in connection with any Regulatory Filings or Identified Communication, and (E) except as may be prohibited by any Legal Requirement, in
              connection with any such Regulatory Filings and Identified Communications, give the other Parties reasonable advance notice of, and permit authorized Representatives of the other Party to be present at each meeting or conference relating to
              such Regulatory Filing or Identified Communication and to have access to and be consulted in connection with any argument, opinion or proposal made or submitted to any third party in connection with such Regulatory Filing or Identified
              Communication.&#160; Notwithstanding anything to the contrary in this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.2</u></font>, the Parties may (y) as they deem reasonably advisable and necessary based on the advice of outside counsel
              to prevent a violation of Antitrust Law, designate competitively sensitive materials and information provided to the other under this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.2</u></font> as &#8220;outside counsel only&#8221; and such
              materials and the information contained therein shall be given only to outside counsel of the recipient and will not be disclosed by such outside counsel to employees, officers or directors of the recipient without the advance written consent
              of the Party providing such materials, and (z) redact information provided to one another pursuant to this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.2</u></font> to the extent providing such information would (1) contravene any
              applicable Legal Requirement (so long as the disclosing Party has reasonably cooperated with recipient and used its reasonable best efforts to permit disclosure to the extent permitted by Legal Requirements), (2) jeopardize any
              attorney-client or other legal privilege (so long as the disclosing Party has reasonably cooperated with recipient and used its reasonable best efforts to permit disclosure on a basis that does not waive such privilege with respect thereto),
              or (3) contravene any Contract to which the disclosing Party is a party or by which the disclosing Party is bound as of the Agreement Date (so long as the disclosing Party has reasonably cooperated with the recipient and used its reasonable
              best efforts to permit disclosure on a basis that would not contravene such Contract).</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">59</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding the foregoing or anything to the contrary set forth in this Agreement, subject to Parent consulting with and considering in good faith the views and comments of the Company, Parent
              shall have the right to (i) direct, devise and implement the strategy for obtaining any necessary approval of, and for responding to any substantive request from, or inquiry or investigation by (including directing the nature and substance of
              all such responses), and lead all meetings and substantive communications (including any negotiations) with, any Governmental Body in connection with Regulatory Filings, and (ii) control the defense and settlement of any investigation or
              Legal Proceeding relating to the Transactions that is brought by or before any Governmental Body in connection with the Regulatory Filings.&#160; Notwithstanding the foregoing or anything to the contrary set forth in this Agreement, no Party shall
              (or shall permit any of its Affiliates to) commit to or agree with any Governmental Body to stay, toll or extend, any applicable waiting period or enter into any similar timing agreement, without the prior written consent of the other Parties
              (not to be unreasonably withheld, conditioned or delayed); <font style="font-style: italic;">provided</font> that Parent and Merger Sub shall be permitted without the Company&#8217;s consent (it being understood that Parent and Merger Sub may
              exercise this right only one time) to withdraw their filing under the HSR Act in connection with the Transactions and promptly refile the notification and report forms within two Business Days (as required by the HSR Act) with respect to the
              Transactions.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding the foregoing or anything to the contrary in this Agreement, neither Parent nor any of its Affiliates shall be required to commence or defend any lawsuit, injunction or any proceeding
              before courts whether judicial or administrative, against any Governmental Body in connection with the Transactions.&#160; Notwithstanding the foregoing or any other provision of this Agreement to the contrary, in no event shall Parent, Merger Sub
              or any of their Affiliates be required to propose, negotiate, undertake, commit to or consent to any divestiture, sale, disposition, licensing, hold separate order or other structural or conduct relief, or other operational undertakings, in
              order to obtain clearance from any Governmental Body.&#160; Nothing in this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.2</u></font> shall require Parent, Merger Sub or the Company to take or agree to take any action unless the
              effectiveness of such action is conditioned upon Closing, and the Company shall not take or propose to undertake any divestiture, sale, disposition, hold separate order or other structural or conduct relief, or other operational undertaking
              without Parent&#8217;s prior consent (which may be given or withheld in Parent&#8217;s sole discretion).</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">60</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During the Pre-Closing Period, the Company shall, and shall cause the other Acquired Companies to, to the extent permissible under applicable Legal Requirements, (i) offer Parent the opportunity to
              consult with the Acquired Companies prior to any proposed material meeting or other material communication with the FDA, EMA, the Centers for Medicare &amp; Medicaid Services (&#8220;<u>CMS</u>&#8221;) or any other Specified Governmental Body relating to
              any Product or material Governmental Authorization (including Pricing Approvals) under a Health Care Law, (ii) promptly inform Parent of, and provide Parent with a reasonable opportunity to review, in advance, (A) any material filing proposed
              to be made by or on behalf of an Acquired Company, and (B) any material correspondence or other material communication, in each case of the foregoing <u>clauses </u><u>(A)</u> and <u>(B)</u> proposed to be submitted or otherwise
              transmitted to the FDA, EMA, CMS or any other Specified Governmental Body by or on behalf of an Acquired Company relating to any Product or material Governmental Authorization under a Health Care Law, (iii) keep Parent reasonably informed of
              any material communication (written or oral) with or from the FDA, EMA, CMS or any other Specified Governmental Body or relating to any Product or Governmental Authorization, and (iv) promptly inform Parent and provide Parent with a
              reasonable opportunity to comment, in each case, prior to making any material change to any study protocol, making any material change to a manufacturing plan or process, making any material change to a development timeline or initiating, or
              making any material change to, commercialization and reimbursement activities or materials (including promotional and marketing activities and materials) relating to any Product or anyway relating to any material change or potential change to
              the Exploitation of any Product.&#160; The Company shall promptly notify Parent of any material data relating to any Product, including information related to any serious or unexpected adverse events (as such concepts are contemplated under
              applicable Health Care Laws) with respect to any Product, in each case which it discovers after the execution and delivery of this Agreement.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During the Pre-Closing Period, the Company shall give prompt notice to Parent of any event, development, occurrence, circumstance, change or effect that has had or would reasonably be expected to
              have a Material Adverse Effect, or would reasonably be expected to make the satisfaction of any of the conditions set forth in <u>Section </u><font style="color: rgb(0, 0, 0);"><u>6.1</u></font> or <u>Section </u><font style="color: rgb(0, 0, 0);"><u>6.2</u></font> impossible or unlikely on or prior to the End Date, and Parent shall give prompt notice to the Company of any event, development, occurrence, circumstance, change or effect that has had or would reasonably
              be expected to have a Parent Material Adverse Effect, or would reasonably be expected to make the satisfaction of any of the conditions set forth in <u>Section </u><font style="color: rgb(0, 0, 0);"><u>6.1</u></font> or <u>Section </u><font style="color: rgb(0, 0, 0);"><u>6.2</u></font> impossible or unlikely on or prior to the End Date.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The delivery of any notice pursuant to this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.2</u></font> shall not cure any breach of any representation or warranty requiring disclosure of
              such matter prior to the Agreement Date or otherwise limit or affect the remedies available hereunder to any Party.</div>
            <div>&#160;</div>
            <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.3</font>&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold;">Employee Benefits</font>.</div>
            <div>&#160;</div>
            <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For a period of one year following the Effective Time (or until the date of termination of the relevant Continuing Employee, if earlier) (the &#8220;<u>Continuation Period</u>&#8221;), Parent shall provide, or
              cause to be provided, to each employee of an Acquired Company who is employed by an Acquired Company as of immediately prior to the Effective Time and who continues to be actively employed by an Acquired Company (or any Affiliate thereof,
              including, for the avoidance of doubt, Parent and Parent&#8217;s Affiliates) during such one-year period (each, a &#8220;<u>Continuing Employee</u>&#8221;) with (i) a base salary or wage rate that is no less than that provided to such Continuing Employee by
              any Acquired Company immediately prior to the Effective Time, (ii) target cash incentive compensation opportunities that are no less than either (x) those provided to such Continuing Employee by any Acquired Company immediately prior to the
              Effective Time under Employee Plans set forth in Section 2.16(a) of the Company Disclosure Schedule, or (y) those provided by Parent or its Affiliates to similarly situated employees of Parent or its Affiliates, and (iii) other compensation
              and employee benefits (excluding equity-based compensation, employee stock purchase plans, nonqualified deferred compensation, retiree medical, change in control or similar compensation or benefits, severance, defined benefit plans,
              post-employment welfare plans and other similar plans or arrangements) that are substantially comparable, in the aggregate, to either (x) those provided to such Continuing Employee by any Acquired Company immediately prior to the Effective
              Time under Employee Plans set forth in Section 2.16(a) of the Company Disclosure Schedule, or (y) those provided by Parent or its Affiliates to similarly situated employees of Parent or its Affiliates.</div>
            <div>&#160;</div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">61</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
            </div>
            <!--PROfilePageNumberReset%Num%61%%%-->
            <div>
              <div style="text-align: right; font-weight: bold;">
                <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the extent that service is relevant for eligibility or vesting under any benefit plan of Parent and/or the Surviving Corporation in which a Continuing Employee participates (other than
                  equity-based compensation, employee stock purchase plans, nonqualified deferred compensation, retiree medical, change in control or similar compensation or benefits, severance, defined benefit plans, post-employment welfare plans and
                  other similar plans or arrangements), then Parent shall provide that such benefit plan shall, for purposes of eligibility and vesting, credit such Continuing Employees for service prior to the Effective Time with the Company and its
                  Affiliates or their respective predecessors to the same extent that such service was recognized prior to the Effective Time under the corresponding benefit plan of the Company, but no credit for any service will be required that would
                  result in a duplication of benefits.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Following the Effective Time, Parent or an Affiliate of Parent shall use commercially reasonable efforts to (i) waive any preexisting condition limitations otherwise applicable to Continuing
                  Employees and their eligible dependents under any plan of Parent or an Affiliate that provides health benefits in which Continuing Employees are eligible to participate following the Effective Time in the plan year in which the Effective
                  Time occurs, other than any limitations that were in effect with respect to such employees immediately prior to the Effective Time under the corresponding Employee Plan, (ii) honor any deductible, co-payment and out-of-pocket maximums
                  incurred by the Continuing Employees and their eligible dependents under the health plans in which they participated immediately prior to transitioning into a plan of Parent or an Affiliate during the portion of the plan year prior to
                  such transition in satisfying any deductibles, co-payments or out-of-pocket maximums under health plans of Parent or an Affiliate, in each case to the extent recognized for such purpose under an analogous Employee Plan prior to the
                  Effective Time, and (iii) waive any waiting period limitation or evidence of insurability requirement that would otherwise be applicable to a Continuing Employee and his or her eligible dependents on or after the Effective Time, in each
                  case to the extent such Continuing Employee or eligible dependent had satisfied any similar limitation or requirement under an analogous Employee Plan prior to the Effective Time.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The provisions of this <u>Section </u><u>5.3</u> are solely for the benefit of the Parties, and no provision of this <u>Section </u><font style="color: #000000;"><u>5.3</u></font> is intended
                  to, or shall, (i) constitute the establishment or adoption of or an amendment to any employee benefit plan for purposes of ERISA or otherwise, or (ii) prohibit or limit the ability of Parent or any of its Affiliates (including, following
                  the Effective Time, the Company) to amend, modify or terminate any employee benefit or compensation plan, program or arrangement.&#160; No Company Associate or any other individual associated therewith shall be regarded for any purpose as a
                  third-party beneficiary of the Agreement or have the right to enforce the provisions hereof.&#160; Nothing in this <u>Section </u><font style="color: #000000;"><u>5.3</u></font> or elsewhere in this Agreement shall be construed to create a
                  right in any Person to employment with Parent, the Surviving Corporation or any other Affiliate of the Surviving Corporation or to any compensation or benefits and the employment of each Continuing Employee shall be &#8220;at will&#8221; employment.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">61</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If requested in writing by Parent no later than five days prior to the Effective Time, the Company shall, at least one day prior to the Effective Time, cease contributions to, and adopt written
                  resolutions (or take other necessary and appropriate action) to terminate, the Company 401(k) Plan (the &#8220;<u>Company </u><u>401(k) Plan</u>&#8221;), effective as of the day prior to the Closing Date and to fully vest all participants under the
                  Company 401(k) Plan, such termination and vesting to be effective no later than the day preceding the Effective Time; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that such Company
                  401(k) Plan cessation of contributions, vesting and termination may be made contingent upon the Closing.&#160; The form and substance of such resolutions and any other actions taken in connection with the foregoing termination shall be subject
                  to the prior review and approval of Parent, whose approval shall not be unreasonably withheld.&#160; If the Company 401(k) Plan is terminated, Parent shall or shall cause its Affiliates to allow all individuals who were participants in the
                  Company 401(k) Plan to be eligible to participate in a 401(k) plan sponsored by Parent or its Affiliates (the &#8220;<u>Parent </u><u>401(k) Plan</u>&#8221;) as soon as administratively practicable after the Effective Time and shall permit such
                  participants to roll over their account balances (and shall use commercially reasonable efforts to permit such participants to roll over participant loans) from the Company 401(k) Plan to the Parent 401(k) Plan.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With respect to Continuing Employees who are employed in a member state of the European Union, nothing herein shall be construed to permit a modification of the main elements of the employment
                  contract or of the national collective agreement applicable to such Continuing Employee.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During the Pre-Closing Period, the form of any broad-based notices or communication materials (including website postings) from an Acquired Company to employees of the Acquired Companies with
                  respect to the Transactions or employment, compensation or benefits matters addressed in this Agreement or related to the Transactions or employment with Parent, the Surviving Corporation or any of their respective Subsidiaries
                  thereafter, shall be subject to the prior review, comment and approval of Parent, which such review, comment or approval shall not be unreasonably withheld, conditioned or delayed.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">62</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Indemnification of Officers and Directors</font>.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For a period of six years after the Effective Time, Parent agrees that all rights to indemnification, advancement of expenses and exculpation from liabilities for acts or omissions occurring at
                  or prior to the Effective Time (whether asserted or claimed prior to, at or after the Effective Time) existing in favor of the current or former directors or officers of any Acquired Company pursuant to the organizational documents of the
                  Company and any indemnification or other similar agreements of any Acquired Company set forth in Section 5.4(a) of the Company Disclosure Schedule, in each case as in effect on the Agreement Date, shall continue in full force and effect
                  in accordance with their terms, and Parent shall cause the Acquired Companies to perform their obligations thereunder.&#160; Without limiting the foregoing, during the period commencing at the Effective Time and ending on the sixth anniversary
                  of the Effective Time, Parent shall, and shall cause the Acquired Companies to, indemnify and hold harmless each individual who is as of the Agreement Date, or who becomes prior to the Effective Time, a director or officer of any Acquired
                  Company or who is as of the Agreement Date, or who thereafter commences prior to the Effective Time, serving at the request of any Acquired Company as a director or officer of another Person (the &#8220;<u>Indemnified Persons</u>&#8221;), against all
                  claims, losses, liabilities, damages, judgments, inquiries, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit or proceeding, whether civil,
                  criminal, administrative or investigative (including with respect to matters existing or occurring at or prior to the Effective Time, including this Agreement and the Transactions), arising out of or pertaining to the fact that the
                  Indemnified Person is or was a director or officer of any Acquired Company or is or was serving at the request of any Acquired Company as a director or officer of another Person, whether asserted or claimed prior to, at or after the
                  Effective Time, to the fullest extent that such Acquired Company is permitted under applicable Legal Requirements.&#160; In the event of any such claim, action, suit or proceeding, Parent shall, and shall cause the Acquired Companies to, (x)
                  pay, in advance of the final disposition of such claim, action, suit or proceeding, any expenses incurred in defense thereof by the Indemnified Person upon receipt of an undertaking by such Indemnified Person to repay such amount if it
                  shall ultimately be determined that such Indemnified Person is not entitled to be indemnified pursuant to the preceding sentence, and (y) reasonably cooperate in the defense of any such matter.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For a period of six years from and after the Effective Time, Parent shall cause the Surviving Corporation to either maintain in effect its current policies of directors&#8217; and officers&#8217; insurance
                  maintained by or for the benefit of the Acquired Companies or provide a substitute policy for the Acquired Companies and their current and former directors and officers who are currently covered by the directors&#8217; and officers&#8217; insurance
                  coverage currently maintained by or for the benefit of the Acquired Companies as of the Agreement Date, in either case, of not less than the existing coverage as of the Agreement Date and having other terms that are in aggregate not less
                  favorable to the insured persons than the directors&#8217; and officers&#8217; insurance coverage currently maintained by or for the benefit of the Acquired Companies with respect to claims arising from facts or events that occurred at or before the
                  Effective Time (with insurance carriers having at least an &#8220;A&#8221; rating by A.M.&#160; Best with respect to directors&#8217; and officers&#8217; insurance), except that in no event shall Parent or the Surviving Corporation be required to pay with respect to
                  such insurance policies more than 300% of the aggregate annual premium most recently paid by the Acquired Companies prior to the Agreement Date (the &#8220;<u>Maximum Amount</u>&#8221;), and if the Surviving Corporation is unable to obtain the
                  insurance required by this <u>Section </u><font style="color: #000000;"><u>5.4(b)</u></font> it shall obtain as much comparable insurance as possible for the years within such six-year period for a premium not exceeding the Maximum
                  Amount.&#160; In lieu of such insurance, prior to the Closing Date the Company may, at its option, purchase a &#8220;tail&#8221; directors&#8217; and officers&#8217; insurance policy for the Acquired Companies and their current and former directors and officers who
                  are currently covered by the directors&#8217; and officers&#8217; insurance coverage currently maintained by or for the benefit of the Acquired Companies, such tail to provide coverage in an amount not less than the existing coverage and to have
                  other terms not less favorable to the insured persons than the directors&#8217; and officers&#8217; insurance coverage currently maintained by or for the benefit of the Acquired Companies with respect to claims arising from facts or events that
                  existed or occurred at or before the Effective Time; <font style="font-style: italic;">provided</font> that in no event shall the cost of any such tail policy exceed the Maximum Amount, and if such cost would exceed the Maximum Amount,
                  then the Company may obtain a tail policy with the greatest coverage available for a cost not exceeding the Maximum Amount.&#160; Parent and the Surviving Corporation shall maintain such policies in full force and effect for a period of six
                  years after the Effective Time, and continue to honor the obligations thereunder.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">63</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event that any Acquired Company or any of its successors or assigns (i) consolidates with or merges into any other Person and is not the continuing or surviving corporation or Entity of
                  such consolidation or merger, or (ii) transfers or conveys all or substantially all of its properties and assets to any Person, then, and in each such case, Parent shall cause the applicable Acquired Company to make proper provision so
                  that the successors and assigns of such Acquired Company assume the obligations set forth in this <u>Section </u><font style="color: #000000;"><u>5.4</u></font>.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The provisions of this <u>Section </u><font style="color: #000000;"><u>5.4</u></font> (i) shall survive the Effective Time, (ii) are intended to be for the benefit of, and will be enforceable
                  by, each indemnified or insured party (including the Indemnified Persons), his or her heirs, successors, assigns and representatives, and (iii) are in addition to, and not in substitution for, any other rights to indemnification,
                  advancement of expenses, exculpation or contribution that any such Person may have by contract or otherwise.&#160; Unless required by applicable Legal Requirement, this <u>Section </u><font style="color: #000000;"><u>5.4</u></font> may not
                  be amended, altered or repealed after the Effective Time in such a manner as to adversely affect the rights of any Indemnified Person or any of their successors, assigns or heirs, without the prior written consent of the affected
                  Indemnified Person.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Stockholder Litigation</font>. In the event that any claims or Legal Proceedings related to this Agreement, the Merger or
                  the other Transactions are brought by any stockholder or other holder of Company securities (whether directly or on behalf of the Company or otherwise) against any Acquired Company or any of the Acquired Companies&#8217; directors or officers,
                  the Company shall promptly notify Parent in writing and shall keep Parent reasonably and promptly informed with respect to the status thereof.&#160; The Company shall give Parent (a) the right to participate in the defense of, and review and
                  comment on all material filings or responses to be made by the Company or other Acquired Company in connection with, any such claims or Legal Proceedings (and shall give due consideration to Parent&#8217;s comments and other advice with respect
                  to such litigation), and (b) the right to consult on any settlement with respect to such claims or Legal Proceedings, and no such settlement shall be agreed to without Parent&#8217;s prior written consent.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">64</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Additional Agreements</font>.&#160; Subject to the terms and conditions of this Agreement, including <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.2(a)</u></font>, Parent and the Company shall use reasonable best efforts to take, or cause to be taken, all actions necessary to consummate the Merger and make effective the other Transactions.&#160;
                  Without limiting the generality of the foregoing, subject to the terms and conditions of this Agreement, each Party to this Agreement shall use reasonable best efforts to (a) make all filings (if any) and give all notices (if any)
                  required to be made and given by such Party pursuant to any Material Contract in connection with the Merger and the other Transactions to the extent requested by Parent, (b) seek each Consent (if any) required to be obtained pursuant to
                  any Material Contract by such Party in connection with the Transactions to the extent requested in writing by Parent; <font style="font-style: italic;">provided</font> that (i) without the prior written consent of Parent, the Company
                  shall not, and shall cause each of the other Acquired Companies not to, pay or commit to pay to such Person that is not a Governmental Body, whose approval or consent is being solicited any cash or other consideration, make any commitment
                  or incur any liability or other obligation due to such Person in order to obtain such approval or consent, and (ii) neither Parent nor Merger Sub shall be required to pay or commit to pay to any Person that is not a Governmental Body
                  whose approval or consent is being solicited any cash or other consideration, make any commitment or incur any liability or other obligation in order to obtain such approval or consent, and (c) seek to lift any restraint, injunction or
                  other legal bar to the Merger brought by any third Person, other than a Governmental Body pursuant to an Antitrust Law, against such Party.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Disclosure</font>.&#160; The initial press release relating to this Agreement shall be a joint press release in a form
                  previously agreed to by Parent and the Company and issued by the Company and Parent promptly after the execution and delivery of this Agreement and thereafter Parent and the Company shall consult with each other before issuing, or cause
                  the publication of, any further press release(s) or otherwise making any public statement or (to the extent not previously issued or made in accordance with this Agreement) with respect to the Merger, this Agreement or any of the other
                  Transactions and shall not issue any such press release or make any such public statement without the other Party&#8217;s prior consent (which consent shall not be unreasonably withheld, conditioned or delayed).&#160; Notwithstanding the foregoing,
                  (a) each Party may, without such consultation or consent, make any public statement in response to questions from the press, analysts, investors or those attending industry conferences, make announcements to employees and make disclosures
                  in Company SEC Documents, so long as such statements are consistent in all material respects with information previously disclosed in previous press releases, public disclosures or public statements made jointly by the Parties in
                  compliance with this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.7</u></font> (or individually, if approved by the other Party), (b) a Party may, without the prior consent of the other Party but subject to giving advance
                  notice to the other Party and, to the extent reasonably practical, allow such other Party to comment on such release, announcement or statement, issue any such press release or make any such public announcement or statement as may be
                  required by Legal Requirement or applicable stock exchange rule, and (c) neither Party shall be required to consult with the other or obtain the other&#8217;s approval in connection with such portion of any press release, public statement or
                  filing to be issued or made pursuant to <u>Section </u><u>4.3(d)(i)</u> or with respect to any Acquisition Proposal or Company Adverse Recommendation Change or response thereto (it being understood that nothing in this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.7</u></font> shall limit the Company&#8217;s obligations under <u>Section </u><font style="color: rgb(0, 0, 0);"><u>4.3</u></font> and <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.1</u></font>).</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Takeover Laws</font>.&#160; If any Takeover Law may become, or may purport to be, applicable to the Transactions, each of
                  Parent and the Company and the members of their respective boards of directors shall use their respective reasonable best efforts to grant such approvals and take such actions as are necessary so that the Transactions may be consummated
                  as promptly as practicable on the terms and conditions contemplated hereby and otherwise act to lawfully eliminate the effect of any Takeover Law on any of the Transactions.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">65</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Section 16 Matters</font>.&#160; The Company, and the Board of Directors, shall, to the extent necessary, take appropriate
                  action, prior to or as of the Effective Time, to approve, for purposes of Section 16(b) of the Exchange Act, the disposition and cancellation or deemed disposition and cancellation of Shares, Company Options, Company RSUs and Company PSUs
                  in the Merger by applicable individuals and to cause such dispositions and/or cancellations to be exempt under Rule 16b-3 promulgated under the Exchange Act.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.10</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Senior Secured Term Loan Agreement</font>.&#160; The Company shall use reasonable best efforts to deliver (or cause to be
                  delivered) to Parent at least three Business Days prior to the Closing Date a customary payoff letter (or similar document) with respect to the Senior Secured Term Loan Agreement, from the lenders (or an agent on behalf of all lenders)
                  under the Senior Secured Term Loan Agreement (the &#8220;<u>Payoff Letter</u>&#8221;), which Payoff Letter shall specify the aggregate payoff amount required to be paid to fully satisfy all Indebtedness outstanding under the Senior Secured Term Loan
                  Agreement (including any &#8220;Prepayment Premium,&#8221; as such term is defined in the Senior Secured Term Loan Agreement, but other than (x) any inchoate indemnity obligations thereunder, and (y) any other obligations which, by their terms, are
                  to survive the termination of the Senior Secured Term Loan Agreement) and provide that, upon receipt of such specified amount, all Encumbrances (and any guarantees) granted in connection therewith relating to the assets, rights and
                  properties of the Acquired Companies securing such Indebtedness shall be released and terminated.&#160; The Company shall use its reasonable best efforts to deliver to the agent under the Senior Secured Term Loan Agreement, at least five
                  &#8220;Business Days,&#8221; as such term is defined in the Senior Secured Term Loan Agreement, prior to the Closing Date, a written notice of prepayment of all outstanding Indebtedness under the Senior Secured Term Loan Agreement, which notice shall
                  provide that such prepayment is subject to and conditioned upon the consummation of the Closing.&#160; The Company shall, and shall cause the other Acquired Companies to, use their reasonable best efforts to deliver (or cause the agent or
                  lenders under the Senior Secured Term Loan Agreement to deliver) to Parent on or prior to the Closing, in form and substance reasonably satisfactory to Parent, copies of all of the documents, filings and notices required to evidence the
                  termination of the Senior Secured Term Loan Agreement and effect the release of all Encumbrances securing the obligations thereunder, including duly executed UCC termination statements, terminations of control agreements, terminations of
                  collateral access agreements, terminations of intellectual property security agreements and delivery of possessory collateral (if any), which shall in each case be subject to the occurrence of the Closing and the repayment in full of all
                  obligations then outstanding under the Senior Secured Term Loan Agreement (other than (x) any inchoate indemnity obligations thereunder and (y) any other obligations which, by their terms, are to survive the termination of the Senior
                  Secured Term Loan Agreement).&#160; On the Closing Date, Parent shall effect or cause to be effected the repayment in full of all Indebtedness outstanding under the Senior Secured Term Loan Agreement in accordance with the Senior Secured Term
                  Loan Agreement and the Payoff Letter.&#160; The Parties shall reasonably cooperate with each other in connection with their respective obligations set forth in this <u>Section </u><font style="color: rgb(0, 0, 0);"><u>5.10</u></font>.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">66</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Financing</font>.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall, and shall cause its Subsidiaries to, use its reasonable best efforts to cause their respective Representatives to, use reasonable best efforts to provide such cooperation as is
                  reasonably requested by Parent in connection with the Financing (which term, for purposes of this <u>Section </u><font style="color: #000000;"><u>5.11</u></font>, shall include any other financing incurred in lieu thereof or otherwise
                  in connection with the Transactions, including, without limitation, any Alternate Financing).&#160; Such cooperation shall include but not be limited to the following:</div>
                <div>&#160;</div>
                <div style="text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; participating (and causing senior management and appropriate Representatives of the Company to participate) in a reasonable number of meetings, calls, presentations, road shows, lender
                  presentations, due diligence sessions (including accounting due diligence sessions), drafting sessions and sessions with rating agencies at reasonable times during normal business hours, upon reasonable advance notice and at mutually
                  agreed locations (all of which may be conducted by teleconference or virtual meeting platforms) and assisting Parent in obtaining ratings in connection with the Financing, including direct contact between appropriate members of senior
                  management of the Company, on the one hand, and the actual and potential financing sources, on the other hand;</div>
                <div>&#160;</div>
                <div style="text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; assisting with the timely preparation and negotiation of customary rating agency presentations and materials, bank information memoranda, syndication documents and materials, lender
                  presentations, offering documents, prospectuses, memoranda, investor presentations, and similar documents in connection with the Financing (which, where customary, shall contain customary exculpatory language reasonably satisfactory to
                  Company);</div>
                <div>&#160;</div>
                <div style="text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (A) assisting with the preparation and delivery of customary definitive financing documents, including, in each case, the schedules thereto, or documents contemplated by the Financing, (B)
                  assisting with the provision of insurance certificates and endorsements, and (C) otherwise reasonably assisting in the pledging of collateral and granting of security interests in respect of the Financing;</div>
                <div>&#160;</div>
                <div style="text-indent: 108pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; furnishing Parent with the Required Financing Information and such other information reasonably requested in connection with the Financing, including any preliminary results or &#8220;flash numbers&#8221;
                  not previously publicly disclosed in the ordinary course of business, in each case, to the extent that such other information is reasonably available and customarily prepared by the Company, it being understood that the Parent shall
                  provide and be solely responsible for the Parent Pro Forma Information;</div>
                <div>&#160;</div>
                <div style="text-indent: 108pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;executing and delivering customary authorization letters to the Financing Sources authorizing the distribution of information regarding the Company to prospective lenders or investors in
                  connection with the Financing and containing a customary representation that the public side versions of such documents do not include material non-public information about the Company or its Subsidiaries or their securities and a
                  customary representation as to the accuracy of the information contained in the disclosure and marketing materials to the extent provided by or on behalf of the Company related to the Financing (&#8220;<u>Financing Authorization Letters</u>&#8221;);</div>
                <div>&#160;</div>
                <div style="text-indent: 108pt;">(vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; causing its independent auditors to (A) provide drafts and executed versions of customary auditors consents and customary comfort letters (including customary change period comfort and &#8220;negative
                  assurance&#8221; comfort upon any notes pricing date and upon the related closing) with respect to the Required Financing Information, (B) attend a reasonable number of accounting due diligence sessions and drafting sessions at reasonable times
                  and places, and (C) otherwise provide customary assistance, in each case of the foregoing, subject to completion of customary procedures;</div>
                <div style="text-indent: 108pt;"> <br>
                </div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">67</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 108pt;">(vii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; taking actions requested by Parent to enable Parent to benefit from the Company&#8217;s existing relationships in connection with the marketing and syndication of the Financing, if any;</div>
                <div>&#160;</div>
                <div style="text-indent: 108pt;">(viii)&#160;&#160;&#160;&#160;&#160; to the extent reasonably requested at least 10 Business Days prior to the Closing Date, promptly furnishing Parent and the Financing Sources at least three Business Days prior to the Closing Date
                  with all documentation and other information relating to the Acquired Companies that any lender providing or arranging the Financing has determined is required by bank regulatory authorities under applicable &#8220;know-your-customer&#8221; and
                  anti-money laundering rules and regulations, including the USA PATRIOT Act, and beneficial ownership Legal Requirements, including a beneficial ownership certification in relation to the Company, which certification shall be substantially
                  similar to the form of Certification Regarding Beneficial Owners of Legal Entity Customers, published jointly, in May 2018, by the Loan Syndications and Trading Association and Securities Industry and Financial Markets Association, or as
                  otherwise acceptable to the requesting Financing Source;</div>
                <div>&#160;</div>
                <div style="text-indent: 108pt;">(ix)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If Parent reasonably requests, file a Current Report on Form 8-K pursuant to the Exchange Act that contains material non-public information with respect to the Acquired Companies, which Parent
                  reasonably determines (and the Company does not unreasonably object) to include in a customary &#8220;public side&#8221; offering or marketing document in connection with the Financing (other than Excluded Information).</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;">The Parties agree that a failure to deliver any of the information in Section 2(c) of <u>Exhibit B</u> of the Debt Commitment Letter would be a material failure to comply with the covenants set forth in this
                  <u>Section 5.11</u>.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything in this <u>Section </u><u>5.11</u> to the contrary, in fulfilling its obligations pursuant to this <u>Section </u><u>5.11</u>, the Acquired Companies will not be
                  required to (i) prior to the Closing Date, reimburse any expense, give any indemnities or pay or incur any commitment or other fee or any out-of-pocket expense (other than customary expenses in connection with the cooperation described in
                  this <u>Section </u><u>5.11</u> that are promptly reimbursed by Parent), (ii) prior to the Closing Date, pass resolutions or consents or approve or authorize the execution of, or execute, the Financing or the definitive Financing
                  agreements or related agreements (other than Financing Authorization Letters) or enter into any agreement, certificate, document or instrument, in each case, that is not contingent on the occurrence of the Closing or that must be
                  effective prior to the Closing; (iii) provide access to or disclose information that the Company or its Subsidiaries reasonably determines would jeopardize any attorney client privilege or conflict with any confidentiality requirements
                  applicable to the Company or its Subsidiaries; (iv) take any action that would conflict with, violate or result in a breach of or default under its organizational documents or any material contract or law to which it or its property is
                  bound or result in the creation or imposition of any Encumbrance on any asset of the Acquired Companies (including any action to the extent any such action would cause, or would be reasonably expected to cause, any representation or
                  warranty in this Agreement to be breached, the failure of any condition to the Closing set forth in <u>Section 6</u> or otherwise cause any breach of this Agreement) prior to the Closing Date; (v) cause any director, officer or employee
                  or stockholder of any Acquired Company to incur any personal liability that would be effective prior to the Closing Date or for which such Person will not be indemnified, (vi) provide any security, give any indemnity or incur any other
                  liability in connection with the Financing, unless in the case of the Acquired Companies that will be an obligor in respect of the Financing, the same would not be effective prior to the Closing, (vii) enter into any definitive agreement,
                  unless in the case of the Acquired Companies that will be an obligor in respect of the Financing, the same would not be effective prior to the Closing, (viii) enter into or approve any Debt Commitment Letter or Debt Financing Fee Letter,
                  (ix) take any action that would result in any significant interference with the prompt and timely discharge of the duties of any director, manager, officer or employee of any Acquired Company, (x) provide any Excluded Information, or (xi)
                  cooperate to the extent it would unreasonably interfere with the ongoing business or operations of any Acquired Company.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">68</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Parent shall, upon request by the Company, promptly reimburse the Company for all reasonable and documented out-of-pocket costs, fees and expenses incurred by any of the Acquired Companies in
                  connection with fulfilling its obligations pursuant to this <u>Section </u><font style="color: #000000;"><u>5.11</u></font>.&#160; Parent shall indemnify and hold harmless the Acquired Companies from and against any and all damages actually
                  suffered or incurred by them in connection with actions taken pursuant to this <u>Section </u><font style="color: #000000;"><u>5.11</u></font>, except in the event such loss or damage arises directly out of (i) the gross negligence or
                  willful misconduct of the Acquired Companies or their respective Representatives, (ii) the material breach of this Agreement thereby, or (iii) any information provided to Parent in writing by the Acquired Companies for inclusion in any
                  materials relating to the Financing.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company will use its reasonable best efforts, and will cause each of its Subsidiaries to use its respective reasonable best efforts, to update any Required Financing Information provided to
                  Parent and the Financing Sources as may be necessary so that such Required Financing Information (i) is Compliant, and (ii) meets the applicable requirements set forth in the definition of &#8220;Required Financing Information&#8221;.&#160; The Company
                  will notify Parent if any of the Required Financing Information or any other information provided pursuant to this <u>Section </u><font style="color: #000000;"><u>5.11</u></font> is found to have contained any untrue statement of a
                  material fact or to have omitted to state a material fact necessary in order to make the statements contained therein not materially misleading.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the avoidance of doubt, Parent may, to most effectively access the financing markets, require the cooperation of the Acquired Companies under this <u>Section </u><font style="color: #000000;"><u>5.11</u></font> on multiple occasions from time to time between the date hereof and the Closing Date.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything in this Agreement to the contrary, in no event shall the receipt or availability of any funds or financing (including the Financing contemplated by the Debt Commitment
                  Letter) by or to Parent or any other financing transaction be a condition to any of Parent&#8217;s obligations hereunder.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company hereby consents to the use of the Acquired Companies&#8217; logos to the extent necessary and advisable in connection with the Financing and only so long as such logos are used solely in a
                  manner that is not intended or reasonably likely to harm, disparage or otherwise adversely affect any Acquired Company or Company IP, or the reputation or goodwill of any Acquired Company.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">69</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.12</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Parent Financing</font>.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Parent and Merger Sub will use reasonable best efforts to obtain the Financing (or in the event any portion or all of the Financing becomes unavailable, alternative debt financing from the same
                  or other sources (such portion from sources other than any source providing the Financing contemplated by the Debt Commitment Letter as of the date hereof, the &#8220;<u>Alternate Financing</u>&#8221;) in an aggregate amount, together with the
                  remaining Financing, if any, and any other immediately available sources available to Parent and Merger Sub to fund the payment of the Required Amount on the Closing Date. Such efforts by Parent and/or Merger Sub, as applicable, shall
                  include, without limitation: (i) complying with and maintaining in full force and effect the Debt Commitment Letter (subject to commitment reductions and/or termination thereof in accordance with the Debt Commitment Letter (as in effect
                  on the date hereof) in connection with the consummation of an alternative financing generating, when taken together with other sources of funds immediately available to Parent or Merger Sub, the Required Amount at the Effective Time),
                  (ii) negotiating and entering into definitive financing agreements (the &#8220;<u>Definitive Debt Agreement</u><font style="font-weight: bold; font-style: italic;">s</font>&#8221;) with respect to the Financing or alternative financing generating,
                  when taken together with other sources of funds immediately available to Parent or Merger Sub, the Required Amount at the Effective Time; <u>provided</u>, that such Definitive Debt Agreements or alternative financing, as applicable,
                  shall not (1) impose new or additional conditions or expand any existing condition to the receipt of the Financing, (2) otherwise materially delay funding of the Financing or make funding of the Financing less likely to occur at or prior
                  to the Closing or (3) adversely impact the ability of Parent to enforce its rights against the other parties to the Debt Commitment Letter or the Definitive Debt Agreements or alternative financing, as applicable (the effects described in
                  <u>clauses (1)</u> through <u>(3)</u>, collectively, the &#8220;<u>Prohibited Modification</u>&#8221; and each individually, a &#8220;<u>Prohibited Modification</u>&#8221;), (iii) satisfying on a timely basis all conditions to the Financing contemplated by the
                  Debt Commitment Letter and the Debt Financing Fee Letter and (iv) enforcing its rights under the Debt Commitment Letter in the event of a breach by the Financing Sources under the Debt Commitment Letter or any of the Definitive Debt
                  Agreements or alternative financing, as applicable.&#160; Prior to the Closing, without the prior written consent of the Company, Parent shall not (x) agree to, or permit, any withdrawal, rescission, termination, amendment, restatement,
                  supplement, modification or waiver in respect of the Debt Commitment Letter or any Definitive Debt Agreement that would result, when taken together with other sources of funds immediately available to Parent or Merger Sub, in the Parent
                  failing to have the Required Amount at the Effective Time, or (y) agree to substitute other debt or equity financing for all or any portion of the Debt Financing from the same or alternative financing sources to the extent such
                  substitution would result in a Prohibited Modification.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">70</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Parent shall keep the Company informed on a reasonable basis and in reasonable detail of the status of its efforts to arrange the Financing.&#160; Parent shall give the Company prompt written notice
                  (A) upon becoming aware of, or receiving written notice or other written communication with respect to, (1) any actual, threatened (in writing) or alleged (in writing) material breach of or default under, or any event or circumstance that
                  (with or without notice, lapse of time or both) could reasonably be expected to give rise to any material breach of or default under, the Debt Commitment Letter by a party thereto, (2) any actual or threatened (in writing) termination,
                  withdrawal, repudiation or rescission of the Debt Commitment Letter or any Definitive Debt, or (3) any material dispute or disagreement between or among parties to the Debt Commitment Letter or any Definitive Debt Agreement, in each case,
                  to the extent such breach, default, termination, withdrawal, repudiation, rescission, dispute or disagreement would reasonably be expected to materially delay or prevent the Closing or result in failure of Parent to obtain, when taken
                  together with other sources of funds immediately available to Parent, the Required Amount at the Effective Time or (B) if at any time for any reason Parent believes in good faith that it may not be able to obtain all or any portion of the
                  Financing on the terms and conditions, at the time, in the manner or from the sources contemplated by the Financing, except as a result of consummation of alternative financing transactions providing, when taken together with other
                  sources of funds immediately available to Parent, the Required Amount at the Effective Time. Parent shall promptly provide any material information reasonably requested by the Company relating to any circumstance referred to in <u>clauses













                    (A)</u> or <u>(B)</u> of the immediately preceding sentence; <font style="font-style: italic;">provided</font> that in no event shall Parent be required to provide access to or disclose information that would jeopardize any
                  attorney-client privilege of, or conflict with any confidentiality requirements applicable to, Parent or any of its Subsidiaries (as reasonably determined in good faith by Parent).</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If any of the Financing or the Debt Commitment Letter (or any Definitive Debt Agreement) expires or is terminated prior to the Closing, in whole or in part, for any reason, or any portion of the
                  Financing becomes unavailable on the terms and subject solely to the conditions set forth in the Debt Commitment Letter or any Definitive Debt Agreement shall be withdrawn, repudiated, terminated or rescinded (other than as a result of
                  any mandatory commitment reduction in connection with the consummation of alternative financing transactions contemplated by the Debt Commitment Letter providing, when taken together with other sources of funds immediately available to
                  Parent, the Required Amount at the Effective Time), then Parent shall (i) promptly use its reasonable best efforts to arrange for Alternate Financing (which Alternate Financing (1) shall be in an amount no less than, when taken together
                  with other sources of funds immediately available to Parent, the Required Amount and (2) shall not include conditions to such Alternate Financing that are more onerous than, taken as a whole, the conditions set forth in the Debt
                  Commitment Letter on the Agreement Date (as reasonably determined in good faith by Parent) to replace the Financing, to be consummated no later than the day on which the Closing shall occur pursuant to this Agreement, (ii) provide to the
                  Company copies of all documents (including all fee letters and engagement letters; <font style="font-style: italic;">provided</font> that any fee and engagement letters may be redacted in a customary fashion as to economic terms and
                  other commercially sensitive numbers and provisions specified in any such letter (including any provisions relating to &#8220;flex&#8221; terms or similar concepts), none of which could adversely affect the availability, conditionality,
                  enforceability or amount (except by reason of any increased fees or original issue discount resulting from the &#8220;flex&#8221; terms or similar concepts contained in any such letter) of the Financing contemplated thereby) relating to any
                  alternative financing to replace the Financing and (iii) keep the Company reasonably informed of the process of obtaining any Alternate Financing.&#160; If any Alternate Financing is obtained in accordance with this <u>Section </u><font style="color: #000000;"><u>5.12(c)</u></font>, Parent shall promptly notify the Company thereof and references to the &#8220;Financing,&#8221; &#8220;Debt Commitment Letter&#8221; and &#8220;Debt Financing Fee Letter&#8221; (and other like terms in this Agreement) shall
                  include such Alternate Financing, as applicable.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">71</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything in this Agreement to the contrary, Parent and Merger Sub expressly acknowledge and agree that neither the availability nor terms of the Financing or any Alternate
                  Financing are conditions to the obligations of Parent or Merger Sub to consummate the Merger, and each of Parent and Merger Sub reaffirms its obligation to consummate the Merger and the other Transactions subject only to the express
                  conditions set forth herein, irrespective and independent of the availability or terms of the Financing or any Alternate Financing.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.13</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Stock Exchange Delisting; Deregistration</font>.&#160; Prior to the Closing Date, the Company shall cooperate with Parent and
                  use its reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things, reasonably necessary, proper or advisable on its part under applicable Legal Requirements and rules and policies of Nasdaq
                  to enable the delisting by the Surviving Corporation of the Shares from Nasdaq and the deregistration of the Shares under the Exchange Act as promptly as practicable after the Effective Time.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">5.14</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">FIRPTA Certificate</font>.&#160; At the Closing, the Company shall use commercially reasonable efforts to deliver to Parent a
                  statement (and an accompanying notice addressed to the IRS), dated as of the Closing Date and executed by an officer of the Company, in accordance with Treasury Regulations Sections 1.1445-2(c)(3)(i) and 1.897-2(h) certifying that any
                  equity interest in the Company is not a U.S. real property interest within the meaning of Section 897(c) of the Code, substantially in a form reasonably acceptable to Parent; <u>provided</u>, <u>however</u>, that Parent&#8217;s sole recourse
                  for any failure by the Company to deliver such statement to Parent pursuant to this <u>Section </u><u>5.14</u> shall be the right to withhold pursuant to <u>Section </u><u>1.6(e)</u>.</div>
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;">SECTION 6</div>
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;"><u>CONDITIONS PRECEDENT TO THE MERGER</u></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">6.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Conditions to Each Party&#8217;s Obligation to Effect the Merger</font>.&#160; The respective obligations of each Party to effect the
                  Merger are subject to the satisfaction (or waiver by the Company, Parent and Merger Sub, to the extent permitted by applicable Legal Requirements) on or prior to the Closing Date of the following conditions:</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Company Stockholder Approval</u>.&#160; The Company Stockholder Approval shall have been obtained.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Approvals Under Antitrust Laws</u>.&#160; (i) Any waiting period (or any extension thereof) applicable to the Merger under the HSR Act and any commitment by the Parties to a Governmental Body not
                  to consummate the Transactions before a certain date under a timing agreement in connection therewith shall have expired or been terminated, and (ii) any waiting period, clearance or affirmative approval of any Specified Antitrust
                  Authority (other than under the HSR Act) with respect to the Transactions shall have been obtained and any mandatory waiting period related thereto shall have expired or been terminated.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">72</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No Restraints</u>.&#160; There shall not have been issued by any Governmental Body of competent jurisdiction in a jurisdiction where either Parent and its Affiliates or the Acquired Companies
                  operate their respective businesses or own any material assets or in any material way Exploit any Product (a &#8220;<u>Specified Governmental Body</u>&#8221;) and remain in effect any temporary restraining order, preliminary or permanent injunction
                  or other order, directive, judgment, decree or ruling preventing the consummation of the Merger, nor shall any Legal Requirement have been promulgated, entered, enforced, enacted, issued or deemed applicable to the Merger (and that is
                  still in effect) by any Specified Governmental Body which, directly or indirectly, prohibits or makes illegal the consummation of the Merger.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">6.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Conditions to Obligations of Parent and Merger Sub to Effect the Merger</font>.&#160; The obligations of Parent and Merger Sub
                  to effect the Merger are further subject to the satisfaction (or waiver by Parent, on its own behalf and on behalf of Merger Sub, to the extent permitted by applicable Legal Requirements) on or prior to the Closing Date of the following
                  conditions:</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Representations and Warranties</u>.&#160; (i) The representations and warranties of the Company set forth in (A) the first three sentences of <u>Section </u><font style="color: #000000;"><u>2.1(a)</u></font>
                  and the first two sentences of <u>Section </u><font style="color: #000000;"><u>2.1(b)</u></font> (Due Organization; Subsidiaries, Etc.), <u>Section </u><font style="color: #000000;"><u>2.2</u></font> (Certificate of Incorporation and
                  Bylaws), <u>Section </u><font style="color: #000000;"><u>2.20</u></font> (Authority; Binding Nature of Agreement), <u>Section </u><font style="color: #000000;"><u>2.21</u></font> (Takeover Laws), <u>Section </u><font style="color: #000000;"><u>2.23</u></font> (Opinion of Financial Advisors) and <u>Section </u><font style="color: #000000;"><u>2.24</u></font> (Brokers and Other Advisors) shall be accurate in all material respects (without taking into account any
                  &#8220;Material Adverse Effect&#8221; and &#8220;materiality&#8221; qualifications contained in such representations and warranties) as of the Agreement Date and at and as of Closing Date as if made on and as of the Closing Date (except to the extent any such
                  representation or warranty expressly relates to an earlier date or period, in which case as of such date or period), (B) <u>clauses (a)</u> through <u>(g)</u> of <u>Section </u><font style="color: #000000;"><u>2.3</u></font>
                  (Capitalization, Etc.) shall be accurate in all respects except for any <font style="font-style: italic;">de minimis</font> inaccuracies as of the Agreement Date and at and as of the Closing Date as if made on and as of the Closing Date
                  (except to the extent any such representation or warranty expressly relates to an earlier date or period, in which case as of such date or period), and (C) <u>Section </u><font style="color: #000000;"><u>2.5(b)</u></font> (No Material
                  Adverse Effect) shall be accurate in all respects as of the Agreement Date, and (ii) the representations and warranties of the Company set forth in this Agreement, other than those referred to in <u>clause </u><u>(i)</u> above, shall be
                  accurate (without taking into account any &#8220;Material Adverse Effect&#8221; and &#8220;materiality&#8221; qualifications contained in such representations and warranties) as of the Agreement Date and at and as of the Closing Date as if made on and as of the
                  Closing Date (except to the extent any such representation or warranty expressly relates to an earlier date or period, in which case as of such date or period), except where the failure of such representations and warranties to be so
                  accurate has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">73</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Performance of Obligations of the Company</u>.&#160; The Company shall have complied with or performed in all material respects the covenants and agreements it is required to comply with or perform
                  at or prior to the Closing Date.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No Material Adverse Effect</u>.&#160; Since the Agreement Date, there shall not have occurred any Material Adverse Effect which is continuing.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Delivery of Officer Certificates</u>.&#160; Parent and Merger Sub shall have received a certificate, dated the Closing Date, executed on behalf of the Company by the Company&#8217;s Chief Executive
                  Officer or Chief Financial Officer certifying to the effect that the conditions set forth in Sections <font style="color: #000000;"><u>6.2(a)</u></font>, <font style="color: #000000;"><u>6.2(b)</u></font> and <font style="color: #000000;"><u>6.2(c)</u></font> have been satisfied.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">6.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Conditions to Obligations of the Company to Effect the Merger</font>.&#160; The obligations of the Company to effect the Merger
                  are further subject to the satisfaction (or waiver by the Company, to the extent permitted by applicable Legal Requirements) on or prior to the Closing Date of the following conditions:</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Representations and Warranties</u>.&#160; (i) The representations and warranties of Parent and Merger Sub set forth in <u>Section </u><font style="color: #000000;"><u>3.1</u></font> (Due
                  Organization), <u>Section </u><font style="color: #000000;"><u>3.2</u></font> (Merger Sub), <u>Section </u><font style="color: #000000;"><u>3.3</u></font> (Authority; Binding Nature of Agreement) and <u>Section 3.10</u> (Brokers and
                  Other Advisors) shall be accurate in all material respects (without taking into account any &#8220;Material Adverse Effect&#8221; and &#8220;materiality&#8221; qualifications contained in such representations and warranties) as of the Agreement Date and at and
                  as of Closing Date as if made on and as of the Closing Date (except to the extent any such representation or warranty expressly relates to an earlier date or period, in which case as of such date or period), and (ii) the representations
                  and warranties of Parent and Merger Sub set forth in this Agreement, other than those referred to in <u>clause </u><u>(i)</u> above, shall be accurate (without taking into account any &#8220;Material Adverse Effect&#8221; and &#8220;materiality&#8221;
                  qualifications contained in such representations and warranties) as of the Agreement Date and at and as of the Closing Date as if made on and as of the Closing Date (except to the extent any such representation or warranty expressly
                  relates to an earlier date or period, in which case as of such date or period), except where the failure of such representations and warranties to be so true and correct has not had, and would not reasonably be expected to have,
                  individually or in the aggregate, a Parent Material Adverse Effect.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Performance of Obligations of Parent and Merger Sub</u>.&#160; Parent and Merger Sub shall have complied with or performed in all material respects the covenants and agreements they are required to
                  comply with or perform at or prior to the Closing Date.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Delivery of Officer Certificate</u>.&#160; Parent shall have delivered to the Company a certificate, dated the Closing Date and signed on its behalf by its Chief Executive Officer or another senior
                  executive officer, certifying to the effect that the conditions set forth in <u>Sections </u><font style="color: #000000;"><u>6.3(a)</u></font> and <font style="color: #000000;"><u>6.3(b)</u></font> have been satisfied.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">74</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-align: center; font-weight: bold;">SECTION 7</div>
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;"><u>TERMINATION</u></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">7.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Termination</font>.&#160; This Agreement may be validly terminated prior to the Effective Time only as follows:</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;by mutual written consent of Parent and the Company at any time prior to the Closing;</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;by either Parent or the Company, at any time prior to the Closing, if the Closing shall not have occurred on or prior to midnight Eastern Time, on June 19, 2026 (the &#8220;<u>End Date</u>&#8221;); <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that in the case of this <u>Section </u><font style="color: #000000;"><u>7.1(b)</u></font>, (x) if on the End Date, all of the conditions
                  set forth in <u>Section </u><u>6</u>, other than the conditions set forth in <u>Section </u><font style="color: #000000;"><u>6.1(b)</u></font> or <u>Section </u><font style="color: #000000;"><u>6.1(c)</u></font> (solely in respect
                  of Antitrust Laws), shall have been satisfied or waived by Parent or Merger Sub, to the extent waivable by Parent or Merger Sub (other than conditions that by their nature are to be satisfied on the Closing Date, each of which is then
                  capable of being satisfied), then the End Date shall automatically be extended until midnight Eastern Time on September 19, 2026 (the &#8220;<u>Extended End Date</u>&#8221;) (and all references to the End Date herein shall be as so extended), (y) if
                  on the Extended End Date, all of the conditions set forth in <u>Section </u><u>6</u>, other than the conditions set forth in <u>Section </u><font style="color: #000000;"><u>6.1(b)</u></font> or <u>Section </u><font style="color: #000000;"><u>6.1(c)</u></font> (solely in respect of Antitrust Laws), shall have been satisfied or waived by Parent or Merger Sub, to the extent waivable by Parent or Merger Sub (other than conditions that by their nature are to be
                  satisfied on the Closing Date, each of which is then capable of being satisfied), then the End Date shall automatically be extended until midnight Eastern Time on December 19, 2026 (and all references to the End Date and the Extended End
                  Date herein shall be as so extended), and (z) the right to terminate this Agreement pursuant to this <u>Section </u><font style="color: #000000;"><u>7.1(b)</u></font> shall not be available to any Party whose material breach of this
                  Agreement has proximately caused or resulted in the Merger not being consummated by such date;</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;by either Parent or the Company if a Specified Governmental Body of competent jurisdiction shall have issued any permanent injunction or other order, directive, judgment, decree or ruling, or
                  shall have taken any other action, in each case, having the effect of permanently restraining, enjoining or otherwise prohibiting the Merger or making the consummation of the Merger illegal, which order, directive, judgment, decree,
                  ruling or other action shall be final and nonappealable; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that the right to terminate this Agreement pursuant to this <u>Section </u><font style="color: #000000;"><u>7.1(c)</u></font> shall not be available to any Party whose material breach of this Agreement has proximately caused or resulted in the issuance of such final and nonappealable injunction, order, directive,
                  judgment, decree, ruling or other action;</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">75</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;by Parent at any time prior to the Cut-off Time, if (i) the Board of Directors shall have failed to include the Company Board Recommendation in the Merger Proxy Statement when filed with the SEC
                  or mailed, or shall have effected a Company Adverse Recommendation Change, (ii) in the case of an Acquisition Proposal structured as a tender offer or exchange offer subject to Regulation 14D under the Exchange Act, the Board of Directors
                  (A) states that it recommends such tender or exchange offer or expresses no opinion or is unable to take a position (other than a &#8220;stop, look and listen&#8221; communication pursuant to Rule 14d-9(f) promulgated under the Exchange Act) with
                  respect to such tender or exchange offer, or (B) fails to recommend, in a Solicitation/Recommendation Statement on Schedule 14D-9, rejection of such tender offer or exchange offer or fails to reaffirm the Company Board Recommendation
                  within 10 Business Days after the commencement of such tender offer or exchange offer within the meaning of Rule 14d-2 under the Exchange Act (or, if earlier, by the close of business on the Business Day immediately preceding the then
                  scheduled Cut-off Time), (iii) after any public announcement of an Acquisition Proposal (other than a tender offer or exchange offer), the Board of Directors fails to publicly affirm the Company Board Recommendation within three Business
                  Days after a written request by Parent to do so (or, if earlier, by the close of business on the Business Day immediately preceding the then scheduled Cut-off Time; <font style="font-style: italic;">provided</font> that Parent has made
                  such request prior to the second Business Day before the then scheduled date of the Cut-off Time); <font style="font-style: italic;">provided</font> that Parent may only make such request twice with respect to each Acquisition Proposal
                  or material modification thereof, (iv) the Board of Directors fails to publicly reaffirm the Company Board Recommendation within three Business Days after Parent so requests in writing (it being understood that the Company will have no
                  obligation to make such reaffirmation pursuant to this <u>clause </u><u>(iv)</u> on more than three occasions), or (v) the Board of Directors or the Company Willfully Breaches its obligations under <u>Section </u><font style="color: #000000;"><u>4.3</u></font> or <u>Section </u><font style="color: #000000;"><u>5.1</u></font> in any material respect;</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;by the Company, at any time prior to the Cut-off Time, in order to substantially concurrently with such termination enter into a binding written definitive acquisition agreement providing for the
                  consummation of the Superior Offer approved by the Board of Directors pursuant to and in accordance with the provisions of <u>Section </u><font style="color: #000000;"><u>5.1(b)</u></font> (a &#8220;<u>Specified Agreement</u>&#8221;); <font style="font-style: italic;">provided</font> that the Company shall have paid the Termination Fee in accordance with <u>Section </u><font style="color: #000000;"><u>7.3</u></font> immediately before or substantially simultaneously with
                  such termination;</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;by either Parent or the Company if the Company Stockholder Approval shall not have been obtained at the Company Stockholder Meeting duly convened and held and at which a vote on the matter was
                  taken, or any adjournment or postponement thereof permitted by this Agreement and at which a vote on the matter was taken;</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;by Parent at any time prior to the Closing, if a breach of any representation or warranty contained in this Agreement or failure to perform any covenant or obligation in this Agreement on the
                  part of the Company shall have occurred such that a condition set forth in <u>clauses (a)</u>, <u>(b)</u> or <u>(c)</u> of <u>Section </u><font style="color: #000000;"><u>6.2</u></font>, as applicable, would not be satisfied and
                  cannot be cured by the Company by the End Date, or if capable of being cured in such time period, shall not have been cured within 30 days after the date Parent gives the Company written notice of such breach or failure to perform; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that Parent shall not have the right to terminate this Agreement pursuant to this <u>Section </u><font style="color: #000000;"><u>7.1(g)</u></font>
                  if either Parent or Merger Sub is then in breach of any representation, warranty, covenant or obligation hereunder which breach would permit the Company to terminate this Agreement pursuant to <u>Section </u><font style="color: #000000;"><u>7.1(h)</u></font>; or</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">76</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;by the Company at any time prior to the Closing, if a breach of any representation or warranty contained in this Agreement or failure to perform any covenant or obligation in this Agreement on
                  the part of Parent or Merger Sub shall have occurred, such that a condition set forth in <u>Section </u><font style="color: #000000;"><u>6.3(a)</u></font> or <u>Section </u><font style="color: #000000;"><u>6.3(b)</u></font> would not
                  be satisfied and such breach or failure cannot be cured by Parent or Merger Sub, as applicable, by the End Date, or, if capable of being cured in such time period, shall not have been cured within 30 days after the date the Company gives
                  Parent written notice of such breach or failure to perform; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that the Company shall not have the right to terminate this Agreement
                  pursuant to this <u>Section </u><font style="color: #000000;"><u>7.1(h)</u></font> if the Company is then in breach of any representation, warranty, covenant or obligation hereunder which breach would permit Parent to terminate this
                  Agreement pursuant to <u>Section </u><font style="color: #000000;"><u>7.1(g)</u></font>.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">7.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Effect of Termination</font>.&#160; In the event of the termination of this Agreement as provided in <u>Section </u><u>7.1</u>,
                  written notice thereof shall be given by the terminating Party to the other Party or Parties, specifying the provision hereof pursuant to which such termination is made, and this Agreement shall be of no further force or effect and there
                  shall be no liability on the part of Parent, Merger Sub or the Company or any of their respective former, current or future officers, directors, partners, stockholders, managers, members, employees or Affiliates following any such
                  termination; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that (a) the final sentence of <u>Section </u><u>4.1(a)</u>, this <u>Section </u><u>7.2</u>, <u>Section </u><u>7.3</u>
                  and <u>Section 8</u> (other than <u>Section </u><u>8.5(b)</u>) shall survive the termination of this Agreement and shall remain in full force and effect, (b) the Confidentiality Agreement shall survive the termination of this Agreement
                  and shall remain in full force and effect in accordance with its terms, and (c) the termination of this Agreement shall not relieve any Party from any liability for fraud or Willful Breach of this Agreement prior to termination (it being
                  understood that in the case of a Willful Breach by Parent or Merger Sub and to the extent permitted pursuant to DGCL Section 261(a)(1), the Company (and only the Company) through actions approved by the Board of Directors may seek damages
                  payable to the Company (on its own behalf or as representative of the holders of Company Common Stock, Company RSUs, Company PSUs and Company Options (including In the Money Director Options)) based, to the extent proven, on the loss of
                  the premium or economic benefit that the holders of Company Common Stock, Company RSUs, Company PSUs and Company Options (including In the Money Director Options) would have received if the Merger were consummated pursuant to the terms of
                  this Agreement, taking into consideration all relevant matters, including the time value of money, which shall be deemed in such event to be solely damages of the Company (&#8220;<u>Benefit of the Bargain Damages</u>&#8221;)).&#160; For the avoidance of
                  doubt, (i) only the Company (and not the holders of Company Common Stock, Company RSUs, Company PSUs or Company Options (including In the Money Director Options) or any other Company Associate or holder of equity securities of the
                  Company) may bring an action pursuing liability for such Willful Breach by Parent or Merger Sub and (ii) the Company may retain, without distribution to the holders of Company Common Stock, Company RSUs, Company PSUs or Company Options
                  (including In the Money Director Options) any damages (including Benefit of the Bargain Damages) received.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">7.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Expenses; Termination Fees</font>.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as set forth in this <u>Section </u><font style="color: #000000;"><u>7.3</u></font>, all fees and expenses incurred in connection with this Agreement and the Transactions shall be paid
                  by the Party incurring such expenses, whether or not the Merger is consummated.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">77</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 72pt;">&#160;(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event that:</div>
                <div>&#160;</div>
                <div style="text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; this Agreement is terminated by the Company pursuant to <u>Section </u><font style="color: #000000;"><u>7.1(e)</u></font>;</div>
                <div>&#160;</div>
                <div style="text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;this Agreement is terminated by Parent pursuant to <u>Section </u><font style="color: #000000;"><u>7.1(d)</u></font>; or</div>
                <div>&#160;</div>
                <div style="text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (A) this Agreement is terminated by Parent or the Company pursuant to <u>Section </u><font style="color: #000000;"><u>7.1(b)</u></font> (but in the case of a termination by the Company, only
                  if at such time Parent would not be prohibited from terminating this Agreement pursuant to <u>Section 7.1(b)(z)</u>) or <u>Section </u><font style="color: #000000;"><u>7.1(f)</u></font>, or terminated by Parent pursuant to <u>Section
                  </u><font style="color: #000000;"><u>7.1(g)</u></font>, (B) any Person shall have publicly disclosed a <font style="font-style: italic;">bona fide</font> Acquisition Proposal or an Acquisition Proposal has otherwise been communicated to
                  the Board of Directors after the execution and delivery of this Agreement and prior to such termination and such Acquisition Proposal has not been unconditionally and, in the case of a publicly disclosed Acquisition Proposal, publicly
                  withdrawn prior to (1) the date of such termination pursuant to <u>Section </u><font style="color: #000000;"><u>7.1(b)</u></font> or (2) the Company Stockholder Meeting (including any adjournment or postponement thereof) with respect to
                  the termination pursuant to <u>Section </u><font style="color: #000000;"><u>7.1(f)</u></font>, and (C) within 12 months after such termination the Company shall have entered into a definitive agreement with respect to, or consummated,
                  an Acquisition Proposal; <font style="font-style: italic;">provided</font> that for purposes of this <u>clause </u><u>(C)</u> the references to &#8220;15%&#8221; in the definition of &#8220;Acquisition Proposal&#8221; shall be deemed to be references to
                  &#8220;50%&#8221;;&#160; then, in any such event under <u>clause </u><u>(i)</u>, <u>(ii)</u> or <u>(iii)</u> of this <u>Section </u><font style="color: #000000;"><u>7.3(b)</u></font>, the Company shall pay to Parent or its designee the Termination
                  Fee by wire transfer of same day funds (x) in the case of <u>Section </u><font style="color: #000000;"><u>7.3(b)(i)</u></font>, prior to or substantially concurrently with (and as a condition to the effectiveness of) such termination,
                  (y) in the case of <u>Section </u><font style="color: #000000;"><u>7.3(b)(ii)</u></font>, within one Business Day after such termination, or (z) in the case of <u>Section </u><font style="color: #000000;"><u>7.3(b)(iii)</u></font>,
                  prior to or concurrently with entering into the definitive agreement with respect to, or consummating, the Acquisition Proposal referred to in <u>clause </u><u>(C)</u> of <u>Section </u><font style="color: #000000;"><u>7.3(b)(iii)</u></font>;
                  it being understood that in no event shall the Company be required to pay the Termination Fee on more than one occasion.&#160; As used herein, &#8220;<u>Termination Fee</u>&#8221; shall mean a cash amount equal to $175,000,000.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If the Termination Fee shall become payable pursuant to this <u>Section </u><font style="color: #000000;"><u>7.3(b)</u></font>, Parent&#8217;s receipt of the Termination Fee, together with any
                  amounts that become due pursuant to <u>Section </u><font style="color: #000000;"><u>7.3(d)</u></font>, shall be deemed to be liquidated damages for any and all losses or damages suffered or incurred by Parent, Merger Sub, any of their
                  respective Affiliates or any other Person in connection with this Agreement (and the termination hereof), the Transactions (and the abandonment thereof) or any matter forming the basis for such termination, and shall be the sole and
                  exclusive remedy of Parent and Merger Sub and any of their respective Affiliates against any Company Related Parties, and none of Parent, Merger Sub or any of their respective Affiliates shall be entitled to bring or maintain any claim,
                  action or proceeding against the Company Related Parties arising out of or in connection with this Agreement, any of the Transactions or any matters forming the basis for such termination and upon payment of such amount(s), if at all,
                  none of the Company Related Parties shall have any further liability or obligations arising out of this Agreement; <font style="font-style: italic;">provided</font> that the foregoing shall not relieve any Company Related Party from any
                  liability for fraud or Willful Breach of this Agreement prior to such termination; <font style="font-style: italic;">provided, further</font>, that although Parent may seek both a grant of specific performance to cause the Company to
                  consummate the Transactions in accordance with <u>Section </u><u>8.5(b)</u> and payment of the Termination Fee (if due and payable), in no event shall Parent be entitled to both specific performance and the payment of the Termination
                  Fee in accordance with <u>Section </u><font style="color: #000000;"><u>7.3(b)(i)</u></font>.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">78</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Parties acknowledge that the agreements contained in this <u>Section </u><font style="color: #000000;"><u>7.3</u></font> are an integral part of the Transactions, that the Termination Fee
                  is not a penalty, but a reasonable amount that will compensate Parent and Merger Sub in the circumstances in which such payment is payable for the efforts and resources expended and opportunities foregone while negotiating this Agreement
                  and in reliance on this Agreement and on the expectation of the consummation of the Transactions and that, without these agreements, the Parties would not enter into this Agreement; accordingly, if the Company fails to timely pay any
                  amount due pursuant to <u>Section </u><font style="color: #000000;"><u>7.3(b)</u></font>, and, in order to obtain the payment, Parent commences a Legal Proceeding which results in a judgment against the Company, the Company shall pay
                  Parent its reasonable and documented costs and expenses (including reasonable and documented attorneys&#8217; fees) in connection with such suit, together with interest on such amount at the prime rate as published in <font style="font-style: italic;">The Wall Street Journal</font> in effect on the date such payment was required to be made plus three percent (or such lesser rate per annum that is the maximum permitted under Legal Requirements), through the date such payment
                  was actually received.</div>
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;">SECTION 8</div>
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;"><u>MISCELLANEOUS PROVISIONS</u></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">8.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Amendment</font>.&#160; At any time prior to the Effective Time, any provision of this Agreement may be amended or waived if,
                  and only if, such amendment or waiver is in writing and signed on behalf of the Company, Parent and Merger Sub; <font style="font-style: italic;">provided, however</font>, that after the Company Stockholder Approval, if any such
                  amendment or waiver will by Legal Requirement or in accordance with the rules and regulations of Nasdaq require further approval of the holders of the Shares, the effectiveness of such amendment will be subject to the approval of the
                  holders of the Shares.&#160; Notwithstanding anything contained herein to the contrary, no amendment, waiver, supplement or other modification to any Financing Source Provision that are adverse to the Financing Sources in their capacities as
                  such may be made without the prior written consent of the applicable Financing Source.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">79</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">8.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Waiver</font>.&#160; No failure on the part of any Party to exercise any power, right, privilege or remedy under this
                  Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy, and no single or partial exercise of any such
                  power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy such that rights and remedies provided herein shall be cumulative and not exclusive of any rights or
                  remedies provided by any Legal Requirement.&#160; At any time prior to the Effective Time, Parent and Merger Sub, on the one hand, and the Company, on the other hand, may, to the extent permissible under applicable Legal Requirements, (a)
                  extend the time for the performance of any of the obligations or other acts of the other, (b) waive any breach of the representations and warranties of the other contained herein or in any document delivered pursuant hereto, or (c) waive
                  compliance by the other with any of the agreements or covenants contained herein; <font style="font-style: italic;">provided, however</font>, that after receipt of the Company Stockholder Approval, no waiver shall be made which by
                  applicable Legal Requirement requires further approval by the holders of Shares without obtaining such further approval.&#160; Any such extension or waiver shall be valid only if expressly set forth in a written instrument duly executed and
                  delivered on behalf of the Party or Parties to be bound thereby, but such extension or waiver or failure to insist on strict compliance with an obligation, covenant, agreement or condition shall not operate as a waiver of, or estoppel
                  with respect to, any subsequent or other failure.&#160; Notwithstanding anything to the contrary in this Agreement, none of the Financing Source Provisions may be waived (and time for performance thereunder may not be extended) in a manner
                  that is adverse to the Financing Sources in their capacities as such without the prior written consent of the Financing Sources.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">8.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">No Survival of Representations and Warranties</font>.&#160; None of the representations and warranties of the Company, Parent
                  or Merger Sub contained in this Agreement, the Company Disclosure Schedule or in any certificate or schedule or other document delivered by any Person pursuant to this Agreement shall survive the Effective Time.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">8.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Entire Agreement; Counterparts</font>.&#160; This Agreement (including its Exhibits, Annexes and the Company Disclosure
                  Schedule) and the Confidentiality Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties and their respective Affiliates, with respect to
                  the subject matter hereof and thereof.&#160; This Agreement may be executed in several counterparts (including counterparts delivered by electronic transmission), each of which shall be deemed an original and all of which shall constitute one
                  and the same instrument.&#160; Any such counterpart, to the extent delivered by fax or .pdf, .tif, .gif, .jpg or similar attachment to electronic mail or any electronic signature complying with the U.S. federal ESIGN Act of 2000 (<font style="font-style: italic;">e.g.</font>, www.docusign.com) (any such delivery, an &#8220;<u>Electronic Delivery</u>&#8221;), will be treated in all manner and respects as an original executed counterpart and will be considered to have the same
                  binding legal effect as if it were the original signed version thereof delivered in person.&#160; Until and unless each Party has received a counterpart hereof signed (including by electronic signature) and expressly released by the other
                  Parties hereto, this Agreement shall have no effect and no Party shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other communication).&#160; No Party may raise the use of an Electronic
                  Delivery to deliver a signature, or the fact that any signature or agreement or instrument was transmitted or communicated through the use of an Electronic Delivery, as a defense to the formation of a contract, and each Party forever
                  waives any such defense, except to the extent such defense relates to lack of authenticity.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">80</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">8.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Applicable Legal Requirements; Jurisdiction; Specific Performance; Remedies</font>.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement, the Transactions and all claims arising out of or relating to this Agreement shall be governed by, and construed in accordance with, the Legal Requirements of the State of
                  Delaware, regardless of the Legal Requirements that might otherwise govern under applicable principles of conflict of laws thereof.&#160; In any action or proceeding arising out of or relating to this Agreement or any of the Transactions, (i)
                  each of the Parties irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of (A) the Chancery Court of the State of Delaware and any state appellate court therefrom, (B) if (but only if) the court in
                  clause (A) lacks subject matter jurisdiction, the Superior Court of the State of Delaware sitting in New Castle County and any state appellate court therefrom, or (C) if (but only if) the courts in <u>clauses </u><u>(A)</u> or <u>(B)</u>
                  lack subject matter jurisdiction, the United States District Court sitting in New Castle County in the State of Delaware and any appellate court therefrom (collectively, the &#8220;<u>Delaware Courts</u>&#8221;), and (ii) each of the Parties
                  irrevocably consents to service of process by first class certified mail, return receipt requested, postage prepaid, to the address at which such Party is to receive notice in accordance with <u>Section </u><font style="color: #000000;"><u>8.8</u></font>.&#160;













                  Each of the Parties irrevocably and unconditionally (A) agrees not to commence any such action or proceeding except in the Delaware Courts, (B) agrees that any claim in respect of any such action or proceeding may be heard and determined
                  in the Delaware Courts, (C) waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the jurisdiction or laying of venue of any such action or proceeding in the Delaware Courts
                  and (D) waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in the Delaware Courts.&#160; The Parties agree that a final judgment in any such action or proceeding
                  shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by applicable Legal Requirements; <font style="font-style: italic;">provided</font>,<font style="font-style: italic;">
                    however</font>, that nothing in the foregoing shall restrict any Party&#8217;s rights to seek any post-judgment relief regarding, or any appeal from, such final trial court judgment.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that the Parties do not perform their
                  obligations under the provisions of this Agreement in accordance with its specified terms or otherwise breach such provisions.&#160; The Parties acknowledge and agree that (i) the Parties shall be entitled to an injunction or injunctions,
                  specific performance, or other equitable relief, to prevent breaches (or threatened breaches) of this Agreement and to enforce specifically the terms and provisions hereof in the courts described in <u>Section </u><u>8.5(a)</u> without
                  proof of damages or otherwise, this being in addition to any other remedy to which they are entitled under this Agreement, (ii) neither the ability of either Party to recover damages for fraud or any Willful Breach of this Agreement nor
                  the provisions of <u>Section 7.3</u> are intended to and may not adequately compensate the Parties for the harm that would result from a breach of this Agreement, and will not be construed to diminish or otherwise impair in any respect
                  any Party&#8217;s right to an injunction, specific performance and other equitable relief and (iii) the right of specific performance is an integral part of the Transactions and without that right, neither the Company nor Parent would have
                  entered into this Agreement.&#160; Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that the other Parties have an adequate remedy at law or that an
                  award of specific performance is not an appropriate remedy for any reason at law or equity.&#160; The Parties acknowledge and agree that any Party seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce
                  specifically the terms and provisions of this Agreement in accordance with this <u>Section</u><u> 8.5(b)</u> shall not be required to provide any bond or other security in connection with any such order or injunction.&#160; The Parties
                  further agree that (x) by seeking the remedies provided for in this <u>Section </u><u>8.5</u>, a Party shall not be deemed to waive (and shall retain) any other remedies expressly available to such Party under this Agreement; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that nothing in this <u>clause (x)</u> shall be construed to expand the nature or scope of monetary damages available to any Party beyond
                  those expressly permitted by this Agreement, and (y) nothing set forth in this <u>Section </u><u>8.5</u> shall require any Party to institute any Legal Proceeding for (or limit any Party&#8217;s right to institute any Legal Proceeding for)
                  specific performance under this <u>Section </u><u>8.5(b)</u> prior to, or as a condition to, exercising any termination right under <u>Section 7</u>; <font style="font-style: italic;">provided, however</font>, that under no
                  circumstances will the Company or any Company Related Party be permitted or entitled to receive both specific performance that results in the occurrence of the Closing and any monetary damages.&#160; For the avoidance of doubt, the
                  commencement of any Legal Proceeding under this <u>Section 8.5</u> shall not, by itself, restrict or limit any Party&#8217;s right to terminate this Agreement in accordance with <u>Section 7</u>, but no termination shall operate to revive or
                  expand any remedy (including expectation damages) that this Agreement restricts or limits.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">81</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EACH OF THE PARTIES IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING BETWEEN THE PARTIES (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE), INCLUDING ANY COUNTERCLAIM,
                  ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT THEREOF.&#160; EACH PARTY (I) MAKES THIS WAIVER VOLUNTARILY, AND (II)
                  ACKNOWLEDGES THAT SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS CONTAINED IN THIS <u>SECTION </u><u>8.5</u>.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything in this Agreement to the contrary, each of the Parties (i) agrees that any Legal Proceeding of any kind or description, whether in contract or in tort or otherwise,
                  involving the Financing Sources, arising out of or relating to this Agreement or any other document, instrument or agreement executed and delivered in connection with this Agreement, the Debt Commitment Letter, the Financing or any of the
                  transactions contemplated thereby (including the Transactions) or the performance of any services thereunder shall be subject to the exclusive jurisdiction of any federal or state court in the Borough of Manhattan, New York, New York, so
                  long as such forum is and remains available, and any appellate court thereof and each Party hereto irrevocably submits itself and its property with respect to any such Legal Proceeding to the exclusive jurisdiction of such courts, (ii)
                  agrees that any such Legal Proceeding shall be governed by the Legal Requirements of the State of New York (without giving effect to any conflicts of law principles that would result in the application of the Legal Requirements of another
                  state), except as otherwise provided in any applicable commitment letter or other applicable definitive document agreement relating to any Financing, (iii) agrees not to bring or support or permit any of its controlled Affiliates to bring
                  or support any Legal Proceeding of any kind or description, whether in law or in equity, whether in contract or in tort or otherwise, against any Financing Source in any way arising out of or relating to this Agreement or any other
                  document, instrument or agreement executed and delivered in connection with this Agreement, the Debt Commitment Letter, the Financing or any of the transactions contemplated thereby (including the Transactions) or the performance of any
                  services thereunder in any forum other than any federal or state court in the Borough of Manhattan, New York, New York, (iv) irrevocably waives, to the fullest extent that it may effectively do so, the defense of an inconvenient forum to
                  the maintenance of such Legal Proceeding in any such court, and (v) knowingly, intentionally and voluntarily waives to the fullest extent permitted by applicable Legal Requirements trial by jury in any Legal Proceeding brought against the
                  Financing Sources in any way arising out of or relating to this Agreement or any other document, instrument or agreement executed and delivered in connection with this Agreement, the Debt Commitment Letter, the Financing or any of the
                  transactions contemplated thereby (including the Transactions) or the performance of any services thereunder.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">82</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">8.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Assignability</font>.&#160; This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit
                  of, the Parties and their respective successors and permitted assigns; <font style="font-style: italic;">provided</font>,<font style="font-style: italic;"> however</font>, that neither this Agreement nor any of the rights hereunder may
                  be assigned by a Party without the prior written consent of the other Parties, and any attempted assignment of this Agreement or any of such rights without such consent shall be void and of no effect, except that Parent may designate, by
                  written notice to the Company, another wholly owned direct or indirect Subsidiary of Parent (<font style="font-style: italic;">provided</font> that it is a Delaware corporation) to act as Merger Sub hereunder, in which event all
                  references to &#8220;Merger Sub&#8221; in this Agreement (and in <u>Exhibit A</u>) shall be deemed references to such other Subsidiary.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">8.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">No Third Party Beneficiaries</font>.&#160; Nothing in this Agreement, express or implied, is intended to or shall confer upon
                  any Person (other than the Parties) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement, except for (a) if the Effective Time occurs, (i) the right of the holders of Shares to receive the Merger
                  Consideration pursuant to <u>Section 1</u> following the Effective Time in accordance with the terms of this Agreement, and (ii) the right of the holders of Company Options (including In the Money Director Options), Company RSUs and
                  Company PSUs to receive the consideration set forth in <u>Section </u><u>1.8</u> at or following the Effective Time in accordance with the terms of this Agreement, (b) the provisions set forth in <u>Section </u><u>5.4(d)</u>, (c) as
                  set forth in or contemplated by <u>Section </u><u>7.3(c)</u>, and (d) if Parent or Merger Sub wrongfully terminates in breach of this Agreement or Willfully Breaches this Agreement, then, following the termination of this Agreement, the
                  Company may seek damages and other relief (including equitable relief) provided for in this Agreement on behalf of and as representative of the holders of Company Common Stock, Company RSUs, Company PSUs and Company Options (including
                  Benefit of the Bargain Damages) (each of whom are third-party beneficiaries hereunder solely to the extent necessary for this clause (d) to be enforceable).&#160; Notwithstanding anything herein to the contrary, unless otherwise required by
                  applicable Legal Requirements, the rights granted pursuant to clause (d) of this <u>Section </u><u>8.7</u> and the provisions of <u>Section </u><u>7.2</u> with respect to the recovery of Benefit of the Bargain Damages will only be
                  enforceable on behalf of the holders of Company Common Stock, Company RSUs, Company PSUs and Company Options (including In the Money Director Options) by the Company through actions approved by the Board of Directors, in its sole and
                  absolute discretion, as representative for such holders and may, in the Company&#8217;s sole and absolute discretion, as representative for such holders, be (x) distributed, in whole or in part, by the Company to the holders of record of
                  Company Common Stock, Company RSUs, Company PSUs and Company Options (including In the Money Director Options) as of any date determined by the Company or (y) retained by the Company for the use and benefit of the Company in any manner
                  the Company deems fit.&#160; Notwithstanding anything to the contrary in the foregoing, the Financing Source Provisions shall inure to the benefit of the Financing Sources, which are hereby expressly intended to be third-party beneficiaries
                  thereof and the Financing Sources shall be entitled to rely on and enforce all obligations and other rights provided in such Sections and provisions.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">83</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">8.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Notices</font>.&#160; Any notice or other communication required or permitted to be delivered to any Party under this Agreement
                  shall be in writing and shall be deemed properly delivered, given and received (a) upon receipt when delivered by hand, (b) upon receipt of proof of delivery on a Business Day before 5:00 p.m.&#160; in the time zone of the receiving Party,
                  otherwise upon the following Business Day after receipt of proof of delivery if sent by registered mail or by courier or express delivery service, (c) if sent by email prior to 5:00 p.m.&#160; recipient&#8217;s local time, upon transmission when
                  receipt is confirmed, or (d) if sent by email after 5:00 p.m.&#160; recipient&#8217;s local time and receipt is confirmed, the Business Day following the date of transmission; <font style="font-style: italic;">provided </font>that in each case the
                  notice or other communication is sent to the physical address or email address set forth beneath the name of such Party below (or to such other physical address or email address as such Party shall have specified in a written notice given
                  to the other Parties):</div>
                <div>&#160;</div>
                <div style="margin-left: 72pt;">if to Parent or Merger Sub (or following the Effective Time, the Surviving Corporation):</div>
                <div>&#160;</div>
                <div style="margin-left: 108pt;">BioMarin Pharmaceutical Inc.</div>
                <div style="margin-left: 108pt;">770 Lindaro Street</div>
                <div style="margin-left: 108pt;">San Rafael, CA 94901</div>
                <div style="margin-left: 108pt;">Attn: Eric Davis, EVP and Chief Legal Officer</div>
                <div style="margin-left: 108pt;">Email: [***]</div>
                <div>&#160;</div>
                <div style="margin-left: 72pt;">with a copy (which shall not constitute notice) to:</div>
                <div>&#160;</div>
                <div style="margin-left: 108pt;">Jones Day</div>
                <div style="margin-left: 108pt;">3161 Michelson Drive, Suite 800</div>
                <div style="margin-left: 108pt;">Irvine, CA 92612</div>
                <div style="margin-left: 108pt;">Attn: Jonn R. Beeson</div>
                <div style="margin-left: 108pt;">Email: [***]</div>
                <div style="margin-left: 108pt;">and</div>
                <div>&#160;</div>
                <div style="margin-left: 108pt;">Jones Day</div>
                <div style="margin-left: 108pt;">250 Vesey Street</div>
                <div style="margin-left: 108pt;">New York, NY 10281</div>
                <div style="margin-left: 108pt;">Attn: Andrew M. Levine</div>
                <div style="margin-left: 108pt;">Email: [***]</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">84</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="margin-left: 72pt;">if to the Company (prior to the Effective Time):</div>
                <div>&#160;</div>
                <div style="margin-left: 108pt;">Amicus Therapeutics, Inc.</div>
                <div style="margin-left: 108pt;">47 Hulfish Street</div>
                <div style="margin-left: 108pt;">Princeton, NJ 08542</div>
                <div style="margin-left: 108pt;">Attn: Ellen Rosenberg, Chief Legal Officer</div>
                <div style="margin-left: 108pt;">Email: [***]</div>
                <div>&#160;</div>
                <div style="margin-left: 72pt;">with a copy (which shall not constitute notice) to:</div>
                <div>&#160;</div>
                <div style="margin-left: 108pt;">Kirkland &amp; Ellis LLP</div>
                <div style="margin-left: 108pt;">200 Clarendon Street</div>
                <div style="margin-left: 108pt;">Boston, MA 02116</div>
                <div style="margin-left: 108pt;">Attn: Graham Robinson</div>
                <div style="text-indent: 36pt; margin-left: 90pt;">&#160; Chad&#233; Severin</div>
                <div style="text-indent: 36pt; margin-left: 90pt;">&#160; John W. Sheridan</div>
                <div style="margin-left: 108pt;">
                  <div>Email: [***]</div>
                </div>
                <div style="text-indent: 36pt; margin-left: 99pt;">&#160;[***]</div>
                <div style="text-indent: 36pt; margin-left: 99pt;">&#160;[***]</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">8.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Severability</font>.&#160; In the event that any term or provision of this Agreement, or the application thereof, is declared
                  in a final judgment by a court of competent jurisdiction to be illegal, void, invalid or unenforceable in any situation in any jurisdiction, such final judgment shall not affect the validity or enforceability of the remaining terms and
                  provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction, and the Parties agree that the court making such determination shall have the power to
                  limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or
                  unenforceable term or provision, and the remainder of this Agreement shall be valid and enforceable as so modified.&#160; In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace
                  such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">8.10</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Obligation of Parent</font>.&#160; Parent shall ensure that Merger Sub (and, following the Effective Time, the Surviving
                  Corporation) duly performs, satisfies and discharges on a timely basis each of the covenants, obligations and liabilities applicable to Merger Sub or the Surviving Corporation, as applicable, under this Agreement, and Parent shall be
                  jointly and severally liable with Merger Sub or the Surviving Corporation, as applicable, for the due and timely performance and satisfaction of each of said covenants, obligations and liabilities.</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">85</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">8.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Construction</font>.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For purposes of this Agreement, whenever the context requires, (i) the singular number shall include the plural, and vice versa, (ii) the masculine gender shall include the feminine and neuter
                  genders, (iii) the feminine gender shall include the masculine and neuter genders, and (iv) the neuter gender shall include the masculine and feminine genders.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this
                  Agreement.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As used in this Agreement, the word &#8220;including&#8221; and words of similar import shall mean including without limiting the generality of any description preceding or following such term, unless
                  otherwise specified.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as otherwise indicated, all references in this Agreement to &#8220;Sections,&#8221; &#8220;Exhibits&#8221; or &#8220;Annexes&#8221; are intended to refer to Sections of this Agreement and Exhibits or Annexes to this
                  Agreement.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The bold-faced headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the
                  construction or interpretation of this Agreement.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The term &#8220;dollars&#8221; and character &#8220;$&#8221; shall mean United States dollars.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Documents or other information or materials will be deemed &#8220;made available,&#8221; &#8220;delivered,&#8221; &#8220;furnished,&#8221; or &#8220;provided&#8221; by the Company if such documents, information or materials have been
                  physically or electronically delivered, in unredacted form, to Parent, Merger Sub or any of their respective Representatives, have been uploaded to, and made continuously accessible to Parent, Merger Sub and their respective
                  Representatives in, the online data room hosted on behalf of the Company by Datasite under the name &#8220;Project Pacsun,&#8221; or have been filed with or furnished to the SEC and available on EDGAR, in each case, at least 24 hours prior to the
                  execution and delivery of this Agreement.</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any reference to (i) any Governmental Body includes any successor to that Governmental Body, and (ii) any applicable Legal Requirement refers to such applicable Legal Requirement as amended,
                  modified, supplemented or replaced from time to time (and, in the case of statutes, include any rule and regulation promulgated under such statute) and references to any section of any applicable Legal Requirement includes any successor
                  to such section (<font style="font-style: italic;">provided</font> that, for purposes of any representation and warranty in this Agreement that is made as of a specific date, references to any Legal Requirement shall be deemed to refer to
                  such Legal Requirement, as amended, and to any rule or regulation promulgated thereunder, in each case, as of such date).</div>
                <div>&#160;</div>
                <div style="text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The phrases &#8220;ordinary course of business&#8221; and &#8220;ordinary course&#8221; shall mean &#8220;ordinary course of business consistent with past practice.&#8221;</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">86</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt;"><font style="font-weight: bold;">8.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Liability of the Financing Sources</font>.&#160; Notwithstanding anything in this Agreement to the contrary, no Company Related
                  Party shall have any rights or claims against any Financing Source in connection with this Agreement or any other document, instrument or agreement executed and delivered in connection with this Agreement, the Debt Commitment Letter, the
                  Financing or any of the transactions contemplated thereby (including the Transactions) or the performance of any services thereunder, and no Financing Source shall have any liability or obligation to, or be subject to Legal Proceeding
                  brought by, any Company Related Party in connection with this Agreement or any other document, instrument or agreement executed or delivered in connection with this Agreement or any other document, instrument or agreement executed and
                  delivered in connection with this Agreement, the Debt Commitment Letter, the Financing or any of the transactions contemplated thereby (including the Transactions) or the performance of any services thereunder, whether at law or equity,
                  in contract, in tort or otherwise; <font style="font-style: italic;">provided</font> that nothing in this <u>Section </u><u>8.12</u> shall in any way limit any Financing Source&#8217;s obligations to the Parent and Merger Sub under the Debt
                  Commitment Letter; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">further</font>, that following the consummation of the Transactions, the foregoing will not limit the rights of any Parties under
                  the definitive documentation for the Financing.</div>
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;">[Signature page follows]</div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">87</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">IN WITNESS WHEREOF</font><font style="font-size: 10pt;">, the Parties have caused this Agreement to be executed as of the date first above
                    written.</font></div>
                <div>&#160;</div>
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0f4aee4d178e427ea7e15f495ce4ceee">

                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;" rowspan="1" colspan="2">
                        <div style="font-weight: bold;">Amicus Therapeutics, Inc.</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;"><br>
                      </td>
                      <td style="width: 47%; vertical-align: top;"><br>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
                        <div>By:</div>
                      </td>
                      <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                        <div>/s/ Bradley Campbell</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;">&#160;</td>
                      <td style="width: 47%; vertical-align: top;">
                        <div>Name:Bradley L. Campbell</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;">&#160;</td>
                      <td style="width: 47%; vertical-align: top;">
                        <div>Title: President and Chief Executive Officer</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;" rowspan="1" colspan="2"><br>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;" rowspan="1" colspan="2">
                        <div style="font-weight: bold;">BioMarin Pharmaceutical Inc.</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>
                      <td style="width: 47%; vertical-align: top;" rowspan="1">&#160;</td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
                        <div>By:</div>
                      </td>
                      <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                        <div>/s/ James Sabry</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;">&#160;</td>
                      <td style="width: 47%; vertical-align: top;">
                        <div>Name: James Sabry</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;">&#160;</td>
                      <td style="width: 47%; vertical-align: top;">
                        <div>Title: EVP, Chief Business Officer</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;" rowspan="1" colspan="2">&#160;</td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;" rowspan="1" colspan="2">
                        <div style="font-weight: bold;">Lynx Merger Sub 1, Inc.</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;" rowspan="1" colspan="2"><br>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
                        <div>By:</div>
                      </td>
                      <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                        <div>/s/ G. Eric Davis</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;">&#160;</td>
                      <td style="width: 47%; vertical-align: top;">
                        <div>Name: G. Eric Davis</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
                      <td style="width: 3%; vertical-align: top;">&#160;</td>
                      <td style="width: 47%; vertical-align: top;">
                        <div>Title: Authorized Signatory</div>
                      </td>
                    </tr>

                </table>
                <div>&#160;
                  <div style="text-align: center;">[Signature Page to Agreement and Plan of Merger]</div>
                  <div> <br>
                  </div>
                </div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <!--PROfilePageNumberReset%Num%1%A-%%-->
                <div style="text-align: center; font-weight: bold;">EXHIBIT A</div>
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;">CERTAIN DEFINITIONS</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt;">For purposes of the Agreement (including this <u>Exhibit A</u>):</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Acceptable Confidentiality Agreement</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Acceptable Confidentiality Agreement</u>&#8221; means a customary
                    confidentiality agreement that (i) contains provisions that are not less favorable to the Company than those contained in the Confidentiality Agreement, and (ii) does not prohibit any Acquired Company from providing any information to
                    Parent in accordance with <u>Section </u><font style="color: #000000;"><u>4.3</u></font> or otherwise prohibit the Acquired Companies or the Board of Directors from complying with the provisions of <u>Section </u><font style="color: #000000;"><u>4.3</u></font> or <u>Section </u><font style="color: #000000;"><u>5.1</u></font><u>,</u> except that such confidentiality agreement need not include explicit or implicit standstill provisions that would restrict the
                    making of or amendment or modification to Acquisition Proposals.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Acquired Companies</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Acquired Companies</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>2.1(a)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Acquisition Proposal</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Acquisition Proposal</u>&#8221; means any inquiry, proposal or offer from any
                    Person (other than Parent and its Affiliates) or &#8220;group&#8221;, within the meaning of Section 13(d) of the Exchange Act, relating to, in a single transaction or series of related transactions, any (a) acquisition, transfer, disposition or
                    license, collaboration or revenue-sharing arrangement with respect to assets of any Acquired Company equal to 15% or more of the Company&#8217;s consolidated assets (based on the fair market value thereof) or to which 15% or more of the
                    Company&#8217;s revenues or earnings on a consolidated basis are attributable, (b) issuance or acquisition of (i) 15% or more of the outstanding Company Common Stock or other voting or equity securities of the Company, (ii) securities and
                    Indebtedness that would, in the aggregate, have 15% or more of the outstanding voting power of any class of the Company&#8217;s securities, or (iii) any options, rights or warrants to purchase or securities convertible into or exchangeable
                    for equity or debt interests described in the foregoing <u>clauses </u><u>(i)</u> or <u>(ii)</u> (the forgoing securities described in this <u>clause (b)</u>, collectively, &#8220;<u>Designated Securities</u>&#8221;), (c) recapitalization,
                    tender offer or exchange offer that if consummated would result in any Person or group beneficially owning Designated Securities, or (d) merger, consolidation, amalgamation, share exchange, business combination, recapitalization,
                    liquidation, dissolution or similar transaction involving an Acquired Company that if consummated would result in any Person or &#8220;group&#8221; beneficially owning Designated Securities, in each case of the foregoing <u>clauses (a)</u> through
                    <u>(d)</u>, other than the Transactions.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Affiliate</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Affiliate</u>&#8221; means, as to any Person, any other Person that, directly or indirectly,
                    controls, or is controlled by, or is under common control with, such Person.&#160; For this purpose, &#8220;control&#8221; (including, with its correlative meanings, &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) shall mean the possession, directly or
                    indirectly, of the power to direct or cause the direction of management or policies of a Person, whether through the ownership of securities or partnership or other ownership interests, by Contract or otherwise.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Agreement</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Agreement</u>&#8221; is defined in the preamble to the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Agreement Date</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Agreement Date</u>&#8221; is defined in the preamble to the Agreement.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-1</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">AI</font><font style="font-size: 10pt;">.&#160; &#8220;<u>AI</u>&#8221; is defined in the definition of AI Technology.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">AI Technology</font><font style="font-size: 10pt;">.&#160; &#8220;<u>AI Technology</u>&#8221; means any and all machine learning, deep learning, and other
                    artificial intelligence (&#8220;<u>AI</u>&#8221;) technologies, including statistical learning algorithms, models (including large language models), neural networks and other AI tools or methodologies and all software implementations of any of the
                    foregoing.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Anti-Corruption Laws</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Anti-Corruption Laws</u>&#8221; means the Foreign Corrupt Practices Act of 1977,
                    the Anti-Kickback Act of 1986, the UK Bribery Act of 2010 and the Anti-Bribery Laws of the People&#8217;s Republic of China or any applicable Legal Requirements of similar effect, and the related regulations and published interpretations
                    thereunder.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Antitrust Laws</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Antitrust Laws</u>&#8221; means the Sherman Act, the Clayton Act, the HSR Act, the
                    Federal Trade Commission Act, all applicable foreign anti-trust laws, any laws relating to foreign direct investment, and all other applicable Legal Requirements issued by a Governmental Body that are designed or intended to prohibit,
                    restrict or regulate actions having the purpose or effect of monopolization or restraint of trade or lessening of competition or intended to prohibit, restrict or regulate foreign direct investment or investment that could affect
                    national security interests.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Applicable Date</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Applicable Date</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>2.4(a)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Board of Directors</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Board of Directors</u>&#8221; is defined in the Introduction to the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Book-Entry Shares</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Book-Entry Shares</u>&#8221; means non-certificated Shares represented by book-entry.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Business Day</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Business Day</u>&#8221; means a day except a Saturday, a Sunday or other day on which
                    banks in California or New Jersey are authorized or required by Legal Requirements to be closed.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Capitalization Date</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Capitalization Date</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>2.3(a)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">CARES Act</font><font style="font-size: 10pt;">.&#160; &#8220;<u>CARES Act</u>&#8221; is defined in the definition of CARES Act and COVID Relief Programs.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">CARES Act and COVID Relief Programs</font><font style="font-size: 10pt;">.&#160; &#8220;<u>CARES Act and COVID Relief Programs</u>&#8221; means, collectively,
                    the Coronavirus Aid, Relief, and Economic Security Act (H.R. 748, Pub. Law No.116-136) (March 27, 2020) (the &#8220;<u>CARES Act</u>&#8221;), as amended by Section 206 of the Taxpayer Certainty and Disaster Tax Relief Act of 2020, which was enacted
                    as Division EE of the Consolidated Appropriations Act, 2021 (H.R. 133, Pub. Law No. 116-260) (December 27, 2020), the Families First Coronavirus Response Act (H.R.6201, Pub. Law no.&#160; 116-127) (March 18, 2020), Paycheck Protection
                    Program Flexibility Act of 2020 (H.R. 7010, Pub. Law No. 116-142) (June 5, 2020), American Rescue Plan Act (H.R. 1319, Pub. Law No. 117-2) (March 11, 2021) and all FAQs or interim final rules issued by any Governmental Body related
                    thereto, including any programs or facilities established by the Board of Governors of the Federal Reserve System to which the U.S. Treasury Department has provided financing as contemplated by Title IV of the CARES Act, and any
                    analogous U.S. state, local or non-US Legal Requirements.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-2</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Certificated Shares</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Certificated Shares</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>1.6(b)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Certificates</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Certificates</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>1.6(b)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Change of Control Payment</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Change of Control Payment</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>2.9(a)(vii)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Clinical Trials.&#160; </font><font style="font-size: 10pt;">&#8220;<u>Clinical Trials</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>2.12(b)</u></font><u>&#160;</u>of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Closing</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Closing</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>1.3(a)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Closing Date</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Closing Date</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>1.3(a)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">CMO</font><font style="font-size: 10pt;">.&#160; &#8220;<u>CMO</u>&#8221; means a contract manufacturing organization.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">CMS</font><font style="font-size: 10pt;">.&#160; &#8220;<u>CMS</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>5.2(f)</u></font> of
                    the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Code</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Code</u>&#8221; means the U.S. Internal Revenue Code of 1986.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company</u>&#8221; is defined in the preamble to the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company 401(k) Plan</font><font style="font-size: 10pt;">.<font style="font-weight: bold;">&#160; </font>&#8220;<u>Company </u><u>401(k) Plan</u>&#8221; is
                    defined in <u>Section </u><font style="color: #000000;"><u>5.3(e)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company Adverse Recommendation Change</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company Adverse Recommendation Change</u>&#8221; is defined in <u>Section














                    </u><font style="color: #000000;"><u>5.1(a)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company Associate</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company Associate</u>&#8221; means each current or former officer or other employee,
                    or individual who is or was at any time an independent contractor, consultant or director, of or to the Company or its Subsidiaries.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company Board Recommendation</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company Board Recommendation</u>&#8221; is defined in the Introduction to
                    the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company Common Stock</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company Common Stock</u>&#8221; means the common stock, $0.01 par value per share,
                    of the Company.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company Data</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company Data</u>&#8221; means all customer, employee, vendor or business partner data
                    used, Processed and/or hosted by or on behalf of an Acquired Company, whether provided by an Acquired Company or any other Person.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company Disclosure Schedule</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company Disclosure Schedule</u>&#8221; means the disclosure schedule that
                    has been prepared by the Company in accordance with the requirements of the Agreement and that has been delivered by the Company to Parent on the Agreement Date.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-3</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company Equity Plans</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company Equity Plans</u>&#8221; means the Company&#8217;s Amended and Restated 2007
                    Equity Incentive Plan, 2025 Equity Incentive Plan, Amended and Restated 2007 Director Option Plan and Company ESPP, each as amended.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company ESPP</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company ESPP</u>&#8221; means the Company&#8217;s 2023 Employee Stock Purchase Plan, as amended.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company IP</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company IP</u>&#8221; means any and all (a) Intellectual Property Rights that are owned or
                    purported to be owned by any Acquired Company, and (b) third party Intellectual Property Rights exclusively licensed to any of the Acquired Companies.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company IT Assets</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company IT Assets</u>&#8221; means computers, computer software, databases, storage
                    media (<font style="font-style: italic;">e.g.</font>, backup tapes), firmware, middleware, servers, workstations, routers, hubs, switches, data communications lines and all other information technology equipment, or other devices or
                    systems that Process Personal Information held by or for the Acquired Companies or Company Data, in each case, owned by any Acquired Company or licensed or leased by any Acquired Company (excluding any public networks).</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company Options</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company Options</u>&#8221; means all options to purchase Shares granted pursuant to a
                    Company Equity Plan.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company Preferred Stock</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company Preferred Stock</u>&#8221; means the preferred stock, $0.01 par value
                    per share, of the Company.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company PSUs</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company PSUs</u>&#8221; means performance-vesting restricted stock units with respect to
                    Shares granted pursuant to a Company Equity Plan.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company Related Parties</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company Related Parties</u>&#8221; means the Acquired Companies and any of
                    their respective former, current or future officers, directors, partners, employees, agents, attorneys, stockholders, current and future holders of any equity, managers, members or Affiliates.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company RSUs</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company RSUs</u>&#8221; means time-vesting restricted stock units with respect to Shares
                    granted pursuant to a Company Equity Plan.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company SEC Documents</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Company SEC Documents</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>2.4(a)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company Stockholder Approval</font><font style="font-size: 10pt;">.<font style="font-weight: bold;">&#160; </font>&#8220;<u>Company Stockholder
                      Approval</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>2.20</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Company Stockholder Meeting</font><font style="font-size: 10pt;">. <font style="font-weight: bold;">&#160;</font>&#8220;<u>Company Stockholder Meeting</u>&#8221;
                    is defined in <u>Section </u><font style="color: #000000;"><u>4.4(b)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-4</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Compliant</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Compliant</u>&#8221; means, with respect to the Required Financing Information, without
                    giving effect to any supplements or updates, that (a) such Required Financing Information does not contain any untrue statement of a material fact regarding the Acquired Companies or omit to state any material fact regarding the
                    Acquired Companies necessary in order to make such Required Financing Information not misleading, (b) no audit opinion or authorization letter with respect to any financial statements (or any portion thereof) contained in the Required
                    Financing Information shall have been withdrawn, amended or qualified, (c) such Required Financing Information complies in all material respects with all applicable requirements of Regulation S-K and Regulation S-X under the Securities
                    Act for a registered public offering of debt securities (other than such provisions (A) with which compliance is not customary in an offering of high-yield non-convertible debt securities under Rule 144A promulgated under the Securities
                    Act and (B) applicable to any Excluded Information), (d) the financial statements and other financial information included in such Required Financing Information would not be deemed stale or otherwise be unusable under customary
                    practices for registered offerings and private placements of debt securities under Rule 144A promulgated under the Securities Act or another exemption from registration under the Securities Act, (e) the financial statements and other
                    financial information included in the Required Financing Information are, and remain through the Closing, sufficient to permit the Financing Sources to receive customary comfort letters from the Company&#8217;s independent auditors with
                    respect to such financial information (including customary negative assurance comfort with respect to periods following the end of the latest fiscal year and fiscal quarter for which historical financial statements are included) on any
                    date prior to the Closing, and (f) the Company shall not have indicated its intent to restate any historical financial statement (or any portion thereof) contained in the Required Financing Information, and no such restatement shall be
                    under active consideration or a possibility.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Confidentiality Agreement</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Confidentiality Agreement</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>4.1</u></font><u>(a)</u> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Continuation Period</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Continuation Period</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>5.3(a)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Continuing Employee</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Continuing Employee</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>5.3(a)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Contract</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Contract</u>&#8221; means any contract, subcontract, lease, understanding, instrument, loan,
                    credit agreement, bond, debenture, note, option, warrant, license, sublicense, commitment, undertaking or other legally binding agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Copyrights</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Copyrights</u>&#8221; is defined in the definition of Intellectual Property Rights.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">CRO</font><font style="font-size: 10pt;">.&#160; &#8220;<u>CRO</u>&#8221; means a Person (including a commercial, academic or other organization) contracted
                    by a sponsor to perform one or more of a sponsor&#8217;s Clinical Trial-related duties and functions, including those defined in (a) 21 C.F.R. Part 312.3(b), (b) ICH GCP E6, (c) and foreign equivalents of the foregoing, each as may be amended
                    from time to time.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Cut-off Time</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Cut-off Time</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>4.3(b)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">DAC 6</font><font style="font-size: 10pt;">. <font style="font-weight: bold;">&#160;</font>&#8220;<u>DAC 6</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>2.14(g)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Data Privacy Laws</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Data Privacy Laws</u>&#8221; means all applicable Legal Requirements governing the
                    Processing of Personal Information, cybersecurity, the privacy of electronic communications, or the transmission of marketing messages through any means, in any relevant jurisdiction.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-5</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Debt Commitment Letter</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Debt Commitment Letter</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>3.7(a)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Debt Financing Fee Letter</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Debt Financing Fee Letter</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>3.7(a)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Definitive Debt Agreements</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Definitive Debt Agreements</u>&#8221; is defined in <u>Section 5.12(a)</u>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Delaware Courts</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Delaware Courts</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>8.5(a)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Designated Securities</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Designated Securities</u>&#8221; is defined in the definition of Acquisition
                    Proposal.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Determination Notice</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Determination Notice</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>5.1(b)(i)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">DGCL</font><font style="font-size: 10pt;">.&#160; &#8220;<u>DGCL</u>&#8221; means the Delaware General Corporation Law.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Dissenting Shares</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Dissenting Shares</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>1.7</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">DOJ</font><font style="font-size: 10pt;">.&#160; &#8220;<u>DOJ</u>&#8221; means the U.S. Department of Justice.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Domain Names</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Domain Names</u>&#8221; is defined in the definition of Intellectual Property Rights.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Effective Time</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Effective Time</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>1.3(b)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Electronic Delivery</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Electronic Delivery</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>8.4</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">EMA</font><font style="font-size: 10pt;">.&#160; &#8220;<u>EMA</u>&#8221; means the European Medicines Agency.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Employee Plan</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Employee Plan</u>&#8221; means any (a) employee benefit plan (as defined in Section 3(3)
                    of ERISA), whether or not subject to ERISA, (b) bonus, deferred compensation, incentive compensation, stock purchase, stock option, equity-based, severance pay, termination pay, death and disability benefits, hospitalization, medical,
                    life or other insurance or welfare benefits, flexible benefits, supplemental unemployment benefits, profit-sharing, pension or retirement plan, policy, program, agreement or arrangement, and (c) employment, consulting, severance or
                    similar agreement, each other employee benefit plan, program, agreement or arrangement (whether written or oral), and any trust, escrow or similar agreement related thereto, whether or not funded, in each case that is (i) sponsored,
                    maintained, contributed to or required to be contributed to by any Acquired Company for the benefit of any Company Associate or other individual service provider of any Acquired Company, (ii) with respect to which any of the Acquired
                    Companies has or could reasonably be expected to have any current or contingent liability (including on account of any ERISA Affiliate), or (iii) to which any Acquired Company is a party, but in each case excluding any statutory plan or
                    arrangement that is required by applicable Legal Requirements.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-6</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Employment Practices</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Employment Practices</u>&#8221; is defined in <u>Section </u><u>2.15(b)</u> of
                    the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Encumbrance</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Encumbrance</u>&#8221; means any lien, pledge, hypothecation, charge, mortgage, security
                    interest, encumbrance, claim, infringement, option, right of first refusal or first offer, preemptive right, title retention, community property interest or similar restriction of any nature (including any restriction on the voting of
                    any security, any restriction on the transfer of any security or other asset, any restriction on the use of, or receipt of any income derived from, any asset, and any restriction on the possession, exercise or transfer of any other
                    attribute of ownership of any asset).</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">End Date</font><font style="font-size: 10pt;">.&#160; &#8220;<u>End Date</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>7.1(b)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Entity</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Entity</u>&#8221; means any corporation (including any non-profit corporation), general
                    partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise,
                    association, organization or entity.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Environmental Law</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Environmental Law</u>&#8221; means any federal, state, local or foreign Legal
                    Requirement relating to occupational health and safety, pollution or protection of human health, worker health or the environment (including ambient air, surface water, ground water, sediment, land surface or subsurface strata),
                    including any Legal Requirement relating to emissions, discharges, Releases or threatened Releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
                    or handling of Hazardous Materials.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">ERISA</font><font style="font-size: 10pt;">.&#160; &#8220;<u>ERISA</u>&#8221; means the Employee Retirement Income Security Act of 1974.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">ERISA Affiliate</font><font style="font-size: 10pt;">.&#160; &#8220;<u>ERISA Affiliate</u>&#8221; means any trade or business (whether or not incorporated)
                    (a) that is, or was at the relevant time, under common control within the meaning of Section 4001(b)(1) of ERISA with an Acquired Company, or (b) which, together with any of the Acquired Companies, at any relevant time would be treated
                    as a single employer under Section 414 of the Code.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Exchange Act</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934 and the rules and
                    regulations promulgated thereunder.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Excluded Information</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Excluded Information</u>&#8221; is defined in the definition of Required Financing
                    Information.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Excluded Shares</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Excluded Shares</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>1.5(a)(iii)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-7</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Exploit</font><font style="font-size: 10pt;">.<font style="font-weight: bold;">&#160; </font>&#8220;<u>Exploit</u>&#8221; means, with respect to a biologic,
                    drug, combination product, compound, pharmaceutical ingredient (including active pharmaceutical ingredients, excipients and other materials), drug substance, device or product candidate: to discover, research, develop, analyze, test
                    (including through Clinical Trials), hold, store, formulate, quality control, manufacture, fill, finish, label, commercialize, distribute, promote, place on the market or otherwise exploit, including to research, make, have made,
                    distribute, use, sell, offer for sale, import and export, conduct all regulatory and other activities related to supporting, securing and maintaining any applicable Governmental Authorizations, as well as conduct any activities that are
                    performed in preparation or as part of, or as a follow-up to, any of the foregoing.&#160; &#8220;Exploiting&#8221; and &#8220;Exploitation&#8221; have the correlative meaning.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Extended End Date</font><font style="font-size: 10pt;">.&#160; &#8220;Extended <u>End Date</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>7.1(b)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">FDA</font><font style="font-size: 10pt;">.&#160; &#8220;<u>FDA</u>&#8221; means the United States Food and Drug Administration and any successor agency
                    thereto.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">FDCA</font><font style="font-size: 10pt;">.&#160; &#8220;<u>FDCA</u>&#8221; means the United States Federal Food, Drug and Cosmetic Act 21 U.S.C. &#167; 321 et
                    seq. and all related rules, regulations and guidelines.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Financing</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Financing</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>3.7(a)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Financing Authorization Letters</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Financing Authorization Letters</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>5.11(a)(v)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Financing Source Provisions</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Financing Source Provisions</u>&#8221; means each of <u>Section </u><font style="color: #000000;"><u>8.1</u></font>, <u>Section </u><font style="color: #000000;"><u>8.2</u></font>, <u>Section </u><font style="color: #000000;"><u>8.5</u></font><u>(d)</u>, <u>Section </u><font style="color: #000000;"><u>8.7</u></font>
                    and <u>Section </u><font style="color: #000000;"><u>8.12</u></font>, together with the defined terms used in each such Section, solely as they relate to the applicable Section.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Financing Sources</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Financing Sources</u>&#8221; means the Persons that have committed to provide any
                    portion of any of the Financing or have otherwise entered into any commitment letter, engagement letter, credit agreement, underwriting agreement, purchase agreement, indenture or other agreement in connection with any Financing (other
                    than Parent, Merger Sub or any of Parent&#8217;s Subsidiaries), including the agents, arrangers and lenders that are parties to the Debt Commitment Letter (including the agents, arrangers and lenders party to or that may after the Agreement
                    Date become party to any joinder agreements, or any similar agreement pursuant to which the Debt Commitment Letter is modified, supplemented, extended or replaced to add agents, arrangers, lenders or similar entities as parties thereto
                    who had not executed the Debt Commitment Letter as of the Agreement Date, entered into in connection therewith), together with their respective Affiliates and their and their respective Affiliates&#8217; Representatives, trustees,
                    equityholders, members and controlling Persons and the respective successors and assigns of any of the foregoing.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">FTC</font><font style="font-size: 10pt;">.&#160; &#8220;<u>FTC</u>&#8221; means the U.S. Federal Trade Commission.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">GAAP</font><font style="font-size: 10pt;">.&#160; &#8220;<u>GAAP</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>2.4(b)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Generative AI Tools</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Generative AI Tools</u>&#8221; means AI Technology capable of generating various
                    types of content (including text, images, video, audio or computer code) based on user-supplied prompts.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-8</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Global Trade Laws</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Global Trade Laws</u>&#8221; means all applicable Legal Requirements governing the
                    export, import and provision of goods (including technical data and technology) and services in the jurisdictions in which the Acquired Companies operate or do business, including (a) Sanctions Laws, (b) all Legal Requirements governing
                    the export, re-export or transfer of goods, software, technology or technical data, including the Export Administration Act of 1979 (50 U.S.C. App.&#160; &#167;&#167; 2401-2420), the Export Control Reform Act of 2018 (Pub. L.&#160; 115-232), the Export
                    Administration Regulations (15 C.F.R. Parts 730 -774), the Arms Export Control Act (22 U.S.C. &#167; 2778), and the International Traffic in Arms Regulations (22 C.F.R. &#167; 120.1 et seq.), (c) the Foreign Trade Regulations (15 C.F.R. Part 30)
                    administered by the Census Bureau, (d) all applicable Legal Requirements governing the importation of products (including Products), technology, technical data and services, including those administered by United States Customs and
                    Border Protection (19 C.F.R. Parts 1-199), (e) the antiboycott laws set forth in Section 999 of the Code, the Department of Treasury Guidelines concerning international boycotts promulgated thereunder, and Part 760 of the EAR, and (f)
                    any other similar applicable Legal Requirements of the jurisdictions in which the Acquired Companies operate or do business.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Good Clinical Practices</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Good Clinical Practices</u>&#8221; or &#8220;<u>GCP</u>&#8221; means, as applicable, those
                    current good clinical practices, standards and procedures for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of human Clinical Trials set forth in Legal Requirements, including (a) the FDCA and
                    its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56 and 312, (b) the International Conference on Harmonization (ICH) guidance titled &#8220;Guidance for Industry E6 Good Clinical Practice:&#160; Consolidated Guidance&#8221; and
                    including related requirements imposed by Regulation No (EU) 536/2014 and Regulation No (EU) 2017/556, Directive 2005/28/EC and, to the extent still applicable to any ongoing Clinical Trials, Directive 2001/20/EC, and (c) other foreign
                    equivalents of the foregoing, in each case, as same may be amended from time to time.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Good Laboratory Practices</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Good Laboratory Practices</u>&#8221; or &#8220;<u>GLP</u>&#8221; means, as applicable,
                    the current good laboratory practices set forth in Legal Requirements, including (a) the FDCA and its applicable implementing regulations at 21 C.F.R. Part 58, (b) Directive 2004/10/EC of the European Parliament and of the Council of 11
                    February 2004 on the harmonization of laws, regulations and administrative provisions relating to the application of the principles of good laboratory practice and the verification of their applications for tests on chemical substances
                    (codified version) and Directive 2004/9/EC of the European Parliament and of the Council of 11 February 2004 on the inspection and verification of good laboratory practice (GLP) (codified version), and (c) other foreign equivalents of
                    the foregoing, in each case, as same may be amended from time to time.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Good Manufacturing Practices</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Good Manufacturing Practices</u>&#8221; or &#8220;<u>GMP</u>&#8221; means, as
                    applicable, those current good manufacturing practices related to the manufacture of pharmaceutical products and any precursors thereto set forth in Legal Requirements, including (a) the FDCA and 21 C.F.R. Parts 210-211, (b) guidelines
                    and regulations of standard compilations in Directive (EU) 2017/1572 of 15 September 2017 supplementing Directive 2001/83/EC of the European Parliament and of the Council as regards the principles and guidelines of good manufacturing
                    practice for medicinal products for human use, and (c) other foreign equivalents of the foregoing, in each case, as same may be amended from time to time.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-9</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Government Contract</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Government Contract</u>&#8221; means any Contract, including any subsequent
                    modification of such Contract, between an Acquired Company and (a) a Governmental Body, (b) any prime contractor to a Governmental Body where the Contract is in furtherance of a prime contract between that contractor and a Governmental
                    Body or where an Acquired Company otherwise has knowledge that the prime contractor is acting in its capacity as such, or (c) any subcontractor (of any tier) in connection with or with respect to any Contract described in the foregoing
                    <u>clause </u><u>(a)</u> or <u>(b)</u> where the Contract is in furtherance of a higher tier contract that is in furtherance of a Contract with a Governmental Body (either as a prime contract or subcontract) or where an Acquired
                    Company otherwise has knowledge that the subcontractor is in furtherance of a higher tier contract that is in furtherance of a Contract with a Governmental Body (either as a prime contract or subcontract).</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Governmental Authorization</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Governmental Authorization</u>&#8221; means any implicit or explicit permit,
                    license, certificate, franchise, grant, permission, clearance, registration, consent, approval, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Body or
                    pursuant to any Legal Requirement, each as amended or supplemented from time to time, including in connection with the Exploitation of a Product under applicable Health Care Laws, including all investigational new drug applications and
                    other authorizations to conduct Clinical Trials, IRB approvals, new drug applications, supplemental new drug applications, abbreviated new drug applications, biologic license applications, establishment registrations and product
                    listings, any Pricing Approvals and national formulary placement in any country or jurisdiction and all supplements or amendments thereto.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Governmental Body</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Governmental Body</u>&#8221; means any (a) nation, state, commonwealth, province,
                    territory, county, municipality, district or other jurisdiction of any nature, (b) supranational, international, multinational, EU, federal, state, local, municipal, foreign or other government, or (c) governmental or quasi-governmental
                    authority of any nature including any governmental board, branch, bureau, division, department, institution, IRB agency, commission, instrumentality, official, ministry, fund, foundation, center, organization, unit or body and any
                    court, arbitrator or other tribunal.&#160; &#8220;Governmental Body&#8221; shall also include any officials, agents, employees or representatives of any of the foregoing.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">GxP</font><font style="font-size: 10pt;">.&#160; &#8220;<u>GxP</u>&#8221; means, collectively, Good Clinical Practices, Good Laboratory Practices, Good
                    Manufacturing Practices and other applicable, generally accepted industry best practice standards for the pharmaceutical or biotech industry.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Hazardous Materials</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Hazardous Materials</u>&#8221; means any waste, material or substance that is
                    listed, regulated or defined under any Environmental Law and includes any pollutant, chemical substance, hazardous substance, hazardous waste, special waste, solid waste, asbestos, mold, radioactive material, polychlorinated biphenyls,
                    petroleum or petroleum-derived substance or waste.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-10</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Health Care Laws</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Health Care Laws</u>&#8221; means all Legal Requirements and guidance that regulate
                    the Exploitation of any pharmaceuticals, biologics, controlled substances, narcotics, pathogens, toxins, human tissues, specimens and other medical materials and products, including GxP and those related to the development, testing
                    manufacturing, sale, distribution and promotional activities, pricing and reimbursement, product quality, the conduct of Clinical Trials, reporting of safety events, conflicts of interest, debarment, exclusion or disqualification and
                    interactions with and licensure and accreditation of health care professionals, including the following:&#160; (a) the FDCA, (b) the PHSA, (c) the Clinical Laboratory Improvement Amendments (42 U.S.C. &#167; 263a) and the regulations set forth in
                    42 C.F.R. Part 493, (d) Medicare (Title XVIII of the Social Security Act) and Medicaid (Title XIX of the Social Security Act), (e) the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b)), the Stark Anti-Self-Referral Law (42 U.S.C.
                    &#167; 1395nn), the Civil Monetary Penalties Law (42 U.S.C. &#167; 1320a-7a and 1320a-7b), the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the administrative False Claims Law (42 U.S.C. &#167; 1320a-7b(a)), the exclusion laws (42 U.S.C. &#167;
                    1320a-7), the federal Physician Payments Sunshine Act (42 U.S.C. &#167; 1320a-7h), the regulations promulgated under any of the foregoing and any similar or equivalent state Legal Requirements, (f) the Patient Protection and Affordable Care
                    Act (Public Law No.&#160; 111-148), as amended by the Health Care and Education Reconciliation Act of 2010 (Public Law No.&#160; 111-152), (g) 45 C.F.R. Parts 46 and 21 C.F.R. Parts 312, 812, 50, 54 and 56 and state research regulations, (h) the
                    FDA software validation principles, (i) the regulations set forth at 21 C.F.R. Part 11, (j) the Federal Controlled Substances Act, 21 U.S.C. &#167; 801 et seq., (k) the Health Insurance Portability and Accountability Act of 1996, the Health
                    Information and Technology for Economic and Clinical Health Act and the regulations promulgated thereunder, (l) EU Directive 2001/83/EC (the Community code relating to medicinal products for human use), Regulation (EC) No 726/2004,
                    Regulation (EC) No 141/2000, Regulation (EC) No 1901/2006, Regulation (EC) No 1394/2007, Directive 2005/28/EC, Regulation No (EU) 536/2014 and Regulation No (EU) 2017/556, (m) GxP, and (n) similar or equivalent Legal Requirements of all
                    applicable jurisdictions.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">HSR Act</font><font style="font-size: 10pt;">.&#160; &#8220;<u>HSR Act</u>&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Identified Communications</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Identified Communications</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>5.2(c)</u></font><u>&#160;</u>of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">In the Money Option</font><font style="font-size: 10pt;">.&#160; &#8220;<u>In the Money Option</u>&#8221; is defined in <u>Section </u><u>1.8(a)</u> of the
                    Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">In-bound License</font><font style="font-size: 10pt;">.&#160; &#8220;<u>In-bound License</u>&#8221;<font style="font-weight: bold;">&#160;</font>is defined in <u>Section













                    </u><u>2.8(f)</u> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Indebtedness</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Indebtedness</u>&#8221; means, without duplication, (a) any indebtedness for borrowed
                    money (including the issuance of any debt security) to any Person, including that portion of obligations with respect to any capital lease that is classified as a liability on a balance sheet in conformity with GAAP, (b) any obligations
                    evidenced by notes, bonds, debentures or similar Contracts for indebtedness for borrowed money owing to any Person (other than a wholly owned Acquired Company), (c) any reimbursement obligations in respect of letters of credit and
                    bankers&#8217; acceptances (other than obligations in respect of letters of credit and bankers&#8217; acceptances used as security for leases), bank guarantees, surety bonds and similar instruments, regardless of whether drawn upon, including the
                    principal, interest and fees owing thereon, (d) all indebtedness created or arising under any conditional sale or other title retention agreement with respect to property acquired, (e) any net obligations under swaps, options,
                    derivatives and other hedging agreements or arrangements that would be payable upon termination thereof (assuming they were terminated on the date of determination), (f) all obligations representing the deferred and unpaid purchase
                    price of property or services, and (g) any guaranty (or any other arrangement having the economic effect of a guaranty) of any such obligations described in the foregoing <u>clauses </u><u>(a)</u> through <u>(f)</u> of any Person
                    other than a wholly owned Acquired Company (other than, in any case of the foregoing, accounts payable to trade creditors and accrued expenses, in each case, arising in the ordinary course of business that are not past due by greater
                    than 60 days).</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-11</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Indemnified Persons</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Indemnified Persons</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>5.4(a)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Intellectual Property Rights</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Intellectual Property Rights</u>&#8221; means any and all intellectual
                    property and industrial property rights of every kind and description throughout the world, including all U.S. and foreign (a) patents, patent applications, invention disclosures, and all related continuations, continuations-in-part,
                    divisionals, reissues, re-examinations, substitutions and extensions thereof (&#8220;<u>Patents</u>&#8221;), (b) trademarks, service marks, corporate names, trade names, logos, slogans, trade dress, design rights and other similar designations of
                    source or origin (whether registered, common law, statutory or otherwise), together with the goodwill symbolized by any of the foregoing and any applications and registrations for the foregoing (&#8220;<u>Trademarks</u>&#8221;), (c) copyrights and
                    copyrightable subject matter and any and all applications and registrations for the foregoing (&#8220;<u>Copyrights</u>&#8221;), (d) trade secrets and confidential ideas, know-how, inventions, proprietary processes, formulae, models, data
                    (including pharmacological, toxicological, non-clinical, pre-clinical and clinical data, analytical and quality control data, manufacturing data and descriptions, market data, financial data or descriptions), databases, data
                    collections, data sets, curated data content and data layers, assays, specifications, physical, chemical and biological materials and compounds, compound libraries, methodologies and the like, in written, electronic, or other tangible
                    or intangible form, whether or not patentable (&#8220;<u>Trade Secrets</u>&#8221;), and (e) Internet domain names and social media accounts (&#8220;<u>Domain Names</u>&#8221;).</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Intervening Event</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Intervening Event</u>&#8221; means any material event, development, occurrence,
                    circumstance, change or effect that (a) occurs after the Agreement Date and prior to the Cut-off Time, (b) was both unknown and not reasonably foreseeable to the Board of Directors as of the Agreement Date based on information
                    reasonably available to it at that time, (c) does not relate to or arise from (i) any Acquisition Proposal or any inquiry, proposal or offer that could reasonably be expected to lead to an Acquisition Proposal, or (ii) any event,
                    development, occurrence, circumstance, change or effect otherwise described in <u>clauses </u><u>(A)</u> through <u>(E)</u> below, and (d) does not involve or result from general business, industry, market, financial, credit,
                    economic, regulatory or political conditions or events (including changes in interest rates, exchange rates or securities prices), changes in applicable Legal Requirements or GAAP, or actions required by this Agreement.&#160; For the
                    avoidance of doubt, the following shall not constitute, or be taken into account in determining the existence of, an Intervening Event:&#160; (A) any breach of this Agreement by the Company; (B) any event, development, occurrence,
                    circumstance, change or effect resulting directly or indirectly from the negotiation, execution, announcement or pendency of this Agreement or the Transactions (including any effect on the relationships of the Acquired Companies with
                    employees, customers, suppliers, distributors, partners, licensors, licensees, lenders or other third parties, or relating to the identity of, or communications by, Parent or its Affiliates); (C) any change in the trading price or
                    trading volume of the Shares or any change in the Company&#8217;s credit rating (it being understood that the underlying causes thereof may be taken into account in determining whether an Intervening Event has occurred to the extent not
                    otherwise excluded in this definition); (D) the fact that the Company has met or exceeded any internal or published projections, forecasts, revenue or earnings guidance or expectations of the Company or any analysts (it being understood
                    that the underlying causes thereof may be taken into account in determining whether an Intervening Event has occurred to the extent not otherwise excluded in this definition); or (E) any change in, or compliance with, any Legal
                    Requirement or GAAP (or interpretation thereof) after the Agreement Date.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-12</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">IRB</font><font style="font-size: 10pt;">.&#160; &#8220;<u>IRB</u>&#8221; means any independent body (a review board or a committee, institutional, regional,
                    national or supranational), including ethics committees constituted of medical professionals and non-medical members, whose responsibility it is to ensure the protection of the rights, safety and well-being of human subjects involved in
                    a trial and to provide public assurance of that protection, by, among other things, reviewing and approving / providing favorable opinion on, a trial protocol, the suitability of investigator(s), facilities and the methods and material
                    to be used in obtaining and documenting informed consent of the trial subjects and includes any such entity as described in 21 C.F.R. Part 56, Article 2 of Regulation (EU) No. 536/2014 or equivalent of the foregoing in any applicable
                    jurisdiction.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">IRS</font><font style="font-size: 10pt;">.&#160; &#8220;<u>IRS</u>&#8221; means the U.S. Internal Revenue Service.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">knowledge</font><font style="font-size: 10pt;">.&#160; &#8220;<u>knowledge</u>&#8221; with respect to an Entity means with respect to any matter in question
                    the actual knowledge, after reasonable inquiry, of such Entity&#8217;s executive officers.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Leased Real Property</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Leased Real Property</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>2.7(b)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Legal Proceeding</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Legal Proceeding</u>&#8221; means any action, suit, charge, complaint, litigation,
                    arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, summons, qui tam action or investigation commenced, brought, conducted or heard (whether formally
                    or informally, whether publicly or privately) by or before, or otherwise involving, any Governmental Body or any arbitrator or arbitration panel.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Legal Requirement</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Legal Requirement</u>&#8221; means any national, supranational, EU, federal, state,
                    local, municipal, foreign or other law, statute, constitution, treaty, resolution, ordinance, common law, code, order, edict, decree, rule, regulation, directive, decision, certification standard, ruling, judgment, award or requirement
                    issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (or under the authority of Nasdaq or another stock exchange).&#160; Any specific references to Legal
                    Requirement or any portion thereof will be deemed to include all then-current amendments thereto or any replacements or successor instrument.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-13</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Material Adverse Effect</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Material Adverse Effect</u>&#8221; means any event, development, occurrence,
                    circumstance, change or effect which, individually or when taken together with all other events, developments, occurrences, circumstances, changes or effects has had or would reasonably be expected to have a material adverse effect on
                    (a) the ability of the Company to consummate the Transactions on or before the End Date, or (b) the business, assets, liabilities, financial condition or results of operations of the Acquired Companies, taken as a whole; <font style="font-style: italic;">provided</font>,<font style="font-style: italic;"> however</font>, that, for purposes of this <u>clause (b)</u> only, none of the following shall be deemed to constitute or be taken into account in
                    determining whether there is, or would reasonably be expected to be, a Material Adverse Effect:&#160; (i) any change in the market price or trading volume of the Company&#8217;s stock or change in the Company&#8217;s credit ratings; <font style="font-style: italic;">provided</font> that the underlying causes of any such change may be considered in determining whether a Material Adverse Effect has occurred to the extent not otherwise excluded by another exception
                    herein; (ii) any event, development, occurrence, circumstance, change or effect directly resulting from the announcement, pendency or performance of the Transactions; <font style="font-style: italic;">provided</font> that this <u>clause













                    </u><u>(ii)</u> shall not apply to the foregoing <u>clause </u><u>(a)</u> to the extent arising from any breach of this Agreement by the Company of any representation or warranty (or condition to the consummation of the Merger
                    relating to such representation or warranty) to the extent the purpose of such representation and warranty is to address the consequences resulting from the execution and delivery of this Agreement or the pendency, performance or
                    consummation of the Transactions (including the Merger), including any representations or warranties contained in <u>Section </u><font style="color: #000000;"><u>2.8(j)</u></font>, <u>Section </u><font style="color: #000000;"><u>2.16(l)</u></font>,
                    <u>Section </u><font style="color: #000000;"><u>2.20</u></font> or <u>Section </u><font style="color: #000000;"><u>2.22</u></font>; (iii) any event, development, occurrence, circumstance, change or effect generally affecting the
                    industries in which the Acquired Companies operate or in the economy generally or other general business, financial or market conditions; (iv) any event, development, occurrence, circumstance, change or effect arising from fluctuations
                    in the value of any currency or interest rates; <font style="font-style: italic;">provided</font> that the underlying causes of such event, development, occurrence, circumstance, change or effect may be considered in determining
                    whether a Material Adverse Effect has occurred to the extent not otherwise excluded by another exception herein; (v) any event, development, occurrence, circumstance, change or effect arising from any act of terrorism, war, national or
                    international calamity, natural disaster, acts of god, epidemic, pandemic or any other similar event; (vi) the failure of the Company to meet internal or analysts&#8217; expectations or projections; <font style="font-style: italic;">provided</font>
                    that the underlying causes of such failure may be considered in determining whether a Material Adverse Effect has occurred to the extent not otherwise excluded by another exception herein; (vii) any event, development, occurrence,
                    circumstance, change or effect resulting or arising from the identity of, or any facts or circumstances relating to, Parent, Merger Sub or any of their respective Affiliates; (viii) any event, development, occurrence, circumstance,
                    change or effect arising from any change in, or any compliance with or action taken solely for the purpose of complying with any change in, any Legal Requirement or GAAP (or interpretations of any Legal Requirement or GAAP) after the
                    Agreement Date; or (ix) occurrence, circumstance, change or effect arising from the matters set forth on Schedule A of the Company Disclosure Schedule; <font style="font-style: italic;">provided</font> that any event, development,
                    occurrence, circumstance, change or effect referred to in the foregoing <u>clauses </u><u>(iii)</u>, <u>(iv)</u>, <u>(v)</u> and <u>(viii)</u> shall be taken into account in determining whether there is, or would be reasonably
                    expected to be, a Material Adverse Effect to the extent such event, development, occurrence, circumstance, change or effect disproportionately affects the Acquired Companies relative to other participants in the industries in which the
                    Acquired Companies operate.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Material Contract</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Material Contract</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>2.9(a)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Maximum Amount</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Maximum Amount</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>5.4(b)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-14</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Merger</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Merger</u>&#8221; is defined in the Introduction to the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Merger Consideration</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Merger Consideration</u>&#8221; is defined in the Introduction to the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Merger Proxy Statement</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Merger Proxy Statement</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>2.4(h)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Merger Sub</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Merger Sub</u>&#8221; is defined in the preamble to the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Nasdaq</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Nasdaq</u>&#8221; means The Nasdaq Global Select Market.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Negotiation Period</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Negotiation Period</u>&#8221; means the period (a) beginning on the date that Merger
                    Sub receives a Determination Notice with respect to a Superior Offer in accordance with <u>Section </u><font style="color: #000000;"><u>5.1(b)(i)</u></font> or an Intervening Event in accordance with <u>Section </u><font style="color: #000000;"><u>5.1(b)(ii)</u></font><u>,</u> and (b) ending at 11:59 p.m.&#160; Eastern Time on the fourth Business Day after such date; <font style="font-style: italic;">provided</font> that with respect to any Determination
                    Notice given in respect of a material amendment to a Superior Offer for which a Determination Notice was previously given, the Negotiation Period shall end on the later of (x) the date and time on which the Negotiation Period was
                    initially scheduled to end in respect of the initial Determination Notice with respect to such Superior Offer, and (y) 11:59 p.m.&#160; Eastern Time on the third Business Day after the date that Merger Sub received the Determination Notice
                    with respect to the material amendment to such Superior Offer.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Non-U.S. Plan</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Non-U.S. Plan</u>&#8221; means any Employee Plan that is maintained outside of the United
                    States.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">OFAC</font><font style="font-size: 10pt;">.&#160; &#8220;<u>OFAC</u>&#8221; means the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Out-bound License</font><font style="font-size: 10pt;">. <font style="font-weight: bold;">&#160;</font>&#8220;<u>Out-bound License</u>&#8221;<font style="font-weight: bold;">&#160;</font>is defined in <u>Section </u><u>2.8(f)</u> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Parent</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Parent</u>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>is defined in the
                    preamble to the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Parent 401(k) Plan</font><font style="font-size: 10pt;">. &#8220;<u>Parent 401(k) Plan</u>&#8221; is defined in <u>Section </u><u>5.3(e)</u> of the
                    Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Parent Common Share</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Parent Common Share</u>&#8221; means a share of common stock of Parent.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Parent Material Adverse Effect</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Parent Material Adverse Effect</u>&#8221; means any effect, change,
                    event or occurrence that would or would reasonably be expected to, individually or in the aggregate, have a material adverse effect on the ability of Parent or Merger Sub to perform any of their material obligations under this Agreement
                    or to consummate the Transactions on or before the End Date.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Parent Pro Forma Information</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Parent Pro Forma Information</u>&#8221; means (A) the proposed aggregate
                    amount of debt financing, together with assumed interest rates, dividends (if any) and fees and expenses relating to the incurrence of such debt financing, and (B) any post-Closing or pro forma cost savings, synergies, capitalization,
                    ownership or other pro forma adjustments in each case arising from the Transactions.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-15</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Parent Share Price</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Parent Share Price</u>&#8221; means the average of the volume weighted averages of
                    the trading prices of Parent Common Shares on Nasdaq (as reported by Bloomberg L.P.&#160; or, if not reported therein, in another authoritative source mutually selected by Parent and the Company in good faith) on each of the 20 consecutive
                    trading days ending on (and including) the trading day that is two trading days prior to the Closing Date.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Parties</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Parties</u>&#8221; means Parent, Merger Sub and the Company.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Patents</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Patents</u>&#8221; is defined in the definition of Intellectual Property Rights.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Patient Assistance Program</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Patient Assistance Program</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>4.2(b)(xxi)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Paying Agent</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Paying Agent</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>1.6(a)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Payment Fund</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Payment Fund</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>1.6(a)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Payoff Letter</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Payoff Letter</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>5.10</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Permitted Encumbrance</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Permitted Encumbrance</u>&#8221; means (a) any statutory liens for Taxes (i) that
                    are not due and payable, or (ii) the validity of which is being contested in good faith by appropriate proceedings and, in each case, for which adequate reserves have been established in the applicable financial statements in accordance
                    with GAAP, (b) mechanics&#8217;, materialmen&#8217;s, carriers&#8217;, workmen&#8217;s, warehouseman&#8217;s, repairmen&#8217;s, landlords&#8217; and similar liens granted, or which arise, in the ordinary course of business as to which there is no default, (c) with respect to
                    leased property, any interest in title of the lessor under the applicable lease (other than a capital lease) entered into by any Acquired Company in the ordinary course of business and under which there is no default by any Acquired
                    Company, (d) non-exclusive licenses of Intellectual Property Rights entered in the ordinary course of business, (e) in the case of real property, Encumbrances that are easements, rights-of-way, encroachments, restrictions, conditions
                    and other similar Encumbrances incurred or suffered in the ordinary course of business consistent with past practice and which, individually or in the aggregate, do not and would not reasonably be expected to materially impair the use
                    (or contemplated use), utility or value of the applicable real property or otherwise materially impair the present or contemplated business operations at such location, or zoning, entitlement, building and other land use regulations
                    imposed by Governmental Bodies having jurisdiction over such real property or that are otherwise set forth on a title report, (f) Encumbrances securing the obligations of the Acquired Companies under the Senior Secured Term Loan
                    Agreement, and (g) Encumbrances created or incurred in connection with any Indebtedness permitted to be established or incurred under <u>Section </u><font style="color: #000000;"><u>4.2(b)(xii)</u></font>.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Person</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Person</u>&#8221; means any individual, Entity or Governmental Body.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-16</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Personal Information</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Personal Information</u>&#8221; means any information that (a) identifies or could
                    reasonably be used, alone or in combination with other information held by any Acquired Company, to identify an individual, (b) is subject to any Legal Requirement governing the privacy of individuals, or, (c) constitutes &#8220;personally
                    identifiable information,&#8221; &#8220;personal data,&#8221; &#8220;individually identifiable health information,&#8221; &#8220;protected health information,&#8221; &#8220;nonpublic personal information,&#8221; &#8220;consumer health data&#8221; or similarly defined personal information under
                    applicable Legal Requirements.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">PFIC</font><font style="font-size: 10pt;">.<font style="font-weight: bold;">&#160; </font>&#8220;<u>PFIC</u>&#8221; is defined in <u>Section </u><u>2.14(o)</u>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">PHSA</font><font style="font-size: 10pt;">.&#160; &#8220;<u>PHSA</u>&#8221; means the United States Public Health Service Act (42 U.S.C.&#167; 262 et seq.) and all
                    related rules, regulations and guidelines.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Pre-Closing Period</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Pre-Closing Period</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>4.1</u></font><u>(a)</u> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Pricing Approval</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Pricing Approval</u>&#8221; means with respect to any country or jurisdiction where a
                    Governmental Body authorizes reimbursement or access, or approves or determines pricing, for pharmaceutical or biologic products, receipt (or publication, if required to make such authorization, approval or determination effective) of
                    such reimbursement or access, authorization or pricing approval or determination (as the case may be).</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Privacy and Security Requirements</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Privacy and Security Requirements</u>&#8221; is defined in <u>Section













                    </u><u>2.8(m)</u>.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Process or Processing or Processed</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Process</u>&#8221; or &#8220;<u>Processing</u>&#8221; or &#8220;<u>Processed</u>&#8221;
                    means with respect to Personal Information, the use, access, acquisition, collection, receipt, processing, aggregation, storage, adaption, alteration, transfer (including cross-border transfers), retrieval, disclosure, dissemination,
                    combination, erasure, disposal, destruction or anonymization of such Personal Information, or any other operation or set of operations that is performed on data or on sets of data, in each case, whether or not by automated means.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Product</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Product</u>&#8221; means each biologic, drug, combination product, compound, device or product
                    candidate being developed, tested, labeled, manufactured, distributed, stored, marketed, sold or otherwise Exploited by an Acquired Company and inclusive of any such product candidates.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Prohibited Modification</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Prohibited Modification</u>&#8221; is defined in <u>Section 5.12(a)</u> of the
                    Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Registered IP</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Registered IP</u>&#8221; means all Patents, Trademarks and Copyrights that are registered
                    or issued under the authority of any Governmental Body, and all applications for any of the foregoing, and all Domain Name registrations.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Regulatory Filings</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Regulatory Filings</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>5.2(b)</u></font> of this Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Release</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Release</u>&#8221; means any presence, emission, spill, seepage, leak, escape, leaching,
                    discharge, injection, pumping, pouring, emptying, dumping, disposal, migration or release of Hazardous Materials from any source into or upon the environment, including the air, soil, improvements, surface water, groundwater, the sewer,
                    septic system, storm drain, publicly owned treatment works, or waste treatment, storage or disposal systems.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-17</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Representatives</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Representatives</u>&#8221; means officers, directors, employees, attorneys,
                    accountants, investment bankers, consultants, agents, financial advisors and other advisors and representatives.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Required Amount</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Required Amount</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>3.7(b)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Required Financing Information</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Required Financing Information</u>&#8221; means (a) the financial
                    statements provided pursuant to <u>Section </u><font style="color: #000000;"><u>2.4</u></font> and the financial information required by Section 2(c) of <u>Exhibit B</u> of the Debt Commitment Letter, (b) with respect to the Required
                    Financing Information described in the foregoing clause (a), drafts of customary comfort letters to the Financing Sources, including customary negative assurance comfort, from such independent auditors, and, at pricing of any offering,
                    final comfort letters and bringdown comfort letters, and (c) such other pertinent and customary information regarding the Acquired Companies (including their assets) reasonably requested by Parent to the extent that such information is
                    required in connection with the Financing or of the type and form customarily included in offering memoranda for a registered offering of debt securities or an offering of debt securities issued pursuant to Rule 144A or another
                    exemption from registration under the Securities Act (including financial statements necessary for auditors to issue comfort letters contemplated in the Debt Commitment Letter).&#160; Notwithstanding anything to the contrary in the foregoing
                    clauses (a) through (c), nothing in this Agreement will require the Company to provide any (i) financial statements of the Company or any of its Subsidiaries, other than the financial statements included in the Required Financing
                    Information, (ii) description of all or any portion of the Financing, including any &#8220;description of notes&#8221; or &#8220;description of other indebtedness,&#8221; (iii) risk factors relating to all or any component of the Financing (excluding
                    information that is historical financial information of the Acquired Companies) or other forward-looking statements relating solely to the Financing or any component thereof, including any such description to be included in liquidity
                    and capital resources disclosure, (iv) any information required by Rule 3-03(e), 3-09, 3-10, 3-16, 13-01 or 13-02 of Regulation S-X or Item 302 of Regulation S-K, (v) any Compensation Discussion and Analysis required by Item 402(b) of
                    Regulation S-K or the executive compensation and related person disclosure rules related to SEC Release Nos. 33-8732A, 34-54302A and IC-27444A including Item 404 of Regulation S-K, (vi) any Parent Pro Forma Information, (vii) any
                    information not reasonably available to the Company under its current reporting systems or consistently maintained in the ordinary course of its business, (viii) information to the extent that the provision thereof would (x) violate
                    applicable Legal Requirements or any obligation of confidentiality binding upon the Acquired Companies or (y) waive any privilege that may be asserted by the Acquired Companies, (ix) any information customarily provided by the Financing
                    Sources, any financing source, any party to the Debt Commitment Letters or their respective counsel, including information that would customarily be provided by an underwriter or initial purchaser in a customary offering memorandum for
                    private placements of high-yield non-convertible debt securities under Rule 144A promulgated under the Securities Act, (x) information regarding affiliate transactions that may exist following consummation of the Merger or the other
                    transactions contemplated by this Agreement (unless any Acquired Company was party to any such transactions prior to consummation of the Merger), (xi) information regarding any post-Merger Closing pro forma cost savings, synergies,
                    capitalization, ownership or other pro forma adjustments, pro forma financial statements or other pro forma information, projections or prospective information, (xii) any financial information with respect to the Acquired Companies on a
                    non-consolidated basis or any stand-alone financial statements for any Acquired Company, other than to the extent prepared in the ordinary course of business, (xiii) any new performance metrics of the Company or financial information
                    that is not reasonably available and obtained without undue effort or expense by the Company from the books and records of the Acquired Companies or historically prepared or maintained in the ordinary course of business, or (xiv) any
                    information concerning or involving only Persons other than the Acquired Companies (collectively, the &#8220;<u>Excluded Information</u>&#8221;).</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-18</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt;">The parties hereto agree that the filing by the Company with the SEC of an Annual Report on Form 10-K or a Quarterly Report on Form 10-Q that includes any financial statements or other information of the
                  Company included in the Required Financing Information or to be provided pursuant to <u>Section </u><font style="color: #000000;"><u>5.11</u></font> will be deemed to satisfy any requirement to deliver such financial statements or other
                  information to Parent so long as such information is Compliant and (y) shall be deemed to have been delivered on the earliest date on which (1) the Company posts such documents, or provides a link thereto, on the Company&#8217;s website on the
                  Internet, (2) such documents are posted on the Company&#8217;s behalf on Datasite or another website, if any, to which the parties hereto have access (whether a commercial, third-party website or whether sponsored by the parties hereto) or (3)
                  such financial statements and/or other documents are posted on the SEC&#8217;s website on the internet at www.sec.gov.</div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Sanctioned Country</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Sanctioned Country</u>&#8221; means any country or territory that is or has been the
                    subject of a comprehensive embargo under Sanctions Laws at any point since April 24, 2019, including, but not limited to, Cuba, Iran, North Korea, Syria (until July 1, 2025) or the Crimea, &#8220;Donetsk People&#8217;s Republic,&#8221; and &#8220;Luhansk
                    People&#8217;s Republic&#8221; regions of Ukraine.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Sanctioned Person</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Sanctioned Person</u>&#8221; means any Person, aircraft or vessel that is the subject
                    or target of Sanctions Laws, including, any Person (a) listed on any list of sanctioned persons maintained by the United Nations or the governments of the United States, the United Kingdom, the European Union or any of its member
                    states, or any other relevant Governmental Body, including, but not limited to, (i) the &#8220;Specially Designated Nationals and Blocked Persons&#8221; list maintained by OFAC, or (ii) the Entity List or Military End User List maintained by the
                    U.S. Department of Commerce&#8217;s Bureau of Industry and Security, (b) located in, resident in or incorporated in, a Sanctioned Country, and (c) any Person which is 50% or more owned, directly or indirectly, individually or in the
                    aggregate, or otherwise controlled, by any Person in <u>clauses (a)(i)</u> or <u>(b)</u> of this definition.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Sanctions Laws</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Sanctions Laws</u>&#8221; means the Legal Requirements relating to economic or trade
                    sanctions administered or enforced by the United States (including by OFAC or the U.S. Department of State), the United Nations or the governments of the United Kingdom, the European Union, any European Union member state, and any other
                    relevant Governmental Body.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Sarbanes-Oxley Act</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Sarbanes-Oxley Act</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>2.4(a)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">SEC</font><font style="font-size: 10pt;">.&#160; &#8220;<u>SEC</u>&#8221; means the United States Securities and Exchange Commission.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-19</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">SEC Clearance Date</font><font style="font-size: 10pt;">.&#160; &#8220;<u>SEC Clearance Date</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>4.4(b)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Securities Act</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Security Breach</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Security Breach</u>&#8221; is defined in <u>Section </u><u>2.8(n)</u> of the
                    Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Senior Secured Term Loan Agreement</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Senior Secured Term Loan Agreement</u>&#8221; means the Loan
                    Agreement, dated as of October 2, 2023 (as amended by that certain First Amendment to Loan Agreement, dated as of April 28, 2025, and as further amended by that certain Second Amendment to Loan Agreement, dated June 16, 2025), between
                    the Company, as borrower, certain subsidiaries of the Company, as the other credit parties, Wilmington Trust National Association, as agent, Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C.,
                    collectively as Blackstone representative, and the lenders from time to time party thereto, as amended from time to time, together with the &#8220;Collateral Documents&#8221; (as such term is defined therein).</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Shares</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Shares</u>&#8221; is defined in the Introduction to the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Specified Agreement</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Specified Agreement</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>7.1(e)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Specified Antitrust Authority</font><font style="font-size: 10pt;">.<font style="font-weight: bold;">&#160; </font>&#8220;<u>Specified Antitrust
                      Authority</u>&#8221;<font style="font-weight: bold;">&#160;</font>means (a) any U.S. federal or state Governmental Body or (b) any non-U.S. or supranational Governmental Body listed on Section 5.2(b) of the Company Disclosure Schedule to the
                    extent such Governmental Body&#8217;s waiting period, clearance, consent or approval is required under Antitrust Laws in connection with the Transactions.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Specified Governmental Body</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Specified Governmental Body</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>6.1(c)</u></font> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Subsidiary</font><font style="font-size: 10pt;">.&#160; An Entity shall be deemed to be a &#8220;<u>Subsidiary</u>&#8221; of another Person if such Person
                    directly or indirectly owns, beneficially or of record, (a) an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such Entity&#8217;s board of
                    directors or other governing body, or (b) at least 50% of the outstanding equity or financial interests of such Entity.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Superior Offer</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Superior Offer</u>&#8221; means a <font style="font-style: italic;">bona fide</font>
                    written Acquisition Proposal that the Board of Directors determines, in its good faith judgment, after consultation with the Company&#8217;s outside legal counsel and financial advisors, is reasonably likely to be consummated in accordance
                    with its terms, taking into account all legal, regulatory and financing aspects (including certainty of closing) of the proposal and the Person making the proposal and other aspects of the Acquisition Proposal that the Board of
                    Directors deems relevant, and if consummated, would result in a transaction more favorable to the Company&#8217;s stockholders (solely in their capacity as such) from a financial point of view than the Transactions (including after giving
                    effect to proposals, if any, made by Parent pursuant to <u>Section </u><font style="color: #000000;"><u>5.1(b)(i)</u></font>); <font style="font-style: italic;">provided</font> that (x) for purposes of the definition of &#8220;Superior
                    Offer,&#8221; the references to &#8220;15%&#8221; in the definition of Acquisition Proposal shall be deemed to be references to &#8220;80%&#8221;, and (y) the reference to &#8220;license&#8221;, &#8220;partnership&#8221;, &#8220;collaboration&#8221; and &#8220;revenue-sharing arrangement&#8221; in the definition
                    of Acquisition Proposal shall be disregarded and deemed deleted.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-20</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Surviving Corporation</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Surviving Corporation</u>&#8221; is defined in the Introduction to the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Takeover Laws</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Takeover Laws</u>&#8221; means any &#8220;moratorium,&#8221; &#8220;control share acquisition,&#8221; &#8220;fair
                    price,&#8221; &#8220;supermajority,&#8221; &#8220;affiliate transactions,&#8221; or &#8220;business combination statute or regulation&#8221; or other similar state anti-takeover laws and regulations (including, for the avoidance of doubt, Section 203 of the DGCL).</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Tax</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Tax</u>&#8221; means any federal, state, local or non-U.S. or other tax (including any net income
                    tax, gross income tax, franchise tax, capital gains tax, gross receipts tax, gross profits tax, branch profits tax, value-added tax, surtax, estimated tax, employment tax, unemployment tax, national health insurance tax, excise tax,
                    alternative or minimum tax, ad valorem tax, transfer tax, stamp tax, sales tax, use tax, service tax, property tax, escheat or unclaimed property tax, business tax, withholding tax or payroll tax), levy, assessment, tariff, impost,
                    imposition, duty (including any customs duty) or other tax or charge in the nature of a tax, imposed, assessed or collected by or under the authority of any Governmental Body, together with any interest, penalties or additions to tax
                    amounts imposed thereon, with respect thereto, or related thereto.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Tax Return</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Tax Return</u>&#8221; means any return (including any information return), report,
                    statement, declaration, estimate, schedule, form, election, certificate or other document or information filed or required to be filed with any Governmental Body in connection with the determination, assessment, collection or payment of
                    any Tax and any attachments thereto or amendments thereof.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Termination Fee</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Termination Fee</u>&#8221; is defined in <u>Section </u><font style="color: #000000;"><u>7.3(b)</u></font>
                    of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Trademarks</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Trademarks</u>&#8221; is defined in the definition of Intellectual Property Rights.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Trade Secrets</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Trade Secrets</u>&#8221; is defined in the definition of Intellectual Property Rights.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Transactions</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Transactions</u>&#8221; means (a) the execution and delivery of the Agreement, and (b) all
                    of the transactions contemplated by the Agreement, including the Merger.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Transfer Taxes</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Transfer Taxes</u>&#8221; means all transfer, documentary, sales, use, stamp,
                    registration and other similar Taxes and fees imposed, assessed or collected by or under the authority of any Governmental Body, together with any interest, penalties or additions to tax amounts imposed thereon, with respect thereto, or
                    related thereto.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Treasury Regulations</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Treasury Regulations</u>&#8221; means the final and temporary regulations issued
                    under the Code.</font></div>
                <div>&#160;</div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">WARN Act</font><font style="font-size: 10pt;">.&#160; &#8220;<u>WARN Act</u>&#8221; is defined in <u>Section </u><u>2.15(d)</u> of the Agreement.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-21</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-weight: bold; font-size: 10pt;">Willful Breach</font><font style="font-size: 10pt;">.&#160; &#8220;<u>Willful Breach</u>&#8221; means (a) with respect to any covenant of a Party, a material
                    breach thereof that is a consequence of an act or failure to act by a Party with the actual knowledge that the taking of such act or failure to act would cause, or would reasonably be expected to result in, such material breach and (b)
                    with respect to any representation or warranty of a Party, a material breach thereof where such breach occurred with such Party&#8217;s intention that such representation or warranty would be breached.</font></div>
                <div>&#160;</div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">A-22</font></div>
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                </div>
                <div style="text-align: center; font-weight: bold;">ANNEX I</div>
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;">FORM OF CERTIFICATE OF INCORPORATION OF</div>
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;">THE SURVIVING CORPORATION</div>
                <div> <br>
                </div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div>
                  <div style="text-align: center; font-weight: bold;">ANNEX I</div>
                  <div style="text-align: center; font-weight: bold;">CERTIFICATE OF INCORPORATION</div>
                  <div style="text-align: center; font-weight: bold;">OF</div>
                  <div><br>
                  </div>
                  <div style="text-align: center; font-weight: bold;">AMICUS THERAPEUTICS, INC.</div>
                  <div><br>
                  </div>
                  <div style="text-align: center;"><u>FIRST</u></div>
                  <div><br>
                  </div>
                  <div style="text-indent: 54pt;">The name of the corporation is Amicus Therapeutics, Inc., (the &#8220;<u>Company</u>&#8221;).</div>
                  <div><br>
                  </div>
                  <div style="text-align: center;"><u>SECOND</u></div>
                  <div><br>
                  </div>
                  <div style="text-align: justify; text-indent: 54pt;">The Company&#8217;s registered office in the State of Delaware is located at 251 Little Falls Drive, City of Wilmington, County of New Castle, 19808. Its registered agent at such address is
                    Corporation Service Company.</div>
                  <div><br>
                  </div>
                  <div style="text-align: center;"><u>THIRD</u></div>
                  <div><br>
                  </div>
                  <div style="text-align: justify; text-indent: 54pt;">The purpose of the Company is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of the State of Delaware, as the same
                    exists or may hereafter be amended (&#8220;<u>DGCL</u>&#8221;) or any successor statute.</div>
                  <div><br>
                  </div>
                  <div style="text-align: center;"><u>FOURTH</u></div>
                  <div><br>
                  </div>
                  <div style="text-indent: 54pt;">The total number of shares of stock that the Company shall have authority to issue is 100 shares of capital stock, all of which shall be designated Common Stock, having a par value of $0.001 per share.</div>
                  <div><br>
                  </div>
                  <div style="text-align: center;"><u>FIFTH</u></div>
                  <div><br>
                  </div>
                  <div style="text-align: justify; text-indent: 54pt;">The following provisions are inserted for the management of the business and the conduct of the affairs of the Company, and for further creation, definition, limitation and regulation
                    of the powers of the Company and its directors, officers and stockholders:</div>
                  <div><br>
                  </div>
                  <div style="text-align: justify; margin-right: 63pt; margin-left: 54pt;">(1) The business and affairs of the Company shall be managed by or under the direction of the Board of Directors of the Company (the &#8220;<u>Board of Directors</u>&#8221;).</div>
                  <div><br>
                  </div>
                  <div style="text-align: justify; margin-right: 63pt; margin-left: 54pt;">(2) The Board of Directors is expressly authorized to make, adopt, alter, amend, change, add to or repeal the bylaws of the Company (the &#8220;<u>Bylaws</u>&#8221;), without
                    any action on the part of the stockholders, but the stockholders may make additional bylaws and may alter, amend or repeal any bylaw whether adopted by them or otherwise.&#160; The Company may in its bylaws confer powers upon the Board of
                    Directors in addition to the foregoing and in addition to the powers and authorities expressly conferred upon the Board of Directors by applicable law.</div>
                  <div><br>
                  </div>
                  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                    <div class="BRPFPageBreak" style="page-break-after: always;">
                      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                  </div>
                  <!--PROfilePageNumberReset%Num%2%%%-->
                  <div style="text-align: justify; margin-right: 63pt; margin-left: 54pt;">(3) The number of directors of the Company shall be as from time to time fixed by, or in the manner provided in, the Bylaws. Election of directors need not be by
                    written ballot unless the Bylaws shall so provide.</div>
                  <div><br>
                  </div>
                  <div style="text-align: justify; margin-right: 63pt; margin-left: 54pt;">(4) No director or officer of the Company shall be personally liable to the Company or any of its stockholders for monetary damages for breach of fiduciary duty as a
                    director or officer, notwithstanding any provision of law imposing such liability; provided, however, that to the extent required from time to time by applicable law, this Article FIFTH shall not eliminate or limit the liability of a
                    director or officer, to the extent such liability is provided by applicable law, (i) for any breach of the director or officer&#8217;s duty of loyalty to the Company or its stockholders, (ii) for a director&#8217;s or officer&#8217;s acts or omissions
                    not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) of a director pursuant to Section 174 of the DGCL, (iv) for any transaction from which the director or officer derived an improper personal
                    benefit or (v) of an officer in any action by or in the right of the corporation.&#160; Any amendment, repeal or modification of this Article FIFTH shall not adversely affect any right or protection of such director or officer of the Company
                    existing at the time of such amendment, repeal or modification with respect to acts or omissions occurring prior to such amendment, repeal or modification.</div>
                  <div><br>
                  </div>
                  <div style="text-align: justify; margin-right: 63pt; margin-left: 54pt;">(5) In addition to the powers and authority hereinbefore or by statute expressly conferred upon them, the directors are hereby empowered to exercise all such powers
                    and do all such acts and things as may be exercised or done by the Company, subject, nevertheless, to the provisions of the DGCL, this Certificate of Incorporation, and any bylaws adopted by the stockholders; provided, however, that no
                    bylaws hereafter adopted by the stockholders shall invalidate any prior act of the directors which would have been valid if such bylaws had not been adopted.</div>
                  <div><br>
                  </div>
                  <div style="text-align: center;"><u>SIXTH</u></div>
                  <div><br>
                  </div>
                  <div style="text-align: justify; text-indent: 54pt;">Meetings of the stockholders may be held within or outside the State of Delaware, as the Bylaws may provide.&#160; The books of the Company may be kept (subject to any provision contained in
                    the DGCL) outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or imposed by other provisions of this Certificate of Incorporation, the Bylaws, the DGCL, or other
                    applicable law, or by any contract or agreement to which the Company is or may become a party.</div>
                  <div><br>
                  </div>
                  <div style="text-align: center;"><u>SEVENTH</u></div>
                  <div><br>
                  </div>
                  <div style="text-align: justify; text-indent: 54pt;">The Company reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and
                    all rights conferred upon stockholders herein are granted subject to this express reservation.</div>
                  <div><br>
                  </div>
                  <div style="text-align: center;">[<font style="font-style: italic;">Signature Page Follows</font>]</div>
                  <div><br>
                  </div>
                  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                    <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">2</font></div>
                    <div class="BRPFPageBreak" style="page-break-after: always;">
                      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                  </div>
                  <div>IN WITNESS WHEREOF, this Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this corporation this [*] day of [*], [*].</div>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" border="0" id="z5dd7235dc75b4d71900061d993b7b9a5" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

                      <tr>
                        <td style="width: 50%; vertical-align: top;">&#160;</td>
                        <td style="vertical-align: top;" colspan="2">
                          <div style="margin-right: 5.4pt;">AMICUS THERAPEUTICS, INC.</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
                        <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
                      </tr>
                      <tr>
                        <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                        <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
                          <div style="margin-right: 5.4pt;">By:</div>
                        </td>
                        <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                      </tr>
                      <tr>
                        <td style="width: 50%; vertical-align: top;">&#160;</td>
                        <td style="vertical-align: top;" colspan="2">
                          <div style="margin-right: 5.75pt;">Name:</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 50%; vertical-align: top;">&#160;</td>
                        <td style="vertical-align: top;" colspan="2">
                          <div style="margin-right: 5.4pt;">Title:</div>
                        </td>
                      </tr>

                  </table>
                  <div><br>
                  </div>
                  <div>
                    <div style="text-align: center;">[Signature Page to Certificate of Incorporation]</div>
                  </div>
                  <div><br>
                  </div>
                </div>
                <div><br>
                </div>
                <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                  <div class="BRPFPageBreak" style="page-break-after: always;">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <a name="Exhibit3.1"><!--Anchor--></a>Exhibit 3.1</div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div>
    <div>
      <div>&#160;</div>
      <div style="text-align: center;">AMENDMENT TO</div>
      <div>&#160;</div>
      <div style="text-align: center;">SECOND AMENDED AND RESTATED BY-LAWS</div>
      <div>&#160;</div>
      <div style="text-align: center;">OF</div>
      <div>&#160;</div>
      <div style="text-align: center;">AMICUS THERAPEUTICS, INC.</div>
      <div>&#160;</div>
      <div style="text-align: center;"><u>ARTICLE VI</u></div>
      <div>&#160;</div>
      <div style="text-align: center;"><u>MISCELLANEOUS MANAGEMENT PROVISIONS</u></div>
      <div>&#160;</div>
      <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">6.5. <u>Exclusive Jurisdiction of Delaware Courts or the United States Federal District Courts.</u></font><font style="font-size: 10pt;"> Unless the
          Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if such court does not have jurisdiction thereof, another state court or a federal district court located within the State
          of Delaware) shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of, or a claim based on, a breach of a fiduciary duty owed by any current or former
          director, officer or other employee of the Company to the Company or the Company&#8217;s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL or the Certificate of Incorporation or these by-laws (including the
          interpretation, validity or enforceability thereof), or (iv) any action asserting a claim governed by the internal affairs doctrine. Unless the Company consents in writing to the selection of an alternative forum, the federal district courts of
          the United States of America shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing or otherwise acquiring any interest
          in shares of capital stock of the Company shall be deemed to have notice of and consented to the provisions of this Section 6.5.</font></div>
      <div>&#160;</div>
      <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>
      <div>
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
        <div>
          <div style="text-align: right;"><font style="font-weight: bold; color: rgb(0, 0, 0);"><a name="Exhibit99.1"><!--Anchor--></a>Exhibit 99.1</font><font style="color: rgb(0, 0, 0);"><br>
            </font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 49.94%; vertical-align: middle; color: rgb(0, 0, 0);">
                    <div><img height="28" width="193" src="image0.jpg"></div>
                  </td>
                  <td style="width: 49.94%; vertical-align: top; text-align: right; color: rgb(0, 0, 0);"><img src="image00002.jpg"></td>
                </tr>

            </table>
          </div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="text-align: justify; font-weight: bold;">BioMarin Contacts</div>
                </td>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="text-align: right; font-weight: bold;">Amicus Contacts</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">&#160;</td>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-style: italic;">Traci McCarty, Investors</div>
                </td>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="text-align: right; font-style: italic;">Andrew Faughnan, Investors</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-style: italic;">BioMarin Pharmaceutical Inc.</div>
                </td>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="text-align: right; font-style: italic;">Amicus Therapeutics</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-style: italic;">(415) 455-7558</div>
                </td>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="text-align: right; font-style: italic;">(609) 662-3809</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">&#160;</td>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-style: italic;">Marni Kottle, Media</div>
                </td>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="text-align: right; font-style: italic;">Brendan McEvoy, Media</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-style: italic;">BioMarin Pharmaceutical Inc.</div>
                </td>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="text-align: right; font-style: italic;">Amicus Therapeutics</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-style: italic;">(415) 218-7111</div>
                </td>
                <td style="width: 50%; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="text-align: right; font-style: italic;">(202) 320-7767</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: center; font-weight: bold;"><font style="color: rgb(0, 0, 0);">BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and</font></div>
          <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0);">Strengthening Financial Outlook</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: center; font-style: italic; color: rgb(0, 0, 0);">BioMarin to Gain Galafold<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (migalastat) for Fabry Disease and Pombiliti<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (cipaglucosidase alfa-atga) + Opfolda<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (miglustat) for Pompe Disease, Adding Two
            Marketed, High-Growth Products with $599 Million in Revenue Over Past Four Quarters</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: center; font-style: italic; color: rgb(0, 0, 0);">Provides Opportunity to Expand Access to Galafold and Pombiliti + Opfolda to Patients in New Markets Across BioMarin&#8217;s Global Footprint; Pending U.S. Galafold Patent
            Litigation Resolved</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: center; font-style: italic; color: rgb(0, 0, 0);">Will Accelerate Revenue Growth Immediately After Close; Expected to be Accretive to Non-GAAP Diluted Earnings Per Share (EPS) in the First 12 Months Post-Close and
            Substantially Accretive to Non-GAAP Diluted EPS Beginning in 2027</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: center; font-style: italic; color: rgb(0, 0, 0);">&#160;Conference Call Today at 8:15 a.m. Eastern Time</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">SAN RAFAEL, Calif., and PRINCETON, N.J., Dec. 19, 2025 /<u>PRNewswire</u>/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin
            has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total equity value of approximately $4.8 billion. The agreement has been unanimously approved by the Boards of Directors of both
            companies and Amicus&#8217; Board of Directors unanimously recommended that Amicus&#8217; stockholders vote to adopt the agreement. The transaction is expected to close in the second quarter of 2026, subject to regulatory clearances, approval by the
            stockholders of Amicus and other customary closing conditions.</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="text-align: justify;"><font style="color: #000000;">&#8220;</font><font style="color: rgb(0, 0, 0);">Amicus, like BioMarin, is a company that has been profoundly dedicated to transforming care for patients with rare diseases since its
              founding, developing and bringing to market important therapies for individuals living with Fabry disease and Pompe disease. BioMarin&#8217;s scale of operations, including our global commercial footprint and industry-leading, in-house
              manufacturing capabilities make the combination of these companies an exceptional strategic fit,&#8221; said Alexander Hardy, President and Chief Executive Officer of BioMarin. &#8220;Immediately upon close, this transaction is expected to accelerate
              BioMarin&#8217;s revenue growth and strengthen our financial outlook, delivering significant value to patients, employees and stockholders. The transaction is expected to be accretive to Non-GAAP Diluted EPS in the first 12 months following close.&#8221;</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">&#8220;I am enormously proud of our Amicus team. Together with our partners in the rare disease community, we created a truly patient-centric biotech and successfully developed two transformative
            medicines for people living with rare diseases, which impacted the lives of more than 3,400 patients around the world,&#8221; said Bradley L. Campbell, President and Chief Executive Officer of Amicus. &#8220;With BioMarin&#8217;s unwavering commitment to
            patients, along with greater resources and scale, Amicus&#8217; medicines will reach even more patients around the world, faster. We are confident that this agreement is in the best interests of our shareholders by providing compelling, certain and
            premium value, and will accelerate progress for the rare disease community.&#8221;</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; color: #000000; font-weight: bold;"><u>Transaction Will Expand and Diversify BioMarin&#8217;s Rare Disease Product Portfolio</u></div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">The acquisition will strengthen BioMarin&#8217;s commercial portfolio, adding two new treatments to the company&#8217;s existing portfolio of medicines that target lysosomal storage disorders: Galafold<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (migalastat), the first oral treatment for Fabry disease, and Pombiliti<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
            (cipaglucosidase alfa-atga) + Opfolda<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (miglustat), a two-component therapy for Pompe disease. Amicus also has U.S. rights to DMX-200, a potential first-in-class
            investigational small molecule for the treatment of focal segmental glomerulosclerosis (FSGS), a rare and fatal kidney disease in Phase 3 development. The transaction is expected to:</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 18pt; color: rgb(0, 0, 0);"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Accelerate Revenue Growth. </font><font style="color: rgb(0, 0, 0);">The acquisition is expected to increase BioMarin&#8217;s long-term CAGR through 2030 and beyond. Both Galafold and
                      Pombiliti + Opfolda have high-growth potential and generated combined net product revenues over the past four quarters totaling $599 million. Based on the Galafold litigation settlements announced today, U.S. exclusivity for Galafold
                      is expected through January 2037.</font></div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 18pt; color: rgb(0, 0, 0);"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Diversify the Commercial Portfolio. </font><font style="color: rgb(0, 0, 0);">The acquisition will add two therapies to BioMarin&#8217;s Enzyme Therapies Business Unit and provide
                      expansion opportunities for Galafold and Pombiliti + Opfolda across BioMarin&#8217;s global footprint.</font></div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 18pt; color: rgb(0, 0, 0);"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Create Substantial Shareholder Value. </font><font style="color: rgb(0, 0, 0);">The acquisition will add revenue immediately after the transaction closes. It is expected to be
                      accretive to Non-GAAP Diluted EPS in the first 12 months after close and substantially accretive beginning in 2027. With strong cash flow generation and a commitment to deleveraging, BioMarin is targeting gross leverage &lt;2.5x
                      within two years after close.</font></div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

              <tr>
                <td style="width: 15pt; color: rgb(0, 0, 0);"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; color: #000000;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Support BioMarin&#8217;s Strategic Priorities. </font><font style="color: rgb(0, 0, 0);">This acquisition demonstrates execution of BioMarin&#8217;s capital allocation strategy to leverage
                      the company&#8217;s financial strength to diversify its pipeline and add innovative new therapies for patients.</font></div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; font-weight: bold; color: rgb(0, 0, 0);"><u>Transaction Terms</u></div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">Under the terms of the agreement, BioMarin will acquire Amicus for $14.50 per share in an all-cash transaction, representing a 33% premium to Amicus&#8217; last close, a 46% premium to the 30-day
            volume-weighted average stock price and a 58% premium to the 60-day volume-weighted average stock price.</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">The consummation of the transaction is subject to customary closing conditions, including approval by the stockholders of Amicus, the expiration or termination of the waiting period under the
            Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other antitrust authority clearances, and other customary conditions. Following the satisfaction of the closing conditions to the proposed transaction, a wholly owned subsidiary of
            BioMarin will merge with Amicus and the outstanding Amicus shares will be converted into the right to receive $14.50 per share in cash, without interest and subject to any withholding of taxes.</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; font-weight: bold; color: rgb(0, 0, 0);"><u>Financing</u></div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">The transaction is not subject to financing conditions. BioMarin intends to finance the transaction through a combination of cash on hand and approximately $3.7 billion of non-convertible
            debt financing. Morgan Stanley Senior Funding, Inc. is acting as sole lead arranger and has provided a bridge commitment for this amount. The permanent financing structure will include a meaningful portion of pre-payable debt, in line with
            BioMarin&#8217;s commitment to deleveraging with a target of gross leverage of &lt;2.5x within two years after the closing of the proposed transaction.</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; font-weight: bold; color: rgb(0, 0, 0);"><u>Pending U.S. Galafold IP Litigation Resolved</u></div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">Separately, Amicus has resolved the patent litigation it brought in response to Aurobindo Pharma&#8217;s and Lupin Ltd.&#8217;s Abbreviated New Drug Applications seeking approval to market a generic
            version of Galafold 123 mg capsules prior to expiration of the certain Amicus patents.&#160; In connection with the resolution of the patent litigation, Amicus entered into License Agreements with Aurobindo and Lupin for Galafold 123 mg capsules.
            Pursuant to the terms of the agreements, Amicus will grant Aurobindo and Lupin licenses to market generic versions of Galafold in the United States beginning on January 30, 2037, if approved by the U.S. Food and Drug Administration (FDA) and
            unless certain limited circumstances customarily included in these types of agreements occur. As required by law, the companies will submit the confidential license agreements to the U.S. Federal Trade Commission and the U.S. Department of
            Justice for review. In accordance with the agreements, the parties will terminate all ongoing Hatch-Waxman litigation between Amicus and Aurobindo and Lupin regarding Galafold patents pending in the U.S. District Court for the District of
            Delaware.</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="text-align: justify; font-weight: bold; color: rgb(0, 0, 0);"><u>Advisors</u></div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">Morgan Stanley &amp; Co. LLC acted as the lead financial advisor to BioMarin and J.P. Morgan Securities, LLC also provided financial advice to BioMarin; Jones Day is serving as legal counsel
            to BioMarin in connection with the acquisition and Cooley LLP is serving as legal counsel to BioMarin in connection with the financing. Centerview Partners LLC and Goldman Sachs &amp; Co. LLC are acting as financial advisors to Amicus, and
            Kirkland &amp; Ellis LLP is serving as legal counsel to Amicus.</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; font-weight: bold; color: rgb(0, 0, 0);"><u>Conference Call</u></div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">BioMarin will host a conference call and webcast to discuss the acquisition today, Dec. 19, at 8:15 a.m. ET. This event can be accessed through this <u>link</u> or on the investor section of
            the BioMarin website at <u>www.biomarin.com</u>.</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: bottom; color: rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify;">U.S./Canada Dial-in Number: 800-715-9871</div>
                </td>
                <td style="width: 50%; vertical-align: bottom; color: rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify;">Replay Dial-in Number: 800-770-2030</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: bottom; color: rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify;">International Dial-in Number: 646-307-1963</div>
                </td>
                <td style="width: 50%; vertical-align: bottom; color: rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify;">Replay International Dial-in Number:&#160; 609-800-9909</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: bottom; color: rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: justify;">Conference ID: 7225321</div>
                </td>
                <td style="width: 50%; vertical-align: bottom; color: rgb(0, 0, 0); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                  <div style="text-align: justify;">Conference ID: 7225321</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="color: #000000; font-weight: bold;"><u>About Galafold</u></div>
          <div style="text-align: justify; color: #000000;">Galafold<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A)
            for the treatment of Fabry disease in adults who have amenable galactosidase alpha gene (GLA) variants. In these patients, Galafold works by stabilizing the body&#8217;s own dysfunctional enzyme so that it can clear the accumulation of disease
            substrate. Globally, Amicus Therapeutics estimates that approximately 35 to 50 percent of people living with Fabry disease may have amenable GLA variants, though amenability rates within this range vary by geography. Galafold is approved in
            more than 40 countries around the world, including the U.S., EU, U.K., and Japan.</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; color: #000000; font-weight: bold;">U.S. INDICATIONS AND USAGE</div>
          <div style="text-align: justify; color: #000000;">Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; color: #000000;">This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication
            may be contingent upon verification and description of clinical benefit in confirmatory trials.</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; color: #000000; font-weight: bold;">U.S. IMPORTANT SAFETY INFORMATION</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify;"><font style="font-weight: bold; color: #000000;">ADVERSE REACTIONS</font><font style="color: #000000;">: The most common adverse reactions reported with Galafold (&#8805;10%) were headache, nasopharyngitis, urinary
              tract infection, nausea and pyrexia. </font><font style="font-weight: bold; color: #000000;">USE IN SPECIFIC POPULATIONS</font><font style="color: #000000;">: There is insufficient clinical data on Galafold use in pregnant women to inform a
              drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus. It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be
              considered along with the mother&#8217;s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition. Galafold is not recommended for use in patients with severe renal
              impairment or end-stage renal disease requiring dialysis. The safety and effectiveness of Galafold have not been established in pediatric patients. To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at
              1-800-FDA-1088 or </font><font style="color: rgb(0, 0, 0);"><u>www.fda.gov/medwatch</u>.&#160;<font style="font-weight: bold;">For additional information about Galafold, including the full U.S. Prescribing Information, please visit </font><u><font style="font-weight: bold;">https://www.amicusrx.com/pi/Galafold.pdf.</font></u></font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="text-align: justify; color: #000000; font-weight: bold;"><u>About Pombiliti + Opfolda</u></div>
          <div style="text-align: justify; color: #000000;">Pombiliti + Opfolda, is a two-component therapy that consists of cipaglucosidase alfa-atga, a bis-M6P-enriched rhGAA that facilitates high-affinity uptake through the M6P receptor while retaining
            its capacity for processing into the most active form of the enzyme, and the oral enzyme stabilizer, miglustat, that&#8217;s designed to reduce loss of enzyme activity in the blood.</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; color: #000000; font-weight: bold;">U.S. INDICATIONS AND USAGE</div>
          <div style="text-align: justify; color: #000000;">POMBILITI in combination with OPFOLDA is indicated for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing &#8805;40 kg and who are
            not improving on their current enzyme replacement therapy (ERT).</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; color: #000000; font-weight: bold;">SAFETY INFORMATION</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify;"><font style="font-weight: bold; color: #000000;">HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS: Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily
              available. If a severe hypersensitivity reaction occurs, POMBILITI should be discontinued immediately and appropriate medical treatment should be initiated. INFUSION-ASSOCIATED REACTIONS (IARs): If severe IARs occur, immediately discontinue
              POMBILITI and initiate appropriate medical treatment. RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS: Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or
              respiratory function, may be at risk of serious exacerbation of their cardiac or respiratory status during POMBILITI infusion. See PI for complete Boxed Warning. CONTRAINDICATION:</font><font style="color: #000000;"> POMBILITI in combination
              with Opfolda is contraindicated in pregnancy. </font><font style="font-weight: bold; color: #000000;">EMBRYO-FETAL TOXICITY:</font><font style="color: #000000;"> May cause embryo-fetal harm. Advise females of reproductive potential of the
              potential risk to a fetus and to use effective contraception during treatment and for at least 60 days after the last dose. </font><font style="font-weight: bold; color: #000000;">Adverse Reactions:</font><font style="color: #000000;"> Most
              common adverse reactions &#8805; 5% are headache, diarrhea, fatigue, nausea, abdominal pain, and pyrexia. </font><font style="font-weight: bold; color: #000000;">Please see full PRESCRIBING INFORMATION, including BOXED WARNING, for POMBILITI
              (cipaglucosidase alfa-atga) </font><u><font style="font-weight: bold; color: rgb(0, 0, 0);">LINK</font></u><font style="font-weight: bold; color: #000000;"> and full PRESCRIBING INFORMATION for OPFOLDA (miglustat) </font><u><font style="font-weight: bold; color: rgb(0, 0, 0);">LINK</font></u><font style="font-weight: bold; color: #000000;">.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="color: rgb(0, 0, 0);">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;"><font style="color: rgb(0, 0, 0);">About</font></td>
                  <td style="width: 50%; text-align: right; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;"><font style="color: rgb(0, 0, 0);">BioMarin</font></td>
                </tr>

            </table>
          </div>
          <div>
            <div style="text-align: justify; color: rgb(0, 0, 0);">BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael,
              California-based company has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the
              full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.</div>
            <div style="color: rgb(0, 0, 0);"><br>
            </div>
            <div style="text-align: justify; color: rgb(0, 0, 0);">To learn more, please visit <u>www.biomarin.com</u>.</div>
            <div style="color: rgb(0, 0, 0);"><br>
            </div>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="color: #000000; font-weight: bold;"><u>About Amicus Therapeutics</u></div>
          <div style="color: #000000;">Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With
            extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases.</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div><font style="color: #000000;">To learn more, please visit the company&#8217;s website at </font><font style="color: rgb(0, 0, 0);"><u>www.amicusrx.com</u>.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; font-weight: bold; color: rgb(0, 0, 0);"><u>Forward-Looking Non-GAAP Financial Information</u></div>
          <div>
            <div style="text-align: justify; color: #000000;">BioMarin defines Non-GAAP Diluted EPS as Non-GAAP Income divided by Non-GAAP Weighted-Average Diluted Shares Outstanding. Non-GAAP Income is defined by BioMarin as GAAP Net Income excluding
              amortization of intangible assets, stock-based compensation expense and, in certain periods, certain other specified items. BioMarin defines Non-GAAP Weighted-Average Diluted Shares Outstanding as GAAP Weighted-Average Diluted Shares
              Outstanding, adjusted to include any common shares issuable under BioMarin&#8217;s equity plans and convertible debt in periods when they are dilutive under Non-GAAP. BioMarin has not provided an expectation regarding the impact to EPS in the first
              12 months after close or in 2027 because BioMarin is unable to predict with reasonable certainty the financial impact of changes resulting from its strategic portfolio and business operating model reviews; potential future asset impairments;
              gains and losses on investments; and other unusual gains and losses without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.</div>
            <div style="color: rgb(0, 0, 0);"><br>
            </div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="text-align: justify; color: #000000; font-weight: bold;"><u>Forward-Looking Statements</u></div>
            <div style="text-align: justify; color: rgb(0, 0, 0);">This press release and the associated conference call contain forward-looking statements about, among other things, the proposed acquisition of Amicus Therapeutics (Amicus) by BioMarin
              Pharmaceutical Inc. (BioMarin) and the business prospects of Amicus and BioMarin, including, without limitation, statements about: the anticipated occurrence, manner and timing of the closing of the proposed acquisition and the availability
              of financing, including the proposed non-convertible debt financing; the prospective benefits of the proposed acquisition, including expectations that it will accelerate BioMarin&#8217;s revenue growth and strengthen its financial outlook
              immediately upon close, increase BioMarin&#8217;s long-term CAGR through 2030 and beyond, strengthen and diversify BioMarin&#8217;s commercial portfolio and be a strong strategic fit for BioMarin by expanding BioMarin&#8217;s rare disease product portfolio,
              create substantial shareholder value by being accretive to Non-GAAP Diluted EPS in the first 12 months after close and substantially accretive beginning in 2027; BioMarin&#8217;s commitment to deleveraging and the expectation that BioMarin will
              reach gross leverage &lt;2.5x within two years after close; expectations regarding Amicus&#8217; products, Galafold and Pombiliti + Opfolda, including ability to expand access to patients in new markets across BioMarin&#8217;s global footprint;
              expectations regarding Amicus&#8217; product candidate, DMX-200, and its ongoing development, including the potential for DMX-200 to be the first-in-class investigational small molecule for the treatment of focal segmental glomerulosclerosis
              (FSGS); expectations regarding the settlement of the patent litigation relating to Galafold, including expectations that U.S. exclusivity for Galafold will be through January 2037; BioMarin&#8217;s capital allocation strategy to leverage its
              financial strength to diversify its pipeline and add innovative new therapies for patients; the potential impact of the acquisition on BioMarin&#8217;s financial results and financial guidance; BioMarin&#8217;s plans for external innovation, including
              BioMarin&#8217;s ability to execute additional transactions in future quarters; statements about BioMarin&#8217;s future financial performance; and other statements that are not historical facts. Actual results could differ materially from those
              anticipated in these forward-looking statements. Except as required by law, each of BioMarin and Amicus assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These
              statements, which represent each of BioMarin&#8217;s and Amicus&#8217; current expectations or beliefs concerning various future events that are subject to significant risks and uncertainties, may contain words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221;
              &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;opportunity,&#8221; &#8220;potential&#8221; or other similar words and expressions indicating future results.</div>
          </div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div>
            <div style="text-align: justify; color: rgb(0, 0, 0);">These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. Forward-looking statements reflect
              current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including, without limitation, with respect to: consummating the proposed acquisition and financing in the anticipated timeframe, if at all;
              whether Amicus&#8217; stockholders will approve the acquisition; the possibility that competing offers or acquisition proposals will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived,
              including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction (or only grant approval subject to adverse conditions or limitations); the difficulty of predicting the timing or
              outcome of regulatory approvals or actions, if any; the effects of the proposed acquisition (or the announcement thereof) on Amicus&#8217; or BioMarin&#8217;s stock price and/or Amicus&#8217; or BioMarin&#8217;s operating results; unknown or inestimable liabilities;
              the development, launch and commercialization of products and product candidates; the parties&#8217; ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the proposed
              acquisition will not be realized or will not be realized within the expected time period and that BioMarin and Amicus will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected;
              obtaining and maintaining adequate coverage and reimbursement for BioMarin&#8217;s or Amicus&#8217; products; the time-consuming and uncertain regulatory approval process; the costly and time-consuming pharmaceutical product development process and the
              uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients, including with respect to current and planned future clinical trials; global
              economic, financial, and healthcare system disruptions and the current and potential future negative impacts to BioMarin&#8217;s or Amicus&#8217; business operations and financial results; the sufficiency of BioMarin&#8217;s or Amicus&#8217; cash flows and capital
              resources; BioMarin&#8217;s ability to fund the acquisition, including BioMarin&#8217;s ability to obtain financing on terms satisfactory to BioMarin or at all; BioMarin&#8217;s evaluation of the potential impact of the transaction on its financial results and
              financial guidance; BioMarin&#8217;s or Amicus&#8217; ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the effects of the transaction on
              relationships with key third parties, including employees, customers, suppliers, other business partners or governmental entities, including the risk that the proposed acquisition adversely affects employee retention; transaction costs; risks
              that the proposed acquisition disrupts current plans and operations; risks that the proposed transaction diverts management&#8217;s attention from ongoing business operations; changes in Amicus&#8217; business during the period between announcement and
              closing of the proposed acquisition; any legal proceedings and/or regulatory actions that may be instituted related to the proposed acquisition; and other risks and uncertainties affecting BioMarin and Amicus, including those risk factors
              detailed in BioMarin&#8217;s and Amicus&#8217; filings with the Securities and Exchange Commission (SEC), including, without limitation, the risk factors contained under the caption &#8220;Risk Factors&#8221; in BioMarin&#8217;s Quarterly Report on Form 10-Q for the
              fiscal quarter ended September 30, 2025 and Amicus&#8217; Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, as such risk factors may be updated by any subsequent reports, as well as the Proxy Statement on Schedule 14A
              to be filed by Amicus. Stockholders of BioMarin and Amicus are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin and Amicus are under no obligation, and expressly disclaim any
              obligation, to update (publicly or otherwise) or alter any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events or otherwise.</div>
            <div style="color: rgb(0, 0, 0);"><br>
            </div>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div>
            <div style="text-align: justify;"><font style="color: #000000;">BioMarin</font><font style="color: rgb(0, 0, 0);"><sup style="color: #000000; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a registered trademark of
                BioMarin Pharmaceutical Inc. or its affiliates. Galafold<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (migalastat) and Pombiliti<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
                (cipaglucosidase alfa-atga) + Opfolda<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (miglustat) are registered trademarks of Amicus Therapeutics, Inc. or its affiliates.</font></div>
            <div style="color: rgb(0, 0, 0);"><br>
            </div>
            <div style="text-align: justify; color: #000000; font-weight: bold;"><u>Important Information and Where to Find It</u></div>
            <div style="text-align: justify;"><font style="color: #000000;">In connection with the proposed acquisition of Amicus Therapeutics, Inc. (Amicus) by BioMarin Pharmaceutical Inc. (BioMarin) (Transaction), Amicus intends to file with the
                Securities and Exchange Commission (SEC) a proxy statement on Schedule 14A (the Proxy Statement), the definitive version of which will be sent or provided to Amicus stockholders. Amicus may also file other documents with the SEC regarding
                the proposed transaction. This document is not a substitute for the Proxy Statement or any other document which Amicus may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT
                DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION
                AND RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy Statement (when it is available) and other documents that are filed or will be filed with the SEC by Amicus through the website maintained by the SEC at
              </font><font style="color: rgb(0, 0, 0);"><u>www.sec.gov</u>, Amicus&#8217;s website at <u>https://ir.amicusrx.com/financial-information/sec-filings</u> or by contacting the Amicus investor relations department at the following:</font></div>
            <div style="color: rgb(0, 0, 0);"><br>
            </div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">8</font></div>
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="text-align: justify; color: #000000;">Andrew Faughnan</div>
            <div style="text-align: justify; color: #000000;">(609) 662-3809</div>
            <div style="text-align: justify; color: rgb(0, 0, 0);"><u>afaughnan@amicusrx.com</u></div>
            <div style="color: rgb(0, 0, 0);"><br>
            </div>
            <div style="text-align: justify; color: #000000; font-weight: bold;"><u>No Offer or Solicitation</u></div>
            <div style="text-align: justify; color: #000000;">This press release is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to
              purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance
              or transfer of securities in any jurisdiction in contravention of applicable law.</div>
            <div style="color: rgb(0, 0, 0);"><br>
            </div>
            <div style="text-align: justify; color: #000000; font-weight: bold;"><u>Participants in the Solicitation</u></div>
            <div style="text-align: justify;"><font style="color: #000000;">Amicus and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information
                regarding Amicus&#8217;s directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in (i) Amicus&#8217; Annual Report on Form 10-K for the fiscal year ended December 31, 2024,
                which was filed with the SEC on February 19, 2025, including the sections therein entitled &#8220;Directors, Executive Officers, and Corporate Governance,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and
                Management and Related Stockholder Matters&#8221;, and (ii) Amicus&#8217;s proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on April 24, 2025, including the sections therein entitled &#8220;Proposal 1 &#8211; Election of
                Class Directors,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Compensation and Equity Tables,&#8221; and &#8220;Share Ownership of Certain Beneficial Owners and Management,&#8221; and (iii) other documents subsequently filed with the SEC from time to time,
                including the Proxy Statement to be filed by Amicus in connection with the proposed transaction and the special meeting of stockholders of Amicus. To the extent holdings of Amicus&#8217; securities by its directors or executive officers have
                changed since the amounts set forth in the filings described in the foregoing, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with
                the SEC. Amicus stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed transaction, including the interests of Amicus
                directors and executive officers in the transaction, which may be different than those of Amicus stockholders generally, by reading the Proxy Statement and any other relevant documents that are filed or will be filed with the SEC relating
                to the transaction. These documents (when available) may be obtained free of charge from the website maintained by the SEC at </font><font style="color: rgb(0, 0, 0);"><u>www.sec.gov</u> and Amicus&#8217;s website at <u>https://ir.amicusrx.com/financial-information/sec-filings</u>.</font></div>
            <div style="color: rgb(0, 0, 0);"><br>
            </div>
          </div>
          <div>
            <div style="text-align: center; color: rgb(0, 0, 0);">###</div>
            <div style="color: rgb(0, 0, 0);"><br>
            </div>
            <div style="color: rgb(0, 0, 0);"><br>
            </div>
            <div style="color: rgb(0, 0, 0); text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">9</font></div>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div> <font style="color: rgb(0, 0, 0);"> </font>
              <div>
                <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
                <div style="text-align: right; color: rgb(0, 0, 0);"><font style="font-weight: bold; color: rgb(0, 0, 0);"><a name="Exhibit99.2"><!--Anchor--></a>Exhibit 99.2</font><font style="color: rgb(0, 0, 0);"><br>
                  </font></div>
                <div style="color: rgb(0, 0, 0);"><br>
                </div>
                <div>
                  <div>
                    <div style="font-weight: bold;"><font style="color: rgb(0, 0, 0);">Amicus Employee Letter</font>
                      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center;"></div>
                    <div style="color: rgb(0, 0, 0);"><br>
                    </div>
                  </div>
                  <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Subject: </font><font style="color: rgb(0, 0, 0);">Our New Chapter</font></div>
                  <div><font style="font-weight: bold; color: rgb(0, 0, 0);">From:</font><font style="color: rgb(0, 0, 0);"> Bradley Campbell</font></div>
                  <div><font style="font-weight: bold; color: rgb(0, 0, 0);">To:</font><font style="color: rgb(0, 0, 0);"> All Employees</font></div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div style="color: rgb(0, 0, 0);">Team Amicus,</div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div style="color: rgb(0, 0, 0);">Today, we are announcing that Amicus has entered into an agreement to be acquired by BioMarin, a global biotechnology leader in rare genetic diseases, for $14.50 per share in cash, reflecting a total
                    equity value of approximately $4.8 billion. The transaction was unanimously approved by our Board. You can read the press release <u>here</u>.</div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div style="color: rgb(0, 0, 0);">Over the past two decades, thanks to all of you, we have created a patient-centric biotech company that did what we set out to do with our mission: we successfully developed two transformative therapies
                    for people living with rare diseases, and together, we delivered Galafold and Pombiliti + Opfolda to more than 3,400 patients around the world. With the guidance and partnership of the rare disease community, we changed people&#8217;s lives
                    for the better and set the standard for what a rare disease company could be.</div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div style="color: rgb(0, 0, 0);">The sale of Amicus to BioMarin meets the most important criteria for a strategic combination of this nature: BioMarin has the resources and scale to reach even more patients, faster, than Amicus could
                    alone; and, at this valuation, the agreement delivers compelling, certain and premium value to our stockholders. Most importantly, like Amicus, BioMarin is incredibly patient focused and dedicated to rare diseases with a strong legacy
                    in lysosomal storage disorders (LSDs). We firmly believe that under BioMarin&#8217;s new stewardship, we will accelerate progress for the rare disease community.</div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div style="font-weight: bold; color: rgb(0, 0, 0);">Company Huddle and Next Steps</div>
                  <div style="color: rgb(0, 0, 0);">I know this is unexpected, and you will have a lot of questions about why this, why now, and what happens next. We will host a company huddle at 9:00 am ET today. In addition, BioMarin will be hosting a
                    conference call for the financial community today at 8:15 am ET. We invite you to listen to the webcast <u>here</u>.</div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div style="color: rgb(0, 0, 0);">While we are announcing this news today, it is only the first step in the process to bring our companies together. We expect the transaction to close in the second quarter of 2026, subject to regulatory
                    clearances, approval by Amicus stockholders, and other customary closing conditions. Until then, Amicus and BioMarin remain two, separate companies, and we will operate largely as usual. The vast majority of our work &#8211; including
                    supplying our medicines to patients, patient support programs, clinical trial operations, engaging with regulatory agencies and health care providers &#8211; will continue as they normally would. Our patients are counting on us.</div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div style="font-weight: bold; color: rgb(0, 0, 0);">Thank You</div>
                  <div style="color: rgb(0, 0, 0);">On behalf of the entire management team, thank you for your extraordinary dedication to our company, to the rare disease community, and to the patients who rely on our therapies. Together, we built an
                    incredibly special organization, and our medicines will continue to improve lives for generations to come. I could not be more proud of this team and what we have done together.</div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                    <div class="BRPFPageBreak" style="page-break-after: always;">
                      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                  </div>
                  <div style="color: rgb(0, 0, 0);">Sincerely,</div>
                  <div style="color: rgb(0, 0, 0);">Bradley</div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div style="font-weight: bold; color: rgb(0, 0, 0);"><u>Important Information and Where to Find It</u></div>
                  <div style="color: rgb(0, 0, 0);">&#160;</div>
                  <div style="text-align: justify; color: rgb(0, 0, 0);">In connection with the proposed acquisition of Amicus by Parent (the &#8220;<u>Transaction</u>&#8221;), Amicus intends to file with the SEC a proxy statement (the &#8220;<u>Proxy Statement</u>&#8221;), the
                    definitive version of which will be sent or provided to Amicus stockholders. Amicus may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the Proxy Statement or any other
                    document which Amicus may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO
                    THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy Statement
                    (when it is available) and other documents that are filed or will be filed with the SEC by Amicus through the website maintained by the SEC at www.sec.gov, Amicus&#8217;s website at https://ir.amicusrx.com/financial-information/sec-filings or
                    by contacting the Amicus investor relations department at the following:</div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div style="color: rgb(0, 0, 0);">Andrew Faughnan</div>
                  <div style="color: rgb(0, 0, 0);">(609) 662-3809</div>
                  <div style="color: rgb(0, 0, 0);"><u>afaughnan@amicusrx.com</u></div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div style="font-weight: bold; color: rgb(0, 0, 0);"><u>No Offer or Solicitation</u></div>
                  <div style="color: rgb(0, 0, 0);">&#160;</div>
                  <div style="text-align: justify; color: rgb(0, 0, 0);">This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation
                    to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale,
                    issuance or transfer of securities in any jurisdiction in contravention of applicable law.</div>
                  <div style="color: rgb(0, 0, 0);">&#160;</div>
                  <div style="font-weight: bold; color: rgb(0, 0, 0);"><u>Participants in the Solicitation</u></div>
                  <div style="color: rgb(0, 0, 0);">&#160;</div>
                  <div style="text-align: justify; color: rgb(0, 0, 0);">Amicus and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information
                    regarding Amicus&#8217;s directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in (i) Amicus&#8217; Annual Report on Form 10-K for the fiscal year ended December 31,
                    2024, which was filed with the SEC on <u>February 19, 2025</u>, including the sections therein entitled &#8220;Directors, Executive Officers, and Corporate Governance,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Security Ownership of Certain Beneficial
                    Owners and Management and Related Stockholder Matters&#8221;, and (ii) Amicus&#8217;s proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on <u>April 24, 2025</u>, including the sections therein entitled
                    &#8220;Proposal 1 &#8211; Election of Class Directors,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Compensation and Equity Tables,&#8221; and &#8220;Share Ownership of Certain Beneficial Owners and Management,&#8221; and (iii) other documents subsequently filed with
                    the SEC from time to time, including the Proxy Statement to be filed by Amicus in connection with the proposed transaction and the special meeting of stockholders of Amicus. To the extent holdings of Amicus&#8217; securities by its directors
                    or executive officers have changed since the amounts set forth in the filings described in the foregoing, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial
                    Ownership on Form 4 filed with the SEC. Amicus stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed transaction,
                    including the interests of Amicus directors and executive officers in the transaction, which may be different than those of Amicus stockholders generally, by reading the Proxy Statement and any other relevant documents that are filed or
                    will be filed with the SEC relating to the transaction. These documents (when available) may be obtained free of charge from the website maintained by the SEC at <u>www.sec.gov</u> and Amicus&#8217;s website at
                    https://ir.amicusrx.com/financial-information/sec-filings.</div>
                  <div style="color: rgb(0, 0, 0);">&#160;</div>
                  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                    <div class="BRPFPageBreak" style="page-break-after: always;">
                      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                  </div>
                  <div style="font-weight: bold; color: rgb(0, 0, 0);"><u>Forward Looking Statements</u></div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div style="text-align: justify;"><font style="color: #000000;">This communication contains certain &#8220;forward-looking statements&#8221; intended to qualify for the &#8220;safe harbor&#8221; from liability established by the Private Securities Litigation
                      Reform Act of 1995, as amended, including, but not limited to, statements about the anticipated timing of closing of the Transaction</font><font style="color: rgb(0, 0, 0);"> in the second quarter of the calendar year 2026; and the
                      timing of the filing of the proxy statement for the Amicus&#8217; special stockholder meeting in connection with the Transaction. Forward-looking statements include any statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221;
                      &#8220;expect,&#8221; &#8220;intend&#8221;, &#8220;goal,&#8221; &#8220;may&#8221;, &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions. Forward-looking statements are subject to certain risks,
                      uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and
                      uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: consummating the Transaction and financing in the anticipated timeframe, if at all;
                      the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; uncertainties as to the ability to obtain shareholder approval; the possibility that competing acquisition
                      proposals will be made; the possibility that various closing conditions for the Transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of
                      the Transaction (or only grant approval subject to adverse conditions or limitations); the effects of the Transaction on relationships with employees, customers, suppliers, other business partners or governmental entities, including
                      the risk that the Transaction adversely affects employee retention; the difficulty of predicting the timing or outcome of regulatory approvals or actions; the impact of competitive products and pricing; the risk that Parent may not
                      realize the potential benefits of the Transaction, including the possibility that the expected benefits from the proposed Transaction will not be realized or will not be realized within the expected time period and that Parent and
                      Amicus will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; the risks related to disruption of management&#8217;s time from ongoing business operations as a result of
                      the Transaction; risks that the Transaction disrupts current plans and operations;&#160;obtaining and maintaining adequate coverage and reimbursement for Amicus&#8217; products;&#160;changes in Amicus&#8217; business during the period between announcement
                      and closing of the Transaction; any legal proceedings and/or regulatory actions that may be instituted related to the Transaction; other business effects, including the effects of industry, economic or political conditions outside of
                      the companies&#8217; control; costs and expenses related to the Transaction; actual or contingent liabilities; the effects of the Transaction (or the announcement thereof) on Amicus&#8217; and Parent&#8217;s stock price and/or operating results; and
                      the other risks and uncertainties discussed in Amicus&#8217;s periodic reports filed with the SEC, including Amicus&#8217; quarterly reports on Form 10-Q and annual reports on Form 10-K. These risks, as well as other risks associated with the
                      Transaction, are more fully discussed in the Proxy Statement to be filed with the SEC in connection with the Transaction. The list of factors presented in the foregoing is not complete and you should not place undue reliance on these
                      statements. Actual results could differ materially from those anticipated in these forward-looking statements. All forward-looking statements are based on information currently available to Amicus and Parent, and, except as required
                      by applicable law, Amicus and Parent disclaim any obligation to update the information contained in this communication as new information becomes available.&#160;All forward-looking statements in this communication or made in connection
                      therewith in writing or orally are qualified in their entirety by this cautionary statement.</font></div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div style="color: rgb(0, 0, 0);"><br>
                  </div>
                  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                    <div class="BRPFPageBreak" style="page-break-after: always;">
                      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                  </div>
                  <div>
                    <div>
                      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
                      <div>
                        <div>
                          <div style="text-align: right; font-weight: bold;"> <a name="Exhibit99.3"><!--Anchor--></a>Exhibit 99.3<br>
                          </div>
                          <div style="font-weight: bold;"> <br>
                          </div>
                          <div style="font-weight: bold;">Amicus Social Post</div>
                        </div>
                        <div>
                          <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center;"></div>
                        <div style="font-weight: bold;"> <br>
                        </div>
                        <div style="font-weight: bold;">Corporate LinkedIn Post</div>
                        <div><br>
                        </div>
                        <div>Amicus Therapeutics has entered into a definitive agreement to be acquired by BioMarin Pharmaceutical for $14.50 per share in cash, reflecting a total equity value of approximately $4.8 billion.</div>
                        <div><br>
                        </div>
                        <div>Together, with our partners in the rare disease community, we have created a truly patient-dedicated biotech, successfully developed two transformative medicines for people living with rare diseases and reached more than 3,400
                          patients around the world with our therapies. We changed people&#8217;s lives for the better and set the standard for what a rare disease company could be, and today&#8217;s announcement is the next milestone in our journey.</div>
                        <div><br>
                        </div>
                        <div>With BioMarin&#8217;s unwavering commitment to patients, along with their greater resources and scale, we can accelerate progress for the rare disease community. Our medicines will be able to reach even more patients, faster.</div>
                        <div><br>
                        </div>
                        <div>Please refer to today&#8217;s press release, available <u>HERE</u> for important information about the transaction.</div>
                        <div><br>
                        </div>
                        <div>&#160;<img src="image00001.jpg"></div>
                        <div><br>
                        </div>
                        <div style="font-weight: bold;"><u>Important Information and Where to Find It</u></div>
                        <div>&#160;</div>
                        <div style="text-align: justify;">In connection with the<font style="color: #000000;"> proposed acquisition of Amicus by Parent (the &#8220;<u>Transaction</u>&#8221;)</font>, Amicus intends to file with the SEC a proxy statement (the &#8220;<u>Proxy
                            Statement</u>&#8221;), the definitive version of which will be sent or provided to Amicus stockholders. Amicus may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the
                          Proxy Statement or any other document which Amicus may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL
                          AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may
                          obtain free copies of the Proxy Statement (when it is available) and other documents that are filed or will be filed with the SEC by Amicus through the website maintained by the SEC at www.sec.gov, Amicus&#8217;s website at
                          https://ir.amicusrx.com/financial-information/sec-filings or by contacting the Amicus investor relations department at the following:</div>
                        <div><br>
                        </div>
                        <div>Andrew Faughnan</div>
                        <div>(609) 662-3809</div>
                        <div style="color: rgb(0, 0, 0);"><u>afaughnan@amicusrx.com</u></div>
                        <div><br>
                        </div>
                        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                          <div class="BRPFPageBreak" style="page-break-after: always;">
                            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                        </div>
                        <div style="font-weight: bold;"><u>No Offer or Solicitation</u></div>
                        <div>&#160;</div>
                        <div style="text-align: justify;">This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase,
                          otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale,
                          issuance or transfer of securities in any jurisdiction in contravention of applicable law.</div>
                        <div>&#160;</div>
                        <div style="font-weight: bold;"><u>Participants in the Solicitation</u></div>
                        <div>&#160;</div>
                        <div style="text-align: justify;">Amicus and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Amicus&#8217;s
                          directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in (i) Amicus&#8217; Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was
                          filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001178879/000117887925000003/fold-20241231.htm">February 19, 2025</a>, including the sections therein entitled &#8220;Directors, Executive Officers, and
                          Corporate Governance,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221;, and (ii) Amicus&#8217;s proxy statement for its 2025 annual meeting of stockholders,
                          which was filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001178879/000114036125015479/ny20044252x1_def14a.htm">April 24, 2025</a>, including the sections therein entitled &#8220;Proposal 1 &#8211; Election of
                          Class Directors,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Compensation and Equity Tables,&#8221; and &#8220;Share Ownership of Certain Beneficial Owners and Management,&#8221; and (iii) other documents subsequently filed with the SEC from time to
                          time, including the Proxy Statement to be filed by Amicus in connection with the proposed transaction and the special meeting of stockholders of Amicus. To the extent holdings of Amicus&#8217; securities by its directors or executive
                          officers have changed since the amounts set forth in the filings described in the foregoing, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership
                          on Form 4 filed with the SEC. Amicus stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed transaction,
                          including the interests of Amicus directors and executive officers in the transaction, which may be different than those of Amicus stockholders generally, by reading the Proxy Statement and any other relevant documents that are
                          filed or will be filed with the SEC relating to the transaction. These documents (when available) may be obtained free of charge from the website maintained by the SEC at <u>www.sec.gov</u> and Amicus&#8217;s website at
                          https://ir.amicusrx.com/financial-information/sec-filings.</div>
                        <div>&#160;</div>
                        <div style="font-weight: bold;"><u>Forward Looking Statements</u></div>
                        <div><br>
                        </div>
                        <div style="text-align: justify;"><font style="color: #000000;">This communication contains certain&#160;&#8220;forward-looking statements&#8221; intended to qualify for the &#8220;safe harbor&#8221; from liability established by the Private Securities
                            Litigation Reform Act of 1995, as amended, including, but not limited to, statements about the anticipated timing of closing of the Transaction</font> in the second quarter of the calendar year 2026; and the timing of the filing
                          of the proxy statement for the Amicus&#8217; special stockholder meeting in connection with the Transaction<font style="color: #000000;">. Forward-looking statements include any statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221;
                            &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221;, &#8220;goal,&#8221; &#8220;may&#8221;, &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions. Forward-looking statements are subject
                            to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and
                            uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: </font>consummating the Transaction and
                          financing in the anticipated timeframe, if at all<font style="color: #000000;">; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; uncertainties as to the
                            ability to obtain shareholder approval; the possibility that competing </font>acquisition proposals<font style="color: #000000;"> will be made; the possibility that various closing conditions for the Transaction may not be
                            satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Transaction </font>(or only grant approval subject to adverse conditions or limitations)<font style="color: #000000;">; the effects of the Transaction on relationships with employees, customers, suppliers, other business partners or governmental entities</font>, including the risk that the Transaction adversely affects
                          employee retention<font style="color: #000000;">; the difficulty of predicting the timing or outcome of regulatory approvals or actions; the impact of competitive products and pricing; the risk that Parent may not realize the
                            potential benefits of the Transaction, </font>including the possibility that the expected benefits from the proposed Transaction will not be realized or will not be realized within the expected time period and that Parent and
                          Amicus will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected<font style="color: #000000;">; the risks related to disruption of management&#8217;s time from ongoing
                            business operations as a result of the Transaction;</font> risks that the Transaction disrupts current plans and operations;<font style="color: #000000;">&#160;</font>obtaining and maintaining adequate coverage and reimbursement for
                          Amicus&#8217; products;<font style="color: #000000;">&#160;</font>changes in Amicus&#8217; business during the period between announcement and closing of the Transaction; any legal proceedings and/or regulatory actions that may be instituted
                          related to the Transaction; <font style="color: #000000;">other business effects, including the effects of industry, economic or political conditions outside of the companies&#8217; control; costs and expenses related to the
                            Transaction; actual or contingent liabilities; </font>the effects of the Transaction (or the announcement thereof) on Amicus&#8217; and Parent&#8217;s stock price and/or operating results; <font style="color: #000000;">and the other risks
                            and uncertainties discussed in Amicus&#8217;s periodic reports filed with the SEC, including Amicus&#8217; quarterly reports on Form 10-Q and annual reports on Form 10-K. </font>These risks, as well as other risks associated with the
                          Transaction, are more fully discussed in the Proxy Statement to be filed with the SEC in connection with the Transaction. The list of factors presented in the foregoing is not complete and<font style="color: #000000;"> you should
                            not place undue reliance on these statements. Actual results could differ materially from those anticipated in these forward-looking statements. All forward-looking statements are based on information currently available to
                            Amicus and Parent, and, except as required by applicable law, Amicus and Parent disclaim any obligation to update the information contained in this communication as new information becomes available.</font>&#160;<font style="color: #000000;">All forward-looking statements in this communication or made in connection therewith in writing or orally are qualified in their entirety by this cautionary statement.</font></div>
                        <br>
                        <div><br>
                        </div>
                        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                          <div class="BRPFPageBreak" style="page-break-after: always;">
                            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                        </div>
                        <div> <font style="color: rgb(0, 0, 0);"> </font>
                          <div>
                            <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
                            <div>
                              <div style="text-align: right; font-weight: bold; color: rgb(0, 0, 0);"><a name="Exhibit99.4"><!--Anchor--></a>Exhibit 99.4</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="font-weight: bold; color: rgb(0, 0, 0);">CEO Letter to Amicus Employees</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">From: Bradley</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">To: All Amicus employees globally, no contractors/consultants</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">Timing: Two Hours after All Company Huddle</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">Subject: A Note from BioMarin&#8217;s President &amp; CEO</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">Body:</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">Team Amicus,</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">Alexander Hardy, BioMarin&#8217;s CEO, will be joining us for a Town Hall. Ahead of that, he wanted to reach out to all of you with the following note. </div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">As you would expect, I have gotten to know Alexander well over the past months. He shares our passion for patients and for the rare disease community and is eager to join in our mission for
                                people living with Pompe and Fabry disease in the weeks and months ahead. </div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">Sincerely,</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">Bradley</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">*********************</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">Dear Amicus,&#8239;&#160;</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">I am reaching out today on behalf of BioMarin to introduce myself and BioMarin &#8211; and to share a few words about how excited I am to combine our expertise in rare diseases.&#160; As I have gotten to
                                know the company through my discussions with Bradley and the team, I am inspired by your mission and focus, which aligns so well with ours, and by the incredible work all of you have done to bring Galafold and Pombiliti +
                                Opfolda to patients. Since our inception nearly 30 years ago, we have brought to market eight medicines for people with genetically defined conditions. Our therapies treat a number of genetic rare diseases, including
                                mucopolysaccharidosis (MPS), phenylketonuria (PKU), neuronal ceroid lipofuscinosis type 2 (CLN2) and achondroplasia.&#160; </div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">BioMarin and Amicus will continue to operate as two separate, independent companies until the transaction closes, which we anticipate will be in the second quarter of 2026, pending regulatory
                                approvals and other customary closing conditions. While we have already begun to plan for integration, that work will not begin until after the deal closes.</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">I know this news may bring questions about your role and what happens next. It is a top priority for us to ensure that the transition does not disrupt the incredible work of this organization
                                in ensuring that Galafold and Pombiliti + Opfolda reach patients.&#160; While many operational details will be determined in the coming months following close, one thing you&#8217;ll find about me and the BioMarin team is a strong
                                commitment to transparency. When decisions are made, we will share them with you. I look forward to joining you at a virtual town hall today at noon Eastern Time to share more about BioMarin and for you to have the
                                opportunity to ask initial questions.</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                                <div class="BRPFPageBreak" style="page-break-after: always;">
                                  <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                              </div>
                              <div style="color: rgb(0, 0, 0);">People in the biopharmaceutical industry often talk about putting patients first. That is especially meaningful at companies like Amicus and BioMarin, where our work has such a significant and
                                personal impact on individuals living with rare, complex conditions. Today&#8217;s news brings us one step closer to potentially reaching more patients living with Pompe disease and Fabry disease, all of whom are counting on us.&#8239;&#160;</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">Thank you,&#8239;&#160;</div>
                              <div style="color: rgb(0, 0, 0);">Alexander&#8239;&#160;</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="font-weight: bold; color: rgb(0, 0, 0);"><u>Important Information and Where to Find It</u></div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="text-align: justify; color: rgb(0, 0, 0);">In connection with the proposed acquisition of Amicus by Parent (the &#8220;<u>Transaction</u>&#8221;), Amicus intends to file with the SEC a proxy statement (the &#8220;<u>Proxy Statement</u>&#8221;),


                                the definitive version of which will be sent or provided to Amicus stockholders. Amicus may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the Proxy Statement
                                or any other document which Amicus may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY
                                AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may
                                obtain free copies of the Proxy Statement (when it is available) and other documents that are filed or will be filed with the SEC by Amicus through the website maintained by the SEC at www.sec.gov, Amicus&#8217;s website at
                                https://ir.amicusrx.com/financial-information/sec-filings or by contacting the Amicus investor relations department at the following:</div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">Andrew Faughnan </div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);">(609) 662-3809 </div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);"><u>afaughnan@amicusrx.com</u></div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="font-weight: bold; color: rgb(0, 0, 0);"><u>No Offer or Solicitation</u></div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="text-align: justify; color: rgb(0, 0, 0);">This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer
                                or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise,
                                nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. </div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                                <div class="BRPFPageBreak" style="page-break-after: always;">
                                  <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                              </div>
                              <div style="font-weight: bold; color: rgb(0, 0, 0);"><u>Participants in the Solicitation</u></div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="text-align: justify; color: rgb(0, 0, 0);">Amicus and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction.
                                Information regarding Amicus&#8217;s directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in (i) Amicus&#8217; Annual Report on Form 10-K for the fiscal
                                year ended December 31, 2024, which was filed with the SEC on <u>February 19, 2025</u>, including the sections therein entitled &#8220;Directors, Executive Officers, and Corporate Governance,&#8221; &#8220;Executive Compensation&#8221; and
                                &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221;, and (ii) Amicus&#8217;s proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on <u>April 24,
                                  2025</u>, including the sections therein entitled &#8220;Proposal 1 &#8211; Election of Class Directors,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Compensation and Equity Tables,&#8221; and &#8220;Share Ownership of Certain Beneficial Owners and
                                Management,&#8221; and (iii) other documents subsequently filed with the SEC from time to time, including the Proxy Statement to be filed by Amicus in connection with the proposed transaction and the special meeting of
                                stockholders of Amicus. To the extent holdings of Amicus&#8217; securities by its directors or executive officers have changed since the amounts set forth in the filings described in the foregoing, such changes have been or will
                                be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. Amicus stockholders may obtain additional information regarding the direct and indirect
                                interests of the participants in the solicitation of proxies in connection with the proposed transaction, including the interests of Amicus directors and executive officers in the transaction, which may be different than
                                those of Amicus stockholders generally, by reading the Proxy Statement and any other relevant documents that are filed or will be filed with the SEC relating to the transaction. These documents (when available) may be
                                obtained free of charge from the website maintained by the SEC at <u>www.sec.gov</u> and Amicus&#8217;s website at https://ir.amicusrx.com/financial-information/sec-filings. </div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="font-weight: bold; color: rgb(0, 0, 0);"><u>Forward Looking Statements</u></div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="text-align: justify;"><font style="color: #000000;">This communication contains certain &#8220;forward-looking statements&#8221; intended to qualify for the &#8220;safe harbor&#8221; from liability established by the Private Securities
                                  Litigation Reform Act of 1995, as amended, including, but not limited to, statements about the anticipated timing of closing of the Transaction</font><font style="color: rgb(0, 0, 0);"> in the second quarter of the
                                  calendar year 2026; and the timing of the filing of the proxy statement for the Amicus&#8217; special stockholder meeting in connection with the Transaction. Forward-looking statements include any statements containing the words
                                  &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221;, &#8220;goal,&#8221; &#8220;may&#8221;, &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions.
                                  Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such
                                  statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things:
                                  consummating the Transaction and financing in the anticipated timeframe, if at all; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; uncertainties
                                  as to the ability to obtain shareholder approval; the possibility that competing acquisition proposals will be made; the possibility that various closing conditions for the Transaction may not be satisfied or waived,
                                  including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Transaction (or only grant approval subject to adverse conditions or limitations); the effects of the
                                  Transaction on relationships with employees, customers, suppliers, other business partners or governmental entities, including the risk that the Transaction adversely affects employee retention; the difficulty of
                                  predicting the timing or outcome of regulatory approvals or actions; the impact of competitive products and pricing; the risk that Parent may not realize the potential benefits of the Transaction, including the possibility
                                  that the expected benefits from the proposed Transaction will not be realized or will not be realized within the expected time period and that Parent and Amicus will not be integrated successfully or that such integration
                                  may be more difficult, time-consuming or costly than expected; the risks related to disruption of management&#8217;s time from ongoing business operations as a result of the Transaction; risks that the Transaction disrupts
                                  current plans and operations;&#160;obtaining and maintaining adequate coverage and reimbursement for Amicus&#8217; products;&#160;changes in Amicus&#8217; business during the period between announcement and closing of the Transaction; any legal
                                  proceedings and/or regulatory actions that may be instituted related to the Transaction; other business effects, including the effects of industry, economic or political conditions outside of the companies&#8217; control; costs
                                  and expenses related to the Transaction; actual or contingent liabilities; the effects of the Transaction (or the announcement thereof) on Amicus&#8217; and Parent&#8217;s stock price and/or operating results; and the other risks and
                                  uncertainties discussed in Amicus&#8217;s periodic reports filed with the SEC, including Amicus&#8217; quarterly reports on Form 10-Q and annual reports on Form 10-K. These risks, as well as other risks associated with the
                                  Transaction, are more fully discussed in the Proxy Statement to be filed with the SEC in connection with the Transaction. The list of factors presented in the foregoing is not complete and you should not place undue
                                  reliance on these statements. Actual results could differ materially from those anticipated in these forward-looking statements. All forward-looking statements are based on information currently available to Amicus and
                                  Parent, and, except as required by applicable law, Amicus and Parent disclaim any obligation to update the information contained in this communication as new information becomes available.&#160;All forward-looking statements in
                                  this communication or made in connection therewith in writing or orally are qualified in their entirety by this cautionary statement.</font></div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div style="color: rgb(0, 0, 0);"><br>
                              </div>
                              <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                                <div class="BRPFPageBreak" style="page-break-after: always;">
                                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                              </div>
                              <div>
                                <div>
                                  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
                                  <div style="font-weight: bold; text-align: right;"><a name="Exhibit99.5"><!--Anchor--></a>Exhibit 99.5<br>
                                  </div>
                                  <div><br>
                                  </div>
                                  <div style="text-align: center;"><img src="image00004.jpg"></div>
                                  <div>
                                    <div style="font-weight: bold;"> <br>
                                    </div>
                                    <div style="font-weight: bold;">Amicus Employee Q&amp;A</div>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">What does this mean for employees? </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>While we are announcing this news today, it is only the first step in the process to bring our companies together. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>We expect to close in the second quarter of 2026, subject to regulatory clearances, approval by the stockholders of Amicus and other customary closing conditions.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>Until then, Amicus and BioMarin remain two, separate companies, and we will operate largely as usual. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>The vast majority of our work &#8211; including supplying our medicines to patients, patient support programs, clinical trial operations, engaging with regulatory agencies
                                              and health care providers &#8211; will continue as they normally would. Our patients are counting on us.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">What are BioMarin&#8217;s plans for integrating the two companies? When will that begin? Will there be changes to Amicus&#8217; employee base? Job reductions?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>While we are announcing this news today, it is only the first step in the process to bring our companies together. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>We expect to close in the second quarter of 2026, subject to regulatory clearances, approval by the stockholders of Amicus and other customary closing conditions.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>Over the coming months, dedicated teams from Amicus and BioMarin will be planning on how best to bring our companies together. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>No decisions have been made about the pace or timing of integration. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>We will provide more information once the teams at both our companies have the opportunity to meet and discuss. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>Our highest priorities in this process are to continue our companies&#8217; respective momentum, support patients and the rare disease community, and support our employees.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">Will there be changes to benefits programs for Amicus employees as a result?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>We do not anticipate any changes to Amicus benefits at this time. If there are any changes to benefit programs post integration, that will be communicated at that
                                              time.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                                      <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
                                      <div style="page-break-after: always;" class="BRPFPageBreak">
                                        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                                    </div>
                                    <div>
                                      <div style="text-align: center;"><img src="image00004.jpg"></div>
                                    </div>
                                    <div> <br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">Will we get our 2025 bonus, merit increases and stock awards in early January 2026? What is the 2025 bonus corporate multiplier?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div><font style="color: #333333;">You will be eligible to receive your 2025 bonus based on your
                                                individual performance rating and with an approved Corporate Modifier of 140%. If you were otherwise eligible for a 2026 merit increase, the transaction will not impact that eligibility, and you will receive
                                                your 2026 merit increase as would normally happen. Any new salary will be communicated once compensation changes have been approved. In lieu of a 2026 equity grant you will receive a cash award valued at 25%
                                                of what your equity grant value would have been. You will receive this cash value at or promptly following closing, contingent on your continued employment through that date.</font></div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">If I have annual leave booked, do I need to cancel it? If I have planned medical leave, do I need to cancel it?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>No, you should keep your current plans, as long as they have been approved by your manager.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">Will annual planned promotions still take place?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>Approved promotions for January 2026 will proceed.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">Will the Company move forward with hiring plans? </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>Most hiring will be paused with the exception of certain roles.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">Should employees expect changes to Amicus&#8217; operating locations, facilities? What about the Company&#8217;s Princeton, Marlow, Philadelphia, and affiliate
                                              offices? </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>No decisions have been made about specific facilities. We will share more information as soon as we have it. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">Will employees have the option to move to California with BioMarin Pharmaceutical?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>While we are announcing this news today, it is only the first step in the process to bring our companies together.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>Over the coming months, dedicated teams from Amicus and BioMarin will be planning on how best to bring our companies together, including whether there are options for
                                              employees to move to BioMarin&#8217;s headquarters in California. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>We will provide more information once the teams at both our companies have the opportunity to meet and discuss. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div> <br>
                                    </div>
                                    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                                      <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
                                      <div style="page-break-after: always;" class="BRPFPageBreak">
                                        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                                    </div>
                                    <div>
                                      <div style="text-align: center;"><img src="image00004.jpg"></div>
                                    </div>
                                    <div> <br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">Will title or job duties change after close? Will there be changes in reporting relationships as a result?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>We expect decisions on titles and job duties after closing to be made as part of the integration planning process led by BioMarin, and we will provide more information
                                              once the teams at both our companies have the opportunity to meet and discuss. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">Can employees buy and sell stock between now and close?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>Until close, Amicus&#8217; stock will continue to trade on the public market NASDAQ just as it does today, and employees can continue to make investment and trading
                                              decisions subject to our existing policies and regulations, including our insider trading policy and any blackout dates. Trading in BioMarin stock will be prohibited during this time unless otherwise indicated
                                              by the legal department. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>If you are involved in integration planning or otherwise have questions about whether you can trade under applicable securities laws or our insider trading policy,
                                              please contact Christian Formica at <u>cformica@amicusrx.com</u> or Ellen Rosenberg at <u>erosenberg@amicusrx.com</u> with questions prior to taking any action.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">What happens to stock options employees were granted as part of their equity compensation?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>All outstanding options (vested or unvested) will be cashed out at closing, provided that the strike price of the options is lower than the transaction price.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>The cash payment for any outstanding options will be calculated by deducting the strike price from the transaction price multiplied by the number of options.
                                              Applicable taxes will also be deducted from the income, and the value will be paid to you via payroll.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>Any options with strike prices equal to or above the closing price will be cancelled for no value. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div>&#160;</div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">What happens to restricted stock units (RSUs)?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>Amicus equity will continue to vest under vesting schedules in place until the deal officially closes.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>Unvested RSUs will accelerate and will be cancelled and cashed out at closing based on the transaction price, which will be paid to employees via payroll (less
                                              applicable taxes).</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                                      <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
                                      <div style="page-break-after: always;" class="BRPFPageBreak">
                                        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                                    </div>
                                    <div>
                                      <div style="text-align: center;"><img src="image00004.jpg"></div>
                                    </div>
                                    <div> <br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">What happens to any shares I have from vested equity awards?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>All Amicus shares will be cashed out at closing. Cash payments will be made by the broker that holds the shares (e.g. Morgan Stanley, E*TRADE).</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">What will happen to the Amicus name?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>That will be determined through the integration process led by BioMarin.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">What will happen to the Galafold and Pombiliti + Opfolda brand names? </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>We do not expect changes to the Galafold and Pombiliti + Opfolda brand names. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">How do the cultures of the two companies compare?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>There is a lot of overlap in our mission and values. Like Amicus, BioMarin is a company that has been profoundly dedicated to transforming care for patients with rare
                                              diseases since its founding.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>In addition to sharing our commitment to transforming care for patients with rare diseases, they believe in building value for all stakeholders and fostering teamwork
                                              and respect for each individual&#8217;s contributions.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">Will employees be eligible for severance if they experience a termination of employment following the closing?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="color: rgb(0, 0, 0);">The terms of the U.S. change in control severance plan and all CIC addenda in international employment contracts will be honored. Those terms will
                                              be provided to all employees in the coming weeks.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">Can employees engage on social media about the news?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>As a public company, there are strict SEC rules that determine what and how we are able to share information on social media about today&#8217;s announcement. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div><font style="font-weight: bold;">U.S. employees</font>: you <font style="font-weight: bold;"><u>can</u></font> &#8220;Like&#8221; and/or &#8220;Repost&#8221; -- without comment -- the Amicus LinkedIn post regarding the acquisition. You <font style="font-weight: bold;">cannot</font> like, comment or repost/share third-party social media posts about today&#8217;s announcement, and you cannot create your own new post or add any information
                                                along with a repost about the news.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div><font style="font-weight: bold;">International employees</font>: you <font style="font-weight: bold;"><u>cannot</u></font> &#8220;Like&#8221;, &#8220;Comment&#8221; or &#8220;Repost&#8221; today&#8217;s Amicus LinkedIn post regarding the acquisition because it links to our website, which is
                                                against our global social media policy. You also <font style="font-weight: bold;">cannot</font> like, comment or repost/share third-party social media posts about today&#8217;s
                                                announcement.</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div> <br>
                                    </div>
                                    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                                      <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
                                      <div style="page-break-after: always;" class="BRPFPageBreak">
                                        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                                    </div>
                                    <div>
                                      <div style="text-align: center;"><img src="image00004.jpg"></div>
                                    </div>
                                    <div> <br>
                                    </div>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt; vertical-align: top; font-weight: bold;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div style="font-weight: bold;">What do employees do if contacted by the press, financial analysts or investors?</div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>Consistent with Company policy, all media inquiries should be forwarded to Brendan McEvoy at <u>bmcevoy@amicusrx.com</u>. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

                                        <tr>
                                          <td style="width: 18pt;"><br>
                                          </td>
                                          <td style="width: 18pt; vertical-align: top;">&#9679;</td>
                                          <td style="width: auto; vertical-align: top;">
                                            <div>All financial analyst and investor inquiries should be forwarded to Andrew Faughnan at <u>afaughnan@amicusrx.com</u>. </div>
                                          </td>
                                        </tr>

                                    </table>
                                    <div><br>
                                    </div>
                                    <div style="font-weight: bold;"><u>Important Information and Where to Find It</u></div>
                                    <div>&#160;</div>
                                    <div style="text-align: justify;">In connection with the<font style="color: rgb(0, 0, 0);"> proposed acquisition of Amicus by Parent (the &#8220;<u>Transaction</u>&#8221;)</font>,
                                      Amicus intends to file with the SEC a proxy statement (the &#8220;<u>Proxy Statement</u>&#8221;), the definitive version of which will be sent or provided to Amicus
                                      stockholders. Amicus may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the Proxy Statement or any other document which Amicus may file with the SEC.
                                      INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY
                                      AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy Statement (when it
                                      is available) and other documents that are filed or will be filed with the SEC by Amicus through the website maintained by the SEC at www.sec.gov, Amicus&#8217;s website at
                                      https://ir.amicusrx.com/financial-information/sec-filings or by contacting the Amicus investor relations department at the following:</div>
                                    <div>Andrew Faughnan</div>
                                    <div>(609) 662-3809</div>
                                    <div><u>afaughnan@amicusrx.com</u></div>
                                    <div><br>
                                    </div>
                                    <div style="font-weight: bold;"><u>No Offer or Solicitation</u></div>
                                    <div>&#160;</div>
                                    <div style="text-align: justify;">This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation
                                      or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the
                                      proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.</div>
                                    <div>&#160;</div>
                                    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                                      <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
                                      <div style="page-break-after: always;" class="BRPFPageBreak">
                                        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                                    </div>
                                    <div style="font-weight: bold;">
                                      <div style="text-align: center;"><img src="image00004.jpg"></div>
                                    </div>
                                    <div style="font-weight: bold;"><u> <br>
                                      </u></div>
                                    <div style="font-weight: bold;"><u>Participants in the Solicitation</u></div>
                                    <div>&#160;</div>
                                    <div style="text-align: justify;">Amicus and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of
                                      the proposed transaction. Information regarding Amicus&#8217;s directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in (i) Amicus&#8217; Annual Report
                                      on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on <u>February 19, 2025</u>, including the sections therein entitled &#8220;Directors, Executive Officers, and Corporate Governance,&#8221;
                                      &#8220;Executive Compensation&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221;, and (ii) Amicus&#8217;s proxy statement for its 2025 annual meeting of stockholders, which was
                                      filed with the SEC on <u>April 24, 2025</u>, including the sections therein entitled &#8220;Proposal 1 &#8211; Election of Class Directors,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Compensation and Equity Tables,&#8221; and &#8220;Share
                                      Ownership of Certain Beneficial Owners and Management,&#8221; and (iii) other documents subsequently filed with the SEC from time to time, including the Proxy Statement to be filed by Amicus in connection with the proposed
                                      transaction and the special meeting of stockholders of Amicus. To the extent holdings of Amicus&#8217; securities by its directors or executive officers have changed since the amounts set forth in the filings described in
                                      the foregoing, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. Amicus stockholders may obtain
                                      additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed transaction, including the interests of Amicus directors and
                                      executive officers in the transaction, which may be different than those of Amicus stockholders generally, by reading the Proxy Statement and any other relevant documents that are filed or will be filed with the SEC
                                      relating to the transaction. These documents (when available) may be obtained free of charge from the website maintained by the SEC at <u>www.sec.gov</u> and Amicus&#8217;s website at
                                      https://ir.amicusrx.com/financial-information/sec-filings.</div>
                                    <div>&#160;</div>
                                    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                                      <div class="BRPFPageNumberArea" style="text-align: right;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
                                      <div style="page-break-after: always;" class="BRPFPageBreak">
                                        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                                    </div>
                                    <div style="font-weight: bold;">
                                      <div style="text-align: center;"><img src="image00004.jpg"></div>
                                    </div>
                                    <div style="font-weight: bold;"><u> <br>
                                      </u></div>
                                    <div style="font-weight: bold;"><u>Forward Looking Statements</u></div>
                                    <div style="text-align: justify;"><font style="color: #000000;">This communication contains certain &#8220;forward-looking
                                        statements&#8221; intended to qualify for the &#8220;safe harbor&#8221; from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements about the anticipated
                                        timing of closing of the Transaction</font> in the second quarter of the calendar year 2026; and the timing of the filing of the proxy statement for the Amicus&#8217; special stockholder
                                        meeting in connection with the Transaction<font style="color: rgb(0, 0, 0);">. Forward-looking statements include any statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221;
                                          &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221;, &#8220;goal,&#8221; &#8220;may&#8221;, &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions. Forward-looking
                                          statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due
                                          to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: </font>consummating

                                        the Transaction and financing in the anticipated timeframe, if at all<font style="color: rgb(0, 0, 0);">; the occurrence of any event, change or other circumstance that could give rise
                                          to the termination of the Merger Agreement; uncertainties as to the ability to obtain shareholder approval; the possibility that competing </font>acquisition proposals<font style="color: rgb(0, 0, 0);"> will be made; the possibility that various closing conditions for the Transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant
                                          approval for the consummation of the Transaction </font>(or only grant approval subject to adverse conditions or limitations)<font style="color: rgb(0, 0, 0);">; the effects of the
                                          Transaction on relationships with employees, customers, suppliers, other business partners or governmental entities</font>, including the risk that the Transaction adversely affects employee retention<font style="color: rgb(0, 0, 0);">; the difficulty of predicting the timing or outcome of regulatory approvals or actions; the impact of competitive products and pricing; the risk that
                                          Parent may not realize the potential benefits of the Transaction, </font>including the possibility that the expected benefits from the proposed Transaction will not be realized or will not be realized within the
                                        expected time period and that Parent and Amicus will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected<font style="color: rgb(0, 0, 0);">; the risks related to disruption of management&#8217;s time from ongoing business operations as a result of the Transaction;</font> risks that the Transaction disrupts current plans and operations;<font style="color: rgb(0, 0, 0);">&#160;</font>obtaining and maintaining adequate coverage and reimbursement for Amicus&#8217; products;<font style="color: rgb(0, 0, 0);">&#160;</font>changes in Amicus&#8217; business during the period between announcement and closing of the Transaction; any legal proceedings and/or regulatory actions that may be instituted related to the Transaction; <font style="color: rgb(0, 0, 0);">other business effects, including the effects of industry, economic or political conditions outside of the companies&#8217; control; costs and expenses related
                                          to the Transaction; actual or contingent liabilities; </font>the effects of the Transaction (or the announcement thereof) on Amicus&#8217; and Parent&#8217;s stock price and/or operating results; <font style="color: rgb(0, 0, 0);">and the other risks and uncertainties discussed in Amicus&#8217;s periodic reports filed with the SEC, including Amicus&#8217; quarterly reports on Form 10-Q and annual reports on Form
                                          10-K. </font>These risks, as well as other risks associated with the Transaction, are more fully discussed in the Proxy Statement to be filed with the SEC in connection with the Transaction. The list of factors
                                        presented in the foregoing is not complete and<font style="color: rgb(0, 0, 0);"> you should not place undue reliance on these statements. Actual results could differ materially from
                                          those anticipated in these forward-looking statements. All forward-looking statements are based on information currently available to Amicus and Parent, and, except as required by applicable law, Amicus and Parent
                                          disclaim any obligation to update the information contained in this communication as new information becomes available.</font>&#160;<font style="color: rgb(0, 0, 0);">All forward-looking
                                          statements in this communication or made in connection therewith in writing or orally are qualified in their entirety by this cautionary statement.</font></div>
                                    <div><br>
                                    </div>
                                    <div><br>
                                    </div>
                                    <div style="font-size: 8pt; text-align: right;">7<br>
                                    </div>
                                  </div>
                                  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                                    <div class="BRPFPageBreak" style="page-break-after: always;">
                                      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                                  </div>
                                  <div> <font style="color: rgb(0, 0, 0);"> </font>
                                    <div>
                                      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
                                      <div>
                                        <div style="color: rgb(0, 0, 0);">
                                          <div style="text-align: right; font-weight: bold;"><a name="Exhibit99.6"><!--Anchor--></a>Exhibit 99.6</div>
                                        </div>
                                        <div>
                                          <div style="color: rgb(0, 0, 0);"><br>
                                          </div>
                                          <div style="font-weight: bold; color: rgb(0, 0, 0);">Amicus Stakeholder Letter
                                            <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center;"></div>
                                        </div>
                                        <div style="color: rgb(0, 0, 0);"><br>
                                        </div>
                                        <div style="font-weight: bold; color: rgb(0, 0, 0);">Subject line: Important Announcement from Amicus Therapeutics</div>
                                        <div style="color: rgb(0, 0, 0);"><br>
                                        </div>
                                        <div style="color: rgb(0, 0, 0);">[Dear Valued Partner / INSERT STANDARD GREETING],</div>
                                        <div style="color: rgb(0, 0, 0);"><br>
                                        </div>
                                        <div style="color: rgb(0, 0, 0);">I am reaching out with important news about Amicus Therapeutics. Today, we announced that Amicus has entered into a definitive agreement to be acquired by BioMarin Pharmaceutical.
                                          You can read the press release <u>here</u>.</div>
                                        <div style="color: rgb(0, 0, 0);"><br>
                                        </div>
                                        <div style="color: rgb(0, 0, 0);">We are enormously proud of our Amicus team and all that we have built over the past two decades. Together with our partners in the rare disease community, we have created a truly
                                          patient-centric biotech and successfully developed two transformative medicines for people living with diseases impacting the lives of more than 3,400 patients around the world. We have changed people&#8217;s lives for
                                          the better and set the standard for what a rare disease company could be. Our combination with BioMarin is the next milestone in our journey.</div>
                                        <div style="color: rgb(0, 0, 0);"><br>
                                        </div>
                                        <div style="color: rgb(0, 0, 0);">Like Amicus, BioMarin is a deeply patient-dedicated company and a trusted partner to rare disease communities around the world. We have full confidence they share Amicus&#8217; commitment
                                          to putting patients first. With BioMarin&#8217;s unwavering commitment to patients, along with their greater resources and scale, Amicus&#8217; medicines will be able to reach even more patients, faster.</div>
                                        <div style="color: rgb(0, 0, 0);"><br>
                                        </div>
                                        <div style="color: rgb(0, 0, 0);">We expect to close in the second quarter of 2026, subject to subject to regulatory clearances, approval by the stockholders of Amicus and other customary closing conditions. Until
                                          then, Amicus and BioMarin remain two, separate companies, and we will operate largely as usual. The vast majority of our work &#8211; including supplying our medicines to patients, patient support programs, clinical
                                          trial operations, engaging with regulatory agencies and health care providers &#8211; will continue as they normally would. Current contracts and your point of contact remain the same. We do not expect changes in how we
                                          work with you at this time.</div>
                                        <div style="color: rgb(0, 0, 0);"><br>
                                        </div>
                                        <div style="color: rgb(0, 0, 0);">We will continue to keep you informed if there is additional news to share. In the meantime, please do not hesitate to reach out to [your normal company contact] with any questions.</div>
                                        <div style="color: rgb(0, 0, 0);"><br>
                                        </div>
                                        <div style="color: rgb(0, 0, 0);">On behalf of the entire Amicus team, thank you for your continued partnership and your steadfast commitment to improving the lives of people living with rare diseases.</div>
                                        <div style="color: rgb(0, 0, 0);"><br>
                                        </div>
                                        <div style="color: rgb(0, 0, 0);">Sincerely,</div>
                                        <div style="color: rgb(0, 0, 0);"><br>
                                        </div>
                                        <div style="color: rgb(0, 0, 0);">Bradley L. Campbell</div>
                                        <div style="color: rgb(0, 0, 0);">President and CEO</div>
                                        <div style="color: rgb(0, 0, 0);"><br>
                                        </div>
                                        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                                          <div class="BRPFPageBreak" style="page-break-after: always;">
                                            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                                        </div>
                                        <div style="font-weight: bold; color: rgb(0, 0, 0);"><u>Important Information and Where to Find It</u></div>
                                        <div style="color: rgb(0, 0, 0);">&#160;</div>
                                        <div style="text-align: justify; color: rgb(0, 0, 0);">In connection with the proposed acquisition of Amicus by Parent (the &#8220;<u>Transaction</u>&#8221;), Amicus intends to file with the SEC a proxy statement (the &#8220;<u>Proxy
                                            Statement</u>&#8221;), the definitive version of which will be sent or provided to Amicus stockholders. Amicus may also file other documents with the SEC regarding the proposed transaction. This document is not a
                                          substitute for the Proxy Statement or any other document which Amicus may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR
                                          WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND
                                          RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy Statement (when it is available) and other documents that are filed or will be filed with the SEC by Amicus through the website
                                          maintained by the SEC at www.sec.gov, Amicus&#8217;s website at https://ir.amicusrx.com/financial-information/sec-filings or by contacting the Amicus investor relations department at the following:</div>
                                        <div style="color: rgb(0, 0, 0);">&#160;</div>
                                        <div style="color: rgb(0, 0, 0);">Andrew Faughnan</div>
                                        <div style="color: rgb(0, 0, 0);">&#160;</div>
                                        <div style="color: rgb(0, 0, 0);">(609) 662-3809</div>
                                        <div style="color: rgb(0, 0, 0);">&#160;</div>
                                        <div style="color: rgb(0, 0, 0);"><u>afaughnan@amicusrx.com</u></div>
                                        <div style="color: rgb(0, 0, 0);">&#160;</div>
                                        <div style="font-weight: bold; color: rgb(0, 0, 0);"><u>No Offer or Solicitation</u></div>
                                        <div style="color: rgb(0, 0, 0);">&#160;</div>
                                        <div style="text-align: justify; color: rgb(0, 0, 0);">This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of
                                          an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed
                                          transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.</div>
                                        <div style="color: rgb(0, 0, 0);">&#160;</div>
                                        <div style="font-weight: bold; color: rgb(0, 0, 0);"><u>Participants in the Solicitation</u></div>
                                        <div style="color: rgb(0, 0, 0);">&#160;</div>
                                        <div style="text-align: justify; color: rgb(0, 0, 0);">Amicus and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed
                                          transaction. Information regarding Amicus&#8217;s directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in (i) Amicus&#8217; Annual Report on Form
                                          10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on <u>February 19, 2025</u>, including the sections therein entitled &#8220;Directors, Executive Officers, and Corporate Governance,&#8221;
                                          &#8220;Executive Compensation&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221;, and (ii) Amicus&#8217;s proxy statement for its 2025 annual meeting of stockholders, which
                                          was filed with the SEC on <u>April 24, 2025</u>, including the sections therein entitled &#8220;Proposal 1 &#8211; Election of Class Directors,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Compensation and Equity Tables,&#8221; and
                                          &#8220;Share Ownership of Certain Beneficial Owners and Management,&#8221; and (iii) other documents subsequently filed with the SEC from time to time, including the Proxy Statement to be filed by Amicus in connection with the
                                          proposed transaction and the special meeting of stockholders of Amicus. To the extent holdings of Amicus&#8217; securities by its directors or executive officers have changed since the amounts set forth in the filings
                                          described in the foregoing, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. Amicus
                                          stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed transaction, including the interests of
                                          Amicus directors and executive officers in the transaction, which may be different than those of Amicus stockholders generally, by reading the Proxy Statement and any other relevant documents that are filed or will
                                          be filed with the SEC relating to the transaction. These documents (when available) may be obtained free of charge from the website maintained by the SEC at <u>www.sec.gov</u> and Amicus&#8217;s website at
                                          https://ir.amicusrx.com/financial-information/sec-filings.</div>
                                        <div style="color: rgb(0, 0, 0);">&#160;</div>
                                        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                                          <div class="BRPFPageBreak" style="page-break-after: always;">
                                            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                                        </div>
                                        <div style="font-weight: bold; color: rgb(0, 0, 0);"><u>Forward Looking Statements</u></div>
                                        <div style="color: rgb(0, 0, 0);">&#160;</div>
                                        <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">This communication contains certain &#8220;forward-looking statements&#8221; intended to qualify for the &#8220;safe harbor&#8221; from liability established by the
                                            Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements about the anticipated timing of closing of the Transaction in the second quarter of the calendar year 2026;
                                            and the timing of the filing of the proxy statement for the Amicus&#8217; special stockholder meeting in connection with the Transaction. Forward-looking statements include any statements containing the words
                                            &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221;, &#8220;goal,&#8221; &#8220;may&#8221;, &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar
                                            expressions. Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those
                                            indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking
                                            statements include, among other things: consummating the Transaction and financing in the anticipated timeframe, if at all; the occurrence of any event, change or other circumstance that could give rise to the
                                            termination of the Merger Agreement; uncertainties as to the ability to obtain shareholder approval; the possibility that competing acquisition proposals will be made; the possibility that various closing
                                            conditions for the Transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Transaction (or only grant approval
                                            subject to adverse conditions or limitations); the effects of the Transaction on relationships with employees, customers, suppliers, other business partners or governmental entities, including the risk that the
                                            Transaction adversely affects employee retention; the difficulty of predicting the timing or outcome of regulatory approvals or actions; the impact of competitive products and pricing; the risk that Parent may
                                            not realize the potential benefits of the Transaction, including the possibility that the expected benefits from the proposed Transaction will not be realized or will not be realized within the expected time
                                            period and that Parent and Amicus will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; the risks related to disruption of management&#8217;s time
                                            from ongoing business operations as a result of the Transaction; risks that the Transaction disrupts current plans and operations;&#160;obtaining and maintaining adequate coverage and reimbursement for Amicus&#8217;
                                            products;&#160;changes in Amicus&#8217; business during the period between announcement and closing of the Transaction; any legal proceedings and/or regulatory actions that may be instituted related to the Transaction;
                                            other business effects, including the effects of industry, economic or political conditions outside of the companies&#8217; control; costs and expenses related to the Transaction; actual or contingent liabilities; the
                                            effects of the Transaction (or the announcement thereof) on Amicus&#8217; and Parent&#8217;s stock price and/or operating results; and the other risks and uncertainties discussed in Amicus&#8217;s periodic reports filed with the
                                            SEC, including Amicus&#8217; quarterly reports on Form 10-Q and annual reports on Form 10-K. These risks, as well as other risks associated with the Transaction, are more fully discussed in the Proxy Statement to be
                                            filed with the SEC in connection with the Transaction. The list of factors presented in the foregoing is not complete and you should not place undue reliance on these statements. Actual results could differ
                                            materially from those anticipated in these forward-looking statements. All forward-looking statements are based on information currently available to Amicus and Parent, and, except as required by applicable law,
                                            Amicus and Parent disclaim any obligation to update the information contained in this communication as new information becomes available.&#160;All forward-looking statements in this communication or made in connection
                                            therewith in writing or orally are qualified in their entirety by this cautionary statement.</font></div>
                                        <div style="color: rgb(0, 0, 0);">&#160;</div>
                                        <div style="color: rgb(0, 0, 0);"><br>
                                        </div>
                                        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                                          <div class="BRPFPageBreak" style="page-break-after: always;">
                                            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                                        </div>
                                        <div>
                                          <div>
                                            <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
                                            <div>
                                              <div style="text-align: center;" class="slide">
                                                <div style="position: relative; left: 0px; top: 0px;" class="frame">
                                                  <div style="left: 0px; top: 0px;">
                                                    <div style="text-align: right;"><font style="font-weight: bold;"><a name="Exhibit99.7"><!--Anchor--></a>Exhibit 99.7</font><br>
                                                    </div>
                                                    <div><br>
                                                    </div>
                                                    <img src="ef20061157_ex99-7slide1.jpg"></div>
                                                </div>
                                                <div class="slideText">
                                                  <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Compelling, Certain, Premium Value for
                                                      Amicus Stockholders&#160;&#160;Accelerating Progress for the Rare Disease Community and Maximizing Value for Amicus Stockholders &#160;&#160;&#8220;I am enormously proud of our Amicus team. Together with our partners in the rare
                                                      disease community, we created a truly patient-centric biotech and successfully developed two transformative medicines for people living with rare diseases, which impacted the lives of more than 3,400
                                                      patients around the world,&#8221; said Bradley L. Campbell, President and Chief Executive Officer of Amicus. &#8220;With BioMarin&#8217;s unwavering commitment to patients, along with greater resources and scale, Amicus&#8217;
                                                      medicines will reach even more patients around the world, faster. We are confident that this acquisition is in the best interests of our stockholders by providing compelling, certain and premium value,
                                                      and will accelerate progress for the rare disease community.&#8221;&#160;&#160;Why did Amicus enter this agreement? Why does the Board of Directors believe it is in the best interest of the Company and Amicus
                                                      stockholders?&#160;&#160;We entered this agreement because it meets our two primary obligations: to the rare disease community, it will accelerate the ability to bring our products to more patients faster than we
                                                      could alone; to stockholders, it delivers compelling, certain, premium value to them.&#160;&#160;Can Amicus stockholders continue to buy / sell Amicus&#8217; stock prior to the transaction closing?&#160;&#160;Until the closing
                                                      of the transaction, Amicus&#8217; stock will continue to trade on the public NASDAQ market just as it does today, and Amicus stockholders can continue to buy / sell the Company&#8217;s stock.&#160;&#160;When / how will
                                                      stockholders receive the $14.50 per share in cash?&#160;&#160;All Amicus stockholders, at the time of the closing, will receive $14.50 per share. Funds will automatically be distributed through usual brokerage
                                                      accounts or other accounts where shares are held.&#160;&#160;Will the $14.50 per share in cash be taxable to stockholders?&#160;&#160;The per share cash payment is taxable, although stockholders should consult their own
                                                      financial advisor as it relates to their specific tax considerations. &#160;&#160;The transaction is subject to approval by Amicus stockholders. How do stockholders vote on the transaction? Is there anything for
                                                      stockholders to do now?&#160;&#160;Amicus stockholders do not need to take any action at this time. In the coming months, we will schedule a Special Meeting of Stockholders to vote on the transaction. Well in
                                                      advance of that meeting, stockholders as of the record date will receive information about how to vote on the transaction. &#160;&#160;Bradley L. Campbell, &#160;&#160;President and CEO of Amicus &#160;&#160;All-cash transaction of
                                                      $14.50 per Amicus share, reflecting a total equity value of ~$4.8B&#160;&#160;33% premium to Amicus&#8217; last close on stock price on Dec. 18, 2025 &#160;&#160;46% premium to 30-day VWAP and 58% premium to 60-day VWAP as of
                                                      Dec. 18, 2025 &#160;&#160;Clear path to close&#160;&#160;Expected to close in 2Q 2026 &#160;&#160;Unanimously approved by boards of both companies&#160;&#160;Subject to regulatory clearances, approval by Amicus stockholders and other
                                                      customary closing conditions &#160;&#160;This transaction is not subject to financing conditions&#160;</font></div>
                                                </div>
                                              </div>
                                              <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
                                              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
                                                <div class="BRPFPageBreak" style="page-break-after: always;">
                                                  <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
                                              </div>
                                              <div style="text-align: center;" class="slide">
                                                <div style="position: relative; left: 0px; top: 0px;" class="frame">
                                                  <div style="left: 0px; top: 0px;"><img src="ef20061157_ex99-7slide2.jpg"></div>
                                                </div>
                                                <div class="slideText">
                                                  <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Important Information and Where to Find
                                                      It&#160;&#160;In connection with the proposed acquisition of Amicus by Parent (the &#8220;Transaction&#8221;), Amicus intends to file with the SEC a proxy statement (the &#8220;Proxy Statement&#8221;), the definitive version of which
                                                      will be sent or provided to Amicus stockholders. Amicus may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the Proxy Statement or any
                                                      other document which Amicus may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS
                                                      WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS.
                                                      Investors and security holders may obtain free copies of the Proxy Statement (when it is available) and other documents that are filed or will be filed with the SEC by Amicus through the website
                                                      maintained by the SEC at www.sec.gov, Amicus&#8217;s website at https://ir.amicusrx.com/financial-information/sec-filings or by contacting the Amicus investor relations department at the following:&#160;&#160;&#160;&#160;&#160;Andrew
                                                      Faughnan &#160;&#160;(609) 662-3809 &#160;&#160;afaughnan@amicusrx.com&#160;&#160;&#160;&#160;&#160;No Offer or Solicitation&#160;&#160;This communication is for information purposes only and is not intended to and does not constitute, or form part of, an
                                                      offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in
                                                      any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
                                                      &#160;&#160;Participants in the Solicitation&#160;&#160;Amicus and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction.
                                                      Information regarding Amicus&#8217;s directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in (i) Amicus&#8217; Annual Report on Form
                                                      10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on February 19, 2025, including the sections therein entitled &#8220;Directors, Executive Officers, and Corporate Governance,&#8221;
                                                      &#8220;Executive Compensation&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221;, and (ii) Amicus&#8217;s proxy statement for its 2025 annual meeting of
                                                      stockholders, which was filed with the SEC on April 24, 2025, including the sections therein entitled &#8220;Proposal 1 &#8211; Election of Class Directors,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Compensation
                                                      and Equity Tables,&#8221; and &#8220;Share Ownership of Certain Beneficial Owners and Management,&#8221; and (iii) other documents subsequently filed with the SEC from time to time, including the Proxy Statement to be
                                                      filed by Amicus in connection with the proposed transaction and the special meeting of stockholders of Amicus. To the extent holdings of Amicus&#8217; securities by its directors or executive officers have
                                                      changed since the amounts set forth in the filings described in the foregoing, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of
                                                      Beneficial Ownership on Form 4 filed with the SEC. Amicus stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in
                                                      connection with the proposed transaction, including the interests of Amicus directors and executive officers in the transaction, which may be different than those of Amicus stockholders generally, by
                                                      reading the Proxy Statement and any other relevant documents that are filed or will be filed with the SEC relating to the transaction. These documents (when available) may be obtained free of charge
                                                      from the website maintained by the SEC at www.sec.gov and Amicus&#8217;s website at https://ir.amicusrx.com/financial-information/sec-filings. &#160;&#160;Forward Looking Statements&#160;&#160;&#160;&#160;&#160;This communication contains
                                                      certain&#160;&#8220;forward-looking statements&#8221; intended to qualify for the &#8220;safe harbor&#8221; from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited
                                                      to, statements about the anticipated timing of closing of the Transaction in the second quarter of the calendar year 2026; and the timing of the filing of the proxy statement for the Amicus&#8217; special
                                                      stockholder meeting in connection with the Transaction. Forward-looking statements include any statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221;, &#8220;goal,&#8221; &#8220;may&#8221;,
                                                      &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions. Forward-looking statements are subject to certain risks,
                                                      uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and
                                                      uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: consummating the
                                                      Transaction and financing in the anticipated timeframe, if at all; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement;
                                                      uncertainties as to the ability to obtain shareholder approval; the possibility that competing acquisition proposals will be made; the possibility that various closing conditions for the Transaction may
                                                      not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Transaction (or only grant approval subject to adverse
                                                      conditions or limitations); the effects of the Transaction on relationships with employees, customers, suppliers, other business partners or governmental entities, including the risk that the
                                                      Transaction adversely affects employee retention; the difficulty of predicting the timing or outcome of regulatory approvals or actions; the impact of competitive products and pricing; the risk that
                                                      Parent may not realize the potential benefits of the Transaction, including the possibility that the expected benefits from the proposed Transaction will not be realized or will not be realized within
                                                      the expected time period and that Parent and Amicus will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; the risks related to
                                                      disruption of management&#8217;s time from ongoing business operations as a result of the Transaction; risks that the Transaction disrupts current plans and operations; obtaining and maintaining adequate
                                                      coverage and reimbursement for Amicus&#8217; products; changes in Amicus&#8217; business during the period between announcement and closing of the Transaction; any legal proceedings and/or regulatory actions that
                                                      may be instituted related to the Transaction; other business effects, including the effects of industry, economic or political conditions outside of the companies&#8217; control; costs and expenses related to
                                                      the Transaction; actual or contingent liabilities; the effects of the Transaction (or the announcement thereof) on Amicus&#8217; and Parent&#8217;s stock price and/or operating results; and the other risks and
                                                      uncertainties discussed in Amicus&#8217;s periodic reports filed with the SEC, including Amicus&#8217; quarterly reports on Form 10-Q and annual reports on Form 10-K. These risks, as well as other risks associated
                                                      with the Transaction, are more fully discussed in the Proxy Statement to be filed with the SEC in connection with the Transaction. The list of factors presented in the foregoing is not complete and you
                                                      should not place undue reliance on these statements. Actual results could differ materially from those anticipated in these forward-looking statements. All forward-looking statements are based on
                                                      information currently available to Amicus and Parent, and, except as required by applicable law, Amicus and Parent disclaim any obligation to update the information contained in this communication as
                                                      new information becomes available. All forward-looking statements in this communication or made in connection therewith in writing or orally are qualified in their entirety by this cautionary
                                                      statement.&#160;&#160;&#160;&#160;</font></div>
                                                </div>
                                              </div>
                                              <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
                                              <br>
                                            </div>
                                            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                                              <div class="BRPFPageBreak" style="page-break-after: always;">
                                                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                                            </div>
                                          </div>
                                        </div>
                                      </div>
                                    </div>
                                    <font style="color: rgb(0, 0, 0);"> </font> </div>
                                </div>
                              </div>
                            </div>
                          </div>
                          <font style="color: rgb(0, 0, 0);"> </font> </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
              <font style="color: rgb(0, 0, 0);"> </font> </div>
          </div>
        </div>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
        <div style="text-align: right;"><font style="font-weight: bold;"><a name="Exhibit99.8"><!--Anchor--></a>Exhibit 99.8</font><br>
        </div>
        <div> <br>
        </div>
        <div>
          <div style="font-size: 9pt;">
            <div style="font-weight: bold;"><font style="font-size: 10pt;">Amicus Stockholder / Analyst Courtesy Email</font>
              <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; color: #000000; text-align: center;"></div>
          </div>
          <div><br>
          </div>
          <div><font style="font-weight: bold;">Subject: </font>BioMarin to Acquire Amicus Therapeutics for $4.8 Billion</div>
          <div><font style="font-weight: bold;">From: </font>Andrew Faughnan, Investor Relations</div>
          <div><font style="font-weight: bold;">To:</font> Amicus Therapeutics Top Stockholders and Analysts</div>
          <div><br>
          </div>
          <div>Good Morning,</div>
          <div><br>
          </div>
          <div>Today, we announced that Amicus has entered into a definitive agreement to be acquired by BioMarin Pharmaceutical for $14.50 per share in cash. You can read the press release HERE.</div>
          <div><br>
          </div>
          <div style="font-weight: bold;">Highlights of the transaction include:</div>
          <div><br>
          </div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Provides compelling, certain, premium value, including:</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 22.5pt; vertical-align: top;">-</td>
                <td style="width: auto; vertical-align: top;">
                  <div>33% premium to Amicus&#8217; last close on December 18, 2025.</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 22.5pt; vertical-align: top;">-</td>
                <td style="width: auto; vertical-align: top;">
                  <div>46% premium to Amicus&#8217; 30-day volume-weighted average stock price (VWAP) and a 58% premium to the 60-day volume-weighted average stock price as of the same date.</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Clear path to close</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 22.5pt; vertical-align: top;">-</td>
                <td style="width: auto; vertical-align: top;">
                  <div>The agreement has been unanimously approved by the Boards of Directors of both companies.</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 22.5pt; vertical-align: top;">-</td>
                <td style="width: auto; vertical-align: top;">
                  <div>The consummation of the transaction is expected to close in the second quarter of 2026, subject to customary closing conditions, including regulatory clearances and approval by Amicus stockholders.</div>
                </td>
              </tr>

          </table>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 22.5pt; vertical-align: top;">-</td>
                <td style="width: auto; vertical-align: top;">
                  <div>The transaction is not subject to financing conditions. BioMarin intends to finance the transaction through a combination of cash on hand and non-convertible debt financing.</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <div>With BioMarin&#8217;s unwavering commitment to patients, along with their greater resources and scale, Amicus&#8217; medicines will reach even more patients, faster, and accelerate progress for the rare disease community beyond what we can do on our
            own.</div>
          <div><br>
          </div>
          <div>Thank you for your continued support.</div>
          <div><br>
          </div>
          <div>Sincerely,</div>
          <div><br>
          </div>
          <div>Andrew Faughnan</div>
          <div>Vice President, Investor Relations</div>
          <div><br>
          </div>
          <div style="font-weight: bold;"><u>Important Information and Where to Find It</u></div>
          <div>&#160;</div>
          <div style="text-align: justify;">In connection with the<font style="color: rgb(0, 0, 0);"> proposed acquisition of Amicus by Parent (the &#8220;<u>Transaction</u>&#8221;)</font>, Amicus intends to file with the SEC a proxy statement (the &#8220;<u>Proxy Statement</u>&#8221;),


            the definitive version of which will be sent or provided to Amicus stockholders. Amicus may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the Proxy Statement or any other
            document which Amicus may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE
            DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy Statement (when it is
            available) and other documents that are filed or will be filed with the SEC by Amicus through the website maintained by the SEC at www.sec.gov, Amicus&#8217;s website at https://ir.amicusrx.com/financial-information/sec-filings or by contacting the
            Amicus investor relations department at the following:</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div>Andrew Faughnan</div>
          <div>(609) 662-3809</div>
          <div style="color: rgb(0, 0, 0);"><u>afaughnan@amicusrx.com</u></div>
          <div><br>
          </div>
          <div style="font-weight: bold;"><u>No Offer or Solicitation</u></div>
          <div>&#160;</div>
          <div style="text-align: justify;">This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise
            acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of
            securities in any jurisdiction in contravention of applicable law.</div>
          <div>&#160;</div>
          <div style="font-weight: bold;"><u>Participants in the Solicitation</u></div>
          <div>&#160;</div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">Amicus and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding
            Amicus&#8217;s directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in (i) Amicus&#8217; Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed
            with the SEC on <u>February 19, 2025</u>, including the sections therein entitled &#8220;Directors, Executive Officers, and Corporate Governance,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management and
            Related Stockholder Matters&#8221;, and (ii) Amicus&#8217;s proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on <u>April 24, 2025</u>, including the sections therein entitled &#8220;Proposal 1 &#8211; Election of Class
            Directors,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Compensation and Equity Tables,&#8221; and &#8220;Share Ownership of Certain Beneficial Owners and Management,&#8221; and (iii) other documents subsequently filed with the SEC from time to time, including the
            Proxy Statement to be filed by Amicus in connection with the proposed transaction and the special meeting of stockholders of Amicus. To the extent holdings of Amicus&#8217; securities by its directors or executive officers have changed since the
            amounts set forth in the filings described in the foregoing, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. Amicus
            stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed transaction, including the interests of Amicus directors and executive
            officers in the transaction, which may be different than those of Amicus stockholders generally, by reading the Proxy Statement and any other relevant documents that are filed or will be filed with the SEC relating to the transaction. These
            documents (when available) may be obtained free of charge from the website maintained by the SEC at <u>www.sec.gov</u> and Amicus&#8217;s website at https://ir.amicusrx.com/financial-information/sec-filings.</div>
          <div>&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="font-weight: bold;"><u>Forward Looking Statements</u></div>
          <div><br>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">This communication contains certain &#8220;forward-looking statements&#8221; intended to qualify for the &#8220;safe harbor&#8221; from liability established by the Private Securities Litigation Reform
              Act of 1995, as amended, including, but not limited to, statements about the anticipated timing of closing of the Transaction</font> in the second quarter of the calendar year 2026; and the timing of the filing of the proxy statement for the
            Amicus&#8217; special stockholder meeting in connection with the Transaction<font style="color: rgb(0, 0, 0);">. Forward-looking statements include any statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend&#8221;, &#8220;goal,&#8221;
              &#8220;may&#8221;, &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions. Forward-looking statements are subject to certain risks, uncertainties, or other factors that
              are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results
              to differ from expectations contemplated by forward-looking statements include, among other things: </font>consummating the Transaction and financing in the anticipated timeframe, if at all<font style="color: rgb(0, 0, 0);">; the occurrence
              of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; uncertainties as to the ability to obtain shareholder approval; the possibility that competing </font>acquisition proposals<font style="color: rgb(0, 0, 0);"> will be made; the possibility that various closing conditions for the Transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the
              consummation of the Transaction </font>(or only grant approval subject to adverse conditions or limitations)<font style="color: rgb(0, 0, 0);">; the effects of the Transaction on relationships with employees, customers, suppliers, other
              business partners or governmental entities</font>, including the risk that the Transaction adversely affects employee retention<font style="color: rgb(0, 0, 0);">; the difficulty of predicting the timing or outcome of regulatory approvals or
              actions; the impact of competitive products and pricing; the risk that Parent may not realize the potential benefits of the Transaction, </font>including the possibility that the expected benefits from the proposed Transaction will not be
            realized or will not be realized within the expected time period and that Parent and Amicus will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected<font style="color: rgb(0, 0, 0);">; the risks related to disruption of management&#8217;s time from ongoing business operations as a result of the Transaction;</font> risks that the Transaction disrupts current plans and operations;<font style="color: rgb(0, 0, 0);">&#160;</font>obtaining

            and maintaining adequate coverage and reimbursement for Amicus&#8217; products;<font style="color: rgb(0, 0, 0);">&#160;</font>changes in Amicus&#8217; business during the period between announcement and closing of the Transaction; any legal proceedings and/or
            regulatory actions that may be instituted related to the Transaction; <font style="color: rgb(0, 0, 0);">other business effects, including the effects of industry, economic or political conditions outside of the companies&#8217; control; costs and
              expenses related to the Transaction; actual or contingent liabilities; </font>the effects of the Transaction (or the announcement thereof) on Amicus&#8217; and Parent&#8217;s stock price and/or operating results; <font style="color: rgb(0, 0, 0);">and
              the other risks and uncertainties discussed in Amicus&#8217;s periodic reports filed with the SEC, including Amicus&#8217; quarterly reports on Form 10-Q and annual reports on Form 10-K. </font>These risks, as well as other risks associated with the
            Transaction, are more fully discussed in the Proxy Statement to be filed with the SEC in connection with the Transaction. The list of factors presented in the foregoing is not complete and<font style="color: rgb(0, 0, 0);"> you should not place
              undue reliance on these statements. Actual results could differ materially from those anticipated in these forward-looking statements. All forward-looking statements are based on information currently available to Amicus and Parent, and,
              except as required by applicable law, Amicus and Parent disclaim any obligation to update the information contained in this communication as new information becomes available.</font>&#160;<font style="color: rgb(0, 0, 0);">All forward-looking
              statements in this communication or made in connection therewith in writing or orally are qualified in their entirety by this cautionary statement.</font></div>
          <div><br>
          </div>
          <div><br>
          </div>
        </div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ef20061157_ex99-7slide1.jpg
<TEXT>
begin 644 ef20061157_ex99-7slide1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0@ S # 2(  A$! Q$!_\0
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M>_#?QT/&&DD3L!J$ 'F=O,4]' _0^]? MSIU]X7UZ?3+AF2[@/FQ9[D<E?Q
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MS.L0/D3&>!7 .1][;\OU0XZ5)?:AX]O->T9KK^U)-7M8B^G;HCYJHH))08Y
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MHM/UI+QKF-FVLC+YTAW*"&W*%'7BL;X2_P#)2O#7_7]%_.M?K2E1G4BOAO\
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M;L8TL';$2H57\*D].MHM]5UMVT['(ZEI-]HMU]FU"RN+"XP&\FYB:-\'H<,
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M^O8C6\MVWLOM6OI;R7I;0[QOBAYGBJ36O[*CCWZ=]@^S13;47]WLW*=IP/\
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M!(Y)+=K,K V]0<1RAB6(W#DHH.#@] ;'PIL]*OO$[1:F;4R_9938I?,!;O=
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M4NNJTTYU?!.FZI;ZL-$UJ74+W38FN)()[+R5FB3AWB<2-NQP<,%)!SVQ3?\
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M^&?_  #_ - '_P G+C_XY1_PH#P%_P! '_R<N/\ XY7H5%']HXW_ )_2_P#
MG_F']CY;_P! U/\ \ C_ )'GW_"@? 7_ $ O_)RX_P#CE'_"@O ?_0"_\G+C
M_P".5Z#12_M#&?\ /Z7_ ($_\P_L?+?^@:'_ (!'_(\__P"%!^ _^@%_Y.3_
M /QRC_A0G@3_ * 7_DY/_P#'*] HH_M#&?\ /Z7_ ($_\Q_V/EO_ $#0_P#
M(_Y'G_\ PH3P)_T O_)R?_XY2_\ "A? G_0"_P#)N?\ ^.5W]%']H8S_ )_2
M_P# G_F']CY;_P! T/\ P"/^1P'_  H7P)_T O\ R;G_ /CE+_PH?P+_ - /
M_P FY_\ XNN^HI?VAC/^?TO_  )_YA_9&6_] T/_  "/^1P/_"A_ O\ T __
M ";G_P#BZ/\ A1'@;_H!_P#DW/\ _%UWU%'U_%_\_I?^!/\ S#^R,N_Z!H?^
M 1_R."_X43X&_P"@'_Y-S_\ Q=+_ ,**\#_] 3_R;G_^+KO**/K^+_Y_2_\
M G_F/^R,N_Z!H?\ @$?\C@_^%%^!_P#H"?\ DW/_ /%T?\*+\#_] 3_R;G_^
M+KO**7U[%_\ /V7_ ($_\P_LG+O^@:'_ (!'_(X/_A1?@C_H"?\ DW/_ /%T
MO_"C?!'_ $!/_)N?_P"+KNZ*/KV+_P"?LO\ P)_YA_9.7?\ 0/#_ , C_D<)
M_P *-\$?] 3_ ,FY_P#XNE_X4=X)_P"@+_Y-S_\ Q==U11]>Q7_/V7_@3_S#
M^R<N_P"@>'_@,?\ (X7_ (4?X)_Z O\ Y-3_ /Q='_"C_!/_ $!?_)J?_P"+
MKNJ*7U[%?\_9?>_\Q_V3E_\ T#P_\!C_ )'#?\*1\%?] 7_R:G_^+H_X4CX*
M_P"@+_Y-3_\ Q==S11]=Q7_/V7WL/[*R_P#Z!X?^ Q_R.'_X4EX+_P"@-_Y-
M3_\ Q='_  I+P7_T!O\ R:G_ /BZ[BBCZ[BO^?LOO8?V5E__ $#P_P# 8_Y'
M#_\ "D_!?_0&_P#)J;_XNC_A2?@O_H#?^34W_P 77<44OKF)_P"?LOO8_P"R
MLO\ ^@>'_@,?\CB/^%*^#/\ H#?^34W_ ,72_P#"EO!O_0&_\FIO_BZ[:BCZ
MYB?^?LOO8?V5E_\ T#P_\!C_ )'$_P#"E_!O_0'_ /)J;_XNC_A2_@W_ * _
M_DU-_P#%UVU%'US$_P#/R7WL/[+P'_0/#_P&/^1Q7_"F/!W_ $!__)J;_P"+
MH_X4SX._Z __ )-3?_%UVM%+ZYB?^?DOO8?V7@/^@>'_ (#'_(XO_A3/@[_H
M#_\ DU-_\71_PIKP=_T!_P#R9F_^+KM**/K>(_Y^2^]C_LO ?\^(?^ Q_P C
MB_\ A3?@_P#Z!'_DS-_\72_\*;\'_P#0(_\ )F;_ .+KLZ*/K>(_Y^2^]A_9
M> _Y\0_\!C_D<9_PIWPA_P! C_R9F_\ BZ7_ (4[X0_Z!'_DS-_\77944OK6
M(_Y^/[V']F8#_GQ#_P !7^1QO_"G_"/_ $"/_)F;_P"+H_X4_P"$?^@3_P"3
M,W_Q==E11]:Q'_/Q_>P_LS _\^(?^ K_ ".._P"%/^$?^@3_ .3,W_Q='_"H
M/"/_ $"?_)F;_P"+KL:*/K5?_GX_O8_[,P/_ #XA_P" K_(X[_A4/A+_ *!/
M_DS-_P#%TO\ PJ/PE_T"?_)F;_XNNPHH^M5_^?C^]A_9N!_Y\0_\!7^1Q_\
MPJ/PG_T"?_)F;_XNE_X5'X3_ .@5_P"3,W_Q==?12^LU_P"=_>P_LW _\^(?
M^ K_ ".0_P"%2>$_^@5_Y,R__%TO_"I?"G_0*_\ )B7_ .+KKJ*/K-?^=_>P
M_LW _P#/B'_@*_R.1_X5+X4_Z!7_ ),2_P#Q='_"I_"G_0*_\F)?_BZZZBCZ
MQ6_G?WL?]FX+_GQ#_P !7^1R7_"I_"O_ $"__)B7_P"+H_X51X5_Z!?_ ),2
M_P#Q==;12^L5OYW][#^SL%_SXC_X"O\ (Y/_ (53X6_Z!?\ Y,2__%4?\*I\
M+?\ 0+_\F)?_ (JNLHH^L5OYW][#^SL%_P ^(_\ @*_R.3/PI\+'KI?_ ),2
M_P#Q51O\(?"4GWM)S_V\S?\ Q==A12]O5>\G]Y2P&$CM1C_X"O\ (XW_ (4_
MX1_Z!'_DS-_\74B_"7PHG32L?]O$O_Q===16;G)[LZ(T*4?A@E\D<J/A;X8'
M_,,_\F)?_BJANOA%X2O$"3:3O4$,!]IF'(^CUV%%1:^YLO=V.-3X/^$8_NZ3
MC_MZF_\ BZF7X4^%EZ:7C_MXE_\ BZZRBIY(]C13DMF<Q'\-/#<?"Z=C_MO+
M_P#%5(/AYX?'2P_\CR?_ !5='14^SA_*ON*]M4_F?WG/_P#" Z#T^P_^1I/_
M (JE'@/0A_RX_P#D:3_XJM^BE[&G_*ON*^L5OYW][,+_ (0?1/\ GR_\C2?_
M !5._P"$+T;_ )\__(K_ /Q5;=%'L:?\J^X/K%;^=_>S%_X0S1_^?/\ \BO_
M /%5!>> -!U"%H;BQ,D;<%?/D'\FKH:*7L:3T<5]PUB*RU4W][//?^% ^ O^
M@#_Y.7'_ ,<H_P"&?_ 7_0!_\G+C_P".5Z%16/U+"_\ /J/W+_(W_M#&?\_I
M?^!/_,\]_P"&?_ 7_0!_\G+C_P".4A^ /@%02="P/^ORX_\ CE>AU6ED\PX'
M2A8'"O\ Y=1^Y?Y"_M#&?\_I?^!/_,\_/P)\!YXT 8_Z_+C_ ..4G_"B/ G_
M $ !_P"!EQ_\<KO:*T^H83_GU'_P%?Y"_M#&?\_I?^!/_,X'_A0_@3_H #_P
M,N/_ (Y2'X"^ FZZ /\ P,N/_CE=_11]1PG_ #ZC_P" H/[0QG_/Z7_@3_S/
M/_\ A0?@$_\ ,OC_ ,#+C_XY4<GP"\ KC_BGEQ_U^7'_ ,<KT2D8;E(H^HX3
M_GU'_P !7^0O[0QG_/Z7_@3_ ,SSV']G[X>3':_AX ]O]-N/_CE2_P##-OPY
MW _\([R#G_C^N?\ XY7;5?MIO-7!^\.M*6 PNZI1^Y?Y LPQG6M+_P "?^9-
M11172<84444 %%%% !1110 44,P522< =2:P=4\76MCE80;F3_9.%'X_X4-V
MW!*YO45\_P#Q3_::TGX<V[/JVIQV;D?);P+ND;V'4U\O>*O^"A]U!JC1V^A2
MR6R\B2\NG4D$\<!2!GZU@ZT$[&RHR>I^D-%?G]X2_P""A6F;HUU?1Y+=G.%^
MS3%^?3Y@N#['FOI/X<?M(^$OB%,EOINK[+QDW_9;C,;XZ9 ;&1GN*<:T);,4
MJ4H[H]NHJA:ZAYD8)(?WJY',L@X-:W1G9CZ***8@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIR1T8>M<3\(/@U?_  SOM$\Z]L[NUT_PQ;Z*QMU=,S)/)*Q1#G;$ X"C<2
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M"74HM//C;P[_ &A+8?VI':?VM;^:]GL,GVA4WY,6P%O, VX!.<5\D?&3X?\
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M^8\<U#J7QD\ Z/X?L->O_''ANQT/4$,MGJ=SJ]O';7*!E4M'*7"N,LHR">6
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MH^*FNQNFTV2MSCCDKD_IC\*]ZG*V7NFMS/#P<L=&HUIW/9--LE)0GDL,=/\
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MQX^&C>;CXB>%#Y4\-K)C6[;Y)I@S0QGY^'D",57JP4XS@T?!_P #R>!?!/\
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M7U%>4?#']G74O!O@77M%U?PUINL7LF@QZ#%/<>.]8NHM2A4%2K)/"W]G*?O
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M.>%.*V?$'Q"T;0=+>[6\MM0E^R+?Q6EO?6T<LUN75/-0S2HFS+K\Y8+R!G)
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MQMU^T1X+TWX@6/@S4]4M-)UZ_GN(+."[U&SS.T1B4 *L[,#(9<(C*')C?*C
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MSP)INLR:GHL6D:KJ-PCSM'XOU+Q(9U2,(C-/?1I(A RNQ01@#GL#4-#!T?\
M:[^'6M1^&=3C\1Z+9^&-9TV\O9=9O]8MH8[&:"2T06TQW%%D;[8#@N"-H&#N
MX] UKXN^!?#>M:9H^K^-/#NE:OJB1R6&GWNJP0W%VLC;8VBC9PSAF! *@Y(P
M*\X^'/P5U_2=3\ R^);/09(?".C:IHL#VMS)=/,)VLQ%< 20)Y3-'!.KH"VT
M. &<,V/._%_[+WQ$UCX;Z!X.M]1TVZL+/PE8Z#Y?_"3ZGIEK8W42,L\WV:VC
MVWZ2#RP%N"H01_=(9@5=CT/I+3OB;X/UCQ-)X;L/%>AWOB*-9'?2+?489+M5
MC<QR$PAMX"NK*3CAE(/(K$\1?&"/PQXTL-"O/"OB :?>7T.F)XB6.V%A]JE3
M<D85IQ.XY +QPL@)(+#:^WE?#GP)O=#E\*S[=)2YTWQOK'BB\FA#!I8;M-02
M, [ 6E"W5NK9P,1D!CM7,'CCX1^)?%OQ2M=9MM!\&Z2UMJ%I/!XZM)98_$$5
MG$R/)9&(08D67$L1)N0GES$F)BNUGJ&AZ-\3OB1IGPI\(W6OZI#=7D</RQ6.
MGHKW-T^"WEQ*S*"=JLQRP"JC,2 I(Y;Q=^T%8>%RS6OA7Q)XDAM=)BUO4YM'
MBMF73+20.4>82SQL[$1RMY<(E?$9^7E=V)\0/A?K/QYT235UU?7OA_J]K;ZM
MI6G6<#VLD-U#*WE)/<1W%I*T9D2-2-@61$E9=V6(K)D^#?Q%\)PZI;^&]1T7
MQ WB'P]9Z+J.I^(KM[:>QF@26,7$<=O:F.Y4K,?W9\CF(?/\Y*K4-#K=!_:.
MT7Q%KFEPVNA:X/#>KW\FEZ9XN9+8Z9>W*!\HFV<S@%HI%5WA5&9?E8[E+=E>
M?%#P;IOBBW\-7?BW0K7Q'<2^1#I$VI0I=R2;%?8L);>6V.C8 SAU/0BO%_A?
M^S_XR^'_ (=\$?#MKC1)/ /@_4_[0M=:6[E;5+Z-'DDA@DM3 (XB'E&Z59GW
M"/A%W_(W4/AKXR\5>/\ XG:?:Z1HUEX;UGQ1I5Y/K6HF:.\$=K9Z=(&MXQ$4
MN 7B=%8RQB)PY^<@K1J%D>D>)/VCOAGX8M/$[S^.?#UU?>&[:>YU+2[75[5[
MR 1':Z-$9 5;>53#8^9E!P35[3_C5X0U+3XM6@US33X;DTMM6/B#^U+/["D*
MR>6VYA-N&UL@OM\L$$%]W%>(>)OV:?'_ (R\875YJNJ64]OYFLF/5+CQ+J5P
M9(KNUN8+=$TMD%K:^4L\:EHRS.$)W LP;>^(WP'\8_$[3-(NKTZ7I.JV&G6D
M3Z?I^O7D44TUO?17 C%Y%!%-&CI%_K40-&Y!"OMY+L+(]9OOC3\/=+\/V.O7
MOCOPS::'?1M-::G/K%NEM<1JZHSQRE]KJ'=%)!(!91U(JC+\>_ =O\0KKP9<
M>)]*M=;M],35V2?4+= T#"1B0#)N)6.,R-\N C*V<&N.\ ? :70_$GA/6+W1
M=-T\:;9:TEU:/KUYKTGVJ]EM")DN[R)9'W1P2ARP4CS-HW DUCZ'\"?%/AGP
MOI.AMI/ASQ-I[^!+3PIJEI<ZS<Z>OFVZRX\IX[61C&YE(W_(Z;0P#'@&H:'L
M7A_XI>"_%GAN_P#$.B>+]!UG0-/W_;-5T_4X9[6VV('?S)48JFU"&.2, @GB
ML^T^.?PWU#P[/X@M?B#X5N=!@F-M+JD.M6S6L<H0N8VE#[0VP%MI.<#/2N5\
M)>!_B=;?"WQAHVI^)(+#7KQ9HO#TBW[ZHVD1F!4B5KQ[:"2X*N&8/+&T@S\T
MDIYK@O O[-/BBQ\=P^(=;ATR"W75-,OOL4_B?4O$4RBU@ODW?:;Z,.6\RZB9
M5 55VMCD98NPLCW72?BMX)U[Q-)X<TSQAH&H^(8X1</I-IJ<$MVL156#F)6+
MA=KH<XQA@>XJ])XY\-QZ?!?OX@TM+&XL9-4ANFO8Q%)9QA#)<*V[!B421DN/
ME =<GD5X[H?P6\76NN:%I-W!X;C\*:'XFO/$MOK5M<SG4[IIVN'$36_DJD39
MNF5Y1.^]8\;!YA"\S#^SS\1=0\%P^%]3E\+PV>D> ]7\&:==6MY<R/>/<):I
M!<S(T $(VVWSQJ9=I/#/G +L+(]Q_P"%U?#W^P]4UK_A//#/]C:7<BSO]1_M
MBW^SVDY( BEDW[8WR0-K$')'%8VF_'KP_)\(]>^(VHRV]EX=TFXU)#<17D<B
M7$5K=2P))'(Q5"9O*4J,XS(J[CU/$>-?@-XBA^*^B^./!]KX===%M-,@MM$O
MKB2R@G^SQ:E"P,D4$GE!$OXS&0C_ .K9<*"&KI_"OPAU73/@1XF\%7LVEVVI
MZRVM.&TY7%I ;ZXN)4500&P@G /'\)Q3U#073_VG/ FH>)8[ ^)M M=*O-.L
M+S2]7EUF 1:A+<S7<7V>+G:[J;0\*S$EB,#;SU\GC_PQ%XOC\)OXCTE/%,D7
MVA-#:^B%ZT>"=X@W;RN 3G&.#7D6O_!#Q'XXTCQS/K-CX=LM<U_P)%X4MTAN
MY+N.WF1KTL3,UO&WE-Y]NQPF<H?E.U26:3^S_J6E_&B\\17=G'K>CW6K)K45
MY+XOU.V>QF6U2$*-,1#:SX,9Q(S(=LF"#L&ZU=$NQ[3J'BS1-)^U&^UG3[(6
MCPQW'VBZ2/R6F8+"KY/REV(50?O$@#-9?BCXJ>"O!-M)<^(O&&@Z!;QW/V)Y
MM4U."V1;CRQ)Y)+L 'V$/MZ[2#C%<%\5_@7>_$+QL+RVNK.WT'4]-^QZW%*7
M$\DD F:P>(*,?))<R.Q)!_=QXSVP])^#_COPCJ&C^++"S\*^(/&$L>J+K-GJ
M5_/:VOF7L\4N^"X6VE<B-;>*':T0WH 2RE<-5V+0]4\6?%7POX1@"7?B#2$U
M.>U:YL=-FU"**:^^1V01*3N;=Y;X*@_=/7!KF->_:(\-:'H_AH2:AI)\4ZX=
M):+PR^JQ)>B*]N(8?-6/&]UC\UFR$ ;RR,KU&)X%_9_OO!MB]NUQIMU*O@N'
MPW#<(C1E)A)<22!5(8I!F6,!0Q($8&/E%<M'\!?&FBV,^EE/#=_HDNLZ'XBG
MU.6:XDOX)+!;)9+>*!8"'RMDVR3S 0)-OE]ZEMC5CV_QUXVUWPOJ>GV.A^$;
MGQ)]HB+RSI,T,<+F:&-$+>6PRPDE<G("K"<XW+GMZP?">O:EKOA?2]1U72#H
M.I75LDT^F/-YS6K,,F-G  ++G!P.H-:GG/Z_I19BN6J*K>>_KG\*<MP>X_*C
ME87)Z*:LBOT//I3J0R.?_5FJU69_]6:K5<=B67:***S*"BBB@ KYA_:8L3_P
MM+0KG'$FF",'_=E<_P#L]?3U>+?M(:"UU'X<U55RMM-);N?^N@5E_P#19_.O
M/Q\>;#R.O"NU97/A3XWY3Q-@=-E>57<Q"$9[5ZY\=(?^*H(_V:\CU&/:N<=J
M^.II/4^CDM#N_@'^_P#&EH6_A<?SK[N\<Z/#'H5K?0Q+'*K+O=1R0>.?S%?"
MG[.T9;QE!G^^O\Z_0KQ#"MSX0NXV[VYQ[''6O7]C&KAJD7V,*-:6'Q5*47UU
M^\\.\=:E+H=A:2A#,K,0(U/+L.@]^_'?%>>S>%M8^*^GRW=@MU=P0S%)8W@*
MRQR*>4VM\PZ'&5YX]J[KQ;)_:-GI<=S(L @NHY7)/7 ."!GG/^-:^IC3YHSJ
M<*M%<C#B2)O+;<!U!!!Z$]/4U\51E&*39^FRYJDG%R_K[T>#:U\!_&.L3VMS
MJ-H?/MRQ\SRRH4@X(R^T=2.?K61X:\3W.FZ\8;;[7-:PW:6GFRK\CR9PP0@D
M,.O3BO4-=\56'B8_9Y[N^NRKD[;BYDD4$MU"N2!D@=JYC6MFE6^ERV:*8H+E
M<(0<$N<#MV)!_"O3<N=<KU..</9KG4ONO^K.WBTU=:\06MK)S%-<I"V#CY<_
M-^E?4^DZ/9^'M)@L;")8K:-.%'\Z^7? >H0W7CS3+9R/*A#L7]9,<_D,U]+:
M?.9X_E;<H& :];+8\L.:Q\GGF(<JRI7TM<L^=R0:S[I0'(Q4UT?)YJO++N :
MO?4CY9F=>'Y<5Z'\+XS'X=E)_CN68?\ ?*C^E>=7C;N:]9\%69L?#-BC#YF4
MR'_@1)'Z$5MAU>=R*[M"QMT445Z)YX4444 %%%% !7->-/B;X/\ AO%:2>+O
M%>A^%H[MF2W?6M1ALQ,RX+!#(R[B,C./45TM>0?'3P#XR\5:CI6I>!(;'3?$
M5G:SV]OXDF\0SV,MCYI3<IM!9W$%Y&=@)2<#!&4*-AU 1UEO\9O VI:KJ^CZ
M5XNT'6O$&E0S37>BZ?JUJ]Y$(N) \9D&S!PI+[0I(R16'XP_:#\+>%;;0[<Z
MGI4OB75I=,$'AN75K=;[R;RZA@\X(C/O5!*S93<C>60&Q\U>6M^SO\1=7\?V
MVKZ[JMAJ0M+C5)?[4E\2:G(+E+FVN(8$CTMD^RV8C$R*3&SLP0G=DMNGM?V>
M?'%C"VAJ/"]YHMSK>@Z_-JUU<SF]@DL%L5DMXX?(*L"+-MDIE4@2;3'_ !5-
MV79'I/Q.^/EE\+]6OK.X\+>(-;MM-TM=8U/4-+^Q^18VK/(F]Q-<QR.?W3G;
M$CM@< D@5U>H?%#P;I.K7&EW_BS0['5+:WDO)[&ZU&&*>&!$$DDKQLP945&5
MBQ& K G@UX]\??V?]6^)WC:]U6S\)^"_$*W>@+I%KJ7B2ZDBO-$N!).WVJU"
M6LI+#S48;986W1#YAPPZNS^$OB/1]*^)9TS7+>V\2>(K:WAT_7F0M<+)%81V
MZR3?+U$JR.,%@-^>I(HU%H=-:_'+X<7WA6\\3V_Q \+7'ANSF6WN=8BUJV:S
M@E;&V-Y@^Q6.Y<*3D[AZUR_@W]H_1/$\UW<79T_1_#]O;ZE=MKDVIH;7R;74
M'LQ*9"JJ$<()-V[ #8Y^]7EGA_\ 9O\ B'X?\;1^-;>WT.34K.]LKFWT/5O&
M6K:O'.(K:^MY#)J%U;O*C#[:'0+"5&UEP-Q<RZA^RAXJU#PZD#7NDV]W#<W&
MH+9Z7J%WIT,DCZV=16 3PH)84V'9YJ99' 8*P&"78[(^C=%^(7A;Q'9Q7>D^
M)='U2UEM&OXY[*_BF1[8,4,P96(,8964OTR",\5'JGC[2M-F\)HCM?P^)[S[
M'I]U9%)(6)M9KD2%MW*&.!L,N[)9>,$D?/WBGX$ZM9>'?!MCI.C?V+K6K:E>
M:1KHM]<U#7HQIEZ#)>R/>W,:R;B+:(JTBJ [;5.7Y]?^+7A/Q'JC>"-0\(66
MD7M]X<UG^T#8ZO?RV,$L1LKJV*K+'!.5(-PK >600I&13)T/1&98U+,0JJ,E
MB< "O./"_P <M.\31OJ1T#6M(\'M;2WEKXOU-;:+3+F",%C*")C+%&4#.LD\
M<:LHR"=RYZK1_P"W=8TR[M_$NEZ;IC2Q+&$TS4I+P-NB'F@L\$)&'+JIP=R@
M,=I.T>5>&_ OQ;T'X:?\(!:WGAG2[72]%DTK2_%=K=W$M[,4B,5J[VA@5+=@
M-C.PFF&4("?,"@!WEG\<_AOJ'AV?Q!:_$'PM<Z#!,;>75(=:MGM8Y0AD,;2A
M]H8("VTG.!GI5S3_ (M>!M7^W_8?&?A^]_L^Q34[S[/JD$GV:T=!(EQ)A_DB
M9"&#G"E2"#BO"O ?[-'BG3_B5IWBC6XM,@M;?5+&^:RF\3ZEXAG"V]EJ4.X7
M-]&'+>9>Q.J@(JA6(^89:MXI_9WUKPO\%=3M;*TT^YOK+POXNLWM=)B=Y;J3
M4)/.A2)!&"Y.P!AP=VW&[K2NQV1[%XB^/7A.Q\+WNM:%KFC>*(=/U>PTF_&G
M:K"ZV3W%Y%;,960ML*"4N5;&=A&1U&LOQF^'[>#V\6CQUX:/A59?(.N#5[?[
M"),XV>?OV;LD#&<YKR'Q%\#O''CBQU2ZO[+P?I-]Y&AV%CIUO+//9S6]AJ*W
M;/<9A0IN7<BP*KA,D>:V[*TO$_[/7C;QA>S>*KZ'2++Q!)X@75F\/Z+XHU'3
M;5XAI_V(%M3MH(Y_._CW"'!4>600=]%V%D>G>./C?;>$Y+AK.PBUJS70UUR&
M[@O (YT:>.)0I"L"I$@8."00.G.:[GQ9XDMO!OA76=?O8YI;/2[.:^F2W ,C
M)&A=@H) +84XR0,]Q7C&H_L^ZG-X;@TW2H--T2%/#"Z.MB^J7-\L$_VN.=@+
MB6/S)4 5AO<!B2/E';O=;M]8^*GPE\7Z8VEC0+[5+;4M,L8[Z1OFC/F0PSR#
M8&C$@VR;<$JK#.3Q3U%H8V@_M)^&;AYH_%EM=?#.9;*+4HE\875C!'<6LF_;
M*DT-Q+%QY;Y1G#@#)7!!KM-!^)?A#Q5KEYHNB^*M$UC6+.)9[G3[#489[B"-
M@"KO&C%E4AEP2,'</6O-=-_9GTCP_P#\(5/I\/VK4=+U.SOM3O=;U.[U*:5+
M>VGCC2&2Y:1E5)9MZ1@HBDLP )YROA9^S[J?@'QIJ%[J&FV^M012:G-I^KW7
MC+5)FD^USM*8WTN2-K6#(?:\D;-DH&V98@+4>AZ3I_QO\$^(9!%X:\2Z+XLE
MCOH+"ZCT76+.9K-Y694,H,PQRC?*,NVT[5;!K(N/VCO Z^.?[!M_$_A^[L[3
M3]0O=8U.+68#'I+6LMM&8K@ D1DFX;EV7;Y1&#GC@/"_P.^(4=C;Z3?7FGZ%
MX6T^_P!.GTK08=>N-:-@D+2&8Q7DUI#/@ADVQ2&4+MPKQH @Y#5OV4O'WB30
M_!-A?_\ ",V'_"$Z0FE6;Z1K%]:S:N(KJQF0S7$4*268<6;\1F4QNX<,^"*+
ML+(^EYOBIX*M_"MIXFE\7Z#%X;O-WV;6'U. 6<^U79MDQ;8V%CD)P> C'L:Q
M-!_:!^'_ (H^($7@[2?%>D:EK,^G1:G:K:ZC;RK=12;R/*"R%G(2/><+@(RM
MG!KE- ^!D\.D_#Z*?1]/TQ]$\43>(M1LYM?O->WNUK=1+(EU=Q++)+YDT,GS
MJH4JQ!) ROPK^$/B7X:?$&]U%8M%N=#U1M0%SY5W+%-:+)JE[>P>7%Y!64LM
MVJN"\>PJ2#)3U%H>B2_%;P3!XT'@^3QCH$?BUL :"VIP"_.4\P?N-WF?<^;[
MO3GI3O#?Q1\&>,;J]MM \7:%KES8PI<74.FZE#</;Q.NY'D",2JLO()P".17
MC?Q$^!?COQK\4H]5:_M;O0H=>TW5;6:X\3:E MI;6[0L]J-+B3[+*Y>.1Q/(
MQ;,F-HVJ5@D_99U*3X:>%O#$%SI&EW&G_#_4O"EW<VJ,5-U="S/F* BEXB]O
M,SYVL?,S@ECA78[(]0\"_&[PU\2O&&N:5X8U72O$&E:7IMG?MK6DZE%=P.\T
MMTC1$QY52@M@Q.XY\P<#&3S][^T=%_PA7B#Q58>"_$,_AZQTB\U;3=:NE@BL
M=62")I (RDKS1+($)62:%%88(W;E#3_#OX>>)U\:>*?$OB[3_#ND2:UHNGZ1
M]A\/7<MT%^S/=EG::2"$MN6Y4 ;!M"XYP">9A^%OQ.;X+:G\*KA/"?\ 8T7A
MJZT"RUY;ZY:YO0;9H+8RVOV<+;G!1I&66;[C!4^<%#4-#TV/XO>%M2\,ZMK6
MAZSIOB:'29!!>Q:1JEHYMYL@&*1WE2.-QGE7=3^.!4/B3XY>!/#-KXJ:?Q9H
M<U]X8LWO=5TV+4X/M5JB@$>9&7S&6)51OQDNH[UR'BWX%WNIW7C Z.NE:?:Z
MMX;TC1;2%0T0C>SN+J0[@J8";)XU7&?ND8  SR'AC]F76-#NO%-O<6MO?_:;
M;6DTOQ!<^,=5G8-?/(^U]+>,VT'$FUY(G))C#!06(4U#0[_3_CY$GP+T_P"(
M^H:7;:E'>O;QPZ?X0U6+5%E>>Y2WB2.XE%O&S;Y%#Y*JI##<<9/6Z#\1+>]L
M'E\0:=/X&ODAFNVTOQ!>V7V@6L6WS+D_9[B9!$"Z@MOXR,XR,\G\8OA3J?C[
MX#IX,M+;2-2OT.EE[35Y62QNEMKFWEEBD812$(ZPLO\ JV^\,C&:X'Q=^SQX
MD\:>$_#6EV'AWP7\-8?#5S-JMCI/AN[DFL[JZ#*T=K,19P;;28F3SU5"6PF,
MX-&H:'NNC_$3PIXB\17^@:5XGT;4]>T]!)>:79W\4MU;*<8:2)6+(#N7D@?>
M'K571?BWX&\2:U<:/I'C/P]JNK6]R;.:PLM5@FGBG D8Q-&KE@^(93M(SB-^
M/E./)/A)^SWJ_@GQ=>7>KVD=PJMJ4MEK\?C/5+J6-KR9I64:9+&+6(@/M,D;
MY8QAMJER%CT/X7_%'0_!'P_T>/2O!K7?P_NK9].9=;NDBUB-+.XLY#,/L6;1
MRDXD&W[0-P*GCYJ=V%D>EZM\>/ FB^.M \(W7B;2TUC6_M*V<?V^ !I895A:
M'!<,9#(60* 26BD'!4BM70_B=X>UC0;O59=2LM-AL<_;DNM0M7-F-S*IF>*5
MXT#;<CYNAYP<@>;>"_A/XV\)ZEX1U6== O[ZUU/7IM4ACO9X8H[?4;_[2'@)
M@<R/&H5?+8(&)/SC'//G]E_79+C0;?\ M6QM=+N8C!XF6"63S)U@O)KNP:W^
M0 LLDQ#[L?+@#.*6H:'NOA?X@>%_'$VI0^'/$FD>()=-F^SWT>EWT5RUK+DC
M9*$8[&^5N&P>#Z5ROB;XUKH^N:MI6A^#?$WC>;1@HU67P_':>78NT8D6)C<7
M$)ED,;*^R$2, RY +*#RO[-_P/U'X2HR:QIMN+VUTRWTF'5XO%^J:N;N&+//
MV6[0)9J3AA'$[@;BN< $Z4WA'XB^"?%WC&Y\&6GAC5]*\3WB:F9-<U&XM)M-
MN?L\5N^(XK>47,9$$<@7?"<EEW8(8/6PM#A]:_;I\%PMXEO-%U3PKJFBZ1IM
MK<13W?B:.SNKJZN-GE1?9VB)CB42)YDKL&0[AY3$5Z?#\>O"NCZ7%=^,/$'A
MKPK&T-JXOYO$5H^GW,D\32*MO,SH[KM4D,\4>\?,H(SCB/#_ .S;J?A/X?>(
M?"]EJEK>+=_V.+:[N"T9?[*(/.>10I"%FC<JJE@,@$BI/$GPC\=:3^T5=?%'
MPQ!X>UR.;2O[(&D:UJ<]CY:GRV:=98[:?#9A5=NSYE;[R[<%:CT/6_\ A8OA
M3_A+(/"__"3Z-_PDT\'VJ+1?[0B^V20X+>8L.[>4P"=P&, T_P ._$#POXPB
MOI-!\2:1K<=@0MV^G7T5P+<E=X$A1CL)7YN<<<UX]I_P!U2T^-M_XGO;&'6=
M)OM777([J3QEJENVGSBU2$(NF)&;6XVF,XD=D.Q\%?D&[I;'X*7"_LSO\,9+
MBQL;V;1)--DN+>(R6PF=6W.5PA=69B6S@MD]S3U%H+XT_:<\ >'_ (6ZWXUT
M7Q9X9\36.GR):JUIKUL+9KJ0@1PO.K,L>=P8\$A06"G&*ZB^^(UOX?\ A>GC
M'58[>YC^Q1W7V?P_=?;X[F20*(XK65EC$WF,RJC$(&++]T&O,;[X/>-_'$WB
M#6-?L_#'AW5KS3]-TJWL=%U"XNX&BMKS[2TLLSV\)SRRI&(SMY^<[R%[OXP_
M#O6_B8/#.G:?XAF\,Z79ZFNI7]Y8K"]XQA4M;I$L\,L1'G>6[%UX\H8ZY!J/
M0LV_QS\"KX'T'Q9JOB?2_#.D:U9I>6KZ]>PV3;6"95M[@!E+JK $X8@>E7;K
MXK>&6TG7KW2M7T_Q$^A3?9M1M=+U*U,EM-N"F*5I)42)Q_=D93P>_%>0^'/V
M:_$.AZY<QWVM6GB/1K6S\06^EWFJ[?MH;4S9RMYB10)$@$T=X/W8 "2( O+
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MZ_L[NR_M#7KJXTZ'Q/J6AQ[KV_>XMIVGLX_-F\J.1E:W8HC%R=YVJ:ZOX2?
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M_:Z/\'/%FK>(&USQ/%X?BN9_&MOXG>QL;F6YB@ABTI+145Y(4+RK+&&#;4&
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M$J3(X0*I8;;>(\$D#K? 7PFU?PM\7/$GBF[N;*33]2^U>3'"[F5?-EA==P*
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M1HLVG0ZCXR\/V$FHK ]DEUJD$9NA-N\DQ!G&\2;'V[<[MK8S@U9\5?$'PKX
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MPB=U,LA1V"1L(V968C*C/'->"^+_ -E[XB:Q\-] \'6^HZ;=6%GX2L=!\O\
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M;A5*SH5CD6<#R]JM$F%"NPLCW3Q5X^TCP7>:3'K%S;V%KJ$C1"^N[VVMX8F
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M<[X0^ ?BN+Q/X9UKQ/>Z/=7$ERNJ^)1922E;F^@\\67DAT **+A26.P@VL0
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MX^T+PE8)=:IJ.H:DNG37$=I<+9V[&VDN,?:O*,#R[44^2)-^U]V, USOP_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;?\ CO\ ]>C^Q?\ IM_X[_\ 7HYXAR2,RBM/^Q?^FW_CO_UZ/[%_Z;?^._\
MUZ.>(<DC,HK3_L7_ *;?^.__ %Z/[%_Z;?\ CO\ ]>CGB')(S**T_P"Q?^FW
M_CO_ ->C^Q?^FW_CO_UZ.>(<DC,HK3_L7_IM_P"._P#UZ/[%_P"FW_CO_P!>
MCGB')(S**T_[%_Z;?^.__7H_L7_IM_X[_P#7HYXAR2,RBM/^Q?\ IM_X[_\
M7H_L7_IM_P"._P#UZ.>(<DC,HK3_ +%_Z;?^._\ UZ/[%_Z;?^.__7HYXAR2
M,RBM/^Q?^FW_ ([_ /7H_L7_ *;?^.__ %Z.>(<DC,HK3_L7_IM_X[_]>C^Q
M?^FW_CO_ ->CGB')(S**T_[%_P"FW_CO_P!>C^Q?^FW_ ([_ /7HYXAR2,RB
MM/\ L7_IM_X[_P#7H_L7_IM_X[_]>CGB')(S**T_[%_Z;?\ CO\ ]>C^Q?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHI&R5('7% 'G5Q\:(9]0U.'0?"?B/Q98:9,UM>ZIH\5M]GBF0D2QJ)I
MXY)F3'S>2DG/RC+ J/0K>X6ZMXID#JDBAU$B,C $9Y5@"I]B 1WKQ;]D_4;+
M2?@=::3>2PV.J^')KNTUR":4![:Y6>1Y'E)Z;@?,W'@A@<D<UCZ7X?\ "OQ6
M^,_Q*7QU8Z7XDMM)M[$Z-;ZJL=Q;6^GRVXD>XA5R57?('W2@ _NU&< "O4J8
M>'M*D-E#KNWJEWMUOZ=S@A6ER0ENY=-K:-_I]Y]"T5\7Z#:GQ];_ +/=CXA:
M?5](N-:UVWMVN9G)OM/CAN/LWFMNS*CQ)'D,2)%X8,&.=,_"7PJ=/_:&L_[*
MC%CH,CRZ)9C_ %&CR-IR3F6SB^Y;R>:Y;?&%/ YP*U>7PB^64]?3^]R]_F9K
M&2DKQAIZ_P!WF['U[17RLUKHOC[XP?!RW\:30ZE'JG@.69K'4)1Y.IW):U?9
M+$?EG_CD",",H&QE01RNK7%_I_@_4/#6D1V=QX ?XEG1H;6\OY+6Q:Q\G>UH
MTZI)Y=N;L&':$*\F/ !I1R_FLN;7?;3=K1WU>GEZA+&<MWRZ>ODGVVU/J#XP
M_$3_ (5/\.=8\5_V?_:O]GK&WV3SO)\S?*B??VMC&_/0]*HZ=\4KO6/&'Q \
M.6&@_:;[PO:VL]N/M@3[?)/"\BQ\J!%RH7<2PYSQBOG7XI>"-3\#_"CXQ0/9
M>%_#.BW=MI=S%X5\-ZF]TEE/]H"//L:W@$*RJB#"K@F)CUS78ZA_R.7[3?\
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MW)\O1?:5^_\ D'UJ7-JDH^]U_E?H?5.L75W9:1?7%A9?VE?0P/);V?FB+SY
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M#&O>$;_6HI)-+;5UM9(KTQIO=%>VGF"N$^;:^TD XS@UZ-7DWAOX6ZWKFO\
MA/Q+XQ\266K_ -@0F72M/TC2FL(8YI(3&TLQ>>9I6",57!11DD@DC'SSH_AV
MW\._LO\ C#QEI=I&/%$VOW]I)K4TA2XLK%]6:*=(K@*SVT0C,C,4&%+.^"<U
MTK"T:[7LY6=TNMKMOO9VLE??4YWB*E)>_&^C?G9)=M-V?;]%>!?"?X=WW@OX
MK6]Y8:-X+\#Z%>Z&\<^A>&=8DN3J#)+&8;ORC:0+\@=T,HW%O-4$]*\1TOX>
MZ'+^R[IGBM+:2V\5KXM\F+7K>=TO[:-]::W:*&<'?#&8W<;(RJY9FQN8DJ.!
MA)VY]+Q6R>LK[ZVTMT;'+%RBK\G1O?M;R\^R/M_6+J[LM(OKBPLO[2OH8'DM
M[/S1%Y\@4E8]YX7<<#<>!G--T*[O=0T6PN=2L/[*U":WCDN;'SEF^SR%06C\
MQ>'VG(W#@XS7S;XR\,Z9X!^('Q(T?P[90Z-I&H?#>YO[JPLT$<,MTDLJ"=E
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M5K)+OZ^7EN<OKGQLT#0/BQHWP_N8;YM7U2(2)=QQ*;2%F69HXY7W95W%O,5
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M_,0=&WM;3Q%I?[-_AKQ##!>>$-2T5GN;"\PUM>7<5E"UM%*A^60#,KA&R"R
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MC$Q&4)4E3MQD''2F?\(WI'_$T_XE5E_Q-?\ D(?Z.G^F?((_WO'[SY %^;/
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MJ+Z;I9M+;^SH'+-;QQF:1P\@>56E:1R XVJN*]EMX([6".&%%CBC4(B*,!5
MP /PJ2BJJ5JE5)3>W^27Y)"A2A3NXK^OZ9S$GPM\&3>*1XF?PCH3^)!()?[8
M;383>;P-H;SMN_(  SGH*EU3X<^$]<\16OB#4?"^C:AKUKL^SZI=:?#)=0["
M2FR5E++M))&#P37145/M:F_,^V_0?LX=D4H=$TZVU:YU2&PM8M3NHTAGO4A4
M32HF=BNX&Y@NYL G W''6LEOAQX2;4-7OCX7T4WNL1&WU*Y.GP^9?1D %)FV
MYD4@#ALCBNCHJ5.2V93C%[HYK1_AGX/\/6DEKI7A30],MI()+5X;/3H8D:%S
MEXRJJ 48\E>A[UI+X8T:,:4%TFQ4:2,:<!;(/L7R&/\ <\?N_D)7Y<?*2.E:
M=%-U)RU;8E"*T2.)^(GPMT_Q[X<UG2$^SZ4->:"+6+J"U4SWMJC#?"S@J<M'
MNC#DDH'.!G%=1>Z'IVI:/+I-Y86UWI4L/V>2RN(5DA>/&-C(005QQ@C%7J*/
M:3:4;Z+_ ('^2#DC=NV_]?J-CC6*-410B*,*JC  '852TS0-+T73WL=/TVTL
M+)WDD:VM8%CC9G8L[%5 !+,22>Y))J_147>Q5D<_X3^'OA;P$MROAGPUH_AQ
M;DJ9UTFPBM1*5SMW>6HW8R<9Z9-3Q^"_#T>BKHZ:%IB:0LWVA;!;.,0"7S/-
M\P1[=N[S/GW8SNYZ\ULT5;J3D[MNY*A%*R1FWGAO2-1NY[J[TJRN;J>U:QEF
MFMT=Y+=CEH68C)C)))4\>U9VN?#?PEXFTFPTK6/"VBZMI=@%%G97VGPS0VV%
MVCRT92J87@8 XXKHZ*2J3C9I[ X1>Z,>3P;H$T @?0]->%;T:B(VM(RHN@VX
M3XQ_K0W._P"]GG-7$T>PCU:75$L;9=3FA6WDO%A43/$I+*A?&2H+,0"< L?6
MKE%+FD^H^5=BGI.CV&@Z?%8:98V^G6,.?+M;2)8HDR2QPJ@ 9))X[DU!<>&=
M'O->M-<GTFQFUJTC:&WU*2V1KF&-OO(DA&Y5.3D X.:TZ*.:5[W'RJUK'+WW
MPM\%ZGK5WK%YX0T&[U>[3R[C4)],@>>90 -KR%=S#"KP3_"/2MNUT33K'4KW
M4;>PM;?4+X(+J[BA59;C8"$\QP,MM!(&2< \5=HINI.2LV2HQ6J1S&E_"_P;
MH=Y-=Z=X2T*PNYKE;R6>UTV&.22==VV5F502XWOACR-[<\FI=4^'/A/7/$5K
MX@U'POHVH:]:[/L^J76GPR74.PDILE92R[221@\$UT5%5[6I>_,[^HO9PM:R
M*VI:;::SI]S8:A:PWUC<QM#/:W,8DBE1AAE96!# C@@\&LGQ%\/_  OXNTNU
MTS7?#>D:UIMH0UO9ZC817$,)"[041U(7"DC@=#BM^BHC*4=8NQ3BI;HR&\'Z
M"VCV.D-HFG'2K%HGM+$VD?D6[1$&(QQXVJ4(!7 &,#&*TKJUAO;:6WN(HY[>
M9#')%*H9'4C!4@\$$<8-2T4<S>['9+9%73]+LM)TVWTZRM(+/3[>)8(;2WB5
M(HHU&%14 P% &  ,8K.T?P/X<\.S6DNE:!I>F2V=NUG;/9V4<30P,^]HD*J-
MJ%P&*C@GGK6W11S2UUW%RKL8[^#]!DTFZTM]$TUM,NIFN+BR:TC,,TK/YC.Z
M8VLQ?YB2,D\]:L6?AW2M/BOXK73+.VBOY7GO$AMT07,C@!WD 'SLP !)R3CF
MM"BGSRVN'*NQSOAKX<^$_!=G>6OA_P +Z-H5K>X%U!INGPVZ3X! WJB@-P2.
M?4U%H?PO\&^&85AT?PEH6E1*966.QTV&%09%5)" JCEU55;U"@'I73T57M:C
MO>3U\R?9P5M%H<_X3^'OA;P$MROAGPUH_AQ;DJ9UTFPBM1*5SMW>6HW8R<9Z
M9-,\6?#?PCX]DMI/$WA;1?$;VP98&U;3H;HQ!L;@ID4[<X&<=<"NCHI>TGS<
M_,[]^H^2'+RVT,'7? /ACQ196-GK/AS2=7M+!E>TM[ZQBFCMV P#&K*0A X&
M,<5%XL^&_A+QY);2>)O"VB^(I+4,(&U;3X;HQ!L;@ID4[<X&<=<"NCHH52<;
M-2>@.$7>ZW,'Q/X!\,>-K&VL_$7AS2=?L[9M\%OJEC%<QQ-C&55U(4XXX[5<
MMO#>D6=W:75OI5E!=6=K]BMIH[=%>"WRI\E& RJ91/E''RCC@5I44N>5N6^@
M^6-[VU,6S\$^'=-:T-IH&EVIL[B6[MC#9QIY$TH82RIA?E=PS;F')W'.<FKD
M.AZ;;WE_=Q:?:QW6H!1>3I"H>Y"KM42-C+X4D#.< XJ]10YR>[!12V1RWA_X
M5^"O"=OJ%OH?@_0=&@U"/R;R+3],@@6YCP1LD"* ZX9N&R.3ZU>U7P/X<UWP
M[%H&I:!I>H:%$J)'I=U91RVJ*F-@$3*5 7 QQQCBMNBFZDV^9R=Q*G!*R6AE
M:3X4T30()8-+T?3]-AECCADCM+5(E>-$"1H0H&55 % Z # XJCX9^&_A'P7;
MWMOX>\+:+H5O>@+=1:9IT-NLX ( <(H#<,1SGJ?6NCHH]I/57>H<D=--C!U#
MP#X8U;PS#X<OO#FDWGAZ%42+2;BQBDM$5/N!8BNP!>V!QVJ]H/A_2_"^DP:7
MHNFV>D:9;@B&SL($@AC!))VHH &22>!U)K0HI.<FN5O0:C%.Z6H4445!0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45YUI?Q]\(:
MY8Q7VECQ#JEA-DQ7EAX6U2X@E )&4D2V*L,@\@D5:_X71X?_ .@?XL_\([5_
M_D6NAX>LG9P?W,Q]M2>JDOO.[HKDO /Q5\+_ !/34SX<U,WLNEW+6=];36TM
MM<6TJD@K)%*BNO((Y7&5([&NMK*<)4Y<LU9^9I&49KFB[H****@H***QM+\4
MVFK>(M;T:&.9;K2?(\]W4!&\U"Z[2#DX YR!^-4HN2;2V_X8ER46D^O_  YL
MT445)0452U?7-.\/VJW6J7]KIMLTB0B:\F6)#([!43<Q W,Q"@=22 *-)US3
MM>MY+C3+^UU&".9[=Y;299561&*NA*D@,K @CJ""#5<KMS6T%=7MU+M%%%2,
M**I66MZ=J5]?65I?VMU>6#K'=V\,RO);LRAE610<H2I! .,@YJ[3::W%>^P4
M444AA1110 4452L=<T[5+J^M;*_M;NYL)!#=PP3*[V\A4,$D4'*,58-@X."#
MWIV8KEVBBBD,**S/$7B;1_".E2ZGKNJV.BZ;$562\U&Y2WA0L0%!=R ,D@#G
MDFK=QJ%K9V$M]<7,,%E%&9I+F20+&D8&2Y8\!0.<],57*[7L*ZV+%%1V]S%>
M6\5Q;RI/!*H>.6-@RNI&0P(X(([U)4C"BBB@ HHHH **** "BBJ6KZYIWA^U
M6ZU2_M=-MFD2$37DRQ(9'8*B;F(&YF(4#J20!32;=D)NVK+M%%%(8445236]
M.DUB325O[5M5CA6Y>Q693.L3,560IG<%)! ;&"013LWL*Y=HHHI#"BBB@ HJ
MIJFK66AZ;<ZAJ5Y;Z?86L9EGNKJ58HHD R69V("@#N35/P[XPT'QA#+-H.MZ
M=K<,)422:==QW"IN0.N2A.,JRL,]0P/0U7+*W-;0GF5[7U->BBJ6KZYIWA^U
M6ZU2_M=-MFD2$37DRQ(9'8*B;F(&YF(4#J20!22;=D-NVK+M%%%(84444 %%
M%% !15*/7-.FUB?28[^UDU2")+B6Q693/'&Q(5V3.X*2K $C!VGTJ[3::W%>
M^P4452U?7-.\/VJW6J7]KIMLTB0B:\F6)#([!43<Q W,Q"@=22 *$FW9 W;5
MEVBBBD,***I3:YIUOJUMI4M_:Q:G<QO-!9/,HFEC0@.ZH3N95++D@8&X9ZTT
MF]A7MN7:***0PHHK+T+Q5HOBC[:=&UBPU?[%<-:77V&Y2;R)E^]$^TG:X[J>
M13LVKI"NKV-2BBJNEZK9:W8PWVG7EO?V4PS'<VLJR1N,XRK*2#R#T]*-=Q^1
M:HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'Q9\*_ACXVUKP9X;U>#3;CQ#H-UH&
MG)8P1>,[S1A:,D;"7]W"C!MQ*G/M[UT/B'X+_$/4='N+?1O#EWH&J/M\C4F^
M)>HW(MV# [O*:,!^ 1@GO7EL<WAT^#/ "ZK<>#$N%\-60VZY?:M#<[<,1\MM
M^[V\G!Z]<]JVO!<.C7'C*!O",WPYFU.W:2ZM=VI:ZSA(U9RS!OEX122#QQ7W
M%15.:53M?H[:?]OI>NA\I!PLH?JK_P#I-_Q.R\??#GXA?"&3Q!X^\.VWAT2Z
M/?:CK/\ :)OYXYKZPFF>YDLKB 0E7 +-M.\%6 8$9(.5XM^/WC'P+\?+W6[R
M#4[WP7;W?V"XT^VOH3;)"NE)=R;(F"L9$8F3S,C<H*@9( S/#-QHA^&'Q<CT
MBX\)2,_A6Z>1?#]YJ<TN IP6%W\H7YCRO.2.U7?$O@M?B-\1KGPP]VU@FJ^)
M+FU:Y6/>8PWAA!D+D9_.LX1AS26(C>RE=M6=K1?=^=BY.5DZ+M=K1.ZOJNR/
MM.BBBOBSZ@*\]\%_\E:^(_\ W#?_ $G:O0J\]\%_\E:^(_\ W#?_ $G:NRA_
M#K?X?_;HG)7_ (E+_%_[;(]"KS#]I#QE>>#OA'K']DQR3>(=7V:+I,,!7S'N
M[D^5'MW$#*[B_) ^0Y->GT5A2FJ=2,Y*Z3V-ZD7.#BG:Y\%WUT? _@GQ+\,)
M]"O_  Q#IOB;0-9T?3M2D@>465Q?0+)@PRRI@7"2GAC@2+GFO</V=;OQ':_#
MO5?^$>TK2]49O&&N"X&IZG)9"-/MTOS)LMYMYZ\';]:^A**].MF"K4W!PW=W
MJ][6?GKON<-+!^RGS*>RMMYW]/+8^6M%^/&KQ^!?B%XEU;Q/=3^(=)AU1KCP
M18VELL^D+#<>7;R*QB+IE,.6G$BMN+*F$*G@U_:,\<V_@/Q+J-SXYTZ>PT/Q
M$L,FI65_8M<7MD;)93#9W3V26LTH=BP5H$:0(Z*V1FON&BB.-H1;;H)W?EMV
MV_X(I86M))*JU]_W[_\  /BZ3QEXA\+>.?B/XOT76;[3X3XG\-07&DWEE #=
MQW,%K'(MQNC+QN%?@1E-K;LYX ]8_:\A\GPKX-U*;Q%=>&]/L?%6FO=7D(M_
M+@5I@HGD::)POED@@G"Y;Y@PXKWFBH>.3J4ZBA\/IJK)=O+SW\BUA6H3AS_%
M^&K??S_ ^59_BYXITGX:^-/$]]XPO;N-?%TGAO398EL+.UT^W%Z(TN9KAK64
M*NTX:1D==NT! WSU@> OC-\0_B!#X,TQO&;6#WR>)!<ZIIUK:3R3BRF3[.ZN
M]N(SP<%A$H=6)V*Q!7[)HJECJ2B_W*O??3M9*UNFY/U6I=?O7:WGWOW^1\EW
MW[0'BF/P3\%?$M_K?V6TUZSMSJFGZ/\ 9H]3O[F1XD5K>*XAD6>,,3YD4)25
M1*K X&*Y.Z_:F\>_\)5XKDT"[_M6&/2=;N+?P_>/;W-U83VMRD<9DAAM8I(<
M+O<1/+.63!+ \G[@HJHX[#QWH)[_ )W[=-B986L]JS6WY>I\E_%C6(=<^%?@
M_6X_BW=:[HUCXPTQI_$D$%@D<"LT>7DD$'D_NG8D,%"KOVR!RIJOJ7Q4U?0?
M'7BZSAU^T\,^'[KQE:6&H>+X;.RC:TMCI<<JO)*T1B9I9 J"68, '"KCY<?7
ME%3''0C'E=.ZU[=6G_+TMZ>7>I823?,IVV[]+^?G_P $^1O#_P 5OB)XONO!
MVDCQ=<:=::E#XADCURUTZU,VI6]G)']CNE$D31KO4G)5 K*Q*@95E[.\^,GB
MF?\ 9-\*>-XIX[36M4M].&HZLL"LEA'-(B7%YL(*#8I9_F&Q>I!4$5]#45$\
M92DXM4DK._375NVWFEVTV*CAJD4_WCU5OP6N_D_OW/B?Q=XBU_XB77AFT'C>
M]UOP[8_$O3['1_%%G!99OD:U9V?<L'DRM#*&565-A.=RL5&/;/VJ=&L-9\%Z
M/'J'B;0] %MJ*W<4?BV$OHFI2I&Y2VO3E5",<,,G[R A6(Q7ME9GB3PWIOB[
M2)=+U:V%Y82O'(\)=E#,CK(G*D'AE4X[XP>*;QJ=2G)1Y5'M;_*W]:6$L*U"
M<7*[EWO_ )_UYGQ1X@\8>%[K1?@5XAU2]T_P;/8^*H4BT*+60NEI9I+<B34+
M>*381;NP78[#:D95%P"=W4?&67Q'>?'[P%XAU7PKJ4]A!XKM;+P]=6MU926T
MMH;:9Y73]^'$DKD,=ZA0ENF&R<'["HK;^TDI*4:?22U;>DNW].YG]1;5G/JG
MMV[_ -*QX%\:M5\ _%[PEI\MSXT\+Z/I^@>)WBE;QA8B6PN+R"*6.2U>*:6#
MS,>:6RK$?)D9KYKN/$6F^*O"GBB;QAX;T7PU)_PB6SP!9VMG]EM[BZ^TW(^T
MZ5"?F265_LK@)F0AHSDJ03^B-%3A\P6'AR*+:OIKMU[=>OEH56P;K2YG)7ZZ
M;_CT_,\%^-?Q"U[X?^#OA:;CQ)_PBCZKJMKIVN:I-% YAC:TE:5R959$*NH;
M>1M!7+ KD'R>;]H#X@W/AWPA&WBK3]*TC4=0UFW3QMJ=Q;:7#?QVTVVT)GDL
M[B!?,C\QL"%=_E?*R\AOKCQ%X-T?Q9=:+<ZK9_:IM'O5U&Q;S73R;A49 ^%(
MW?*[##9'/2MJHIXNA3A%2I*3UOMY^5^J^[;J.>&JSDVJC2T[^7GY?B>!?#_Q
M9XV\4?%;0-(U/QA83:?;^$+36;Q?#<<$]GJ5R]Q-$72>2,MY+(JG";3D+M*C
M(;BOVI/[8^)WCJX\-^'?#^IZ_-X.T=M7673I+9!::M*RM9._G31DA$AE)"!F
MQ+]WFOK*BHIXU4ZRK1@KI:+IZZ6OU+EA74I.E*;U>O\ 3/CKQE^T%XM\7:;K
MWB/PEXKN- TFQ^'MOXKM[.&RM9MUYYLRR12M+$YV_)M95(.4&&'.YGCGXD>+
MK%]>T/5=:@\1P0S^%-2@?4M*M'\AKR]"S1HGE;=@V90L&D3@[R1NK[(HK:..
MI1M:BK+TOTZVOT?WF;PE25[U7KZ^?2_G^!\?7WQY\6+X.UO7V\<"Q\0V.N"'
M5?"9L+9AHE@FJ10F1B8_,16MR69Y2V[S-R;-AKI=5^-GB+7/!?Q6U?PYXLTN
M&STKQ#;6VDZI>20V]L+,V]M(ZQW+Q/$ID9Y!'-,KQYD7DJ5KZ<HJ'C*._L5O
MY=UIMY6^;*^JU?\ GX]O/SUW\_P/!_$?Q.UF_P#V8=+\8^'=:?1KZ[M[:<:C
MXJ:VLY6C+C>&E$+6T3R*"J2M%Y670XPPKQ'6/B%KNI:MXA^(?AOQ!K6CWMG\
M,+76(Y-2LK-KF\*7-P56=?*\O8V"<Q*FX%2I X/W-111QM.BG:DG=^6VFFVN
MP5,+.I:]1Z+\>^Y\D6O[17B;5OVAO#^C6FJBTTJYUE-*O= O+BV:4H=/\_SX
M[<6HF2(N1ME:Y8,01L .%TM:^*7Q!T?X6_$_QA!KLFH3Z;XFNM&L[5[2".WT
MRRCO1&]R66%G9XXV8EW#H%12T;88M]2T4/&4;QY:*LK7\[.[Z=06%JVE>J];
M_*Z]>AX;\!_BQ-JE])X?\0^.O#GB_5+Z6:;27T#44U-_(B2,S+<3P6MO"&5I
M%(_=H2K@?,1DT/B]XZ\=:/\ $OQ/:^&=2F:VT+P5_;]MH<-C%-]OO/.N$5'8
MH9-A"+E$*L2J[67YMWM7_"*:4WBH>)&M ^MK9_V>MTSL2D&_>452=JY;!) !
M;:N2=JXUZR>(I*K[2-/1K9VM?RT[?/J:>QJ.GR2GL]];GPCXX\:>*OB%^SSX
MOEO_ (C:#XCTTQZ/.(M%U:TO[^"22\C5XYUCL;=8HV# A&4N&C(+LI*UU]UX
ML\1?"W1_V@-3T*X?4-6LO$6FP2ZE>(F^.)K.T2:Z<1Q%%*(6D+"(HN,F,J-I
M^OZ*ZO[1A;E]DN6][?..FW]W\?(Y_J4K\WM'>UK_ /@7GY_@?&^A_&SQ@WB^
MRT;7OBUX;L_"\T%U<V?B?0[RSU9I[M/)":=/*+2&%F^=Y!'%$DKJ54-D9.7\
M7=6F\)?&;Q^)/$_FW][?>%Y;?1M4L[&6.Y@>[",Z1R0%B(>55U.Y"V6)8*1]
MN441S"G&?-&DDK6MIW3_ )?+_*P/!SE'E=1MWWU[-=_,^5_'?Q9\<:+XV\<7
M=IXEDATKPWXJT/3(-'6RMC%<6]X+83)+(T9DX,C%2K*06.2PVA;/P/\ BQXF
M^(OQEO+2Z\:(VG6,VK+<Z"USI0\PQW9BM1#!&IO41(@6D,Y0EMN,J<'Z?K@O
M#/P,\%^$=>M=8TS3+F.[LS.;..XU.ZN+>S\XYE^SP22M%#NR?]6J\$@<'%3'
M%X=TI0E32E:R=D^EO+KK?5Z^13PU95%)3NKW:N^]_/II;R\SQ/4OCYXC;]J#
M3O#-CJ_V?1_^$A.B7FA7L]LTK1BQ,PN$MUM1-'$7(VRM<L&((V '"]#^TE-+
MHOQ7^$>LOXCN]%MX[N_@C5?LR0-<&T=HX]\L38:8CRL$\@_( WS5]$45C];I
MQG"4*:5HM/SNFK[>9I]6FXRC*=[NZ\M4[;^1\M_ _P"+/BOQ]XJ\-V#>-'U]
MM8T&ZO/$5C;VMHK>%KP.@BB79%NC8%G01W/F,?*R>AKQ"U^.6M?"[X1V^B^'
M/'5Q!KMC%K=]/'J%SIT$4,\-X5%F(S8R22S-N\WR=T38<D/M*A?T3HKIAF%&
M,FW13CH[:=+_ -WS_#J8RP=244E5:>NNO6WGY?B>#_#R^DU3]I[Q->2A1+<>
M"M&F<(,#<TUR3CVYKB?!_P 9/B%KWQ5U6VG\2>&K*2RUF^LF\$ZAJD4-[-;1
M*_DF"T^QB<NZB.02&Y=&#-A ,!?JZBN58N%Y.5-.Z27E96[?UW-_JTM$IM:M
M^MV?$&E_M#>.]6\.M-H_CIM>UVX\#ZKKEWIL6FVI;2=3B:'9;@+%G]V&8>5)
MN?NQ8,F-?QY\>+SQC_:*:3K6G:_H5NGA.6-C96UW;BYGU!DN64O&RLV%49&?
M+93MVLIQ]87/A'2;SQ58^))K3?K5C:S65O=>8XV0RLC2+M!VG)B3D@D8X(R:
MV*ZGCL/=2C17X=[]NRMTW9SK"5K.+J_GVMW[ZGQ[H>N>(? &E_&S4-!\77NJ
MZ_X<\6'5K[P_=0V9ENK!5A>9BBP*Z^;%O =?ES$NT [B?4/#'BGQUX\_9W\1
M^+-*U22WU[5OMNI^'!):0YM[4.QM(2I3#;XT4DL"W[T\\#'L7B'0;+Q5H6H:
M-J4;S:??P/;7$<<SQ,\;J590Z$,N02,@@U+I&DVF@Z39:9I\"VMA9PI;V\"9
MQ'&BA549]  *PJ8R%2*?LUS73V6R2T^;7Z:FU/#3@[<[Y;/ONWO]Q\KV/[2F
MM^*?A#XE^(<%_=:;HFH:SIVCZ,?]'M$TW(A2YN)KB:WF5(O.>16=XY  @"@$
MY&'\'?B!XB^(GQ*\ :MJ]_%JNLPZ3XILXKVW\MA.L5W D3 I'&C\!?F$:!N#
MM&<5]GT5?UZC&,HPHI-WUOLN6UMOF^[(^J5'*+E5;M;[[WOO\O(^//#/[3'C
M#6/#/AU])U.'Q-XFM_ NJ:EJVF1VD;EM6@: 1QR+&H*2#<^85*G# D<J:[[]
MG;XC>*_%EAK=]>>,O#?CFU33(;NWL],UB"]O[>X96)2406=LL2-@ (RLX96&
MX]!]"T5%7%T9PE&-%*_7YW[+T+IX:K&2E*HW;_*W<^6?@G\6O%?CSQ1X=L6\
M9OK[:QH%W>>(K&WM;16\+7@9!%$NR+=&P+.@CN?,8^5D]#6_^R7X5FUK]E'0
M=/N/$&L1C4X[AOM5K+';W%JIG<,L,D<:LN2&.YBS@NV&'R[?H>BIK8Q3BXTX
M*-VGTZ<WDN_X=1T\*XM2G+FLFNO6WGY?B>'?%;X7V.E_"?Q)INJ?$76K#3M1
MFM4_M+Q'/]LM;*%)%VV\GW,P.,I(\K[G#?/(W%>5^%]6\0^,OA'>>'="\ Z5
M<: -=>VURZ^'=[ NE7]HL*22&Q2YDB01R/MAD",>DS9+-7USK&DVGB#2+[2[
M^+S[&]@>VN(MQ7?&ZE67(((R">0<U+8V,&F6-O9VL8AMK>-88HQG"HH 4?@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQIXXL?B)^R7XOUO3X]0BMWT+4+8KJJHMSOA62%_,V$J3NC;E20:\E\,/:?\
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MALUF2UA6Y=);@(HE>-=JLV.2!DX&>V:+R5(;6:202&-$9F$*LSX YVA?F)]
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M%_A_P=I>JJ8/%OBSP_<>++2UO[O2X'N;EK2.=89-L48V.51-X@$8DP1@!L
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7"11(H544>@  J]6)-XX\.6_A^WUV77]+CT2X9%AU)[V,6TI=MJ!9-VTEF(
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M*Z&YWY$H7RXR74L _P!)44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>2Z]^TQX7\/ZUK>E2Z9XDOKS2+XV
M-RNEZ/->C<((IB^8@VU LR#+;23NP"!FO6J^8/!_ACQAXD^*_P 8U\*>-E\&
M^3XDA:Y8Z1%?FYS86VQ?WC (!ALX&3N'(QSZ&$I4JG.ZNR5^O=+HF^O8X\14
MJ0Y53W;_ $;ZM?F>N_#CX]^"?BQK%]I7AG5)KS4+&W2YN+>XL+BV:-&9E&1+
M&O(92"!TKT*O(_AG\)_%N@_$K5O&GC'Q7I_B+4;K28-&A73M+-DHBBEDE#L#
M*^6)D.0,"O7*QQ,:4:EJ+NM/OZ]%^1I0E4E"]56?]>;_ #"N.\,>(+_4/B)X
MUTRXG\RQT[[%]EBV*/+\R$L_(&3DCN3CM78UY[X+_P"2M?$?_N&_^D[4Z,4X
M56UM'_VZ)-:34Z23W?\ [;(]"K,\2>)M*\':#>ZUK=_!I>E649EN+NY<*D:C
MU/J3@ #DD@#DUIUYG^T3X!U?XC?#&YTW0C%)JMM>6FI06MQ)Y<5VUO.DWD,W
M0!]F 3P#C/%948QG4C&;LF]6:U92C"4H*[2)?^%^>%Y;[PY:01ZM)/KNI#2X
M([C39K*2*0PR3*\D5RL<@C98VPX4@D8&<''H]>%>/-)\9_%#Q!\/-0A\'WWA
MJ#1-?-U/_:5]9M/'&;*XC,VV&:1=@>2,##ER2V44 %O(_!7P!\<^%_!NOR1:
M'K3_ !$?0[VQENM0;1'T;69I& +2&,"YN6<#>AO 0"6#G!8-Z?U2A.*:J*+[
M-I]7U5NEOO.'ZS5C)KD<EWLUT1]HT5\>Z#\ ?%\/P:^)GAE/#U[8PZSX@TZ]
MTS3;B?3[:7[.CVAG;;9,EO"P\J0XCVD[01ECD]K^T[X=TS1=+^$6BZ;X8AO]
M'B\5PP+X=L4A@BGA-K<[H%1BD>&!(VN0C9(8@$UG]3I^T5.-2]V]K;))WW\[
M?)ZE_6I\CG*G;;\6UV^?S/HVL2Z\9:1:^)O^$>DNC_;1L'U,6HC?)MU<(S[L
M;?O$#&<\],5\6^,OV=_B9JWPWM] B\'JVG^5K5QI>FV[:5-<:--/=*]I TUR
M6$40BW<VC!PV!NP 1[C??">[3XZ>%O%L_@NWU?=X8?3KO5U%J9[._!CV32&1
MP[?('0/'O89QT.:N6#H4U=UD_BVMTVOKU_X:Y$<55GI[-K;>_7?IT_X>QZQ\
M.?'FG_$[P/H_BG2X;FWT_5(?/ACO%5957)&&"LP!X[$U=T_Q9I6J>(]7T&UN
MO-U;24ADO;?RW'E+,&,9W$;6R%;[I.,<XKYS_9]^ OB#X8^(/AGJ#^'HM'DA
M\-7UCXEN(9X6>6Y,T+6ZRE7)EP%?:1N"@8R!@51^*OP#UO4/B-X^U#0O UK=
M6NNKI5Q_:%JUG"UW#%,3J%DQ9UD5[A-N3C9)C#N*;PN&=:4%5]WH]/YK:Z]M
M?Q!8BNJ49.GKUW_EOV[Z?@?6-<O\1/B%IWPS\/Q:QJD-U/;27MK8!;-%9_,G
MF2%#AF4;0S@GG.,X!Z5Q/[/O@/4?!<GC2YDT+_A#]"U;55NM)\,;X3_9\0A1
M'.V!WBC,CJS[(V(&03R2!XY=_ GQ=<>&KZQF\#FY\8GQ)'?WGB[^T+8#5;4:
MK%<)_P M?,;RX$P%E5=GE[8\[R*SI8:BZKC.HN5-=M;[]>G6URZE>JJ=XPU=
M^_3;IU\['V#17ROX2^"OBRS^)FAZC=>&S9Z[9>)[_5=5\=?:;<_VGIT@E$-H
M-LAG8;7A7RY$5$\DX)XSAZQ\"?B'_9_Q3TW0=$^R6>K3PWL=]?/8#5-3;[89
M+FT6Y3=Y]N\8;9]L12/-$; H&Q2P5%RY?;+IVZNW?Y][;I$_6JEK^R?7\K]O
ME_F?8E%>3_L\_#U/A[H.L00Z;XCT:*[O!.-/U[^RT2,^6JEH(M-_<1HV.1@$
ML"2.<GUBO.JPC3FXQE=+J=U.3G!2DK/L%%%%8F@4444 %%%% !1110 4444
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M** "BBB@ HHHH **** "BBB@ HHHH *9-"EQ$\4J+)&ZE61QD,#P01W%/HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML)9/,$8.$Z4>+?@?XUUGQAXVBM+7PFWAKQ9XBTK6)M4NKF<:E916<-DNU81
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MZ#\:_"'B7Q)=:%8ZA="^MUF8R76F75M:R^2P6<0W,L2PS-&QPZQNQ0@A@,'
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M&H:D^J:684NX-/T._O?*>8(8(]T$#J9)/,79&"6<[@H)5L 'I-%<JOQ*TAO
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MQNJ*)!)@@-E.1M@^$_[+UK\)?&6J:SIT'@B3[0UY-;:@O@\1:Y')<2M*1-J
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ML/H>B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?B@T_P"RBY@?>DRS-:M=1OG@M%.AP2!@$YY>Q_9'\/VNDW.E7'BOQ7J.E?\
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M=U]Z_P P]K'L_N?^1T-%<]_PD&L?]"O>?^!5O_\ '*/^$@UC_H5[S_P*M_\
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M_N?^1T-%<]_PD&L?]"O>?^!5O_\ '*/^$@UC_H5[S_P*M_\ XY1[*7=?>O\
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M#6/^A7O/_ JW_P#CE'LI=U]Z_P P]K'L_N?^1T-%<]_PD&L?]"O>?^!5O_\
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M44EY#)$(G60J,[D!.QCU*Y^4DCM72US2CRR<7T-XRYDGW"BBBI*"BOF'XO\
MQH\;>";_ ,4Z+IU]YVK:=K<&L6XCLT=SH$=D;NXBV[2"7>UNK</]X>8A!+#%
M:NO?M%ZIX3T?6?$$%A<>+;?6?%,FA^&-.MK:X>)8K>V/GR.UG:W%PRF6WNSN
M6&7GRQA4W.H!]$T5X%K'[4&H:/\ "GP]XDE\ ZM%XDUK5)-)M]!N++4U DC6
M:1I2%L&O/),<#,K?8]QW)N1%W,N)!^UIXIN]+UB^C^&#V4/AW1!K^O#6M1NM
M-DBMA/=QM]EAGL5FF8I9O(GFQP!@P#%#U /IBBOGW7/VBO%7@ZZ^)MWK'A33
M;O0O#VH6.FZ,-(O;NXOKR:[6V\E9H$M&8*3<AF:(2.H!58I2 6;\/?VFO%'C
MGQ1I^@3?#>;1+QTN;N\NM3FU"QMDM(&M@\MN+O3H)YV_TK&TPQKNC8;\$-0!
M]"45\L^'?VU-8\2103P?"_54M=82 >'[BXBU.UAGFGGBBMX[NXN-.B@AW"8,
M6MY;H8CDV[_DW]'I_P 7OB+:> _CEK.HZ/I$?B7PC>N+#1Y-0:6PBC32[2Y(
M%RD"22J6DDD&Z-6);9\@ ( /H.BOFK5_CQ\1_"NOZ[?:AX9T:]TK1_!NG>(]
M7L(-:9(K%6FU#[0]M*;/S+B5HK>,B-UC0&,C>I.6M>)/VD=7\(W5]'!H]O=V
M"ZS?6LVO>*M4DT[2=/CA6 JDMW;:?,L&[SL)]H"@[2/.=B%H ^BZ*\(^.G[2
MUW\&=>BMX/#MKXCTZ&P34=2-E/J,M[9PEW!<Q6VG3PQJ51BCW%Q KE'&5",P
MYK3_ -LFZU74/';V7AC1=1TGPKIFJ:A<?8/$WG:C"]I.84M[NV^RA;628J[H
M&E;Y$)YP< 'TY17SK\1/VHO$_@'7+;0E^&T^N:[#IT>J:G:Z.=5U".&*669(
M8H);32Y@\Q6!R5G^SH"RA7<;F7&N_P!M745O->NK'X8ZY?>&].7442^-GJ<,
MIDLTF+&5GT\6<4;20,@<7;L-Z;D#;E0 ^HZ*^?W_ &BO&ND^([K3]<^'.G6-
MGI^J:78ZA>6OB4W!2/49HX;5X4-HGF2*[GS48HJ@ I)-DA>>U[]M*_TC4O%,
M]M\-M8U+PQHO]J1C5(K74U9Y+%)][/(=/^QI"TENR!UNW8;TR@.Y4 /J&BOG
M#6OVA/B99^-] \*Q^ O#%GJ][>V;3PW7B6XD065U%>-$1(ED-DP:QF#+AT&%
M"L^\LG9_%#QQXWT+XM>#="\'Z;8:VNI:-JUU<:?JE_\ 8+8O!-8+'*\ZP32+
MM6>50J(0QD&[ &Y0#URBOE2T_;GEU6\BGT[X<:Y>:#:_9H]7NH++4[F>TEDB
MCEE$9M["6UD2)95W-)=0M\CD+C87[/5_C[XST/X;:=XKO?!>@6LNLSV_]CZ/
M_;U_=WEU#+$\N#%::7/)YZJH9HH4F4*)6,@6/+ 'O%%?/WAO]K >(? ?C+Q%
M_P (K+:R^&?"S>(9[.:YDB,LR3ZA#); 2P))& ^G-AY(U?$@W1(5*UG:M^UU
M?^'Y/$YU/PA:V+Z=+]GT[1I+^]_MR_=KR*UBG%B-/R]HSRJQN+5[D8P%5W.P
M 'TE17@VG_'O6_$GP;\5^(]1\+ZMX/U/1KB.((L-U;K<*3$0\#ZCI\+LOSE&
M+6V 58*3PU=;\$O'GB_QWI?B2Z\5Z+HFD_8-9O=.L_[&U&:Z\U()Y(B9!)!'
MM(V#D%@V2<)]V@#TRBOF.;]J_P ;V_AUM<E^%NGQZ?\ \(N/&0/_  E.773E
M7,RLHM.+D94I&"T;C=NEB("LR^_;8DT_6-=N6^'>O77@S2GU")]7L]/U.2<F
MS68.YS8+9"-I(&166]9OGCRJDLJ 'T_17ROI_P"U1\2_$7B#P[I6G_"ZSTU[
M_58;2:YUN;6K"UDBDAN)-L4EWI%NQF7R"3B-U *C)+DIZ?\ #OXU:GXU^)6O
M>&-0T/3?#B:>;G[/:WVIW$>LW4<4RQ"X%E)9QHULV<B>&>9,E5SN+!0#UFBO
MGCQI^U/K'@SPUJWC&3P1:W7@>&;4K+3[U=;*W]S<VB7!)EMOL^R*&1[25%<3
M2. T;&(98)T7C;X]:KH/Q2TSP'HGA2WUC5-1M[.:"XO-5-I OGQZA(=Y$$C
M(NG'E0Q)E' VY(![+17E?Q"^(7CCP]\5/"GAWP[X=T'5]*U33;Z\N9-0U::T
MN5> P@+&%MY%Q^]'WC\VX\IM^?F=#_:NLO$EQ90V.@2$ZE'I']GB>ZV-<379
MA:XBV^62#;17,,C-R#EA\NTF@#WJBO'-'^.NL:EXBTR:3PI:P>!]6UNXT#3]
M875B]^UQ$TR&26S\@(D+/;2JK"=WP8R8UW-LI^,/V@]=\,ZYXM:W\%VU[X6\
M*:K::7JNJ2:SY5T3<0VLBO;VP@82!/M:[P\L?"Y7>3M ![?17SU>?M$Z[:^
M_"WC?4/#;:?#JFD:AK5OHEEJT<PN((M/%U&L[O:@I(2"N(VVKD$L_P!T2O\
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M&OVD_"WBKP?JNOV$5Q.VGW<-@VFVMS9W<\UQ,46"..2WN)("79U S*-O._:
M34WAWXN:[JWQ)N] U'P+K'A_3(=+COFNM0EL&:$EY@6<PW<F4(C 4*I8,&W8
M&#6W-BXQG&5M.]KZ:Z=]_/<RY</*491_"]M=-?N.AU3X<BZ\9?\ "2:;XAU;
MP_=S1PPWUOIZVSPWZ1,S1K*)H9"N [KNC*,0W)X7">$_AR/!FI73V'B'5FT6
M9YY8] F%JUG;O+(9':-A )_OLY"M*5&X@# 4#G[']H#2KBSDO;SP_KVD6,NF
M7&KZ;<WT, 75+:% [M"$F9D;858),(F(;IPVUUY\=HK.3PY:_P#"'>(&U?Q
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MWCR'X7_&*W;5]!'C'P;;R>1K^G:5(+.1OL270!M)+B0I(BOMVF9QRCD8;RZ
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M-G%=.UN]N+J*U;8L3%9=SRKY9"J'/""N6_9__MZ;QCX?D_XN E^-(G_X3?\
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MTMU?_06)0V03R ;C?G?_ ,MJY[5/#?B35+;2M.U'3OB"WBNRU?PN^DV5K%J
MT*/2X'TYY6F51]CWK(MTS^9_I"E!@!%6@#ZZTOX8^#M$T:?2-.\)Z'8:3/9?
MV;+86NFPQP26N9&^SM&JA3%F:8["-N97X^8Y@7X1^!8_&P\9+X+\/+XO'3Q
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M[O+2YD%XL<,3R0SS0H9!)@95WB>/.[ED9<Y!%<K-X%^''@?Q1X<U0-H_A?\
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M%6BI<_$*6YB\(6%SX?M/!CWXACU62?44C>?[*=J[BD0S<D6Y$9\S.U: /?\
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MB3Q+X6T#PZMFMS);(ALY;K[0X*P-\HCN%,:X^8H5/ECYJ]BH **** "BBB@
MHHHH **** "BBB@ JO>:?:ZAY'VJVAN?(E6:+SHP_ER#.'7/1ADX(YYJQ10
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M&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M23:D]/4;IT4TG%:^@S_A7?A3_H6='_\  "+_ .)H_P"%=^%/^A9T?_P B_\
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MC/0U&I7EM)]M^Y,J=&.\5]Q>_P"%=^%/^A9T?_P B_\ B:/^%=^%/^A9T?\
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M#<[5C$K'RV<-Q&0YXX4@].:/;5?YG]X>QI_RK[C1_P"%=^%/^A9T?_P B_\
MB:/^%=^%/^A9T?\ \ (O_B:YG1?V@O!/BSPY8>(/#&L6OBC0[R*ZE2^TN[MV
M"F"+S7C,;R+)YFW^ *2O5]@YJP?CQX#M]5\):1J'B73](UWQ59+?Z3I&H7"1
M7-S&P4@!<XW$N %SEB&V[MIP>VJ_S/[P]C3_ )5]QO?\*[\*?]"SH_\ X 1?
M_$T?\*[\*?\ 0LZ/_P" $7_Q-8GPO^.'@OXO:/;WGAS7]/N;MK"WU&ZTG[9
M]]I\<T8DC%S$CL8FP>_'7!-:?A'XJ>"OB!IU_J'A?QAH/B2PT\[;RZTC4X+J
M*V.-V)&C8A. 3SC@4>VJ_P S^\/8T_Y5]Q8_X5WX4_Z%G1__   B_P#B:/\
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MG!X.*/;5?YG]X>QI_P J^XV?^%=^%/\ H6='_P# "+_XFC_A7?A3_H6='_\
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MRGSC:<'MJO\ ,_O#V-/^5?<0?\*[\*?]"SH__@!%_P#$T?\ "N_"G_0LZ/\
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M2TE'(SN XQD@]M5_F?WA[&G_ "K[CH?^%=^%/^A9T?\ \ (O_B:/^%=^%/\
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M\4_M7>!?"UG>71M_%>KVUK=)9O<Z1X1U2ZM7D:X6 B.Y6W\B7;(V"$D8Y5E
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MI'C^S\4:9XBMHI5U:_O;FVN]-:59+:[6W$D*%9TV2 VR%92&'S,#&>"/6:*
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MV]J;DPV<=_<?9D\^7S9/W!D\O&[[@V_NP2J;5)!Z2B@ HHHH **** "BBB@
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M_P#DJNAHH]K+LON7^0>RCW?WO_,Y[[#XK_Z#6C_^"B7_ .2J/L/BO_H-:/\
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M_P#DJNAHH]K+LON7^0>RCW?WO_,Y[[#XK_Z#6C_^"B7_ .2J/L/BO_H-:/\
M^"B7_P"2JZ&BCVLNR^Y?Y![*/=_>_P#,Y[[#XK_Z#6C_ /@HE_\ DJC[#XK_
M .@UH_\ X*)?_DJNAHH]K+LON7^0>RCW?WO_ #.>^P^*_P#H-:/_ ."B7_Y*
MH^P^*_\ H-:/_P""B7_Y*KH:*/:R[+[E_D'LH]W][_S.>^P^*_\ H-:/_P""
MB7_Y*H^P^*_^@UH__@HE_P#DJNAHH]K+LON7^0>RCW?WO_,Y[[#XK_Z#6C_^
M"B7_ .2J/L/BO_H-:/\ ^"B7_P"2JZ&BCVLNR^Y?Y![*/=_>_P#,Y[[#XK_Z
M#6C_ /@HE_\ DJC[#XK_ .@UH_\ X*)?_DJNAHH]K+LON7^0>RCW?WO_ #.>
M^P^*_P#H-:/_ ."B7_Y*H^P^*_\ H-:/_P""B7_Y*KH:*/:R[+[E_D'LH]W]
M[_S.>^P^*_\ H-:/_P""B7_Y*H^P^*_^@UH__@HE_P#DJNAHH]K+LON7^0>R
MCW?WO_,Y[[#XK_Z#6C_^"B7_ .2J/L/BO_H-:/\ ^"B7_P"2JZ&BCVLNR^Y?
MY![*/=_>_P#,Y[[#XK_Z#6C_ /@HE_\ DJC[#XK_ .@UH_\ X*)?_DJNAHH]
MK+LON7^0>RCW?WO_ #.>^P^*_P#H-:/_ ."B7_Y*H^P^*_\ H-:/_P""B7_Y
M*KH:*/:R[+[E_D'LH]W][_S.>^P^*_\ H-:/_P""B7_Y*H^P^*_^@UH__@HE
M_P#DJNAHH]K+LON7^0>RCW?WO_,Y[[#XK_Z#6C_^"B7_ .2J/L/BO_H-:/\
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M70T4>UEV7W+_ "#V4>[^]_YG/?8?%?\ T&M'_P#!1+_\E4?8?%?_ $&M'_\
M!1+_ /)5=#11[679?<O\@]E'N_O?^9SWV'Q7_P!!K1__  42_P#R51]A\5_]
M!K1__!1+_P#)5=#11[679?<O\@]E'N_O?^9SWV'Q7_T&M'_\%$O_ ,E4?8?%
M?_0:T?\ \%$O_P E5T-%'M9=E]R_R#V4>[^]_P"9SWV'Q7_T&M'_ /!1+_\
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M ^+O#OCSX@^)M)TF?3O&_@_QUKT=QJPT?5]"U*QUUP\>GI,+6:YBL+6.-GD
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M\/:+^TEJNI^$]2^'OC/QQK\\D;:?8Z5%-XIT(+I7EB;[8L[E( 8(\I)#&O\
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MW;8/DDGF_>RL.[R .>K@-D#IZ** "BBB@ HHHH **** "BBB@ HHHH ****
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MSAP%!?Y0IR"2H[^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]8_\"_\ ZU'_  A__4;UC_P+_P#K5T-%'MI]P]C#L<]_PA__ %&]8_\  O\
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MC>L?^!?_ -:C_A#_ /J-ZQ_X%_\ UJW;BXBL[>6>>5(((E+R2R,%5% R22>
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M/_ZC>L?^!?\ ]:M>35;*'4[?3I+RWCU"XBDGAM&E42RQQE!(ZIG)53)&"0,
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MO6/_  +_ /K4?\(?_P!1O6/_  +_ /K5T-%'MI]P]C#L<]_PA_\ U&]8_P#
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M110 4444 %%%% 'G5QI=ZWQ\CU 6<YT__A%I+?[5Y3>5YIND8)OQC=@$XSG
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M&T@O["[B:"XM;J-9(IHV!5D=&!#*02"",$&JNG^(M,U#6M3T:UG#W^EK";J
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MC1_VQ<:C9V<-]<QV^A7TJPI*5"([K"564AU;R2?,"Y8J%!( .SHHHH ****
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MJ1#8P%;EK>VA1WPP,?[MO+;&!DX:OJ&BBGBH0I\C@G]W=/MY=PGAY2GS\_\
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M@_\ $/PSX/\ B%IVC?#VZN8?'/ABXT;2](M-2L8X/#2?:-0>&WG+SJ BQWR
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MW@M&ALG%HD8=H[=Y+:$R7"&7;$S '#DAV8#D]:_9L'BC0/$]Y;?"VTT*\M_
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M*&*VUM)<2X) XCC5F;KV!]:NT>VJ[\S^]C]E2_E7W'/?\*[\*?\ 0LZ/_P"
M$7_Q-'_"N_"G_0LZ/_X 1?\ Q-:6J:Y8Z--IT-Y/Y,FH7/V2V78S>9*4=]O
M./EC<Y.!Q]*-4URQT:;3H;R?R9-0N?LELNQF\R4H[[> <?+&YR<#CZ4_:5OY
MG^(O9T?Y5^!F_P#"N_"G_0LZ/_X 1?\ Q-'_  KOPI_T+.C_ /@!%_\ $UT-
M%3[:K_,_O'[&G_*ON.>_X5WX4_Z%G1__   B_P#B:/\ A7?A3_H6='_\ (O_
M (FNAHH]M5_F?WA[&G_*ON.>_P"%=^%/^A9T?_P B_\ B:/^%=^%/^A9T?\
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M3["X*E#+:VJ1MM/494 XX'Y5K445G*4I.\G<TC%15HJP4445)04444 %%%%
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M6^N;UEU2PNYKJ&.6)8].=H[27;#;#:CM& VU05]K^%/[3G@_XF^$;/6)9Y=
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MYQIOPT^)EGX-\ 6S:%X)&J^ ;F#^S;.'6;E;#4XELIK1W<_8MUG(JRAT"K<
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M #+-?B643FWAD+$0(I0I@&/*D[B2 <7K/['NI^,-!T?1_%/C33-<T[P_H_\
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M!W@?0=&U;2K308S8:M8#3=0BN9Y;C[9!NF<B5I'8N[-<SL\C$N[2$LS'FI_
MOP>\+?#J[U"[T:TO7OM0@BMKR^U75;O4KF>*(R&-'EN99'95\V3 )X#8Z "N
MTHH \QT/]FOX=^'6G-KH4TR2Z?/I(BO]3N[R*"QFV>9:PI-*ZPP_NH\11A57
M:-H%1Z'^S/X!\.^)K7Q'9VFM/X@MV0KJMYXFU.ZNI%7=MBEDEN6:6+YCF)RR
M'"Y4[1CU*B@#B/!'P;\,_#G5);W0!K%FCQ-"FG2:_?W&G6\98-M@LI9VMX ,
M *(XUVC*K@$BH+GX#^!+S6KS5IO#\;ZA=ZS;>()IO/F&Z^MTV0S8WX&%S\H
M5B6+ DDGOJ* .1U/X3^%=8\27&OWFE>=JUQ$T,EQ]HE7<AA:$C:'"C]V[+P.
M^>O-: \"Z&L?AI!9?+X<8-I8\U_]'(@>W'\7S_NI'7YL]<]0#6]10!YO??L\
M^!]2U/5[N>RU3R=6%P+_ $J/7]0CTNX^T(R3E[!9Q;%GWLS-Y>2[%\[_ )J;
M<?L\^#KK1]/T^5O$CG3Y99+74?\ A+=6_M&$2!1)&M[]J^T>4VQ"8O,\LE%.
MW*@CTJB@#S_6O@+X&\2^'[[1=8T>75K"_6Q6[^WZA<SRS_9"#;EY7D,C,I R
MQ;+Y.\MDYL:E\&?#&I>,AXIVZQI^L&6&:8Z3K]_86]U)$ $:XMH)TAG(550F
M5&RBJARH '<44 <QXE^&GAOQ?JD.HZOIOVN\A%NJ2>?*F!#=1W47"L!\LT,;
M].=N#D$@I;_#/PU:>+I_$\6F[=<GGDN9+KSY3ND>"&W=MA;;S%;0KC&/DSU)
M)ZBB@#S#1?V:OAYH%U'/:Z+=.T,D4EI'=ZO>W,5@(YTN$CM(Y9F6VB\V*)C%
M"$0^4@*D*H'677P\\/WEW/<S:?OGFU2'6I&\Z09O(HXXHY<!NR11C;]T[<D$
MDD]'10!YYK7P!\$Z[:0V\VGWUJL5S>W8DTS6;VQE=KN8SW2/)!,C/%)(VYHF
M)CR%^7Y1A++]G_P+IUG>6=MI-Q#87FGVVF3V*:G=BVD@MU18<P^;L\Q5CC7S
M<>854*6(XKT2B@#S'2_V:_AYH]CK%E!HUU)9:IIT^D2VMWJ][<16UE-_K;:T
M229A:1-A<I;B-?D3CY%QVUOX2TFU\07NN1V@&IWME!IUQ,SLP>WA:5XDVD[>
M&GE.0,G?R3@8V** /&;G]C_X67FH6%_-HVK27NF[AIMPWB75-^FJPQMM#]IS
M;*!]U8=@3C:!BMV^_9V\"WWA_1M(&GZE8P:09S:76FZ[?V5Z//;?<;[N&=)Y
M?-?#R>8[;V 9LL 1Z310!YE=?LV_#NZU;3K_ /L&2#^SS9O;V%KJ5U!8*]IL
M^S2&SCE$#21B.,*[1E@$5<X %;>G_"'PMI?@'5?!4-E=/X8U.*X@N-/N-1N9
MP(9E*211L\A:*/:2%2,JJ9^4+7944 <+XP^"?@_QU?27VK:=<_VBT=K$NH6.
MI75E=0BW:<PF*:"5'B8?:K@%D969965B5.*(?@CX)AL?"UHNB*T7AF];4M,:
M2YF>2.Z;?OFDD+EIG<R.S-*7+.=[98 UW5% '+:!\,?#'A?P&_@S3-)CM_##
MQ3P-IY=W5HYF=I5+,Q8AB[=^,X& !7,ZE^S9X!UB'38KZQU:Z2QM!IY\WQ%J
M+&\M0[.+>\/VC-[$"[XCN?,4!W4##$'T^B@#F_%OPZ\.>.I_#\VNZ7'?R:!J
M$>JZ:S.Z?9[E%94<!2-V Q^5LKG!QD C'TOX'>#=&\:2>*K73;I=5:XFO$BD
MU.ZDLH+B4$2SPV;2FWAE<,^Z2.-7/F29/SOGO** /,Y?V<_ SZ-8:9%:ZS90
M:?---93V'B/4K6ZM!+M\R&&XBN%EC@.Q/]'5Q$-B80;1C1\4?!3PMXRTW0[/
M4TU@MHL+6]E?VFOZA:WZQLJJZ/>0SK/*KA$+B1VWE%9LD CNZ* .,E^#?@V3
M2]5TT:%#!I^IZ'%X;NK6WDDAC;3HA,([=51@$"BXF *8;YNO QHZ]\/]$\2:
MMH.IWL-R+_0Y&DL9[2^GMF7<%#H_E.OFQMM7=')N0[5)4X%=%10!P%]\!_ N
MHZ#HVBW&A[].T;2VT;3HQ=SJ]K:EH' 1P^X.KVENRRY\Q&B5E8')K>\%>!M.
M\ Z7+8:9<ZQ=023&=GUK6[W59@Q &!+=RRNJX4?*&"@Y.,DD]#10 4444 %%
M%% !1110 4444 %%%% !1110 5!>V<&HV<]I=01W-M/&T4L,R!TD1AAE93P0
M02"#4]% 'SOX9^!\4W@'X=^&+WP';Z78:1KC3:U9L+58+U5L;F+[25AD(E22
M1XE*N-[#ATVYKFO%GP!UN^TW0M.N=&UB]\-:;<:S#;:/H/\ 9$LMFLM\SV<L
M8U -$B+;_*IC99(OE50 6 ^K:*]..85HRYM._7S\_,X'@J3CR_UT\O(\+UOX
M*W^H6WQ,O[*U$/BK4K*.ST;7+QXGNP@L8HW D&[RB[JZLP R0"0P"UO?L]^
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MTA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9G.60-7:T5S5,34J7OI?_A_S-H4(4[6"BBBN4Z HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ef20061157_ex99-7slide2.jpg
<TEXT>
begin 644 ef20061157_ex99-7slide2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0@ S # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %58]5LI=4GTU+RW?48(8[B6S653-'$[.J.R9R%8QR $C!*-CH:M5X/\
M4_AKXN\2?$#Q'>Z*=0L+#5+'PS8-J&EZD+.X,,&J7<E^BNKK(F+><<C!(?"$
ML. #WBBO(X?!_C/1_@GXK\/:5?:@=>2348M$N=0U-KF[-NTKFW'VJ1W??Y9"
MJ\C%E^4L>*\V\7>"?&%YH.AKHOA/XH6VEQV5_%#H_P#PG2KJ=IJ3R(8+J[NC
MJC>?;A0^(_/E"YYA.1M /J6BOE2R^$GQ=TOP/JUW_;OB*\\<:II?B"WNY/\
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M,&1@TN4!#%<$@'OFI:G9Z+I]S?ZA=P6%C;1M+/=7,BQQ1(HRS,S$!0!R2:L
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M'K-E;W/F:YI/A+65TG4;H&W=4V7'VBV 19BK,JS)N 'W@"K87P'^$OB3PO\
M$'4O%?BIM4DU.]\-:78-)<ZW-<QF6.2Y,D;P^:T9DCC-L#+LY9I65B9)"P![
M<VMZ<FLQZ0U_:KJTD#726!F43M"K!6D$>=Q0,R@MC + =ZNU\Z>+/AC\1[KX
MN2_$6R;398;/4HK.TT1;+&I2:=Y36\A%Z;Q8ECW3S77E&$L3&@SNP!D:)\!O
M&^DQ:;?GQ!XVGU6VTS0;EH[KQC=30R:HMRQU(O&UP8V0PA 8L>003L3=S0!]
M,:;JMEK$#SV%Y;WT,<TEN\EM*LBK+&[1R(2"<,KJRL.H*D'D5:KYL\%^"_B%
M9_$R\N?%NG^+]6LY=0U%]$OM/\3B+3],A>^O7C^V6PO(S.&ADM?+'E3[%"KM
MC*'/#>*/#_QI\0>%]$LI/"OC^.\TC2M/LI?LOB2UC34[V$3"XGD>WUFUF\J0
M.F',H<MM+PL$VT ?85UJEG8W%G;W-W!;W%Y(8;:*615:=PC.50$Y9@B,V!SA
M2>@-6J\2^/\ X+UGQ9I?P]GB\/:_K2:3JAN]2T[PIKJV%^$-C<0XBNWN+5B!
M)*F2)49ESD$$J>4\':5\1=)^(7@/PMJFNWTMO>Z7!K.M1S7[33V8LB\8@,NX
M[C,\]B'(.U_LEP26\PY /</&OQ2\%_#9K!?%WB[0?"S7[,MF-:U.&S-RR[=P
MC\QEWD;ESC.-P]:Z<'(R.17C?QB^$.K_ !/^)GA66#6=5\/^'X-"UC3]3O=(
M-F9)1<26.VV9;B*4[)$BF):-0R^6/G7(SX_\5_AK\99OB=K7_""66OZ3H4=A
M/:V-S:Z[+]ED7^S'CAV++J_EQR"X,7 T]<%-WG')+ 'V+17REI?PQ^*WAWX_
M(]O>>))O!-O*PLKI]3GOH#:&T(,-PUQK0)D\]G/F&PE<?(!+M'R9D?P#\;Z?
M-\-]0U2/QSXJ:Q73+_6[5?&TXG74#!=Q74D9>\C155I8"T<;"-D5@JME@P!]
M97>MV-CJEAIT\X2^OO,^SP@$LX1=SMP.  1DG RRCJP!DCU2SFU&XT^.[@DO
M[>-)IK59%,L:.6",RYR Q1P">#L;'0UX?^T1X-G\:>(UTB*VFDFUCP5X@TFQ
MEAO&M6^UN;.1(1(K*5+B)CUP5B8'C-<F_P %?%MYJ\WBC1;7Q9X9U6UT70K;
M2K/4/%3RL)HKRX>[2]*74JW86*1?]>TJ[7.SYLX /J:N4\8?%GP/\/49_%/C
M+P_X:19%B+:QJD%H [+N5?WCCDKR!Z<UX[^R?X3^*7AN_P#$+_$636=\]O;C
M;J$GG6\MT"_FS6[-J]\RJ<CY%BM4QLQ&#E5T/VEO"_@7PC\,/B+KU]?:3X>\
M1>)-&U+2+;4-=UI+.*ZNKFT5! KW$JQ*SBTAP.,"(G@;J /9?"GC#0?'FAP:
MSX9UO3?$6CSEEBU#2;N.ZMY"K%6"R1DJ<$$'!X(-;%?'_C3X[?#S4/$?C35[
M;XQ>&+R*'PK!:Z!IMK\2(;&VEOBMV+@>7#>Q?O"&M@)'9=I"E)(R&<>,^!?B
M38ZMIVIP>)/CE8Z5:06FJW&E01_$^&UF%X8;$68D8:W>R.OF)>,%DN7C^8[E
M4,%H _2:BOSO^)/[0&DZAXP\57.C_$'3=2M[VQMXQ<2?$ZVLX8I5:W#FRAM?
M$-NC\*QV-'9MQ*3</N$;W_@O\</"]GJ6C0_$?XHVVIQ-#+#97=A\4;2VM]*1
MI[LD7\(UJ22=S$]N%;S+QEV@;U*[B ?>\>JV4NJ3Z:EY;OJ,$,=Q+9K*IFCB
M=G5'9,Y"L8Y "1@E&QT-6J_.;P/\6O#OAGX?SZ+!\3;'3M,M-*T.SFTK_A:N
MGRWEZT%Y='4!8W#:DWV;S86M]I\R#Y<(#&5^74\(_%;P]-J>IZQ??&^RTNVL
M9M.E\,:/??%6TFDMX?[0F:ZBO=E_)'=/]GV9,SS#:RJK,RDT ?<,WQ(\+QK,
M5UZPN3!=0V4ZVLPG:&:6X:V1) F2F9U>/+8 9'!QM..DKQ[XK> ]&\)_"3Q-
M9>'[4:?J6M&WL()R[S2/=2SJD!+.Q)Q-,7//WGD<\LQ/2:CXJU/Q[\*M:U#P
M7;7$&JW2W=CI<UXJ(/,65X$NQ\^&AR/.4A@7CQ@ L!0!V&CZWIWB*Q6]TJ_M
M=3LF=XQ<6<RRQED<HZAE)&5964CL5(/(I^I:K9:-;K<:A>6]C;M+' );F58U
M,DCK'&@)(&YG954=2S #DU\S>$_@!XV\.W]EX,U#4)G\%'4DU2XU+P9<3^'8
MO+-A/ UKM2^DN1B:&UF+(X#-.3T#BDT_X2_%7P[X'AM]*UOQ)<>(+VR\.RWM
MQJ_B)[OR[Z+4%:_*[YBJ)]GR'2+"2*, ,Q.0#ZDHKYL\*Z3X\\)>&?"FH0>$
M/'UWJNF:L)?$.FZAXJM[Z;5]UA-$\UL9]0:%;?SWCD$3-!C;N$0( J'X!^%_
MB7I7Q.COO%FC^*4LYM'6.[NM>U\3VL-R%B&VWBAU*:*3.WJUG$X(D8S/N"L
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M_'[PY_PF$L_B9_#6DIXQT2&#3VO;V>2*:"6,K)OD3RF_?S.$+GA,8"Z7\9O
M_A?XF!+3XMP:A90:GYT.LW7Q8M;G2SI/V;#69MIM2,C7)EWXE>$D,RL)U50J
M@'W?6)XN\<>'/ &F)J7B?7]+\-Z=),MNEWJ][':Q-*V=J!Y& +'!P,Y.*^';
MO]HR#PKX$CO8?C;X5O/&$-['96R2>.;.]MI+2ZMOLT7FHLV-]G,\<TTS)^\\
MF1PV)-L?>_';]H#X5MX1\-)X;^)NB>(-<T8.EEJ>B^.=#%_!(;<Q;ITU"<07
M$,JEDE#EF&Y652P#H ?7X.1D<BEK\WO'GQ2\*:=J?B9]!\<Z+-?ZOJ%C>R:C
MH/Q3CCT]$&GQQ2QP6:^(-/9=L\1'+JHC:/ ?8%1?%GQ6TJ.RT[4]-^*NAW7C
M&\\'Z-IVI:G;_$NU$*3V\S_;H6MQK%ONEDCD^21)1AMY\^-F+L ?I!17YV>$
M?B%H&M>''D\1?M 0V-_;R:9'IT*_$JVL7AA.I3-?!TCUB\$Q^RL@#SSS-M"[
M-KCA/BK\8+6WT71=(\+_ !OT6[T>RO-6"-;>/K:[U)%>X#64LDSZ]8-,BQ%P
M!---_"'B. 5 /T4KG-6^(WAC0_[7%WKMBL^D02W5_:Q3"6XMXHXXY)&:),O\
MJ31,?EZ2H?XAGXCF\>^#]6\$^(8=5^.VBZCJ_B'2_$5IJ$%U\3+9;<L\^=,$
M4*WICM_W8 _<X^5F60G.*^D_">C^#] ^!]SXTM=*NK**\\.RW4MQJ6K?VQ<O
M \(<DW(N+A9MZI%\Z2OO5(ADA$"@'M:L&4,I!!&01WJL^J6<>I0Z<]W NH31
M//':-(HE>-"JNZIG)52Z D# +KZBN%^$=\=:^'J^';U;[[9H=M!H5_?;O)%S
M<):0^>\$D;[L*[M&6!4K)&X'W<UX!X=_9U\43>$?!]I_9_C#PU?>&_"FK6*,
M/&$GGR:F6M/LS+-'=N[6[F%W6%V$2A0'C7@4 ?8=%?,?P'\(_&'2_C/JVI^.
MYM6.FS1W@>3S!)IMQNF4VXC4ZO*(V2, ?N]/M\_/N8\%OIR@ HHHH **** "
MO,?BI\?M ^&-];Z5)#>:IK<T]C$;6VLKEX(%N;I8$:>Y2)X8"27*+*RF0IM7
MDUZ=7F/C?X#:?XX\52:S)XCU[28+IK%]0TG3GMA:Z@]I-YUN\ID@>52K8SY4
MB!@H#!A0!S'Q8_:W\,_#NQNH-+L-6\1>(!?1Z=:6BZ+JB6=U,UPD#[+N*SF2
M18V?#>2)6# )M+D+6U-^TQX0T#2[:?Q'>-:7DT^I1"WT:PU#4PB65RT%Q*Y2
MU5D2-@N]V0(I/#LN'/-Z3^Q3X#T3QU=^*+*6XM[FXU)=5\F+2]*1TF%XEV?]
M+6R%XZF2/!62=AM8CC"[>SM_@!X>MOMNV\U,_:K;6[5\RQ\+JEV+JX(_=]5<
M83T7[VX\T 0P_M">'_\ A:TO@)X+^YU1I72"YTO3KR[MD"V]I,?M$RP".$D7
M:$$.Z!=I9U9PE2^$?VAO!?B;P7I'B!]<LHH[Z"25U@\]TC,=NMQ-S)#')L6-
ME8.\:;A)'QEU!2S^ FEZ7XZ3Q7IVO:WI^H&Z:XGAB>W:&Y1K2TM6@</"Q$96
MQ@?*E7#AL, =M<]I/['_ (#TK2-4TQFU*^LM1\.1^&98KN6)@(%@B@>9<1C]
M])';VJN3E6%O'\HP<@'H7A?XI>'_ !AH.J:OI[ZE%;:8S+>0:EH]Y8W<)6,2
M'-M/$DW*,"/D^;/RYK/U;XY>"])M#<?VG<:F"MLR0Z+IMUJ4TPGC:6+RXK:*
M1Y"8D:0A%)5,,V%()K?!/X&Z%\"= O\ 2=#E6>&]N?M,C_V1IFGG=M"X*6%I
M;1MPO5E+<XW8P!Q.L?L6> -9\ 6OA.5KQK6UU5M6M[J[M;"_DC?R?LZ1>5=6
MTL#QQVX2% \3,J1IAMPW$ ZR+]I;X?W5GJ%W::EJ>H6]B+?SWL- U"Y_>3B(
MQ0)Y<#;YR)XF\E,R -DJ "0W_AHGPK:VM_=7TE]'''J46FVMC::/J5QJ<TCV
M45WL>Q%J)UD$<A9E57"HH+,IW(E&P_9ET'2/ACK?@?3M7OK'3-8EBENY(]-T
MIU94MX8#&+5[)K01LD"9008R6V[1@"MHW[+>C>&=(AM]#\6>)M'U:"]COH=<
MADLY;J)UL8K%E5);9X/+>*%<H8MJG_5A J*H!N^&?VC_ (>^,?$EIH>CZU<7
MU[=.L4<BZ7>+:B5H/M"P-<M$(4F,7S^4SA\9^7(Q6Q\0/C#X6^&-Q9V^OW=Z
MEQ=12W"0Z=I=WJ$B0Q[1)/(MM%(8HE+H#*X5!N&36)X'_9Z\-?#^PM[33;K4
MI$AUE->+7$T;-)="U%LQ8A!D, 78#'SL2"!A1?\ B1\'X/B)J$%]%XDUSPM>
MBRFTVXGT0VNZ[LY2K/!(+B"4 94$-&$<9.&&30!E> _CO!XZ\6?$6SBTF>U\
M/>#Y$@;5I(+S?>/Y(ED,4;6RHZ!6&TQ2R,X*MM"O&S[-K\</!6IS7-OIVNPW
M]W!]C!@A20EC=0F:VQA>0\8+Y&0H!+8P:UO!/P]TGP!_;"Z2)D@U.Z2Z>"1@
MR0E+:&V5(^,A0ENGWB3DGGL.&\'_ ++WA'P1JNBW]A<ZK(^DQW<5O%/.AC*S
M96,, @S]GB+0P_W8W8'<3NH I_#O]JKPM\2--\(2VA;3;_6O(,]CJEO>6OE"
M2SN+@-;R26RI=(/LLJ^:I6(A'(?<%1ZVH?MA>!]/\0:5;O!KW]B7UA=WPU<^
M'-4 VP-;_O$C^RYDMRD^\W2GR5"C+?,*WXOV;_"R7'@V22YU*X3PM8P:=:PR
MRQ[)XHK6ZMAYV(P23'>2YVE>0N, $&/1/V=['3(6@OO%WB37X8]%N_#UHFHF
MR'V.QN!"&C0PVT98J+=-KREVY;<6SP >AZSXJTKP_!IT]_>+!!J%U%96TP5G
M1YI3B-=R@A0QP 3@$D#.2 >*D_: \(7WARPUC0]7M-4M[Z6U$+R"XCC,<U^E
MD&++"Y5O-9E564!F4Y**&=>@\<?#?3?'OP_N?"-[<7EK9RQ1)'>6;JMS;R1,
MKQ31LRLHD1T1P2I&5'':N4M?V;/"=C;ZW!;3:E##JFI:9J+1K,A%O]AFBGAA
MB!3Y8C+&SL#DEII3N&X8 )OA!\;/^%K2V*?V-_9?VGPKI'B;/VKSMOVXW(\C
M[BYV?9OO_P 6_P"ZN.:?@K]ICPGXH;5K?4&NM!O=-EU,2_;+&Z6TDBLKEX97
MANVA6&9@%5FCB9F3<5/*DUT'PX^#>B_"^2U?2KJ_N#;:!IWAQ/MDB-FWLC.8
MG.U%_>'[0^X]#A<*O.>2N/V5O#NJ6^M6.LZ]KVNZ%J$>I)#HUZUH+:P-_(SW
M+PF.W21F)=P/.>0 ,1CF@#T'P9\2-"\>:7>W^ER7T$5C*8;J'5],NM,N(&"!
M_G@NHXY%!5@P8K@@\$UR?_#37@/^Q;?53)XC2SN-[1E_"6KK(T2JC-<>6;7>
M+<"1,W!7R@6 WYXJU\&_@3HOP/\ #.IZ+H%VP2_G-P]S%I&E:>Z.4" A+&SM
MXF(QD%T8]B2, >6:E_P3_P# >L;9M0U?4;_41<SW!O+S1- G3]]Y9D M'TTV
MJ,S1*S2I"LS$G=(PP  >@^-OVI_A[X%N-<MKV^U2]N]'C=KF/3-$O+F,R+;_
M &D0+.D1A,K0_.$,@)7YN@)'7:A\5/#VC^ [?QAJ$FH6&CSB(11W.E727KO(
MX2.(69B^T&1F8*(Q'N)(P*Y[6OV>_#>O:/K6F7%SJ$=KJU^=0G6!XH]CFP%C
MM0"/"IY0!QCAN^/EK8UCX7+K_@'3_#=]XDUJ>]T^2"XMO$?^BKJ"7$+AXY\"
M#R"P(P082A!(*G)H K:9\>/!FL7F@6=G>ZA-?:V\Z6MD-%O1<1F&18YC<1&'
M?;!'D0,9P@7>N2,BI?%'QN\'^#?%D7AS5;^\BU1UMW<6^E7=Q!;+/(T4+W$\
M4310*[HRAI74$J>>*@\$_!72_!6N6>M+JNJZOK4,-]%<7^H-#OO7NIH99995
MBB1 X-O&JB-44*,;>]8'BKX#W?C;XKZOKVH>)M0L?"U]IVF6DVA:?]GV:BUM
M/<2LMR9+=I%3][&!Y,J$_.&XQ0!8OOVI?ASI]Y<VSZEJ]Q+;RW$4IL_#>IW*
M#[/(8[B3?';LIBB<;'E!\M&X9@3BM;Q/\<_">@^&]6U.#6+.YEL8KYA%*9E3
M?:VYN)=[1Q2.D8CV-Y@1@5D0J'+H&Q=5_9OTNZM4BTOQ3XC\.2M_:,5S<Z:]
MHTEW;WMRUS-;R>=;R*$$CG:R!9%'1^22_4OV9?!VH7GBR93?V:>(]!;P]-!;
MRIY=I \"0220;D)65XH;969BP(MHOEX.X 8G[3/A.X\<1Z!;O</9QV&HWU[K
M-Q9W5O9QBS:))!!+)"([H!I&5FA=MA0 \L!5+Q;^UIX'\-^$=5U:$:Y=ZA96
MUS/_ &--X=U.VNU\F)9"UQ$]MYEK"?,C_P!(E18AO!W&HY/V3?#5Y#J-CJ6O
M^(-6T&XL-1TVVT.ZDM1:V$%\X>X2+9;K(V652/.>3:!@?*2#@:-^P_X5\.:3
M?6.C^)]:T)=1M[BQU&71-+T/33?6<RH'MY5MM.C3'R9$BJLJ[V D P  >L^.
MOBMI7PY\#VGBC6;/5)[*XFM(/(T?3YM0G5[B1(T_=PJ6(!<9(&3T +%5-:U^
M.7@Z]\91>%XKZ^&K22+!F32+Q+5)VA$RV[W+1"%)_+(;R6<2<CY<\5J>,OA_
M:^,O [>&7U&_TJ(?9VAU#3VC%S;R02)+%(GF(Z%@\:GYD93CD5S5O\![&'QA
M%K4GB;7KFR6_35Y-!E-H+&;4%B$?VMBMN)@YVA]BRK%O&=E %[QY\6H_!'C+
MPUH?]E2ZA!J4J+J%]'+M&F1RR+!;NZ[3N\R=UC'(P [9^7!P-4_:Q^&>CWUW
M:7.JZL9+4W(=[?PUJ<T3BVD\NZ:.1+8I(L+\2,A81_QE:T/'W[./@7XF:MJN
ML>(M&MM2U^ZMDM;+6KBTMY;S1U0-Y;64KQL865W:4-S\YSR  +B_!'1/[-6S
M>^U*119:M8F1I(][)J,RS7#'$8&X,HV8& "<ANM $$GQ[\,V?BR^\/7$\]UJ
M,5^EG!;:)IU]J<VUK>VF,LZPVQ$*#[7&/,+-$ R$R!BR);UOX\>"?#^DV^HW
M6IW,L%S<7%I;QV6F7=W//-!<"VECCABB:1V65@N%4YY(RH)K'C_9WT[3?&]S
MXLT/Q1X@\/:S>31O>261LY$NH5@M8?L[K/;R 1D6<397;(&:3#@-@8FO?LHZ
M;KTFH1MXW\30:5=-?&+1VM=)NK.V6\G$]TBQW-A+YBR..DQDV@D+MH ])UKX
ME:'X>\%P>*M0_M.#2YQ#Y4/]CWCWSM*RK'&+-8C<>82P'E^7N'.0,''':;^T
M_P""+^/Q'++%XFTR'0I[>WG;4_"VI6S3R3K$8HX(W@#RRL9D40JOFDG.S:58
MZVI_!6QU#X.V_P .5UO4H-*BM([*2\DMK&\FGA7&4DBN;:6W*L."@A"J,! @
M  YS2OV7]*T31[G3;+Q?XHAAD^PSP.9+-VM+RT2-(KR+=;$"0K$BF,@P;1M6
M)1Q0!NZ/^T-X+\1W\&GZ1<:MJ&HRQN[VT>@:@ILBID79>DP8LF)B<!;CRR=O
M /%<S-^U=X;M=!\&:JUC?W4.N7,-E=IIME=WSVD\EC)=>7$L,#-=NIC\MEB&
M4R2VW:16GX/_ &<[/P/XBN]:TSQEXE%[JSF;Q!YHL&77IOG"RW(^R_NV57VC
M[-Y(VH@(.VI_ O[-_A?X<IX<MM#NM2MM+T"Z%[8:7YD7V6*<VDMM*X41@KYH
MF:1U4A3+EP 6?> 7- _:*\ ^*M;LM*TG6+B^FO!&(+I-+NQ9&1X!.D#79B\A
M)S&0WDLXD&0-N>*Y*;]K;P_:^ O"&M3:?=_VSX@LM)OFTNW@N9[>P2^ECC3[
M1>I 88<;WV^:8S(8\*,FM7PK^S'HG@_4K!K+Q'X@?0K.\74E\.SO:FR>]6(1
MBY9A;B?=P&VB41[AG9G.:,W[)?AUM)TK1X/$WB6ST*UT_3-.N]+@FM?*U-+!
M@UL\[FW,BN"!DPO$&  ((XH Z./]H_P%)I.HZD=1U*&TL7ME8SZ#J$3W/VB3
MRK=K9&@#722/\J/ '5B1@G(SN^ /BQX?^)K7O]@KK#QV;;9)]1T&_P!/A<[F
M4B.2YAC64AD8'RRVTCG%>:_#G]C/P1\,;.YM-(N+A+:6[T^[18M+TFSDC^QW
M"SPHTUK912S*610QG>1B 3N#$L>J\(_ BW\&^+/$OB.T\5ZU)JWB"X@GNY?L
MNF0 K')OV,L%G&)=R_NC)-YDJIPDB$EB :'Q@^+"_"G2]/NQI,VM/-,SW$$$
MFQK>RB7?=71^4[A$F#M'WBRKD9S6?XD_:5\ >%/$5QH5]J&JR:E!<"R:/3_#
M^HWJ-<F$3BW22"W='F,1$@B5BY7D+BM7QY\#_!'Q4UJUU#QGX<TWQ:MG:O:V
MEEK=E#=V]MO8-)+&DB';(VU 6ST0 8YS4\(_ _2/"-GH\,>JZOJ4FFZDFJ)<
MW\L32S3+8?81YA2-008AN. #OYSCB@#/N?VDO!MI>6Y-]+>V=]IMCJ6GQZ5I
MM_?:A=+<FY*XLX;9GVA;5V."S+M?>D852^]K7QK\&^'=*U+4=1U62VMM-N_L
M-UNL;@R1W'V877E>6(R[-Y+!L ').W[WRUR5Q^S!HL>I:9JVC^)O$7A[7=,T
M^UTRSU6P>TDFAAA-UQLGMY(V+B\E#;D(^5"H4KDR>)/V;[?Q%KUYJ<?CKQ1I
M27=TNH2V-HFFR6[7HM!:&Y*S6<C%C$ #&6,6>?+H [:/XG:!_P (#>>,[J34
M-)\/V<$MS<S:QI5W830Q19WN]O/$DR@!2>4Y'(R"*YKP[^TIX"\4^)(=!L;W
M6(]5EN&M/L]_X<U*S\N<0F<12--;HL;M$#(B.077E0P-3^%?@1HGA3X/WGPY
M@O\ 4+C1KJ*XA>=DMH)$68L6$44$,=O"HW85(XE4=2I)8G6O/A7I-[K%SJ3W
M-\L]QJ\>M.L<JJ!,EF+0*"%R%\M0>N=W(('% &3HO[1'@76M6?3/MVIZ1?I$
M\YM_$&@ZAI+&-4DD9Q]K@BRNR&4Y'!$;X^Z<;WB#XFZ+X;\,:=X@N(=:O=-U
M 1M!_8^@7^HSE73>K-!;0R2H-O4NH ) ."0*\(7]@_PMH/AV]TS1;R2YDU6^
MT\ZA=7EI864GV2%I5G138VD/F2307-S"TDNYV69LOQ7KOQK^!^B?'3PW8:)K
M5U/9VEG=K>(L-G8WD;L$= KP7MO/"PPY()CW*0"I'.0#&TW]IKPM=0ZO=S1:
MC)IT.IV^G:;)I.F7FIW.HB73;>_$HMK>!I4 2<@Y4A=F6(+;1TGA3XV>$/&W
MB:?0=(O[R:_C\X*]QI5W;VUP87"3+!<2Q+%.T;':RQ.Q4@Y P<<#=?L?>&)/
MA]-X-L]?UG3]&GN+2XF3[)I=UO-M96]G" MS92HFU+6-PR*K!\E6 PHZGP)\
M M,\ Z]97UOXBU_5=/TQ;@:3HVJ302V^FF=MTK1R"%9Y&.6&9Y9<!F Q0!C^
M)_VBAH/Q@O\ P3%HF+73;?3)+W6-1%_;Q>;?7B6T,4+)9212'Y^"95RWR\!)
M7BO>'_VD?#.H7 L]32]TW4&U>]TH);6%U>V\/DZA-912W%Q%"8K83/"2OG,@
MR2 6VDUO>*/@[HOBS6M1U.[NK^.>^?2'E6&1 H.G7C7<&T%"?FD8A\DY7@;3
MS7G-_P#L3^ K[QY;>+?-N/[5BOY=0D:[TS2K_P UWOIKS:'NK*62%5DN)%!@
M>-MNW+%E#4 >F_$#XP^%OAC<6=OK]W>I<744MPD.G:7=ZA(D,>T23R+;12&*
M)2Z RN%0;ADUP'B7]KSPEX>\8Q:"-+\17FS6!I%S>6^@7\T;,UBUVCVODV\G
MVO("KMC^8*QDQL 9NS^)'P?@^(FH07T7B37/"UZ+*;3;B?1#:[KNSE*L\$@N
M()0!E00T81QDX89-4;'X!:-I?CZS\36FKZQ!!9SQ7=OH*O ;".9+%K$2#,/G
M9,! (\W;E%..N0"U=?M >!K0Z(3JEW/!J]O!=V]U::3>3V\44[;86N)HXF2U
M#MD+Y[)DAAU!QO\ @?XB:%\1/"Z>(M#N;B719!NBO+RQGLTE3:&$J>>B%XRI
M!$B@HPZ$XKR;7OV*_ >O>(O#^M2RW OM'M+:R62YTO2K]IXX)&>/+W=E,\)!
M=LFW:(G(/4 CU[PUX)T[PSX#TSPC#YMWI-AIT>EK]J8&22%(Q&-Y4 $E1S@#
MKT% 'F^G?M7>#-1U;6E7^TH=$TW3[*\74)])OHYKU[J>2&%+:V:W$MPKF-=D
MD(=9"^%SM-=#H7[0G@GQ-JEIINEW>K7E],K-+#'X?U#-CM9U*WN8,6;$Q286
MX\MCMX!XKF]._9;TVQLY5E\;>++_ %".WL;73M4NI+'S]+CLY6DMA"$M5C8H
MSODS)*7#$.6&*T/!G[.EEX%\276MZ;XP\2&\U20S^(%F%BR:_-\X66Y M08V
M57VC[,81M1 0=M &[J'QU\$Z7X?MM:GU>0Z?=65GJ%NT%A<S230W<GE6Q2)(
MR[-(Y"A N_) V\BL+3?VJOAMJWGBWU35@\*2-Y4WAS4HI)7CF2&2")'MPTMP
MLLB(UN@:4,P!2H_"?[->E>%Q DOBKQ'K<-FNFPV,.HO9A;*WL9_/MX$\FVC+
M*&X+2%W8=7SS3/B%^RSX/^)GAU=&UF6^DMH[R]OX]R6TZK-<W:W3$Q30R12!
M9$&U)$9=N0P?K0!=M?VGOAU>:I8Z;'JNHK>W1B4PRZ#J$9M#).]O&+LM !:%
MI8W0?:/+R1BFV/[37@R\TB?4&M?%4"Q:M<:*ML?">IRW,]Q"TH<PPQV[/)&!
M"Y+J"%X#[6^6J/@3]ECPI\/]"U#2["[O##?)9),T-GI]BO\ HMU+<QE8;.UA
MA4EY6#$1_, /XLL3Q?\ LRV'C+P[K&@7/C#7X=$U+5Y=9:Q:STF[CMY9':1D
MB^TV,I5?-<R!B3(K?=<#B@#M/&'Q>\(^ $G?Q%K"Z2L-FFH.;B"48@:9(0_"
M\XDDC4J.5WKD $&N6^(7[2GA;X=:A91W?VS4[>:6:U=-(TZ\O;L31W-I;L(X
M8H&$B*]XH=MX(8!461B0NYXT^"OA[Q]=^&9]5>]D.@I+#&OGA_M<,D:JT5PS
MAFD7='#+U!+PH22,@\S<_LN>'9O#/A[2(==\06D^AV,]I:ZK'<0/=M)+=VMX
M]U(TD+*\WGVD;Y*[3N?*G(P 7_"_[17ASQ!\1-7\&3PW^FZK:Z@EC:/-I]WY
M%R6LHKL!YS"(H9BKO^X=_,Q'G'.*9\2?VBM%^'EYXPTQM+U>\U?PYX?;Q#)N
MTZXCL)8@LI"?;?+:)&_<M]X]\+N*L%WK#X0Z79:@]\^H:C=W<FMQZ_++,\0\
MRY2S6TY"QJ I1 Q  ^8G! ^45O'?P6T_Q]JVL7=UKFL6$&L:&V@:A86+6X@N
M(29"DAWPNZR(9I-I5@/F^96XH RU_:@^'S:7]M-YK0VR.DUI_P (SJAN[8*D
M<C2S6_V;S8H0LL;>=(BQX=?FYJW\;/C&_P )]$T74+:RTR[AU*[%L=0UK53I
MNF6RF-G5IKL0RB,N5"1[E"N[JN]2RYY7XL_L=>"/C!XH;Q#J\UQ'JS''F2:;
MI>HQA#'#&46*_L[B-<B",[E4/G(W;3MKT#Q]\,6\;>'[32;3Q5KOA&.")K9I
MM!-J#- R;&B>.>"6+:1C!$89<?*R@D$ \SO/VKH],\=>.-&O;#P[#;>%(&FG
MT]?$ZOXBN<6D,X,6FB#:4+SK$'^T;=P)KUCP'K/B_5K>Z7QAX8T_PY>1LK0_
MV5K!U*WE1ATWM! ZR*0=R^7MP5*NV6"\9;?LVZ3:W'B"U3Q-X@_X1/78?)O_
M  F39_89!]CCM 1+]G^UHPCAC(*W PRY]J[/P'X)O?!MO=+J'C#7_&5Q,4"W
M6O-:AHD4':B);00Q]68EBA=LC<Q"J  8<G[07@I;&_NXKG5[V&SOWTLBQ\/:
MC<O<7*-(LD=ND<#-<F,PR[S"'";&W%<53L?VF/ .J:JNG6%WK6HW#VS7,;6/
MAG4YX9%6!;AD25+8HTHC9<Q!C(&8)MW_ "UF^//V5O!_Q#\#V/AC4Y;EK:QU
MB[UNVN)[2QOFCGN))Y)08;NVF@=?](D4;XB5&T@[ANKRWPC^QSK'AWX@:^BS
M:-8^#]4TR;1IM2T^'3HM3GLVMEB2,11Z3&82K(C%1=/;_N\"V56"1@'M6D_M
M&>!=:U*RTVWN]8BU.ZFEA6PO/#NHVUS#Y8B:22>*6W5X(E%Q 3+*%3$BG=S7
M/6W[5/AS5]6U*'2X9O[,LH=)F&I:M:7U@DXOKTVJ&)'M=\B' 9)4#12%L;T4
M,ZO^$W[)O@[X07%S-I<UU=FZAO+>>%[.PLK>1;E;59/W%E;01J=MG$ 549RY
M.XG(-._99T:WT^:UU'Q;XHU\-%I=M!+J$MH'MK?3[L75M GE6R J'!#,X:1E
M8Y?(! !K:3^T[\.]<T"]UFPU/4[FRM5M9 $\/ZCYUTEPYC@DM8?(\RZ1V! >
M!77@\\&KNL?'SPMI/PQL?'JQ:[J'A^]NH;2%;/0;U[PM+.( 3:F(3* Y[H">
M-H8LH;AOBQ^S*=<^%MMX;\,-#J$]KINFZ,+;7[B%8)[2TD+KO+V=S$9"3D^9
M;2QG;@(IPZ]9X?\ A'J-]\"=)\#>)-4_LW4;6* )>^'%MXS9&"=9;80_Z+'"
M3&(XES]F1&V$^4H.T %+3_VHO!__  EWB/P_K+7FA3:3=>0EU=:?=BVE7[#'
M>?/.8!%#-L>3_1W?S"(\[>0*[SP-\0M%^(EC=76CG4$%K-]GN+?5=+NM-N8G
MVJX#07,<<B@JRD$K@@\$UQOBS]FWPQXY\.:]HNNW>IZC:ZY?_P!I7S220JTL
MWV%;(\+&%"F-0Q7&-Q/\/RUH_!+X&Z'\"=!O]*T.43PWES]JDD_LG3-..[:%
MQLL+2VC;A>K*6YQNQ@  KK^TG\/?M&LQR:S=6\6D0WEQ=7ESI%[#:%;1REUY
M5P\(BG:)@0RQ,S#!R.#3M#_:-\">(=<BTBUO=6BO))#!NOO#VHVD,<WEF7R)
M)IH%CCF,?S"%V$A!4A3N&>.\/_LLBZT?7;3Q?XKU;5(=0EUM;33;9K5;73(K
M^YE=G@86RRM*8I #YSRJI9PHQBNLOO@)877BJXUA/$&M+827O]K'PV6MO[.:
M_$/E+<D^1]HSPK;!-Y>X9V9S0 S3?VGOAUJVB7FK6^K:A]BMXK:=#-H6H127
MD=P_EV[VD;P![L2/A5,"R9) '45>\-_M ^"_%VN6ND:3<:Q=7TR,\BGP]J,:
M61#2*4O)&@"6CYB?]W<&-N!Q\RYX?P'^RJ=(\!:-8>(_&FNZGXHT_3=/L[35
MH39 Z.UJ5=5LP+1$9/,'6XCE9E #9Y%:&F_LIZ):>,=+\27WBGQ!K5_927$\
MAO(--22[EG#"9I+B&SCN$5P5!BBECB(C0%",@@&S_P -.?#\PNR7FM2R[T2"
MUC\,ZF]S>JZR,LMK"+8R7,)6*1O.A5XP%R6Q@TL/[0>CVOP3\.?$G5-,U1=.
MUE+(K9Z-93:G/&US(B)A8H]S %QDA<GH 6*J>%\&_L-^$?AS/%=^$_$.K>&=
M3MG7['J6DZ1H5M<V\8CDC:(NFF@SJRR8)N/-;*JP8-ECZ=+\&=+'PBL/A[::
MIJVGZ?I\-K'::E!+$U["UO(DL,@:2-D9P\:GYD(..0: *FH_M$>#=-U"^L1'
MXFU"ZL'CCNX])\(:O?\ V>1XDE6.0P6KA'V2(Q0X8!AD#--T+]I'X>>)=?MM
M'T[6[B>YN%0I.VEWB6@9[8721O<M$(4E,!$@C9P^/X:QO'W[+?ASXC:'?:=J
MNKZE)]NUB/6[F6>TTZ\66X6S2UPT%U:2VY4I&K<Q95\E2HXK2\%_LY^'? /A
MZQT?2-0U2*"QOH-0MY6> NDL-@EC& !$%VB.-6QM^]_L_+0 C?M->"$T&'6W
MB\6II$NYA>MX(UH1+&JJYE=C9X2+:X(E;"$!L,=K8->_:6\&:%I>IZ@L7B35
MK/3[^#3I;C2O#.HW,,DLMP+?]Q*L'EW 63(;R6?!&WEBJGS?6OV ?!'B33WM
M=5\1:UJ"RW%S<S>=I>AF)WG6,2,L T[R8928\F>&..=BYW2-A-OHT?[/MM!X
M7UGPY;^,_$UOH=Y/'=6%E']AQHTR7(NE>U<VI=OWH!VSM,H P !Q0 A_:5\&
MZ?H]M?:K=W,;7-SJ$<=OI>E:C?2QPV=RT$LT\:6HD@5"%$C2((T8E0[ !CM6
M?QV\$ZAXZ'A&VU6>?6?.%MNCTZZ:S\YH!<+%]K$?V?S&A(D">9N*G(!KF;G]
MF73?[/2#3_&/B?1KISJ2WNH6361GOX;ZZ:ZN(91):NBKYCL5:)4=0<!N3G<'
MP)T6SM+J'2M2U31'DU--6@FLVA9K29+%;*,1B6)U*K&BL X;YASD?+0 ?&[X
MB>*?AGH>FZIX=\,Z/XDAGU"UTZX35-;ETUHI+FZAMH"FRTGWKOFR^=I55R Y
M.*RO!?[1&GZQXWU/P3XBL3H7BRQODT\QV:7=[ITLQLH[HHM\;:.(/AY L;E9
M&6/=M^8"N^\:>"[+QUH<&EZA-<1P17UEJ >W95<R6MU%<Q@Y4C:7A4,,<@G!
M!P1D+\)M(76+O4OM-[Y]SKJ^(77>FT7"VBV@4?)GR_+4'&<[LG..* ,_X7_'
M3P]\4ELX-+-Y<7TEA#>S3VFEZ@VF)YD4<NQ+Z6VBB=MLJ'8=LF#RBD$#T:O'
MOAC^S+HGPN\5Z;KMEX@UG4I=-T:+0K6"\@T^,+;1HB(LDUO:Q3SX"$A9I70,
M[,%!VE?8: "BBB@ HHHH *^8_P!HJZ\7ZUXYCT"WE\5)I:W.AW.G:;HOA_[9
MIVHA;]7O'O+O[,_D-$D:LJ^=#G .)=VVOIRO,/'/QZL/ GC=O#L_AG7M2BM[
M:QO-0UBQ^R?8]/BN[F6WA:427"3-EX7R(HI"!@]Z /#M=^('Q?M]:ECM]1\:
MY;4;B/Q'!!X05K?0-/%VJPSZ3)]A;[=,8MOR[[K(9W\M2@2NVU+XF>+=!OH=
M/LG\9Z];:II^BG1M0NO"4PE>0WDJW[W?EV<:6K^1Y1*S+%@<HH.:Z"\_:GT;
M3-4O+.^\)>)K0?:;NQTF9DLY%UNYM[Q+-X;58[EG5C-(@!N%A7!W%E )&C#^
MTAH-C:W,WBC2-8\#-8W@LM237_LH73V:#SH9)I8)Y8_+E4%5='8;QL;:W% '
MG.L6'QHO/ME]:^._$VG^?:>(+M+"W\/Z>T=O):W833H(]]HSXFB)+;V=I N8
MS'UKA=/^(O[0GB#QEJ&GROK'AT76H16KPQZ)/<1V%NVHP1>?;/)HR6^1;-([
M;[ZZ W%MHV,J_1]C\=](N[_3]-FT;7-.UJ_:P^S:5>VT:7+QW2.ZR[?,("QK
M#<>8"0R^0XVDE-UC7/C'#IOCR]\)Z=X7UWQ'J-C91WEW)I7V3R[?S1+]GC82
MW$;YE,+JKA#$I^_(@#$ 'FVD+X\L?B3X"&O>*?&T^FP7.M:7.]MHT+6^H[+F
M(V<M^(K0K$'B#XF7R4^0;2F]@^3\7/$7CGPL?'MSH9U[1Y'\5V[6K>'?#3SW
M.I6HTFT#_OH],O@<2[P)983DQ"+S8PO'=Z3^TQ;7W@?7_%5_X!\7:'I^DW<F
MGI#=C3YKB_NH[E[:2"WCM[R4EUEC927V*1RI(R:N:E^T(MKXTT70=/\  ?B?
M7K76; ZK8:[ITVF?89[-1 99QYMZDH5/M4608]QR=BN!F@#"\97GQ+N/'5Q?
M:/JFNZ7H>EV6ASQ:,NDVLT>H2SW<B7L<\OE.Q,<*H2()$V$[B2I KRGQQXD^
M+6J/>Q0>(_B-87-OJ;W&M66C^%$6#3+.+48A%_9LYL&-ZS09+(LEP7&[*J,Q
MGV.;]J&ST[X/S?$C5? 7B_2= (LI+.&5+">ZOX[ET6.2&."[DX&]25<H^#PK
M'BM+QU^TKX5\!^(+S1YK;4M6N;3PU<>*9'TQ(GC^RQ8P@9Y%_>N,E1]W"DEE
MR,@' ?M2^./B+X7T7PLWP]E\63WTUC/*9K/3#(ES*JQ>4ES&FC7K([%B=K?9
M$^^/,!'R=#\?O%OC+0_$G@5/#5UXE"7$V+[2_#^C-,+@,\8!DN7T^ZAC"_,"
MDDMI\KLQF&T5TL'QZM;3Q%X0T+Q%X2\1>$-3\3R7<=G%JGV*58S L9S+);7,
MR()#*JIR<L-IVEDW9.C_ +2R^(/$?A;2],^''C"]@\26/]IV.IK)I:6_V53
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MU#X9O_&_G>#?$ESHG@^VFN-3U^W:P^R;H[-+LQ1HUTL[.8Y$ _=!=QP6 !-
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M^/\ XA>)/B=';^*)O%UQ87&CK.]K?>'GTRQL)PL6Y7:738M[DDD-%>RY+L#
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M(3>(Y/B9\.[T:OXKT_2+S2[ZWO=,T731<V$MV1;M$MW_ */(T*D><!(73:4
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MXU8J%SN95:G8_M9>$+_X8^$O&RZ?K45IXFU6+1[33)K>);Z.:20INE3S=H0
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MJBMI'_";Q:*\"PQ$"W/AZ6\:$MMW ^>J29SN' SM.* -KX5_!CQ%X1E\,_\
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M=ZAXP\$_\)9KG@S4?MOV7_A'-7;5/+\K?]HW6=S;>7G<-G_'SNW8/W,8YR/
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M?'3QGX&\:>)X+K55&@7_ (AT;1-$N/LL(^PW3)82W%NY*Y<7$5S.R%@2K0N
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M>U:U1VBD1G4F)SM;,1*C>#Q0!ZLVF^'/!VE0WK6NEZ'INAV+PQW!CCMX;"S
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M5A.JJ%4 ]UU+X9^$-:\&Q>$=0\*:)?>%(4CBCT*YTZ&2Q1(R#&H@92@"D#
MXP,5G7S?#GX>#PYH-Z?"_AD74;Z/HFF3_9K3SHW*;[6UB.-RMB/,:#!PN1TK
MP/6=/^+?@+P':7TVJ7Y\7MJ<&E6*W>K?:K:X@O+?[-;QN@(!EM)GCEEE*$R^
M1(X.)-L?<?%[P/XECUSPA)X5T/6]9U*TM(],?6A?V4MK+;^=$98=5@O&#R1,
M$63S;<//N5PI3<1( >SS^&='NK?3;>;2;&:#3)(YK&*2V1EM)$4JCQ C",JD
M@%<$ D"H(_!?AZ.UN[9-!TQ+:[OAJ=Q"MG&$FNPZR"X<;<-*'1&WGYMR*<Y
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MX9\*:A!X0\?7>JZ9JPE\0Z;J'BJWOIM7W6$T3S6QGU!H5M_/>.01,T&-NX1
M@"J;_![XB>*M'L+K6-6\7:7JUO8:#"D.G^*I;=8Y/MDAU0N(IPDK_9V4%I-W
M0&/YAF@#W"/X.^ H?!+^#4\$>'$\(2/YC^'UTFW%@S;P^XV^SRR=P#9V]1GK
M6Q8^$-!TVPT>QL]$TZTLM&(.F6T%I&D=B1&T0,"@8CQ&[I\N/E9AT)%?(^O?
M"OXXZ7\0+"WTJ_\ $\_A2QO2-+N8]5DOIH(?MTSM]K>;6K7SE:$PJ#-#>,$!
MP%8;6VKSX#^-_P#A5BV&H-XQ\2WTVF:!J6H6+^,9_M,VJV]V)+U+>9KI! 3&
M. CQP[E0C#*& !]5WFE66HSV4]W9V]U-93&XM9)HE=H)2C1ET)'RMLD=<C!P
M[#H36<VG^'(;ZSTMK;2X[W?/J=M9&.,2;B2L]PB=<DW#!W ZS')^?GQSPCX3
M\6-\=-:N;K1O%UMX0OM)^S_:M:\0OY5N_E1(%MT@U2568X/SM:Q2!A(_VARP
M#>=>'?V=?%$WA'P?:?V?XP\-7WAOPIJUBC#QA)Y\FIEK3[,RS1W;NUNYA=UA
M=A$H4!XUX% 'TCX;^#/P_P#!NEZOIOA_P+X:T/3M8C\K4K/3=(M[>&]3:R[9
MD1 )!AF&&!X8CN:ZFXTVSNI+22>U@FDLY/-MGDC#&!]C)N0D?*=CNN1V8CH3
M7Q%K7P?^,'BOQ%XDEUG0O%<FB>:MX-,L_%=Q +V6+4[29/LLS:Y(J,8([@KB
M"R5"RC'"[?3_ -J7PC\2O$FB^%H/AWI?B".YAL9PUQ::W-'-:3[8A"MP$UBR
M23G<3(_VOE&_=D,=X![.OP=\ KXET_Q$O@?PV/$&GKLL]6&DV_VNV4ECB.79
MN09D<\$<NWJ:NZQJGA+X>:2JZK=Z+X9TS4+QH5%Y+#:0W-U<.S,HW$*\DKL[
M$<L[,QY)-?.GCGX8_%E?AE&VDW/B"]\07_B6\N=9M5UNXEG:P$MU]C6V":I8
MK @5K8LL5S"2%&]9""I[.?X3>(?%&G_ B[UV36[K5O"]T;G5;@ZG)82J?L$R
M!IXX+N196\WR58>;/D,X+,CR;@#K?#/PQ^#5]X7O/#'A[PGX%N/#FJ0V^JW6
MC:9IMDUI=Q.3]GN7A1=DBL8CLD((/EG!^7B_JWPE^%NG7>BZ[JG@SPA:W.AI
M;V6EZE=Z7:H^GJKA;>*"1DS$ [ (JD8+ *,FOFCQ9\)_C@VD^'+NR@U2:_;P
MMX>T[7VMM3W:A=7%NNI-<()8]3L78K+<6[,XNT# G'FX9:VO$GPP^)WB&'PK
M9ZOIOBWQ!<P6V@O#J$>N0V%E926]V);X:A9C4'6XE9$7:W^E?,!B12"Y /I+
MP3\*?!/PSDOG\'^#M \*/?%3=MHFEP69N-N[;YGE(N_&YL9SC<?6MAO#.CR-
M=LVE6+->7,5[<DVR$S7$8C$4S\?,Z"*+:QY'EI@_*,>(_%KPGX]U3XI+>:/:
M^)[J!H]/71M0TG7UL]*TITG8W;7]I]IC-T'0K@>3<9 V@(<D[6A_#7Q8OPK\
M;PR:SK5GXWUB[U*:RN[K69KA;;;=3MI_E+YICAC\OR R1A=R\."<T >ERZ;X
M<\(KJVOR6NEZ*IC>XU'5&CC@!C4%GDFEP/E RQ+' Y-8.FZ-\-;C3H-"T^Q\
M*26!F:ZATVVAMC%YMB\432+&HQNMW2%"P&8F6,?*0!7BJ^#_ (VZIX=\;+<R
MZI8W-_H&I:KI4*:U&)K;5KR$I#IZ.D@"I:["5<G9NG4JQ\O=6[\.OA7XKT/Q
M9H]]J&F&&""/QF)9#<Q,0;_5X+BTX#DGS(D=O]G&&VG H ]5\*?#OX?V4TWB
M/PSX9\-03:S*FIRZMI-A;JU](0Y2X:6-?WC$2R$.23B1L'YCFE\3/!/PNG\.
MZGJ?Q"T'PC)H2W":A?WGB:SM3:B94$*3RO,NW>$VQAV.0,*#CBOFOPO\*?B]
MX=^$-WHWAS3/%7AZ\@T;2K&[L]<\1"_DO;B*5?M<FG"+4U%JAA#J%6XL\Y3;
MY>W=7<Q_!WQ=XU_9Y\,>'?$__"12ZW:>)K*_DCEU673[V&U34%=PT\6IW3R!
M(2Y4M=R/\J$8=5P >UVLO@3Q8TL%L_AW6#K%C+821Q&"?[=:6[M'+"0,^9%$
M\[(R'*HTI! +8*:]\/? 8\11>.=:\->'!KNDP$Q^)+^PM_M5E"BL21<LNZ-%
M#/\ Q  %O4U\Z_$KX7_&/4+6RO=#2\DU6U?Q+ ]PVHA[G[#<ZY9S6\,3"\MW
M#/90N$VW$.P*%,D1VUD^)/A=\5]=^$6GZ%JNE^--?DGTG5[2*TM->CTR:QO9
M9!]EDOF.KW!NK98RZ[7N+HX^_$Q(  /K5?"?AZ[.G7(T;3)C97,FH6,PM8V\
MBXE#^9/$<?*[B63+KRWF-DG<<QS:7X8U*2[\/RV>DW4BO%JESI;Q1.0[3,\5
MR\6.IEA9ED(Y>,D'*\>*_$3PC\5[/Q!:7/A&2_N-+M]/L]6^PQZG'"DE_9AT
M;3OG? CNUDBR0 BFW9F(+#/.^*_@_P"/;WQIX*U/5H?$_BK3]&BTB:YBT?Q.
M]B6O"-46^E1?M4((5KBT)!/S1+L7< 4H ^@(/!_@CQ-80M#HGA_5;*WL[C0X
MVCM()HXK4L(KBS7 ($>8@CQ#Y<QX(^7 3PKX/\$?">SAT3PUHGA_P=:ZE<LT
M6G:5:06*75QY>6*QH%#OY<1)P"=L?HM>8?!KX1^(_A_XMBU2:?64@U&]\03:
MI9W.M/<62++J!EL6BM3(8HB8RQS$BM\[>8237'Z9^SSJE]J.GZ/=:9XNTO2K
M3QUJ6KW>IKXOGW7%G-#?&&2VD2\,\"EIX4=4$3,Q8D,"S$ ^@]:^%W@SQ)HZ
MZ3J_A'0M4TI;9+(6-[IL,T MT972'8RE=BLBL%Q@%00.!7 7O@O]GK2];;3;
MO0OAG::QX3TXW+6<UGIR7&C6.6D,A0KNMX<RLV["KF0G^+GRKX8^ _CGIGQD
M\.WGBJ[UV;1;58HGNDN1<VK6RV80Q7 .L(C2F7<QE&GRON*GS2,[='XI?#/Q
MQKFJ?$S3O#?A/5[?3M:TK5&9KJ_TV?3[J]EMEBAFL"[_ &FWN) $61)0EN C
MGEFWN >K:Q\3O@EK/A2W\2ZIXL\ 7WAEQ/H4.KWFI6,EFPE13-9K,S%#O5%W
M1 _,$&00!6]KGP\^'7B+QQI.JZQX9\+ZGXQM8!/IM]?6%M-J$4,3@AX793(J
MH\B\J<*9!T+5Y-HMGX[T;6/#?B_4?!/C7QI-9:?J&BS6&NW'AZ/6(O.DMY5N
M$%M/%9F%A"T;?.)?DC^5@6-1_'3X;^(]:U;P=?Z-X2\1.ECX;OM-CM?!/B*/
M2?[,O)6M#!ND^TVIDMX_)<%5#J=JYB;@  ]I\$_"GP3\,Y+Y_!_@[0/"CWQ4
MW;:)I<%F;C;NV^9Y2+OQN;&<XW'UKJJ\'^'=OXV7XX:EH.K:]-J6B:):)K%Q
M*D[XDN[R&.);;!/,<;07TP0X %S!@?(*]XH **** "BBB@ KS_QY\6H_!'C+
MPUH?]E2ZA!J4J+J%]'+M&F1RR+!;NZ[3N\R=UC'(P [9^7!] KS#Q]^SCX%^
M)FK:KK'B+1K;4M?NK9+6RUJXM+>6\T=4#>6UE*\;&%E=VE#<_.<\@   S]4_
M:Q^&>CWUW:7.JZL9+4W(=[?PUJ<T3BVD\NZ:.1+8I(L+\2,A81_QE:U9/CWX
M9L_%E]X>N)Y[K48K]+."VT33K[4YMK6]M,99UAMB(4'VN,>86:(!D)D#%D2=
M?@CHG]FK9O?:E(HLM6L3(TD>]DU&99KACB,#<&4;,# !.0W6LN/]G?3M-\;W
M/BS0_%'B#P]K-Y-&]Y)9&SD2ZA6"UA^SNL]O(!&19Q-E=L@9I,. V  ;&M_'
MCP3X?TFWU&ZU.YE@N;BXM+>.RTR[NYYYH+@6TL<<,432.RRL%PJG/)&5!-.\
M3_&K0?"=KX/N;RQ\12Q>*+I;2Q6U\/WLLT3F)Y0;B$1>;#\J'(= PY) "N5X
MK7OV4=-UZ34(V\;^)H-*NFOC%H[6NDW5G;+>3B>Z18[FPE\Q9''28R;02%VU
MU[_!>S3P7X.\/6?B'7-/;PM<0W-CJD#V[73-'&\15P\+1;'2612BQJJAL($"
MK@ Y70_VN/ UU!J2ZS+J&B7UCJ%WI_V?^RKZX2Y:&^^QJ+:5;?9<R,[0YBA+
MLC2A2,BNKMOCUX*NO%$?A];[4$U%BL9:;1KV*VCF: 3BWDN&A$4=QY9#>0[B
M49 *YXK/O/V=_#E]#H,<E[J@71M6N-9M]LL>6FFOTOF5_P!WR@EC"@#!VDC)
M/S5-<? C3+KQI)K<FO:T=+EU :O)X9#6W]G/?"(1BXSY/V@-@!MHF$>X;MF<
MT +K_P"T=X!\-Z7I6H76J7UQ!JEC#J5G'INBWU]-+;2))(DODP0O(%VQ2$DJ
M-H'S8R,YW@C]ICPKXT\;W_AA4O[*\6\BMK":;3;Q;>[62QBO$WS- L<$Q21_
M]'D<28CSMYQ7DGQ6_8KU+5M)T2VT#6Y/&$6GI#9Q:?XRGTY+>SM(4D$$<(;2
M+J%RGFN-TT#RD$$3+A@_N/A?X/0Z;;VEWJVI7%]KK:I!KU]/"$CAEODL4M&V
M($^6(JF[;U!/4#B@#-^)/[16B_#R\\8:8VEZO>:OX<\/MXADW:=<1V$L064A
M/MOEM$C?N6^\>^%W%6"JO[4'P^;2_MIO-:&V1TFM/^$9U0W=L%2.1I9K?[-Y
ML4(66-O.D18\.OS<UJ>._@MI_C[5M8N[K7-8L(-8T-M U"PL6MQ!<0DR%)#O
MA=UD0S2;2K ?-\RMQ7&?%G]CKP1\8/%#>(=7FN(]68X\R33=+U&,(8X8RBQ7
M]G<1KD01G<JA\Y&[:=M 'HOC#XO>#_ *3OK^MQ:;'#9IJ#221R,AMVF2$.K*
MI##S)(U(&2-ZDX!!JCXF^.G@WPFC-?7U].$GG@D&FZ1>7YC,.WSI'$$+E(HR
MZJTS8C5CM+ \4[QK\%?#OCZ\\,SZH+@#04FABAM_+2*XADC56AE79@Q[HX9-
MJ[?GAC[ J?//%O[%/@7QAX;\):3>W5[++X<@GMX-1U"PTS59[D3R+),\RWUG
M/%YCR+O,B1HV21G!(H W/"/[4W@WQ%9ZP]^][H\^F/J;2;].O)+:XALKAX9'
MM[GR!%<OA58Q0L[J7VX)!IMU^U1X5LO%6DZ/)I_B)O[6%NMK&GAG55O8WE-X
M-UQ:O:*T,7^A/M?)9OF8HJ+YA71OV9=/T,7$=MXQ\1FU5+X:;:20Z:T.DO>2
M%[B2!/L>')W.H6?S4"L0%%9OA7]D'P[X+_L^71_%'B.QU"QDM7@O+=;"(1B"
M2\81I;I:"WCC9;^=&2.)5V[2H5]SL >C:#\6O#/B;Q;=^&]/N;V34[82G?-I
M=U#:S^4X24073Q+#.49@K")V*G(.,''(ZI^UC\,]'OKNTN=5U8R6IN0[V_AK
M4YHG%M)Y=TT<B6Q2187XD9"PC_C*U'\.?V6?"'PM^)FK>-=$)2^U%KEWMWTK
M2U*-/+YLA%VEHMX_S9XDN'&#C& N.B?X)Z')9&U-UJ'E_8]7LL^9'G9J,ZS3
MG[G564!.P'4-UH I>./VA/"_@EM6MKEM0@OK.QGO(KB_T;4H-+G\JV>Y*K?K
M:O"W[M&8B,R/A6PC,NVJ-Y^U-\/[;3_$=S#=ZKJ#:#:7EW<QV>AWK"<6KA+E
M+:1H5CN'C<A6$;'9G+;0"1S/B[]BCP3XU\9:GXDU#4M4^V7]E-8L([73?,B2
M2Q:R;9=-:&Z \IV(C,QC#'.S&!7;?\*!\._\(^=&:[U)K0P:Q;DF6/>5U*4R
M7'(3JI8A/0==W6@"SH7QX\*^(-=TW1X8?$EA?:BN;4ZQX5U33H)6\II=@GN+
M9(M^Q6.S=N^5AC((K)\!?M->!_'5QHVGP:H3JVH00N?LUA?/IZ326HNA"+V2
MVCCWF%MZH^R1EYV#I6)X>_9'\/:+\5-.^(5[XBUGQ#XEL3N6[U2RTKSI&^RF
MVRUQ%91W&WRV)\L2B/<<A!6[X)_9M\+^!?#-AH5G=ZI=6-G>V]ZOVN:,N[16
M"6*JQ6-?E,48)Q@[B2"!Q0 [_AISX?F%V2\UJ67>B06L?AG4WN;U761EEM81
M;&2YA*Q2-YT*O& N2V,&H;C]H.TL_@;X9^)<VDRFRUA]-!LK9I+B2-;N>*+*
M".(O,R^;D(J;G("@9(KC/!O[#?A'X<SQ7?A/Q#JWAG4[9U^QZEI.D:%;7-O&
M(Y(VB+IIH,ZLLF";CS6RJL&#98^DW7P1TJ3X4:-X"M-7U?3;'1S9M9:E;R0R
M7D3VLJ2PN3+$\;$-&N=R$'G(H ?IOQ^\"ZGITM['K$UND-M)=20WVG75K<(L
M<X@=6AEB602"4HGE%=^73Y?G7.3\2?VBM%^'EYXPTQM+U>\U?PYX?;Q#)NTZ
MXCL)8@LI"?;?+:)&_<M]X]\+N*L%S-0_9MLY]4\#2'4+C5O[(UJ?6M7U35'1
M;W4G;$JHPAB2/;]IALY"JJBC[)& IKJ/'?P6T_Q]JVL7=UKFL6$&L:&V@:A8
M6+6X@N(29"DAWPNZR(9I-I5@/F^96XH RU_:@^'S:7]M-YK0VR.DUI_PC.J&
M[M@J1R-+-;_9O-BA"RQMYTB+'AU^;FIOB3\:)? OC3P?H5MING7,'B!CMO\
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M6_L;^ O%GBOP_K[(UG=:-96>G11G2M+O@\%L285WWEG/)"1N8;H'B)R#G(!
M!H>"/VK?!?BWP';^(K@:OIDYL;&[GTPZ'J$L[&Z(6,6JBV#WJ&3*B2W5U.,\
M"K.B_M,>&=6^(<?A#[)K(OKDL;>2/0]1"P(MO:3D7OF6R"U?%VGRL2JKMWLC
M,$&9:_LJ:9#X1N_#\WC3Q'J-O+ID&B03:E::3=&UTZ(Y^R+%)8F&1&PNXS1R
M.=J_,,59\(_LMZ#X)U"QO-,\2>(Q+ S"X$TULZWL3V=K:O!(/(^6,K90-B+R
MRC A"B80 ';>"/BUX:^(DU_%HEQ?R/9QI,XO-)N[/SHG+!)H#/$GGQ-L;$D6
M]#C@\BN1F_:H\$0ZMIFF"S\7M?W]['9+;2>#=6AFC,D<SI(\<MLK^4?L\HWJ
MI&5.>%8JWX'_ ++WA/X _P!KKX;D<Q:C!';%?[+TRSDBC3=M7SK.T@FE.&^]
M,\C9&<[BQ/.>!/V*_"OPXF-WH/B/6]/U3[9:7HU&SL=(M9=UNMP@5Q#8HDN]
M+J97>57D(8?." : .TUS]H#P_P"%?BQ/X'UJ.[LYOLEA<0:A#9W-S 6NIIH5
M6=XXFCMAOB15>9U#F3 ^Z:S/#?[57@WQ/XPMO#=MI?C""^N)K^!9[OPGJ,5J
MK6DPAE)G,.P*6.=V<+P'*,54]=KWPGTCQ#K.M:E<W%ZD^K0Z=!.L3H%5;*XD
MGB*Y0D$M(P;).0!C!YKGH?@%#I_B8ZY8^,/$4,B7FH7<6GL;,VJK>LLEQ;'-
ML9/*:5%D^_O4CY7"_+0!6M?VL/AO?0P26E]KMXUR(GM+>U\*ZM+/>12([I/;
MQ+:EYX=L;DS1JT8XRPW#/4>*_B!+:3:;INBPO_;%]J]MIR?VC8SQQ;#']IG=
M2P3S-MNLO*,0) %;Y@RUX]I/[%ZZI\.=#T/Q=X^U[5-1M-+L].E<66CW,$$<
M*@B&W6;3B @DPZRLOG HA\P8KU*Z^'^NV_BZXUJSU;^T(K#1I;;0[/59MRP7
M<BQJQ=UBWE,01G>[2R$SS]!M6@#*A^.]GINK:S/K]SIVG>&H$U:[MKK$_GBT
MTYK>&YE951D=1-+-SN0A5CVI)N9D[.?XC:3;^"5\5-:ZX^EL PAB\/W\E]@O
ML'^A+";CKS_J^GS?=YKDM0_9WT'6O"^DZ/?WVH#[#X:O/#+36TB*98KH6YGF
M;<C?O2ULK ],N^0V1C9^)_PCM/BQX9U;P_JVLZA#I.H1VR_98H+*:*%H93)N
M$<]O(DOF?*KI,)(R$7"*<D@'.WG[6'PSL8X7GU;58PZH9%_X1S4RUJ7GDMXU
MN5%OFW=IHI(E28(S.NT G JQ<_M)^#8(M(OOMTJZ9J$%ZZ1RZ=?IJ1FM[FWM
MF@2Q^S>:TGFW 4QG;)G;MC<%BE3P#^R[X4^'7A>30M,N]0-I)-9SM^[M+<![
M:^EODVQP01Q(#+,X*HBKMP%"]:G\3_LV^'_$VI6>I_VOK6F:K8W%]>6-]920
M>9:SW5U;W3RH)(74E7MD"AU9=K.&#YX .F3XQ>%/L5U=3W]S8):VMG>W,>HZ
M=<VDT$5U*\4!DBEC5T+/&X*L RXRP4<UBK^T?X(;PY9:YO\ $*V5_=?8K&-_
M"FJK=7LGDF;_ $>V-MYTR^6K/OC1EPK<\&J'B3]G=/%%[!>7'C[Q7!=M:V=K
MJ,UNNG*=5^RS--;R3@V9",LCL<0")6SAE(XJ/P/^S+HG@5K>:W\0:S=WL&KS
MZVERT&GVJ_:9;66V=O(M;6&#)$SN6\O>[X+LX 6@#K]+^,/@_6?#&J>(K/6H
MYM#TRW6YO+[R9%CA4Q"7:25&7"%2T8^=2P#*"0*Q-3_:,\$:+IFG7M_)X@M!
M?)/+%:S>%M56[2&$JLL\ML;;SH85+KF:1%3YA\W-0Z?^SQH>E^&]7\.0:SKG
M_"/:M;RI=:;)<1.K7,@3?>"1HS*LY=#(<.$,DDCE"S9J'6_@#-X@M+3[9\1_
M%QU:.UN-.NM:C33$N;ZSF96:WE467E!05&UXHTD&3\_)H JWG[7/PNL9IHVU
MG5)UB%PPN+/PYJ=Q!*EN^RY>*6.W9)4A;B1T9ECR-Q JE\<OVB;GX3WD1TO1
MCXC@6"T62""VNY2]S>W(ALQOMH9VCCVQW+,?)D)*Q*HW.H/3:?\  'PUI/A^
MUT6SEO[?3[73=4TJ&-94^2"_E664 E.J% $/8?>W'FDT_P"#D5Y8:G%K=TYF
MN=>M-6B>SD!*1V3P_8XBS)T*VZ,Z@?>EDVGHU &?-^TQX0T#2[:?Q'>-:7DT
M^I1"WT:PU#4PB65RT%Q*Y2U5D2-@N]V0(I/#LN'.K)^T#X)M;C7(KV\U32UT
M:RN-1NKC5-!O[.W:V@*B::":6!8[A%WH<PL_#*1D$&H;?X >'K;[;MO-3/VJ
MVUNU?,L?"ZI=BZN"/W?57&$]%^]N/-<3H_[%'@G1]8\6:DFI:I+<>(]-O=*N
M9#:Z;%,D-TZO)_I$5HD\S HH4W$DNT"@#LM-_:4\!ZQ<6EK97.MW.H7%P;<:
M='X9U,WD1 B/F36_V;S(8<31$32*L9#C#46G[0GAH7L5E?C4(IYM3N-+BNK'
M1=2N=.$L=[):*DM[]E6"*0R1[2KL &8 ,ZE7:74O@79W'Q#E\:Z5XFU[PWKM
MP4CNY-.^R/'=6ZK$OV=UGMY0$/D*=R;9 6;#@'%<7JO[%O@K6/'&G>)[C4=4
MDN['4GU6.&:UTVX"SMJ$M_\ NYI;1YX%\V8C$$L>Y54-N.6(!W.B_&"+5O@[
MX1\>36EOIJ>((])<6ES<2,L+7LL$:H)(X6+,#. OR*K-C<8U)=>&^)7[9?@[
MP;IUU'H5OJ?B;Q NH#2[:Q71M4CM;BX%TEM,JW,=G*'$3OA_*61@VU0I9E!Z
MBS_9B\ Z?X=T+3H-(ACU'2+?2[2/Q$MM;C59X+">">"*6X$>60O;1;EP 0#C
M:<$2WG[._AR^AT&.2]U0+HVK7&LV^V6/+337Z7S*_P"[Y02QA0!@[21DGYJ
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M&:3XB\3ZW<:IJFJ:CX@L[NRNKF:UTV"?%Q*DKN;BWM(II75XT*F:23;C@8H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "L?6?%5AH,@2[6\!*A@\-C/+'R< ;T0J"3Q
M@G/(]16Q7 >+O!.H:]XFBU&.QL9X[?RO*::]5&.P[\\VDC1_,2/DD&0!GO71
M0A"<[5'9?UW,*TYPC>"NS5TSQ];S>'K+5=0M+JRCNT:55AM+B<1H.[L(ALXY
MR1CN"1S6C=>+]*M+6.=[AV21WC00P22.[(X1@JJI8D,<<#GJ.*XK7/ .L:]I
MNF6-QIFFB"P@^SQ@ZF)2RX49/F6+;6POWDVGD\U!J?P^\0ZDOE-!9?9?,=UM
M9-3$D4>]P[@*UB=V6 /[S>!S@=".WV%"33YK:OJMNAQ>WKQ37+?1='OU.KM?
MB-I=SJBVW^D)#+%%)%.UM, 2[NF'!3]W\R  OC.>.E7[?QEI5W<7,$,L\LEN
M)"P6TF(;RSM<(=F)"#P0F3[5R]AX9\26MJT,NGZ7,6CAAW)J;1 )#(SQ@*MF
M%!PV#@ '' %23>&]>FLFMCI>GJC+<KN769,CSVW/_P NF.#TR,>N:B5&C?1_
M^3(N-:M;5?@S;D^(6APJ#)-=1MELQ/87 D0*%+,R&/<J@.IW$ 8(YJIXF\??
MV+>?9[2UCNR@S++-)*J+P&X\J*5L ,I9BH4;U^;)Q6!HO@+5]#CN%@TK33Y\
M4T3[=3$0Q($#$+'8JH.(U[>N<U!KW@GQ;JE\9K>TT2&*08EBEU6\RWRHIPT*
M1<$1IPP89&1BM(T<.IZO3U1G*MB'#1:^C.SM?'%BT=O]JAN[2:1S"W^B321)
M()#&5,RIL'SJ0,D9!' S3+?XB:#=311QW-P3+Y91FL9U4JYPC[BF C'@/G:3
MWKE=0^'NJ7^H65T=(TV/[($$<9U4RG*N7#>9)9-("6.25<;N^>:U%T'7UMUB
M&E:;M6WM[<?\3F3.V%BR'_CTZDGG^E0Z-#=/\46JU>]FOP9O6?C"QNKHVNYW
MN1)(A%O!-*B!'=,NX0!"=C?>P,@X+#DK<>--)MH[5S---]JC2:%+>TFF=T8$
MA@B(6QA3VX[US5AX;\2:7J$MU:6EG"L\DDEQ;C5R8YRSN_S9LBPP9"!M(X S
MG%9D_P /?$5Q:?9I%MY(!''"D<FIQ2!(TR44!M//0GAOO<#FA4*+E\6GJ@]O
M64?AU]&=Q/XTT>UO9;6:YDBDA.V1VMY1&C;-^TR;=H;:0=N<\]*MZEKUGI-K
M!/<&;$Q"QQQ6TDLK'!.!&BEN "3QQCFN0N/"^NW<4\4NF6+133BX=?[<EY<1
MJBG=]ESE=BL.?O#/88FO])\6WZPL8K.&YADWPW4>K?/'E-C* ;$J0>2=P/)X
MQ@ 9^QIW5GZZHT]M4L[KTT9MIXZT5OM)-U(B6Z22/+);2I&50X?:Y4*Y4]0I
M)'-%CXXTC4;Y+.&6Y6Y9_+V364\6U]NX*Q= %)7D XR.1FN67P?XAVR12VMI
M/;&.6.*!]8(6#S/OE"+(')R?O%@,\ 5NV.E:Q-JXGOM/L;>%[H7;R6^I/*RN
ML7E@!#;KD8 S\PZD^U.5&C%.S_%"C5JR:NOP9U=%%%>>=X4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_A?OAQ?%.JZ)+'/:MI>L#1;N]O+FTMK=)/L OO,4RSJTB")L$(K."&)38K.
M#TNBO'O%7[6_PG\&V>CZIJ/C?03X:U82+;>(+;5[.>T>5)8HC$H28RR,&E!9
MHXV2,*QD9!C.SJW[27PIT6RURYN/B-X8==$L#J>HPVVJPW$]O;80B5H8V9\'
MS(]N%.XR(!DL 0#TBBO/-*^/G@?6+>^U&#Q%I*^&K73+?5V\12:M9BQ-O+))
M&&)\[S$ :)@6D1$)^569E<+8L_CU\,]2N-)M[3XB^$[J?5V1=.BAURU=KTLS
M(HA ?,A+(ZC;G)4CL: .[HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "OC[]I;X+:W\1/%/Q*2R\%>+]0?Q!I&FZ;8:YI46C/#92
M0+=B2:,7&JP2OOCOYH&5HX\ /@L&!K[!HH ^(/#OPO\ &V@^-+.\/PV\<77A
M>W\21>+3IC6WAX7K:C'8"T&+O^W"H@^4/L\DN/N^9MXJ;Q-\.O'FO:UXLL8O
MAUXZM?A_XLUZV\0ZSH+V_A^2\>XB\@O'#=C756.&5K:(NK0.W,F&&[*_;-%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT?QAJESI'C0:C;:=!XEFM+Z.P?3_ "6<N^M76Y5G8L4>\<E"X50'*&Y+\/\
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MCGIZ+_(I9;A5+G4-?5_YA1117FGIA1110 4444 %%%% !1110 4444 %%%%
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MF?3_ "3&"ERBOOB9O-&T%>=K=,5>A^+'@BX\27OAV+QEX?D\06,D<5UI*:I
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M+M8A3M)P3BH=;_:&^%_AS4H=.U+X@^&K6^EOQI8MWU6'>ET59A#(-W[MB$;
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MELY5F#)AO,"%6 IWOP%U*Z\;W=ZOB2RB\+76MCQ')IO]DL;\WPMA /\ 3/M
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M+6*$IAPC2!X\-DB,+T]P?X8^#I/&1\7/X3T-_%;((SKK:;";XJ  %\_;OP
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M%_C?6-);P?'K6D6,5QLU"RN-0#-/%827?DR.VGBS1B(RNT7;N-RDIU ]?L_
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MQ_\ $G5=!C\*6GAC0K77-;\23M'9V^JZBVGVL:);O.[2S)#.P.U,!5C8DGL
M6'G7PN^*WCKXI_%C5+R&&UT[PC9^%K2\M='&HHPGOIY+A"9B;(OM#V\BJ\<P
M78JOY;F3$7L_BKP)X8\?: NC>)/#ND>(]$W)(NGZK9175ME?N,(W4KD=CCBI
M-!L/#MC>W<&BVVEV]W910:?<1V"1K)!'&FZ"!PO*JJ2$HAX ?(&&H ^<[?\
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MH(I%LX@S7%FNIY2,;92K'38T+RH1<2;D9^C\;? O6=>\5?$.VMM)\31VVO\
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M*,OD2S2P+'%/Y8W>2["3!!V\C-+P[^TKX'\874-OH3>(M5>:U^V126_A353
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M%>7J6?\ 8^HZ*7L[/3]/S#>R122OY5I:Q0B0&% K+&!C.X,3FO/?ACK7Q?\
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M (K1ZO9>$X_&OB1K.3Q"L4WBS^Q; W:V)TMYV /V7[,%%TJQAS$2-VPEFP:
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MR4&<]]\7O$7@S4=*\0VUV^I:3JFAV37D>AP2+>R2ZI!-->01R12)BWMFC'F
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MVZ5YA\<?@OJ7QA;2;>+7=*TW3+65)G6_T(7MW;2JX(N+"X$T;6EQM+IYA$H
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MQ6C;V8,OEH5& N'E8Y=O2O'OQ'U30X_"UIX9T2SUK7/$<S1V=OJVHMI]LBI
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M@CP[XJN_$^D^#O#^E^);M#'<:S9Z7!#>3*<95YE0.P.U>"?X1Z5U5 !1110
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M>&OB-<7T&AW%]))9HDK"^TJ[LA-$Y8)- 9XD$\3;&Q+%N0XX;D4 ?'5MX?\
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M=0 I*8OW/P7^(?AOPSXF/A_6?%UYK%YI/B:PM5U#Q9/<B/=(?[(,?G3D)($
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MTOQ1'X=^(WA_3_"&I7B6\FFS:5JLNJ6MR99#%Y3RM:P&*17V#!4H?-3:Y)(
M!X=I/P_^._\ :_Q%DFG\1VD][I&J0Z7(M\&MGE=Q]A$4DFM3"*6- @WI8P D
M/O=OO/Z3\-? ?BCPA\>M3*6'B^X\&_86CCU+Q+XEGO(%D CP($;4Y_,#$''F
MV<3KASYS A#VTG[1WP[C\+P^(D\0_:=(FB66*>ULKB=G#7/V5 $2,N6:?,:I
MC<Q!P#@TVS_:.\!ZA-ID<&H:F[7\@AYT'4 +.0S- $O"8,63&5&0"Y\LDJ<=
M* /+-%^#?C;P7I.OWNEQZ[=ZAJT?B=[G2G\2S):L\UXTNG^1&MRB6SLA)#P-
M$^7/F2*3N'-_#+X=_'738([6]N==LM,UC4VLKQ=2U5GN--L,6DGVF,R:I?R*
MQ\J^A&RY=@US$^U5CPONMM^T?X&O_$2:'93Z[J-^]W+9#[!X8U2X@\R*;R92
M9H[8QA$E^1I"VQ6!!88-<_H?[5GAG6EN;1DDTW6H-:?2?LVH6U[':S!-42P+
M0W8M3',^98F,<9;8TBK(R -(H!S7P:\(_%G2_CSXAU/Q?-JQT*8WP23S#)IM
MQ&TX-J(PVKR^6R1!1^[T^WS\^YB>6H:I\)_%OB_0=>T;5])\8IK5SXCL+F[U
MU_% -A<V<>JK,7T^(7A:S,=L!G;# ^5^4NP#'V?PO\;O!_C+Q5/X=TF_O)M2
MB:Y0--I5W!;3-;R>5<)#<R1+#,T;_*RQNQ&#D<&EF^-W@ZW\;2^%'U"Z_M:*
M;[-)(NF71LDG\KSO(:\$7V<3>60WE&3?@CY>10!\X>)/AA\9M/\ '^AVV@P^
M*)=$TW4E\C5)O$MS=*]B-1D<I<>9K,08BV( :6TNW8,H9E*C;4^(F@^,?@S\
M#WNM9\4^(;&34=+T-=5O]8\52R>7J@G8W:I,]_;"W5EVJ1'=6L3<!7+$(_TY
M\-_C3X1^+?V@^%]0NKP0PQ76ZZTVZLA-!+N$<T)GB3SHF*,!)'N7*D9K@/"_
M[5&E:AK'C-=;N/"^GZ;X>U"?3C:Z/KTNK:XTJ7K6L0ETR*T$D9E9045'E8[E
M !SD 'ANC^'?B[XOT_X>:MX(UWQ-?^'5TZV^SZQ+>->%+M;J7[5+=!M?CCGA
M?Y-A(U%?* \MCQO]@_9M\ ^*O#_C;5];\0Z%XFT@W.@:?87,WB?Q FK275_%
M).]Q+ 5N9_*@;S4*H#&H^;$4?\7:ZI^T]\.=%TBSU*]U>^M[>YBNIS&VAWYG
MMH[9U2Y>YA$'F6RQLZ!C,J!=ZYZBI?#/[27@+Q9XFM_#]A>ZO'JTUP;,0:AX
M=U*R$<_DF812O/;HL3M$/,17*EUY4,* /*/#/@WXIQ?%J>[33?%=IX<?Q!+>
M3WFM^(=QDMFL]041I;IJ5S"81/);$;(K4K^YS$^PNF3'\(?B7X<T_P *?;/^
M$_\ %>D3:593>*=*T_QJ\6I3ZF(K@2&WN)+V'R461HB\<,T4;!5P&VE6]F^/
M7QFOO@W8Z7>6EAX=U7[8[QIIVJ>(CINHWTHV[;?3X/L\HNYWR0(]T>6VC/S9
M'7>.?B5H7PYT^QNM<EO5-]/]FM;/3].N=0N[B38SE8[>VCDE?"(S':I"A23@
M4 >&V?@_XLK^TU;ZO.VN0^"4G3[.8YS-:)9_8PI@N%;654R>=O)D&GRONVD3
M$<K]-5Q.@?&7PEXJ\0:?HND:A<:C?WVGQZI']GTZY>*.WDW^6\THC\N$L8I%
M"RLK%D9<9!%=M0 4444 %%%% !7GGCOX+:?X^U;6+NZUS6+"#6-#;0-0L+%K
M<07$),A20[X7=9$,TFTJP'S?,K<5Z'7S=\1/#OF?M-:)J=CH^J7NLW$,-E]N
MG\-RS+IT'ES$W5CJZ@PVF-["6VGW"8H@"#=F0 V_BS^QUX(^,'BAO$.KS7$>
MK,<>9)INEZC&$,<,918K^SN(UR((SN50^<C=M.VO0?B5\*=*^*'PZN/!NH7$
MUGIDP@4O:V]M)Q$ZNJF&>&2!U.P H\3(0?N],?*?A7QW\7]'U#X::3::E\2=
M893IT.MGQ+H310NQNO+NU+)H3;E2,.?-DO8-PV,&DZLGC'QE\:_!D]]I>AZS
MXZU!4UG5VFU'4]#ED2(BYS910M;:#>F:V>%RY*JH!78LT>!&0#Z!\ _LN^%/
MAUX7DT+3+O4#:236<[?N[2W >VOI;Y-L<$$<2 RS."J(J[<!0O6K7B+]G?3=
M:GGN-/\ %'B'PU=W1ODO+C2GM"UU;W<HEFMW\^WD"IN'RL@61<G#\FO+IK7X
MWZGI[:E_PG7B33+FZT_7KUM.L_#UB8;::UN573X(O-LS)MFC8DB0L\@7*>7S
M7.?$[XH?'NS^(7B*#0K34K&V@L9#IEG%H]U=VMP/[/\ ,60;-(D3SOM!("OJ
M*#Y IBR1N /7+?\ 9-\.VMCJ&E1^)/$8\.3V.H:?9Z$)+06VFQ7K![CR&%OY
MK$L,@S22;>0..*ZGQ;\%+/Q-<W%[9^(]<\-ZM)J<&JQ:EI1M6E@FBM3:@(L\
M$L95HF8$.C<L2,<8\E\;1_$7PQ]A6_\ ''CZ[TW1_$\+2:OHWAV"[N[JSETU
MF*R6UM8L)X4N2%_=Q94,=S%D5U[']G/Q1XSU[P)XDDUV7Q!K.LVEU(EE>>)-
M..FI=?NE*".)]/L943=]X/$X4L0LTNT[0#J_A/\ !6Q^$6CZY8Z;K>I7\VKW
M;WLUW<6UC;%)F4 ND-I;0P!B06+F(L['YRP  \FU+_@G_P" ]8VS:AJ^HW^H
MBYGN#>7FB:!.G[[RS(!:/IIM49FB5FE2%9F).Z1A@#A-<T?X@_&GP*/#>K:S
MXXU33;FZT%]<76/"-M9>1<M?(+NUABGL EQ:(A,C,5G4>2FZ5T9U;U;]KKPI
M#J_@[P-9G1++5=*LM?5Y[>]\%W/BFTAB%A=HK2:=:E790[(H8$!&93VQ0!ZI
MX7^','A+Q5K>L66K:@UOJR0>;I$BVXLXI8H4A$T86(2*QCBC4KO*?+PH-<AJ
MO[-^EW5JD6E^*?$?AR5O[1BN;G37M&DN[>]N6N9K>3SK>10@D<[60+(HZ/R2
M?!(_&'QL\))\,- TRQUG2])M-$TR#?-8W=TM\XD:.;[6(M'NFB8Q)$P62>S*
M&4[BVUBO3S^(OCCX8^%-Q?F_UWQ)KVH:'H^HRFYT>*WETFXFG9;Z*W2WL96)
MCCPPC>WN9%(R5<';0![3=? G0V\*^(M!T_4-4T6#6+ZUU%;BQDB\VQFMTMD@
M,'F1NN%^QPG$BOD[LY!P+W@_X0Z7X-;17AU#4;^?2WU&1)KQHMTSWL_GSM($
MC5?O_=VA0 >AKY2\&^$/B#XGT_XL^/?$\>J>)/$Z^ YM.T&#5/#<<@=F:^_<
M(ESI-G-(Y\N'?&(5CD\X;D=3%M]&_MSQKK/A76EOW\5:IXH@\0Z5YOAR\\)Q
M#3+"W768AOL9GL@MQBW7S#(9Y3&1O_=%?E /9O$WP=T7Q5XHNM>N[J_CO+@:
M2&2&1!&/[/O);N# *$_-),P?GE0 -IY-^3X:Z7-X/\2^&WFNC8>(&OFNFWJ)
M%^U%S*$.W QO.W(..,YKY9^$OB#XI>//B1X1D\4V7BB]T73?$-O>0W&N:9+#
M+:[]+U>.4.W]D:<H4%K520LJ!I% E.X"NT^/GAG0-6\?>)&\;> M:\;M=:##
M;^$9K'0)]2CLKH&?S1#-$CBPN&D>!OM$AA&%C/F8B)4 ]1;X"Z5?:?J5OJ^N
M:UKL^I6.G:?>7MX]NDTZ6<\DT3'RH44,S2L&*J 0!@*<DYWP)_9C\*?L]S:F
MWAERT=]%%!L?2=+M6CCC+;5,MI9PRS?>^].\C'&<Y+$^;ZMXR^.?@^^DT];"
M]\0#24BWR1:8)4U$WEO%%;A950#_ $:\%PTI'(A",_49F\=ZI\;O#C>*M9T#
M5-8U^;3=1.F:;X?DT>V2TO8!I*R_:S(MOYQ;[42 R/Y>1LV,>* /2=4_9N\,
MZMI%WITU]JRP7.FZ]I;LDT081:M<)/<L,Q_>5D C., 9W!SS5BQ_9[\.V$=S
M''>ZH1<6NM6;;I8^$U.Z%S<$?N^JN,)Z+]X,>:\<^'OBGXP>*O#>DV^H:]XA
MTU)O$,T5UJ_]@2O?P6*:=+, ZW6BV*%3<)&H9+4Y#[ Y<@BAX7MOB-\4K;P7
M#?:]XWLK[3_%TY?Q5=:#%;2Q6W]EW(WPPW.E6HB1F94/G6\JJTNU)I",J =-
MI?[-/BVT^-_B7Q%%?Z5HVB:O;2V,FL626-UJDEL8$CCBV7&E-(I#1QD[[N:$
MB/ @4,JQ^G^&_@%H/AOX.7?PW2^U"YT:YCGC-P5M[>6+S&+ PQV\,<$(0D%5
MCB505R5)+$^ Q_$'Q_X?TNS;Q)?>(O"%QKOBJWM+W4_#_@]+C5+N)?#L4C21
MVZV<YE8W,)5I#%)L",GRJ@">D>)/%'C^W^$_P\NM3O\ Q-H$MV^/$.K>'/#R
MZCJ\48AD,+?8Q;3A&D<1>9B!O++%<(/F4 L>*?V._#/CK0[JT\3>(=:\2:G<
M:JFL/K&L6>E7<OGK;?91_HTED;3;Y("X\C((W ALL:UO^QAX<M=5LM3B\5Z]
M;7^G6D%KIMQI^GZ+8-8^2R-$Z_9M/C$@4H2(9O,A'F-B,?+MR--U;XS:M+8Z
MI=:IK6F1Z;INASG28M$M_+U66>\ECNOM!:!I$86ZQ.T<+1F)G)/'RUT_QQ^$
MEQ\4OBU\/G.D>&=1T[2[#4IIYO%?ADZU;1,9K#:L0\Z(0SL%?;(2W"O\IYP
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M]!C^VVUQXG\3W^BS6]_!:Z1=7-NT5B;R42SR1RB 3O(9%#AII9"#[<5N:?\
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M"0JJ"2W0 9-97Q.^"^H_$+4O%'D>(;73M)\2>&6\/7UG/I9N) 09S%-'()D
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M?ACX.\7:UI&L:[X3T/6M6T=Q)IM_J&FPSSV3!@P:&1U+1D,JG*D<@'M69>?
MKX;:AIMKIUU\/?"MSI]I=R7]O:3:);/%#<N<O,B%,+(Q )<#)[F@#RB^_:8U
MW4OA"/B9;>'FTWP=)J=C_9YL99;_ %F]MC?K!/'+8_9@(9&4, J2R,-W.P@X
MAOOVC/&.A^*;[5IM TO5O!4.@Z)J=Z-/UL2M9B\N;F/S+1EMO],+*L3$,\2@
M)\A8MS[?9_"_P9INN:EK5IX1T*UUC4YH[B^U"'384N+N6-]\<DL@7<[*P#*S
M$D$9'-1V?A_P9I^K3:%::+I%O>S6R7<UI!81J&B2=GC9\+CB9Y'7/.XR,.=Q
MH \9OOVB/%FH^'-.>XT.Q\*WVI2^'=3T^33]3&J"73KW5;:WD2??;QK%*8Y2
MN$\Q?F8I)E<U@^./VMO$OA?Q-H>IGPW;_P#"+:FFIVNE65K>37=YJ5S#?6MG
M&;B"&RDEMPKRL=L N&*L=R[@%/O-G\-_AQX!L[O[)X6\+^'+74[^VFN?)T^V
MM4N[P3*;=WPH#RB8J4)RV\C;S1<? _X<W5YK=U/X \+S76N C59Y-&MF?4 3
MDB=BF9<GGY\\T >:V?[1WC+6M-T1-)^&#R>(+W3]2U&XTS5+Z[TW8EI-%%B$
M7%@L\GFF>-DWP1<!N,X#:MU^T%J5K\#QXU'ARTO-?-ZEA_PC]I<:@Q25IQ'L
M=6T];P.J'S#&+,R8'"E?GKN[7X.> ;'PZ- MO _ANWT(6\UH-+BTFW6U\F9U
M>:+R@FW8[JK,N,,5!.2*Q?&G[/WA'Q9\+A\/K&QM_"?AE)EFCL=#TZR%LI$A
MD*FUG@EMG5F)8J\3#<=PPP#  \RE_:W\26>I^'M-NOA?J']IW-E:7^KV=G'J
MMT^G17,TB18*:84#!(S(ZW36I7D<D-B>W_:SUBS\!R>(=;\!QV-Q>Z=I>I:)
M8Z?J5QJ+727\QAA2<069EC=6 ++#%<<'Y=Q&VO0/#O[-/PXT70?#6G7OA+1?
M$DWAU2NFZEK6D6<MS;$RF4F+;"J0#>Q8)"J(O 55  &VVB_#KQ-8_P#".&P\
M+ZK9W5I+IO\ 9)AMIHY;:TE$<L'E8(:."5@C)C$;, 0": /+O"7[3GB3Q1;:
M[-/X"@\/1Z#HYU/49->O[^R^=GND@2&&73EN'C<VN2[0HP$@VQR'Y3PFK?M4
M^,?$>D^*9[73W\&:AHOA3Q-=/9M;7# WEK;Z;-:S@7]C;3C:+QQM:$(V?XQM
M-?1GA_X=_#OP_9ZIX4T/PQX8TVUELUAU#1-/T^VB1[61IMJ2P(H!C=FN,!AM
M),GJU0>$_A;\,K+1+BS\,^$?"<&CM]LT^:WTG3;5;<[V$5W RQKM^9H%21#U
M,0##Y<  ROA3\:C\2M:NM%.C/8:CI-JSZP'GW"TN/M4UO'$/D&\.+::4-\OR
M&(X(D!&/\9?B=XR\"_$+2(/#6EZ=KFFKX<U75]1L-3U+^SX]MO+:8D29;>9C
M(%E<!"%0[B68;16YHWPU\(>*+;6+ZRN+F[M]1\3+K%_P(_,O;%XX4B8;%8)%
M)9Q8'4F(?,RL<]/XP^&/@[XAR64GBKPGH?B9[%B]HVL:;#=FW8D$F,R*=IRH
MY&.@]* .-\&?'R'QEXXM_"T.ASVNHOYUW()I<>78+!;RQ7.-G)D:[ACV=F68
M;CY1SR/B+]J+6]#\-KJB>!X[J34=?O-"T6TM[N_O);G[*]RL\T\=GI]Q+"/]
M%8J(XYLAAN,>"1[+I_@?3M-\<:SXK3S)-7U2TM;&5I-NU(8#*R(F%!QNGD8Y
M)Y(Z8Q5'Q?X'\!ZIX7&C>*?#_AR[\.S7JN-/UBRMWM'NI93M/ER+L,KRR'!Q
MN9W[DT >#:E^VU?Z'?6K:C\/KB#39[4EF)U.*XM;L6+71MIS-ID=M$04*D&Y
M\Q5*N8Q\RK'XA_:4\9> '\47WBK2H#=:1XA:S&AZ#JL4]L(D\/RZAY?VB6S2
M1P[1AN4B978?,8UVO[A:_ /X8V.I#4+;X<^$K>_%I]@%U%H=JLOV;RO)\G<(
M\^7Y7[O9G&WY<8XJWIOP9^'^C:&FBZ?X%\-6.C)(\RZ=;:1;QVZNT;QNPC"!
M0QCDD0G&2KL.A- 'D_B_]IKQ?X-T.XCN/AQ;7WB^#5!8MHVE:I>ZA$\368NE
ME1[;3I)V/S+&1]F"*Q^:0 @GN?'7C_QMX>B^&ZZ;X=T)K_Q!J266JV>IZO+$
MMIFTFF9894MW\Q@T1 +(H;:!@;]R4_BY\"_!OQ^M'T^ZOXK>33K\27JV-EIM
M\&N/(556X@O+:XB,BQ.A5FC$BJPVL%8ANU?X:^&;KPAI'AK5-'L]>T;24MQ:
MP:S EV$:!0(I#Y@/SK@$-U!YH ^>X_VK/%G@70[JX\3>%8=8@O=7U73]!O+*
M\FEN;N2'5?LD44]K;63O$@$J -"+B1A$28]S8KI_'/QD\6:W^S8?%6F:1K7@
M[Q//K%AIGV.UM0MX!)JD%LYMEU2V@4F2-SL:XAC4%P2 !FO6/^$-\#>./"\*
M?V'X>\0>'+^&2:-?LD%S:7,=PPED9>"CK*V'8C(<X)SUJUHWPY\*>'/#=OX>
MTGPQHVEZ!;3+<P:59Z?%#:Q2K*)5D6)5"JPD <,!D, W7F@#PR?XX>/OA+X5
ML+;Q)X;N/$.I_8=4UJ>37-3M+._AL+>XACB286<+VSW#"YC_ -64B"J27!!S
MN:Y^TKJO@72]3?Q=X3T^SU/2]0AL;RWTG7?M4($]LTT#QRRV\!;E<2AD7RDW
M2DLBDUZQJ$GA35;._P!8OFT>\M+*WNK&\O[@Q.D$((^U0R2'A4!C'F*3C*?,
M.*Q_ /@7X:P^%-.D\$^'O"J>&IA)=63Z!96PLY!,FR22(Q+L(D0!2R_>'!R*
M ,?PW\:IM9^(Y\#76A"S\0V\EP]XL5V988K2.&W=+E',:EUD>[BC PO*S<GR
MR#Y4WQA^(WA$>(&:YL_$FM7%]9S:;:ZM=VL.ARZ?/J*VRS6-U9PM.%"31*Z7
M2,RN2R-(B?/] :'\/='\/>+=3\164/E7M]8VFF>6JHL4%M;&4Q11JJC:N9G.
M"3U&,  53C^#'P^AA\10Q^!?#21>)&WZW&ND6X75&W,V;D;/WQW,Q^?/+$]Z
M /%[[]JOQ7YOCG3;?P;I*:EHVA:GJNG7PO=4?3[J2R>-)$:>;3+>-P#)_P N
M\DW*%25R&JMJ_P"V-XAT#4M7M+CX:3:FNBP2+J-SHLVI7%NETMF+G8ETVFI:
M^20T:>8\Z.&?_58P6]:\+^ _A!I'C'Q%IWASP[X)LO%;6P76[32[&SCOC;S<
M@7*(N_9)C/SC#8[TEU\#_@_H%Q8ZE<_#_P $:=/ D>FVEY+HMG$T:R?NDMXW
M*# ;S-@0'G?M YQ0!RFE_'KQG;^+I-+\3^ M)TG3K75?['O=0TWQ(]ZR3-8_
M;8VBB:SB\Q-A56+,A5C\H<#=7)>$_P!L#Q5XZN-'M-&^%L@N=?N(ET>XU:YU
M+3+*6%[>XN-TL]SI:?.J6XRMNMPO[Q<2$<U])-X>TIKIKEM,LS<M<+>-,8$W
MF=8Q&LI.,[Q& @;KM&,XXKG?#?P9^'W@W5I=4\/^!?#6AZG+-]HDO=-TBWMY
MGEVNN\NB!BV)9!G.<2,/XC0!QWPS^,7BGXA>/+>T;P]H^G^&)_#5CK1E;5)'
MU"&:=YT:/RA!Y<B!H2N[>I  ;!W[4Y3XJ?M:WWPO\;ZQI+>#X]:TBQBN-FH6
M5QJ 9IXK"2[\F1VT\6:,1&5VB[=QN4E.H'N%OX!\,6NL:=JT/AS28=5TVV:S
MLKZ.QB6>U@8Y:*)PNY$)ZJI /I7+3>!_A'XJ^)&MR2^'_!6K^/XK9%U5GLK.
M?54MY(_+03DJ90CQC:-_!48Y% '*CX[>,3<)X>;P/H\/CF75#81V+^))/[-\
ML60O/,-V++S VPE?+$!^8'YMH+#-L_CYXBT7]G7X=^+CIUKXI\1Z]:V[2VLA
MO \S-"TCO''IUA=NY&W)VQ! ,DL. ?7O%'PS\'^.+&XLO$?A30_$%G<3)<S6
M^J:=#<QR2HNQ)&5U(+*ORACR!P*9XB^%O@OQ?X;M/#VN^$-!UO0+-UDMM*U'
M3(;BUA9055DB=2JD!F (' 8^M 'C_@7]J+Q#X_;3[VP\ 6T6A7LT%A'<3ZXR
M77VV;2TOT3R#:X$7SK$TC.'!Y\LCBNBTC]I6QUSX;^+/&EGH=R^G>'[*"1X7
MF"2R7CVR3R6IW*!'Y7G0HSD\,9 0/+.?0H_#GA#P;8VJII>B:'9K=PFW"V\-
MO&+DJMO#LX \PKLB7'.-JCL*;X1^'>C>#_"USX?MH/MFGW5Q=W-TMXB/]I>Y
MFDFG,@"A2&:5^,8QQ0!Y#KWQW^(EGJ5AH4?@_P +VGB)-:33=2A?Q'<2VB0R
M6$UU$\$_V)6:3]TV4>( 84<B0.F#X2_:F\5:'\(-/U;QGX4AN->FT71KW3SI
MM[->'4VO9/(1IHK>R+P/O&YHX(KC ;Y=Q&*]NM?@G\.[+PLOAFW\!>&(/#:W
M0OET>+1K=;,7 QB80A-GF# ^;&>!S6G??#OPKJFBR:/>>&='N](DLX].>PGL
M(G@>U0Y2 QE=IC4\A,;1V% 'FOP;^/7B/XK>)Y-*N/ A\-PV%E'=:G-J5S=V
M\R-)+<QPBWM[BRAED1OLVXO*L! D&%;!%1>-?VBM3\'KXYNO^$2CN],\/:I:
MZ%:217MS-<W]_.MLR+]FM[25UB NERZ>;)E&Q$W!KT7X?>#_  1X5TQAX&T3
MP_H^GY:U8>'[2""+,4L@:,^4 /DE:;*]F9^A)J?4?#WA#Q%_;OAN_P!,T34_
M[02.[U?2+BWAE^TH_P"[CEN(2#O#?9RH9P<^3@?<X /GNR_:QU^U_P"$GUK5
M_"^H67V72M'CL_#$UC?(QOKG4;^U\Q=UBMZT4@A@;_CU+ *=L1).[J/ _P"U
M1=>)KZRT;5O!-[X<\27EQ$L-E?&ZMXGM2;DS70-S:P3+'&MG*?GA7.^$?+Y@
MQZ=8_!?X?:7X=N] L_ GAJTT*\@6UN=+@T>W2UFA$CR"-X@FUD#R2.%(QN=C
MU)JWX;^%_@SP:+ >'_".A:$-/BF@L_[-TV&W^S1RN'F2/8HV*[*K,!@,5!.2
M* /!?#/[7GBKQ7KEOX>T_P"'5C)K]]<V\=B;C5-2L;":&6"\F\XS7>E0R%0M
MD^###*K;UPW7'??#/XQ>*?B%X\M[1O#VCZ?X8G\-6.M&5M4D?4(9IWG1H_*$
M'ER(&A*[MZD !L'?M3L?"OP:^'_@.?[1X:\#>&O#LWG?:/-TK2+>U;S-CIYF
M8T'S;))%SUP[#H35K0_"O@S4IM$\3Z/I&@W4L%EY6E:S8VT+M':2 -M@F4<1
M,"#A#M.<T >&:U^TYXDTWQ)!K,VA6MOX*&DZ]=V=M;:FLMYJ4EE<00 SH\""
MUP[-C;+(,.2^TJ!72:%\?/&FM?$Z?X=-X&T*#Q=IT2ZAJG_%33M816+&(*\$
M_P!@#S3_ +TYA:*,+M4F3#KGTRS^$O@?3=:U?6+3P9X?M=6U@.NI7\.EP)/?
M!\AQ-($W2!LG.XG.3FL31?@S\)+W1;&TTGP+X+GTC2=1EN+2"RTBT:WL[Y'\
MN5XU5-L<RO%M8C# QX/*T <UJ_[2/]E^%9M87PY]IFC@\03+9K?!6D_LRX,&
M 2F/WIP<GA,@?-UKF?$O[4WBSX>QZY>>+_AWIMEI&AWCZ??7.C^(Y+Z4S&P^
MVQ>3$;*,R*5*HQ)5E9OE60#->QQ?"'P)!KFK:U'X*\.QZSJZ-'J.H+I4 N+U
M6^\LTFS=(#@9#$YJ748?!5_I.KZE?QZ#<Z9%/+)J5W<"!H4EBC,$K3.?E#(B
MF-BQR%!4X Q0!X38_M;>--02>WB^%/V?4;.QO]5NAJE_J.EV[6=JMN7:W-YI
M<,TLA-QM"F%$W(<R8.:ZN;XV>/(Q\1[NT\%:3K-AX?N[6+3(;/4[MKR>.6"W
MF9KB&*SE<;4F9OW"RL2-@0X\P^A>%_@S\/O!-K/;^'/ WAK0;:XCEBFBTO2+
M>V25)0@D5@B $.(XPP/!V+G.!1X@^#/P^\637TNN>!?#6LRWT4,%V^H:1;SM
M<1Q',22%T.Y4/*@Y"]L4 <3_ ,+@\5ZMX@\ P:3I7AN?1_$&AWNI:A<C5[CS
M;66 P*R6X:T7S=IF(*RK$Q(.X1E"K>;^&_VJO'NE_#OPQ)KW@W2]0\2ZEI&G
M:C;"'4[^YDU&&>*4O*T%AI4\D<P,.YHTC>-5?_6C;@_0EGX,\#:]I^@FTT+P
M]J-CX>D:'2##9P2Q:8\6862WP"(2FPQD)C&TKQC%,\1?![P%XNTFUTS7?!'A
MS6M,M(XHK>SU'2;>>&%(@PB5$="%"!W"@#C<V,9- '%?L^?&;Q-\97UO4-2\
M/Z1HV@QI92Z>;;49IKW$]E;W.R>)[>,+CSS\P;/&W9\NX\7JG[7>M:?XVU#P
M[#X'M=09KK[)I-]%?ZC#:WC_ -H6UE\\\^F1PX#72LQMI+G;L8<\$][IOCSX
M$^#;&3QEI_B+X=Z'9,R: _B"VOK"WC)A7*61N%8#,:C(BW?*!P!2Z?IOP*L?
MB%;I8VGP\M_'/B5%U:%;>.P74]57?]H6Y4 >9,-T9E$@SS'NSE<T 8^D_M':
MMJ7QF'@<>"+N6SMKE=.U+6+&+4KB&TNS:K.V)?[/%J8071-[W*29;/E#C.#H
M?Q,\=_\ "\-8M-<NO)\/2>,5\-Z7I^G7MN\21IHTUZ9)E>P$N6Q&Q"W!^8A1
MA8SY_M%U\+?!=[XU@\8W'A#09_%T"A8M?ETR%K^,!2H"W!7S -I*\-T)%:A\
M*Z*UX+PZ/8&[%W]O$_V9/,^T^28?.W8SYGE$Q[^NP[<XXH ^9/@G^V!K7BRT
M\*6.H>%=4UN#^RK7^VO$EKI]^2MXVG)=R/B.Q^QK&2ZK_P ?2N&?B+&,]Q\+
M?C1XH\6>--:G\1:;8Z1H2^$]/\16&GZ7J U%FAGDN2)'8P1,LI2)5,8WH-HV
MNV3CT6U^#'P^L?$6G>(+;P+X:M]>TV!+:RU2+2+=;JUB1/+2.*4)N150E0JD
M *<=*N^#_AEX/^'K7C>%?">A^&6O'\RY;1].AM#.W7<_EJ-Q]S0!X_#^TWXE
MCT6VGO? NFQ:GJUMI5[HMI:^(FGBF@OKI+:,W4OV5?(=6D1F5%F! ;:S%>>G
M^*WQVO\ X3_V?;7GA4ZIJ=_IAN[6UT^^RL]S'-"D]LC/$N2J3^8K$ NL;_*N
M*[+0?A'X&\*I>IHO@OP]HZ7UU'?72V&E00"XN(WWQS2;$&Z17^96.2#R#FMW
M4M TS6+JPN;_ $VTOKBPD::SFN8%D>VD:-HV>,D$HQ1W0D8)5F'0F@#YW\>_
MM&ZA>W7@^X\,336>FZSJ'E6MY%+#-!>6L>N:3922%'A+?O$NYU0I( %.[#%D
M,>KJ7Q2\90_!NYUO39X;_P 1+X]FT2W2X\N"*2W'B![-('<1/L7R0$,@1G R
MP#-U]B7X>^%5M=*M1X9T<6VDQK#I\(L(MEG&LD4BI"NW$:AX(7 7 #11GJHP
M[5/ /AC6_#]WH.H^'-)O]#NY7N+C3+JQBDMII'D,KN\3*59FD)<DC)8DGGF@
M#PCQ1^USK7ANWLM/C^'TFK^+A/J$=_I6DR:EJ,$:VDL<;F":TTV9Y"QFCV^;
M% F=RLZD<R_M"?%#QSX9\4V,VARR:5X4LO!FL^)[];>Z@@U">2WCCV1&.XL;
MA5VM+'C#*=S,6R(_+E]8U3X&?#?7/#>E>'M2^'WA74- TDL=/TJZT6VEM;,M
MRQAB9"L><G.T#.:Z/4O">B:Q&R7^C:??(UG+I[+<VJ2 VLFWS(""#^[?8NY/
MNG:,C@4 ?-WBO]JSQ!X$^(7C#PY:^&[WQM>6^I;[.QMK2]<V]DFFZ;*ZJ;&P
MN6:1IKMBOG*B?,09% 5:ZG5OCAXGU;XD^&-.TG2;;2_"DGBD:#>7MU>XU">4
M:=+=-";-H,1Q_<.\3>9E/N;26KTSQ5\&_ 'CI67Q+X&\-^(5:?[4PU72+>Y!
MF\M(O,/F(?G\N.--W7:BCH *+/P#\/[KQQ=>(;7PYX:F\8V(CM;C58;&W;4+
M<>6I2-Y0OF+^[*$*2/E*XXQ0!YSXP_:IM/ _BK4]&U3P],BZ7<W4-[<QW0(B
M1;:*>S<*5!;[291"H'2167+8JCI_QL\<7GQLU+PE;Z+I8TN$SF^EU#5R)[1X
M[#3)RMJD=H!(JF];Y97+.=S;XU"QUZZ-#\%^+]1U:X&GZ#K=_%/;VNHR^1!<
M2I-;-YT$<QP2'B:02(K<H7W#&<TSQ'X-\$1R2>)->T/P^DFG2OJKZOJ5I #:
MR+"L;W)F<?(PAC53)D$(@&<"@#SG]GKXN>-/'?@_3X?%.@V%MK\GAFPUNTNH
M=4\U-06=' :<+;H+9R\>2D8E50_#'&*XFW_:%^*3:9X%UY_"_AV\_M#PCJ7B
M'5-)M-<>.V\N!K-EECF>S:3SMLLBB#&S+G=*=H-?2VE^'])TA8#INFV5DL-K
M'9PFU@2,);IGRXEVCA%R<*.!DX%96D_#/P=X?MI8-,\*:'IMO(EPDD=IIT,2
M,L[*TX(50")"JEQ_$5!.<4 >9_!_]I:Y^+GCR\TJU\&:E9>&\77V/7I+34 C
MO!,(F65I+*.U&XARODW,Y.SD*<@>Y5Q?A+X>?#N#6#XX\,>&?#$>JZM '_X2
M32;"W$]Y"X5@?M,:[I$8!#]X@X'M7:4 %%%% !1110 5X1X\\(^)YOC9:W_A
M_P -:H+.]%NFJ:DUY82Z/=011R[3-!*WVJ&ZB9V$;VR[6WIYC,%VQ^[UR&M?
M%KPEX=UQ=&U+68[+4FOK335MY8I 6N+E7:W4';@AQ')A@=N48$@@B@#YX^&/
M@OXC^&? OPZDUGPEXRU^]\$7$+R:)KEUX?5Y%.GRVI.G-:S)&PA9P1]K='*.
M^'9@!7L/C/P_X@\7?"K3K'2-'OO!M[>ZO9SWNFZ9J,=K=6]HU^DEV&GMW"K(
MT)E9_*<G<SA'<X8W]4_: \%:9)81_;[RY-\BO#-;:3>36R!Y&BB:>=(6CMUD
M=6"/,R*^"5)'-<_X(_:M\%^+? =OXBN!J^F3FQL;N?3#H>H2SL;HA8Q:J+8/
M>H9,J)+=74XSP* /%/C-\(?C-X@\8>-M/TG^W+[PU=Z/>:=I(CO3-:2V[Z6T
M*6]P9]9C7S&G+$S-82/N*DS$9*V?C)\(_BMX[^)7B*TT[3M>MO"M[IUS:-)!
MX@N([.[5M+D2-0/[8"1L;DQ@JNGH/E),I!8M[7HO[3'AG5OB''X0^R:R+ZY+
M&WDCT/40L"+;VDY%[YEL@M7Q=I\K$JJ[=[(S!!UG@CXM>&OB)-?Q:)<7\CV<
M:3.+S2;NS\Z)RP2: SQ)Y\3;&Q)%O0XX/(H \2\-_"OQSX@6QTW4D\:^&O"L
MGB6.XELKCQA*VH0Z:NB)'Y37<-Y)+M^W*20DI8DEONDFO._V??$FM?\ #3D>
M@>+?%NNWVMZ?;/:'1EU_[0B2QV<2[[JW74R=F$D82-IR*TDJM]HE+(S_ $'-
M^U1X(AU;3-,%GXO:_O[V.R6VD\&ZM#-&9(YG21XY;97\H_9Y1O52,J<\*Q6_
MKG[0'A_PK\6)_ ^M1W=G-]DL+B#4(;.YN8"UU--"JSO'$T=L-\2*KS.H<R8'
MW30!QOQ2^&WBJX^*'BW7O"UGKRZAJWA%+"QUBTU\PV=K=1/<9C>V>X"AW25/
M+D$+JC[F)4DENE^"/AC6[32/%%MJNG^*- T&\F5=-TOQ1X@.I:K IA"S.;M+
MJX959^4 G)4@D;,@5#X;_:J\&^)_&%MX;MM+\807UQ-?P+/=^$]1BM5:TF$,
MI,YAV!2QSNSA> Y1BJF2U_:P^&]]#!):7VNWC7(B>TM[7PKJTL]Y%(CND]O$
MMJ7GAVQN3-&K1CC+#<,@'C?AW]G7Q1-X1\'VG]G^,/#5]X;\*:M8HP\82>?)
MJ9:T^S,LT=V[M;N87=8781*% >->!73_  '\(_&'2_C/JVI^.YM6.FS1W@>3
MS!)IMQNF4VXC4ZO*(V2, ?N]/M\_/N8\%O9?$GQ E6TT2+0H7&HZMK*Z7"FJ
MV,\&%C9WN7\MQ&Q AAF*,/E8[""RD9YN'X[V>FZMK,^OW.G:=X:@35KNVNL3
M^>+33FMX;F5E5&1U$TLW.Y"%6/:DFYF0 XCQ!\)?$Q\;?$4:/9>*K*/Q%KVC
MWO\ ;-IXIDBMY+$-:)>Q11_:P\$@2*?+)&A*%51^%4>?0_"/XRW'Q#U>TMU\
M7:)X0FNTMGE_X2JZE:2U&IVI\R&XFUFYDR;1+DEDMK1QO*@,< ?4&J?%G0])
M\)6'B2:S\22Z=?/Y<45IX7U.YO ?FYDM([=IXU^4_,Z*.5Y^89Y2?]K#X9PW
M$$,>K:K>M<&-(6L/#FIW22RR6ZW*0*T5NRM.8663R0?,VY.W@T ><>*_A_\
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MM=/N/$NV2'3/%=U96ZZ/_9@&U(89U"9O #N4"8$G#!#7O]% 'R)KO@+XS_\
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M* "BDSCD\"JVEZI9:YIMKJ.G7<&H:?=1+/;W=K*LD4T;#*NCJ2&4@@@@X(-
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M7&2!7%6/PC^)6GZEX+U62P\57/BB70/"]IJVK1>*R+>":TOT?48[F$W868O
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MKSWXF>./$?PX\%:S8Q:I=7-QX;URXLI9DU75 -0$?@R6[(D:2\DG13-A@J3
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M?%%]XFT;Q7X;\8^&[;0?#]S>1V-E<-!J1N;VZA=K +=NELQ7&6;S]Y1%(&*
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MN)R.AN/V>=%O/&$>N7&M:U/;)=1WIT1WM_L33KI\FGF0_N?-RT$F"!)MRBD
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MKHC^RSH<<>F6UGXDUS2M+M8-.AN]*TV'3K6UU$V,OFVTDJ1V@\HAL96W\E&
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M &U_$=QXXU[1K;5O"[:3;M(AUK4-+CM$T-5O;>W,]_;KJ\MP$59G)6XBLCE
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MCOS),UO?2:?IEM#<D-'A71[*=A(I+J'4KR6 Y_X=^![BV_;0U/7M5\&WM[?
M2PIK\^FR1+;XLXH_/%R^F 3*PC\M0-2DQYQ/V>,[Q& ?4^L>-M#T&)Y+S4H4
M$=];:9(L>96CN9VC6&)U0$J6,T74# <$X'-;=?./C#]EZ/Q/XJ\>,?"W@_\
MLCQ1K6CZI<Z@P*7MW#;RVK75I<(MOAXV%O(XS*0S2D,HR6KA]2_8S\26OQ.T
M?5=)?14\*Z9J"SZ9I]M<VMF^APK?RW&VT\W2;ITW+(@*036H^3;N(PR@'U]J
M.GVVK:?=6-Y"MQ:7430S0N,JZ,"&4^Q!(KF? 'PK\/?#-+L:(NIR2W2QI+<:
MQK-YJDY2/=Y<8ENI976-=[D(I"@NQ RQ)\R^,'P)\3^+O'<OB'PQJ6GV2BWM
M]2BM[R::-3K5F9!9R.(U.872=DEY)Q#$ IR2O)^*_P!E/6K[4--%G9>&M9G3
M3M/M8O%6L7$D>IZ#<0RO)<7%B@MY S3LY=B)826^\7&  #Z8U[7++PSH>HZQ
MJ<_V;3M/MY+NYFV,_EQ(I9VVJ"3@ G !-6K6XCO+:*XA;?%*@=&P1E2,@\^U
M?)GBS]CJ]N/AGX7\,Z7X8\#ZO+;^&Y]*OAJ\DD,5GJDL<*MK%N5MI&FN<QM\
M[>5(1MQ(N37H'@/X)ZWX9_: U+QI)HOAFSTZ[TU;.?48YTN]2NG6.%%()L(I
MH%Q& 5-W-'B-=L2EBR@'K&@>/= \4:MJ.F:5J*7E]IQ*W42(X\HB62(Y)&#^
M\AE7@]8W]#5R;PWIMQXDM/$$EONU:TM)K*&X\QALAE>-Y%VYVG+0QG)&1MX(
MR<^=_&CX,V_BSX7Z_H/A3P]X9BU'5'@,T6H6-LL%PJ7'G,',EI<Q[@7E96>W
ME =R=N6+#Q?P'^Q'<:?H4B^)[#PSJ6JV\5G'I+L$F73%35+JZG2$I9V\<8:"
M>.+]S#$&VE2BIB@#ZNL_$6GZA)IXLYFO8;^V:[MKNUB>6V>)=G/GJ#&"?,4J
M"P+C<5!"L18CU**35)[ )<">&&.=G:WD$)5V< +*5V,V4;*JQ905+ !E)^3Q
M^R/X@A\%^!=(MO#_ (&L[?PU8W=G>Z#;SR)IVO![O3Y1]HQ:#:)DLY/-S')A
MB@_>J6J/XH?L_P"O7OC?P+>VOPU\%ZOHSP:?ID_@Q[J4:):_9K;6&<2.M@RB
M -=P>63  9 !M0[30!]5^'?#>F^$=)73M*MOLMFLLL^S>SDR2R-+(Q9B22SN
MS$D]35O3]0M=6L;>]L;F&\L[B-98;BWD$D<J,,JRL."".017R)XB_8]\4:UK
MWPX:6#PE>:?X>M=.@N;N6.U%S$D-TTLUM&9=,FGD@\HB) EU;#:2&4Y.<[Q3
M^QCXJU;X;^!O#>GZ3X/TVV\/P75K/I.FW-M!:W$KF()J2O<Z-=A+DK&V=D2N
MI<D3MR" ?6'B3XB:!X1UC3-+U6]>WOM2Q]EB2VEEWYG@@&612%S+<PK\Q'WB
M>BL0NK?$+P]HGB.VT"]U)(=8N$62*T\MV9E82LO0$<K!,>O2)ST!JAX#MQXD
MT73];UKPVNG:U"TD$,E^JRWGDQ22QPRLYC1E:2-C)L*@KYS*><UKZEX/T>^O
MI=3.DZ>VM&/9'J#VR&=2$D1?WF-PPLLB]>!(X_B.0"UX=\06'BS0--UO2I_M
M6F:E;1W=K/L9/,BD4,C;6 89!!P0#ZU1E\<:/%XN/ACSKB36EAAN'MX;.:18
MHIOM'E/)(J%$5C:SC+,!E5!P70-\9W/[#?C*;POI%A8Z3X(\/1Z?:V=IJ.DZ
M7=12VWB>2&.5?MM\]WI$\8F5I RA[:<DEOWJD*1ZKH/[-?BG3?&'@+5CJ=G!
M!H.F:;93>9>M<W"/;VFLP-L=;:%) &U*WVG9$"(W^5,*& /I:BOB7P'^QE\1
M?!MO>75EK6EZ/XDD\NU?5K/4+<"]ADBF@N[B2.VTBU87&)A.C2R7#-)#&'DP
M"YZ+Q!^SSXK^'WQHG^)&BZ;;>(].TI5;1[&UO+:VOEC2R%M%IX_XE,TY@+]3
M]M2-1(SF,;3N /I33_B)H&J^+KWPQ:WKRZW9^9Y]O]FE"KY:6[OB0KL.!=P=
M&/+D=58"30/'N@>*-6U'3-*U%+R^TXE;J)$<>41+)$<DC!_>0RKP>L;^AK0T
M[0].TV>>ZM--M+*ZN?FGDMX51I"69SN8 %OF=VY[LQ[FO,OC=\$5\:?"_6]
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M.UD7[0&A<G;Y;'((E4EL_1,]F/A[H^F-HOAB#4=7O+FTL;C[#&(<JTN9YY)
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M&C\?Q(IZ@5\Z:Q^Q7H&N?;+N^\.>&;W5KRT\0"YO+B$O)/=7=V)K"61C'ES
MFX*S9,1/[OCF@#Z?KF[OXB:!8^,K?PK->NNNW"QM';+;2LIWI<.F9 NP$K:3
MG!;C8,XW+GY$O/V6_'?@KQ-XI^(4=CH+:Q913W^EQ^'(K?S]2OEO()[<2QPZ
M9!-AUB>*0S7-RV+B0AER37U)X ^'^F_"WP38"2UCU'6K&Q+7^K0V8:[OIRJM
M<2G:"[/*Z;MHR20HYP* -[QAXXT+P#IL=_X@U&/3+.1VC6616()6-Y6^Z#P$
MCD8GH I)K:AE6:))%W;74,-RE3@^H/(_&N:L](M?B#X3T6Z\7^%+&._FM%FG
MTG4$CO192RQ;98@[+AL!WC+ #<">,'%>4>)?V4/#OC3X@7'B3Q!X=\/:U+<^
M)?[1N);^#SI9M-_LP6PM&W(=R>>%D,)/EG&XY;B@#W6SU**^N+V"-+A7LY1#
M(9K>2)68HKYC9E D7#@;D+*&#+G<K 9UMXTT2Z77V748HX]!F-OJ<L^8H[5Q
M"DQW.X"X$<J,6!( /7(./B/XP?L[ZWX/^%MMX>U/25\2V5WKL%VD.DZ?<:E'
M#%#HL%BJNHTK4"AW12;&^R, -I$T385N\U+]C2P\;^$]7OU\)^'=$UO6GC:U
MCU"+S)]/L#HJ6BV+N(S\J3C<8U^0[0WWN  ?2_C;XB^'_AWIUO?:_?-9VMP9
M!&\=O+/N\N"2=SB-6( CAD;)&. !RP!F\7>.="\!Z;'J&OZC'IEG([(LLJL0
M2L;RMP 2 $CD8GH I)KC_AQH(CAM/#FJ?#O0O#]KX=T^U6V?2U$MA'<.[/+!
M:![>([(_*MG\Q5 +/C :(FNZUWPOHOBB&.+6=(L-7BCW[$OK9)U7>A1\!@<9
M1F4^H8CH: $\0>*-,\*^%]2\1:K<-9Z/IUG)?W5PT3L8H(T+NQ0 L<*"=H&>
M,8S6G'(LD:NIRK#(/M7QO\1_V;/$_P 7/&GQ7-CX8\.Z-/>7\\=AXTU.>9-3
M:.31HH/LL2"U/^B/([!V6<C/F_NRPJ?XO?LB^,_B%\5->\0Z>OA;3;>\LKBU
MBU*)K>WO)5DTQ[4),8],^U'$CAMWVYEVHN(@0  #ZR\1^(;#PGX?U+6]5G-M
MIFG6\EU<S+&TA2-%+,0J@LQP#PH)/0 FLQ?B)X>;PR_B WY32$NFL3/)!(I\
M];@VQ0(5W$^<-@P.3@C((-<!X3^&MG\*=<G\.:'X-TUO"/B'5DN_L-A"(K/2
MXX;)-]P\?E^7YCW,,6%!#,9#)DE&KU"X\,Z/>:7;:9/I-C-IULT;06<ELC0Q
M&,@QE4(PI4@$8'&!B@"30M<L?$VC66K:9<+=Z=>Q+/;W"@A98V&5<9 X(P0>
MX(-7Z^5/BE\!-4\>?&;4K;1_!GAV'2K71-$@TWQ-J3/#-H+0W-TS?V9&MLZ&
M0((PP66' \L'<N!6+\0/V+=:U3X=_#KP_H,'A\+HNF/#J]CYEK:Q7&HO' KZ
M@DUQI5\6G_=./-$4<OSY\P<J0#ZHU[QKI'AN^@L;Z:?[;/:7-]#:VMI-<2RQ
M6X0RE$C1BS#S$P@!9BV%!-:EYJ5IIMLMQ>7,5I SQQ"2X<1KO=@B+EL?,S,J
M@=22!U-?),?[(OBN2/Q.C6'A&UU.^\.Z_HS>*$O9I-3UV:_(-O-J!%HF#$%V
MY#2\,=@0?(=J[_99O+[P3XLT2_\  ?P[UK5;K4H-2B\0:C(TEQKS1W_VD1ZB
M#9$Q@1DPA@\XPQPJK\M 'T#XD^(F@>$=8TS2]5O7M[[4L?98DMI9=^9X(!ED
M4A<RW,*_,1]XGHK$2>)?'N@>#[S3[35]12SN=0;;:Q%'=I3YD<>!M!_CFB49
MZF11U-97P]MH_$.@Z9K6J^#;+PUJL.^"VM=@DDMX(I)8X"C-%&R!HV+!"JE!
M*RD YKH=2\+Z+K&H6U]?Z187U[:X\BYN;9))(L2+(-C$$KAXT?C^)%/4"@#4
MI.E?%6B_LJZYX_U)M0U#P?X8\.VB^*+ZXU"^N)96U+Q'8_VT)OL][$UJH\GR
M8B8U,LJL/+'R(QKT2Z^ EUX5^*<WB^#P_P"'8=*T^_758_$NGI/+K\%C%9B+
M^R8+2*U;,'R8"1S8(;B$OR0#Z(TO4HM8TVUOH$GC@N8EF1;JWDMY0K#(#Q2*
MKHW/*L 0>" :=)J%K#?063W,*7L\;RQ6[2 22(A4.RKG)"ET!(Z;ESU%?"NB
M_L;>/_$:Z5K;WUM8276AV\45U<W-O:7]@O\ 9J0-8R1_V4]T82^\.BWT8_>L
M?+#*0WJVL?!R[\%MX,\::1\%?AW%JWA>#484\-Z%,2L3SO$T$EG.-.3$GF(P
M8M'&J":1B^ <@'O&G_$30-5\77OABUO7EUNS\SS[?[-*%7RTMW?$A78<"[@Z
M,>7(ZJP$F@>/= \4:MJ.F:5J*7E]IQ*W42(X\HB62(Y)&#^\AE7@]8W]#6AI
MVAZ=IL\]U::;:65U<_-/);PJC2$LSG<P +?,[MSW9CW->;_&;X+V'B[X::YH
M'A[PGX?FN]4>$S0W3Q6$,NR9IE>1C9W22;9'>0)+!(C,[9')- 'K%9\FO6$.
MOV^BO/C4[BVDO(H-C?-#&\:.V[&T8:6,8)R=W X./BJ3]BCXDW.M27QU?P_I
M5Z^F&TM=4T.2SLVTL&P^S"TBC&C-,]N&W$A+J")MY<6Z8\LZ_@']C7QAX9NK
M"\D?0K2UL;B:Y?PN+RVFTG42SV9$<J6ND6*1+BW9\K$V)4A=O-&4H ^JO$GQ
M$T#PCK&F:7JMZ]O?:EC[+$EM++OS/! ,LBD+F6YA7YB/O$]%8CCOB1X9^''C
M'QYI>E^);F^'B*6W6".QL=5O[-+R!S*ZPW$=O(D=Q&?(N#Y<P9=JR\8+9ZOP
MGY?BZU@\0ZKX7BTC51/-';?:XPUTMO'+*D$A+(K1EXV+^6>4\YE/.<Z&H^"?
M#VKWTM]?:#IEY?21^4]U<6<<DK)LDCVEBN2-DLJX_NR..C'(!HZ=J%IJMA;W
MEA<PWEE<1K+!<6[AXY$(RK*PX((Z$59KX?L_V*?%MIJ/@06/AOX=^'(/#GV%
M&O\ 0_LT=S+Y%SYDDS,^CM.7F0#*Q74 5G<$R DMF?&#X V_A&R^#OAMOA['
MXGCT?3U;4H=)T=Y[?4+[?;"=C<#2[P))*8!NED:R9E;FX(W>4 ?==]J%KI<
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M')!74/V<_#,<FM7WA^;5/#VNZE#=6\>I1:K>3#3ENG#W36<+S^5:NY&[,2J
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M[244^K:_;Z?I,WC96UR'3O#UOX4>W>2_MVTJUOVG,T]Q'!L F<[_ #%!7RP
MS'GLY/@CX/F\>+XQ:PO#K:W0OE']JW8M%N1#Y/V@6GF_9Q+Y7R&3R]Q4D$\F
MG>(O@IX1\42:A+>65[;W=]J"ZK-?:9JUW870N5MDM?,CG@E22/,$:QE4958
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M3&UK0H=)T/6_%'_"1Z1IFI:1I>DVEL+A_M:7LH+3RW:18$=DY(.U5*\22>8
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MVUH5OXDU3PYHOA+5/$?B"PN(H_[/L=9T5Y)8VO(+4R;%OFDA.;F,JEPD1.X
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M:?=?M*>&]%U7Q1!K%IJT.GZ-?K:+J>E:1?:K;R1&QM;LSRO;6[I;H!= 9D8
MB,MG&0H!\\^#?AS\<K1E;QC8^.]<TEIHCJ^DZ)KHTZXO)A%.//M+M_$,K)$)
M6C+1(;-6781$=IC'MGA#P'XX\-_"[X)Z)$ES:7VB2*GB"&"_0 1#3+R/#L&
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M@ FO-[S]K#X9V,<+SZMJL8=4,B_\(YJ9:U+SR6\:W*BWS;NTT4D2I,$9G7:
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M\5:[JMYJGB+3[:VMIM1O]'T6[EO1 [.C.9K!_(;+MDVOD=0>H!'EWQ,_:O\
M'/PW^%'@'Q->:GX4_MOQ-I<FLIIG]DQQ1/'Y4,B6T<MUK%L6D!E*DQ+,[;E(
M@7&'Z^P^/7CM=/U76M4OO!>FZ/=6^O\ ]E_;(9K5-/DT^Z\B.2[N9+G9(CCY
MF4+#M.!OP<@ [[Q%^SCI&O>$?#/AV'Q%K^CVFA:--H"2V+VQDN[.6&.)XY_-
M@=3GR8VRJKRN.5)4\QI?[%/@?2_ 4WA.*_U..PFU.XU622SM=.L"9IM/DL&
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M/B/Q7JFJ:+=:Q'JEKH"&V6UED2P@MA<7#+;+-YVZ-VVI*(ON';G('/\ @O\
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M0&^S/"&"C(SDG(C_ &'_  8/$?A_6[C6-2U2_P!%2W@MI-6TK1;Y_L\$C/!
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MXHL=+\3#^SO"*V6J+I9A\$I=R_V,D-MJ-Y<RZ<7^R_\ 'LR7*8(@P7+@Q;,
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ME\4ZIX7\;Z7YV@ZW#/(EEX;T_5Q'+;VVFM>F\E1Q<6=S%'+EUB0F"=0EI;G
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M6DVJI8(2'.VMR^\/Z;J^J:5JES;K<W>FM))92,Q*Q-(FQG5<[=VPLH;&0'8
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M(/*E ;KY@SG#\8?LQZUXCU33[FR\(>!=);^SM/M+.YAO)/-\'-;RN\@TI19
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MI^#]<TRZN-*T>\LO#*1VDUY<RW\]Q%$(KA;LQ,KF#($@AV*I9V^;;'WGASX
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MB_M*>'_$/QMN/AEIVE:E=:M;PFXFODN+'R8H_)CE$CP?:?M:(?.C0.T 5F;
M)'-=*OP5\&1ZQJ^J+HV+[5K66RO9?M4W[V&6&W@D7&_"YCM+=<J 1Y>0068G
MC_"OP$UCPO\ &*[\71>,Y5\/2RR2KX?MUO8U.Z(1A)5-ZUHP7 ;>EHDI*J6D
M8[RX WXL_'K6/ =UX^T_3_!M[.?#GA?_ (2"+79I;>2Q=R+C;$\*S+.<F @;
M5.3NSM 5FP?&'[:GAWX=Z4+OQ5X3UWPY-'.]O<V6K:EHEI/"5ABF#*LFHJ)]
MT<RD+ 97&"K*K8!]"U7P5\//BMK5S?R7,6M7EYH8L;F/3]:F6.XTV=I0ADBA
ME".C,)]DC*2"'V,,&J?B'X(_#KXJWUYK,Z75Y/,TUE>7&B^(;VT2XV[8)K><
M6TZ+(JF (T3Y *,",EL@&O\ "7XF7GQ0TO5KZY\*:EX7CLM3NM/B_M"XMIA=
MB&>2(R)Y,KD#,?(<*020-P^8X-Q^TAX<L?CG:_"NYM)H->NB5MYO[3TQQ(?L
M[7'-LEV;Q%V(PW/;JN0.<%2>W\)^ =%\#S:O)HT-S;#5;MKZYBEOIYXO.8DN
MT<<CLL.XDL1&%!))()YK(7X,^%5\??\ "9"WU(:U]H^UA/[9O?L0G,/D&867
MG?9Q(8R5+B/<<DYR2: ,#XT_M&:'\$=9\-:5J6DZEJ^H>(':*RM]/N+"%Y'$
MD481!=7,!F<M,F(X?,?&25 P30D_:CT&T6^N[[PYXBT_0(4O);779XK8VM^E
MI)MNGA59VF"QJ'DS+&FY(V*;^ 9/C-\#=<^)OBO1-9T;QI)X3^PP-;S?9DO4
MG=3(K[DDM;VV4D8X2Y2XBS@^7RX?9A^#_P /?"_B"6]E@,5WKANK**SU'6+F
M6U9IU:6YCM;264PQ-(J2.X@120KD\9H Y#XE?MF_#_X7QH^IO-,KWE[:(?MV
MGV8E6T9$N98S=W4(E5)6,>R,M*S(^U& S6A#^T_I^H:79W^D>"?%>MPZGJ\V
MBZ0+-+%3J<T(N#,\7F72!(U^RR_-,8\_+MW9K6M/@=\._$7A'PK%HWVZ'1M,
MLO*TC4/#GB2_LY'M9-KD?:[:X22='*JYWNX8@-R>:W])\#>#=-O]-TJRBA^W
MZ#<RZW;VGVZ22>WDNS<J\[J7+%9#)= ;\KG=MY7@ \ZL_P!K;3M9:Q.B_#WQ
MMK<%[<QZ?;W%K;V,:/>O9B\^S8ENT8,(229"!$"I7S,XS7U[]MKX>>&]3\*V
M%\;FWN=>L[2^$-Q>:?;S6:7+E(A)!-=)-*VX,"+9)MNTDX!!/J'A_P"$?A/P
MK!90Z7I7V6.SO_[3@7[3,^RX^S?9M_S.<_N3MP>.^,\U@VGP6^'VN36&HZ2]
M_"--4::'T'Q+?VL4GV:5U\BX6WN%6X,<GFH5F#[274]Q0!R7_#64=_X0_MS2
MOAQXLNI91I5Q9:?=/86TM]9WUP((KF(FZ*J-W\$IC?)7(5277*U;]LK3)O$U
MYX3TS2&T_P 5V6I6%M<6NHZEI=YMAEU2SLKC='8WTTL,BK=Y43*G(Z-@K7JU
M]\$?!FH>&UT&32I4TU=-M=(1;>_N89([:V?S+=4E202(R/AA(K!\@?-7,:1\
M!_AC;^++NQAM]6N]6L5M]2-GJ&OZG=0VP>\%S')#'-.T:!KBS#L(P,F+##!P
M0#LOBM\4=$^#G@>^\4^()1%IUJT<6#/!!YDDCK'&GF3R1Q)EF W2.B#J6 YK
MR_PC^V=X4\<M:OHGA[7]2L,VZZCJ5D^GW-II9GNY+6/S98KMEES+$W-MYV%P
MW2O9/&'@W2?'F@RZ/K,$LUE(\<H-O<RVTT4B.'22.:)EDC=64$.C!@1P:Y;P
MO\)_ RZ7>'36NM;@NC#:W-Y>Z]>:G+(;2YDD2-IYII')BG:4$;L@@J>%"@ \
M\\3_ +5&I:#X(N/$<O@#6K![;6]3TJ+39Y+*9M3%G;WTK&.5+L"W'^ADLSJY
M&"JH^X2#N]/^/&F3:M9:+J>AZQH/B.[DL8X]&O1;O.?M2SLKAH9GC*HMK<LY
M#G @?&> ;=W\!/ ^H+?I=:5<7,-[J%QJDMO-J=T\*W,\$UO,\<9EVQ!X[F<%
M4"J2Y;&X!AC:EX \%?#GQAX,\4ZQK]MI-GH=C)X?T@>(-1:222XN739_I5S*
MSRR[4>-%)+8ED /.* -+XL_&^S^$LT<4WAGQ!XC?^S;K6+C^PXK=A:V=L8Q-
M*YFFBSCS4PB;G;G:IQ7,>(/VK-'\*>#]0U_6O"NM:(+#4H]-N+'6-0T?3Y$,
MD GBE\VYOXX"KHPPHE\P'(*#!QW<UGX'^*-[KD*7FG^(+JSMKKP[JD5CJ&][
M5)MAGMI5C?\ =N=B'G#C'&,U'XH^"_A3Q@TDE];:C;7+W27IN])UF]TZX$J0
M>0")K::-U'E?*5#!6ZD$\T 8?PU_:.\*_%1]&BT6+4!=:IYCI;3QQ[XH4MH+
MGSWVR,OEE+NUP5+9,Z<=2-#XG?&>#X::G9Z<OA?7O%%[<6%UJC0Z&MK^XM;=
MHEFE<W$\0.#,F%4L[9.%.#2^"/@GH?@+QO>^(--18U;1K+0K*VVLQM+:WWG'
MF.[,[/NCW,<$B&,'.W-5_B1\"='^*?C/1=:UR^U);'3M-O-/;3M.U*[L/M(G
MD@8^;);S1EXP("IB<,C;\D?+R 85W^U!ILGB!](T+P7XI\5SM<K:6LNEK8I%
M=S&TCNV6,W%U%@+!*CEW"ISM#%\+698_M3)=^-UMH_#&KWWA2?3=*NCJEK!"
M&TN6[NKBV9;P/.&.)(D7$"2%2LA/R[374V?P[^&/Q2T*>]T*YAU#3Y]3-[_:
MGA77I[=H[N.%;5O*N;296BQ%&(F2-E& 0PY-:FF?"_P%9RW>BV-C;+/%8Z=!
M<64=Y(94M[>622T+KOW#]YYQWGER&W%L&@#S+1OVJKI?''B73[_PYJ&J^&M)
MG6"?6M-M(+=--)U2^LBURLMX6>,?94PT"NQ =V2,,J+U7PQ^.][X^^(FN^%A
MX6U)[+3'NL^) +6"U_=W]Y:B(P_:7FR#:%1(%^<AF*0@J#J/^S?\/VUXZP-*
MOHKI[DWD\,.M7T=K=2&ZEN\SVZS"*<">>5PLB,JE\    <1=6'P7U;Q=JWAS
MPE\1]'T#XC7HO],DMM'\5L=0C>>XFN+L?9%N1F=7EN71F0F%F)4 +MH ]@\?
M>.+;X?Z"NHS6%[JT\US#96FFZ<(S<7=Q*X2.)/-=(P23U=U4 $D@"O"K[]MW
M0/ OA:WU'QUITFC:G=ZIJMM'I+WVG6<]O;V=R86:0W-XD<LBY0%;>24N23&K
M+S7O?C#P3I'CWP\^BZU#//9,\4H:WNYK6>.2-U>.2.>%TDC=64$,C C'6N/;
M]F_P)_9>GV5O:ZUIWV%[B2.\TWQ+J=G>N9Y!)/YMU%<+-,'D =A([ L-QYYH
M \^U7]LO1? G@6U\2^*K));&]UC6K&WN+#4=.LT\BSOI88V$=[>0R3.T2(Q6
M!9"3G"KE5/JG@/XR:%\1M2%AI,5X+M+66YNHYXU4V>RZEM?+EPQP[2P7  &0
M1"YR.,YVN?LX^ _$%C#:7-AJD%O&]\[+8:_J%F9_MDQGNDF,,Z&9'D)8QR%E
M&2  #BK_ (5\!Z+\*;WQYXHNKZUMEUJ\_M2^O9P+>*TMXH$149V8@(@220L2
M!NED; R: */C+XZZ=X,\53Z/)H&N:G:V*6LFK:S8I;_8]*6XD*1&;S)DD?.T
ML1#'(57!8#(K<^'OQ&B^(T>K7%GHFJ:=I]C?3Z?%>Z@(%CO9(9I(9FB5)7<*
MLD3#,BIG@J".:K^)O@YX2\:>)K7Q#J=G=S7\0AW"WU2ZM[:Z$3F2$7-O%*L-
MR$8DJ)D<#)Q72>'?#6F^$]-:PTJV^RVC7$]V8][/^]FE>:5LL2?FDD=L=!G
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M;61Q:+.(%D:%F0R*@?DG.3F@"]\9OB!J/PV^#?B?Q?IFDMK6IZ7IDEY#9(4
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MU[#%^TM\/[JSU"[M-2U/4+>Q%OY[V&@:A<_O)Q$8H$\N!M\Y$\3>2F9 &R5
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M,--;1_#OC35?">I17]TWBA=L=V[12K=3J_DS%96EE\\#;@NBY(X8 'IVA_\
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M!?PVADUVTM;>;6KIHY],U5M3UZ\U.Y N(K=I(II)YY) QCBM2-QW*H0K@'D
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MNTUTWP?^)M]\4=%U*_O?"6I>%?L>HW.GH+^XM9ENO)F>(R1F&5R!E.0X4@Y
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M?[;WPYD\7:_H2R3R_P!BF8W=Y;WNGSJD<$Z0W,KP1W37,4<18LQFA3*(S+N
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M,U_#Z;4KN_O]*O\ 7+JY22)FUW6[_4ECCD26-XHEN)W6*,K,X*(%7[IQE%(
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MC^T%X$TR/P^TFJW5P_B"W@N]+M['2KRZGNXIDD>-DBBB9^4BE8@C*A&+  4
M>/>/OAG\1D^&<O\ 9T'BC6/%&H^)[RYN_L_B:[\RVLA/=?93#%'J^GHL?E-
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M!2;]HSX?P:QI6F'6+J2ZU**VN(6ATF\DACCN)6B@>>983';K)(K(IE9 2,4
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M(FN]2T[2M2FOC%.\XDEEN[*62.1I)9&9K=H22V>"%(\E^%_Q?^(WQ]^*6EW
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MBUFZT2VU!]2TO2;RQTF]M=+ED,ID$,=S8RB16\Y^)_-V\;"F!77^!_@'X>\
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M;7QKH=]JVF:;:ZE#=W6IV,FI6?V?,D<]LC1*TJR*"A&9HL<\[LC(!QP/PA^
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MO@@UO!H/AOX>:EJF@Z1;W>FV4V]];DAD6::35/M&GE4F==T;"2"Z^^X?>.*
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M<@'%K^U5H"V^O7USX9\366C:7:ZG=1:I-;6YAU :?+Y5TENBSM+N5NGF)&'
M.TFK2_M'0O;I;KX"\6GQ3)J/]G1^%=M@+YS]F%SYOF&[^S"/RB#EI@0?EQN(
M6KFL>$?A/;W=KX"U.YTFVU'4+34GM]!N-7:.[N+>[=I;UTC,HD968,2P^[@X
M*@5@ZWK7P%^(>@ZWXC?QYX?DTVQO8+G4/$.B^,39FPN#%]GBW7EM<(T!>/\
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M31X:^"GA'PI-9SV=G?7-[:7S:C'?:IJ]YJ%T9S;M;[GGN)7D<")V0*[%5!X
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M@MD&@!GPY^,VH?&2'2=3\,Z ^FZ+'J4]KK$FK7EC<2Q1QP$[$%G=S>7-YSQ
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M1(6^4ID9-<_=_M+^(V709K7X8Z]F\\57WAUM-$UA-<WJ6\5X3+;L+M8X\/;
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M*HP);!&YL@%'0_C9J.H? SQMXZU737T"[T%]9_T*:U6>6W6SDF55DB2XV2R
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M.P$J222 <WJ'[1G]H>-O#&D>&M!OK[0M0UI=+N?$\T</V$L;&2Z,40$XG\P
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M+NTMM3UF_N;>WVV<5J"\,MP\<\VV-C]HD0R?O,9XS0!E6?[5VGWFI:#IG_"
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MC1V]OK*V<>I) DU[:&13I^)'&V.[26+. $4V[,Q!89][KR/4OVA++2_C=>^
M[G3)[6PL+.QEN=:N+>]5#<WD_D6T$6VU:&0,Q4%S.N"6 5O+E* 'F/BOX/\
MCV]\:>"M3U:'Q/XJT_1HM(FN8M'\3O8EKPC5%OI47[5""%:XM"03\T2[%W %
M*[#X-?"/Q'\/_%L6J33ZRD&HWOB";5+.YUI[BR19=0,MBT5J9#%$3&6.8D5O
MG;S"2:W?B-^T/8^"1J;6&G?VXFGZ!KVLRMY[6_[W2VMUDMN8S]]IR/,&0-G
M;/':>%/B9X<\:M91Z1J(NI[NTDO4A$4BLL:2^2Y<,HV$2!DVMAB4? ^5L 'S
M]IG[/.J7VHZ?H]UIGB[2]*M/'6I:O=ZFOB^?=<6<T-\89+:1+PSP*6GA1U01
M,S%B0P+,<[X8^ _CGIGQD\.WGBJ[UV;1;58HGNDN1<VK6RV80Q7 .L(C2F7<
MQE&GRON*GS2,[?4?$G[4OAO3-?U+2]-BEO$T[2-6U2YU.^MKVTL0;#RQ(L<_
MV9UN%#.RN]OYIC*8*L6 K9D_:2\#Q1W#>9K\YANS8H+3PMJL_P!KF7S-ZVFR
MV/VL+Y4A9H-ZJ%RQ (- ',^//"/B>;XV6M_X?\-:H+.]%NFJ:DUY82Z/=011
MR[3-!*WVJ&ZB9V$;VR[6WIYC,%VQ\!\,?!?Q'\,^!?AU)K/A+QEK][X(N(7D
MT37+KP^KR*=/EM2=.:UF2-A"S@C[6Z.4=\.S "OHR/XG^&9))8SJ1BDAU!=*
ME6:WEC,=TUL+D1MN48_<L&)/ Z$@@BN9TS]I+P3K#Z4EH/$SMJC$6H;P?JZ;
MD'E_OVW6HV0?O4_?OB(Y/S?*V #8^'_BZ/5YM0T1?#%QX8OK&".]NK/]PT4$
MES),XA9X6*&XVJ)954LH,ZD/)NW'PZR^$OQ9O?#NDWUWK/B.U\5:3X:\/0V2
MGQ&_V8ZFDLG]HO<Q)-Y=R=GE[C,'5A]S+<UZI_PTY\/S"[)>:U++O1(+6/PS
MJ;W-ZKK(RRVL(MC)<PE8I&\Z%7C 7);&#5OPO\:;3Q%X*^'/B*2WM]/B\8LH
MB@EN)':/-I/<XC*0D.VV _?\M=NX[MP5' /$-<^%?Q"U[X6Z!::/H?B[1_&>
MGZC<7-[?^(?%2WKR7)T6^M_M5I+]LF\F)KB:,*BB$KOW>4@!(Z'Q-9_$GQD;
MC4K_ ,&^.+3P]-K4;R^&-,\36EAJS6RV'EJZ3V^H)''&+D;VC6X4L""0W*GU
MKP'\=/!OQ,L]0NO#E]?7T-E:QWS>9I%Y;M/;N',<UNLL2FXC;RW :$."1@'/
M%<*G[8G@WR_">H3Z?X@L="\0:3=ZHEU=:#?BYMU@:W#>9;);LXBVSEC<9\H!
M/O$,#0!P/A'X'_$IKCX<Z!K%UX@TGPC8Z'I5IK,>C^)7LR)H8=4\]0]O,DF3
M))I^YX\%\)R0C <I-XDUG1_VBOACX9\6>+=>@O[.QTNWN-(M-?Q/=3YFPTL"
MZG ;A&8QF61;*\!6-MTJ;9 GU=X;^+_A;Q9XHN/#^EWEW/?PK(ZS2:9=16EP
M(V"2_9[IXQ!<%&8!A$[E3G.,&O*?"?[7^GZMXV\5Z7K%MH&G:-X?;5S>76FZ
M^U_?V$5A<&%IK^R6V4VJ2A2Z$229X&.<T -\6?#'XCW7Q<E^(MDVFRPV>I16
M=IHBV6-2DT[RFMY"+TWBQ+'NGFNO*,)8F-!G=@#(T3X#>-])BTV_/B#QM/JM
MMIF@W+1W7C&ZFADU1;ECJ1>-K@QLAA" Q8\@@G8F[FO5M#_:,\"^(M=BTBSN
M]86]DD, ^U^'=2MHDG\OS1;O++;JB3E,,(682$,I"G<,W]+^.W@76?LYM-?C
M>&XC:5+AX)4A^6W^T.AD9 BR+#\[1DAU .0,&@#RGP7X+^(5G\3+RY\6Z?XO
MU:SEU#47T2^T_P 3B+3],A>^O7C^V6PO(S.&ADM?+'E3[%"KMC*'/#>*/#_Q
MI\0>%]$LI/"OC^.\TC2M/LI?LOB2UC34[V$3"XGD>WUFUF\J0.F',H<MM+PL
M$VU[GXX^.P\,^)/ VGZ?IME<V/BA!-#?ZSJ+:6L@9HPEO;>9"RRW;+(76VD:
M%F5&P3M;;!;_ +5'@B33KV_GLO&-E9V=[=V4]Q+X+U=H8S;R-')(TJ6S(L8*
MD[V8  '=M*L  ;?BSP?JMA\*?%<'A"U_LSQ=JMM+=,8+UGEDO&C53MN)<'=A
M1&DC8"A4X4* /$?A_>>.=-UK5I](\.^.[K3O#OBN(R^$=6\2P7VJ"SET?&QI
M[B^>*1?M$RS;&N6P,$<J$7V"Z_:2\'6.O>(M(N8/$J7FB7J6$BP>&-1N1=RM
M"LP%KY,#F?"-N(0$A5+D;,.:<_[6'PSAN8H$U;5;UYG2&,V'AS4[I7F> 7"V
MZM%;L#.86$GD ^9MR=O!P >.?#WP/\;8?BWX;U'5]/\ $&GZ9#!MU.6XU^6[
MM9@=/=<$'6&C#BX9!A-/'*;A,<DM9T/X)_$+PG'=:EIT/BFZ\<ZKX @M6US4
M_%LUY:6NM(LYE2:WDO-IW-*IC\J,QHP<@Q[BQ]SG_:#\"P+H;_VG>3V^L6UO
M=V]U;:1>S0113MMA:YE2$I:[VR!YYC)(8=0<84G[67P\D\+SZ]83Z]J]C#+8
MILL?#>H---'=S>5!/#&T :>$L&_>1!E)7:"6*J0#S3X"_"WXFIXNT^?QK<^+
MK3P]8I>7,5C?:O+"!=$V8@#[=:U&6XC(6Z.R68Q@E@8P"N;'[+_A?QUX1US0
M_ ^N7]RFD>$_#]G?75JUYYK1WES:Q0+9,RLRND+6][+MSM'VB#:/D!KU_4OC
M]X3T7Q3JNAZD-8TUM,T6/7KK4+O1;N.QBM7$A^:<Q[5<")OD8@D_* 65E6#5
M/C[H"_"WQCXSTB&]O%\,VDUS=:;JMC=:3<JT<7FA7BN84DC#+@ARA!!R,XH
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M4\7P7&F:;IVFW=POB1!-=W427 GNXUM-;LFE1R8ANFN$<[@3$Q7CV_4/VI/
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MY\,8O$M_JH\*>*++0=1?36LM'T:ZM;J]9M+^VQR(9+R18@C%4*G=O +;H^E
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M*SN-NP[F&?E /HCPW\)](\+WFF7-K<7LCZ?-J<\0F="&:^N//F#80<!^%QC
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MS'J7Q"O?$W@)-4&H-#:WGG6:6"1"54\M]NKR6[7#*'*I]O1<N@9E((/*Z/\
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M5[/\:?A9<>,/@K=>"O#>GZ+,!':V]O9:U%"]KY,4D9V_OK6ZC5@B?*SV\H!
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M6>YN=S2GY@&8D ^O->URR\,Z'J.L:G/]FT[3[>2[N9MC/Y<2*6=MJ@DX )P
M36!XW^*GAWX>Z1I.I:Q+J#P:M<+:6,6EZ3=ZC<7$K1/,%6"VBDD/[N*1B=N
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ML Z=^!^&/['I\,0Z3>^(+;0M3\1V]W:QW.K*6>X?34T>.QFM1(8E(1Y5=C&
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M(X())VC@#D GRE3H*8O[.?@6/16TV.TU>%6O$O\ [=#XBU%-0$Z6R6H<7JW
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M5TQTYW?> 8 '"_$O]JK2_@[X9T?6?&GA'6?#::BTX^QZEJ^A07$(BVY.U]1
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MJ8TF[AN/M;WLT-OJ][%;7<S7,ET6N8%F$5P!-+(ZK*KA=Q"@#BNGT?X>>']
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  < , # 2(  A$! Q$!_\0
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MVF@_$/2[&SO;G4-,@M-)M[S^S-2M6T72[ZWTR7Q/^VU?@9_P<!:79^%?@?\
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MUDL9OVKB/!^)3XNSJED\\@AD6'QV)K4Z&/Q?!,LOPN48=*I6J9E@<55GB:>
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M3+SP_'>0VHW)''?2W)FBDEAO6NH9'0_L+\/OAUX"^$_@_0_A]\,/!GACX?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" &8 9@# 2(  A$! Q$!_\0
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M:[O['E_/^!Q_VG'^4^X-K_W6_*DVO_<;\J^(/[?UG_H,:E_X%2?XT?V_K/\
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M\ _M./\ *?;VU_[C?E1M?^XWY5\0_P!OZS_T%]2_\"I/\:/[?UG_ *"^I?\
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M:OCKXH?\E&\2?]?TG\Z[LH_B2]#DS+^&O4YBBBBOH#Q0HHHH **** "BBB@
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M1KUUDNY;.W$4ERP.1O;)SSS@8&:DU'Q[JM];ZA&]OIL4FH&-KN>&VVR3E&#
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MX:M=+UV"QO\ 4[VYUJ]A>XEFMO*"6XD+L/O$LW3ZU'M:U]OP?^>G4KV=/O\
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M_I/YUW9/_$EZ')F7P+U.8I-PQG(Q78?#"Q@O=<O&DMHKV\MK*6>RLY<%;B<
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M#J-GIF(T&U8X "S,!V9P.3UH>(UY4M?^"O\ /\ 5#3FOI_PYY!D<<]:"0.I
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M=4TV[TN2WCOXO*>X@2YC4L"3&XRIXZ9'8\UZSKFGK';>,8-+CB"PC3]"+PJ
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MZ\UHZ<7*]]?^'(4Y*-K'JT?Q TF]34DO7>V$FK27T;/IT=YOC("J &(".H4
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M>W]?Y'LVAS)8:OX7T$V>GFTBTAK[56DMHW:4,CRE2Q&1@%0,8/-><^#]*O\
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MFG[2LGMU[,7)2:W.%\0>%M6\/1JVL00V[,P7R_M$;R#(R,HK$@8[D58/@GQ
M+:SF^PJ?MBH]O$)XS+*K_=*Q[MQ'OCCO6?XHU+^W/$VIZFY8+=W+RC/4*3P/
MP&.*[.W\:Z=#\3'UE5G.E+9_8+=C"&>%/)$:ML)P<')VYYR:N4JJBK+6U_\
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M4WVWMU=M%!'%*DD31*F2^Y2<_,<<'UJC-X3UF'2/[3FMHTMO*6?#3QB7RV.
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M@L<[F8Y]2:]+TCP]X>L-4U]M6L-:^SZ;IGGM!=B-761SL&".&^\I4]/K7/\
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M<OH^GQ>%-,TUQI[/;1,9W*A8Y5DQN=B6+$YQS]*\)^I-&3C&3CTS4O"M[O\
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MW>7[75I:0-;VL9MPP\V./;)+N.<R-_$?0U4KL@FHV>YRR:;T"BBBJ)"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /J
M?X!?\DSL?^NTW_H=%'P"_P"29V/_ %VF_P#0Z*^1Q7\>?JSZ7#?PH^B/16KX
MZ^*'_)1O$G_7])_.OL5J^.OBA_R4;Q)_U_2?SKNR?^)+T.3,O@7J<Q1117T!
MXH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0:EXB2OIM_6Y2HQ:6NYYW?:=?:>R+J%E=6C/RHGA:/=],@9JK7H'AN_N]9\
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M&+17\SR+>"."-G_O%44 GW-8=%%7&*BK15A.3D[MGU/\ O\ DF=C_P!=IO\
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M[T'Q'\0],L=4U VL6AB]C$URTC1S'^)6)R/PK7ZE9VO_ %=?YD?6;K;^M?\
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MIF**QP.N[:PYQ[5T7AV[BN["-K*T6VLE4+$JE0!C((P.!@BG?V#I?F22?88
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5F_O_ *"BBG8!K,SMN<Y-%%%(#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  P )P# 2(  A$! Q$!_\0
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4"C"@#C)[=ZUZSJ.+?N[%1O;4_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image00004.jpg
<TEXT>
begin 644 image00004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !X M0# 2(  A$! Q$!_\0
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M %1R'M3R<"H&.330!1113$)3>M*U"TP%%+124@%I,TA-)3 7-)FBB@04444
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MW33="HKIK;]056#MKN=K17%Z=XYDNYM,>30-1ATW4Y!':WA:-@Q(RI90V5!
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MAC1KK1(-'N+"*3382#';DG:N,X[Y[FHM1\(Z#J6GV5C?:;#-:62[+>)B<1C
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M% !1110 4444 %%%% !1110 4444 %%%% !112$X% #)#VJ.@G)HJA!1110
M#FIP,#%1QCO4M)C(I!WJ&K1&158C%-"8E%%%,04H% &:=0 4444AA33UIU-
MS0  44ZB@"Q1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *CE/:GDXJ!CDTT 4444Q!0!DT4^,=Z )%&!BE
MHHJ1B5 W4U8J&08:F@9&1Z4E/HQFF(0=*6I/+I/+HN RBI!'2X"C-*XR(@CK
M12L<FDIB"BBB@"Q1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH CD/&*CHHIH04444P"IU&!1128T+1112 *
F:XR*** (:5?O"BBJ$3T445(Q"<=:A9MQHHIH!****8@HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
